0001493152-22-007802.txt : 20220328 0001493152-22-007802.hdr.sgml : 20220328 20220328060618 ACCESSION NUMBER: 0001493152-22-007802 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220328 DATE AS OF CHANGE: 20220328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: enVVeno Medical Corp CENTRAL INDEX KEY: 0001661053 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 330936180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38325 FILM NUMBER: 22773078 BUSINESS ADDRESS: STREET 1: 70 DOPPLER CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-261-2900 MAIL ADDRESS: STREET 1: 70 DOPPLER CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: Hancock Jaffe Laboratories, Inc. DATE OF NAME CHANGE: 20151215 10-K 1 form10-k.htm
0001661053 false FY 0001661053 2021-01-01 2021-12-31 0001661053 NVNO:CommonStock0.00001ParValueMember 2021-01-01 2021-12-31 0001661053 NVNO:WarrantToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001661053 2021-06-30 0001661053 2022-03-24 0001661053 2021-12-31 0001661053 2020-12-31 0001661053 2020-01-01 2020-12-31 0001661053 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001661053 us-gaap:CommonStockMember 2019-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001661053 us-gaap:RetainedEarningsMember 2019-12-31 0001661053 2019-12-31 0001661053 us-gaap:CommonStockMember 2020-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001661053 us-gaap:RetainedEarningsMember 2020-12-31 0001661053 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001661053 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001661053 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001661053 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001661053 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001661053 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001661053 us-gaap:CommonStockMember 2021-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001661053 us-gaap:RetainedEarningsMember 2021-12-31 0001661053 us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001661053 us-gaap:IPOMember 2020-01-01 2020-12-31 0001661053 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001661053 srt:MinimumMember 2021-01-01 2021-12-31 0001661053 srt:MaximumMember 2021-01-01 2021-12-31 0001661053 NVNO:LaboratoryEquipmentMember 2021-12-31 0001661053 NVNO:LaboratoryEquipmentMember 2020-12-31 0001661053 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001661053 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001661053 us-gaap:ComputerEquipmentMember 2021-12-31 0001661053 us-gaap:ComputerEquipmentMember 2020-12-31 0001661053 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001661053 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001661053 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001661053 us-gaap:SoftwareDevelopmentMember 2020-12-31 0001661053 2021-11-17 0001661053 2021-11-16 2021-11-17 0001661053 NVNO:PresentValueOfMonthlyLeasePaymentsMember 2021-12-31 0001661053 NVNO:PaycheckProtectionProgramMember 2020-04-12 0001661053 NVNO:PaycheckProtectionProgramMember 2020-04-11 2020-04-12 0001661053 2021-09-07 2021-09-08 0001661053 us-gaap:DomesticCountryMember 2021-12-31 0001661053 NVNO:ResearchAndDevelopmentMember 2021-12-31 0001661053 2020-11-30 0001661053 us-gaap:PrivatePlacementMember NVNO:SeriesCConvertiblePreferredStockMember 2020-07-15 2020-07-17 0001661053 us-gaap:PrivatePlacementMember NVNO:ExchangeAgreementsMember us-gaap:PreferredStockMember 2020-11-16 2020-11-17 0001661053 us-gaap:PrivatePlacementMember NVNO:ExchangeAgreementsMember us-gaap:CommonStockMember 2020-11-16 2020-11-17 0001661053 2020-07-17 0001661053 NVNO:SeriesCConvertiblePreferredStockMember NVNO:SecuritiesPurchaseAgreementMember 2020-09-30 0001661053 us-gaap:PrivatePlacementMember NVNO:SeriesCConvertiblePreferredStockMember 2020-01-01 2020-09-30 0001661053 NVNO:SeriesCConvertiblePreferredStockMember NVNO:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001661053 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001661053 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001661053 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001661053 NVNO:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001661053 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001661053 NVNO:WarrantsMember 2021-01-01 2021-12-31 0001661053 NVNO:WarrantsMember 2021-12-31 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember us-gaap:WarrantMember 2020-11-10 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember NVNO:WarrantOneMember 2020-11-10 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember us-gaap:WarrantMember 2020-07-01 2020-07-31 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember NVNO:WarrantOneMember 2020-10-01 2020-10-31 0001661053 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2020-11-10 0001661053 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2020-11-10 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-11-10 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-11-10 0001661053 us-gaap:MeasurementInputExpectedDividendRateMember 2020-11-10 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-11-10 0001661053 NVNO:BoardOfDirectorsMember us-gaap:CommonStockMember 2020-11-10 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember us-gaap:CommonStockMember 2020-11-10 0001661053 NVNO:AdvisorMember 2020-11-09 2020-11-10 0001661053 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2020-11-30 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-11-30 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-11-30 0001661053 us-gaap:MeasurementInputExpectedDividendRateMember 2020-11-30 0001661053 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2020-11-30 0001661053 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2020-11-30 0001661053 2020-02-25 0001661053 2020-03-31 0001661053 2020-06-30 0001661053 2020-09-15 0001661053 2020-07-01 2020-09-30 0001661053 2020-01-01 2020-09-30 0001661053 2020-02-24 2020-02-25 0001661053 us-gaap:CommonStockMember 2020-02-24 2020-02-25 0001661053 us-gaap:CommonStockMember 2020-04-26 2020-04-28 0001661053 us-gaap:CommonStockMember 2020-06-01 2020-06-03 0001661053 us-gaap:CommonStockMember 2020-07-15 2020-07-17 0001661053 us-gaap:PreferredStockMember 2020-11-15 2020-11-17 0001661053 us-gaap:CommonStockMember 2020-10-08 2020-10-09 0001661053 us-gaap:CommonStockMember 2020-02-10 2020-02-11 0001661053 us-gaap:CommonStockMember 2021-08-01 2021-08-31 0001661053 us-gaap:CommonStockMember 2021-09-07 2021-09-09 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-02-25 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-09-15 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-02-25 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-09-15 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-02-24 2022-02-25 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-03-30 2020-03-31 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-06-29 2020-06-30 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-09-14 2020-09-15 0001661053 NVNO:TwoThousandSixteenOmnibusIncentivePlanMember 2021-01-01 2021-12-31 0001661053 NVNO:TwoThousandSixteenOmnibusIncentivePlanMember 2021-12-31 0001661053 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001661053 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001661053 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001661053 srt:MinimumMember 2020-01-01 2020-12-31 0001661053 srt:MaximumMember 2020-01-01 2020-12-31 0001661053 2019-09-12 2019-09-13 0001661053 2019-09-13 0001661053 2021-11-29 2021-11-30 0001661053 2021-11-30 0001661053 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001661053 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001661053 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001661053 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

OR

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to ___________________

 

Commission file number: 001-38325

 

enVVeno Medical Corporation

(Exact name of registrant as specified in its charter)

 

Delaware   33-0936180
(State or other jurisdiction
of incorporation or organization)		   (I.R.S. Employer
Identification No.)

 

70 Doppler

Irvine, California 92618

(Address of principal executive offices)

 

(949) 261-2900

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class:   Trading Symbol(s):   Name of Each Exchange on Which Registered:
Common Stock, $0.00001 par value   NVNO   The NASDAQ Stock Market LLC
Warrant to Purchase Common Stock   NVNOW   The NASDAQ Stock Market LLC

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2021 (the last business date of the registrant’s most recently completed second fiscal quarter), based on the last sale price of the registrant’s common stock on such date was $58.5 million.

 

As of March 24, 2022, there were 9,469,850 shares of common stock outstanding.

 

 

 

 

 

 

ENVVENO MEDICAL CORPORATION

TABLE OF CONTENTS

 

PART I
   
ITEM 1. Business 2
   
ITEM 1A. Risk Factors 8
   
ITEM 1B. Unresolved Staff Comments 29
   
ITEM 2. Properties 29
   
ITEM 3. Legal Proceedings 29
   
ITEM 4. Mine and Safety Disclosures 29
   
PART II
   
ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer of Equity Securities 30
   
ITEM 6. Selected Financial Data 30
   
ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
   
ITEM 7A. Quantitative and Qualitative Disclosures and Market Risk 33
   
ITEM 8. Financial Statements and Supplementary Data 33
   
ITEM 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosures 34
   
ITEM 9A. Controls and Procedures 34
   
ITEM 9B. Other Information 34
   
ITEM 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 34
   
PART III
   
ITEM 10. Directors, Executive Officers and Corporate Governance 35
   
ITEM 11. Executive Compensation 42
   
ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 53
   
ITEM 13. Certain Relationships and Related Transactions, and Director Independence 54
   
ITEM 14. Principal Accounting Fees and Services 55
   
PART IV
   
ITEM 15. Exhibits and Financial Statements Schedules 55
   
ITEM 16. Form 10-K Summary 57
   
Signatures 58
   
Financial Statements and Supplementary Data F-1

 

 

 

 

PART I

 

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains, or may contain, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and do not constitute guarantees of future performance. Actual results could differ materially from those contained in the forward-looking statements and are subject to significant risks and uncertainties, including those discussed under “Risk Factors,” as well as those discussed elsewhere in this Form 10-K. Actual results (including, without limitation, the actual timing for and results of the clinical trials described herein, and FDA review of the Company’s products in development) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).

 

You are further cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Form 10-K or, in the case of documents referred to or incorporated by reference, the date of those documents.

 

All subsequent written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S. securities law. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Unless the context requires otherwise, references in this Annual Report on Form 10-K to “we,” “us,” “our,” “our company,” “NVNO”, or similar terminology refer to enVVeno Medical Corporation.

 

We use our registered trademarks and trade names, such as VenoValve® ™ in this Annual Report on Form 10-K. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the ® and ™ symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

 

1

 

 

ITEM 1. Business

 

Overview

 

enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. We aim to develop products to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in the deep venous system of the leg and is called the VenoValve®. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and that have been commercially successful. We develop and manufacture our products in a 14,507 sq. ft. leased manufacturing facility in Irvine, California, which has been ISO 13485-2016 certified for the design, development and manufacturing of tissue based implantable medical devices.

 

On September 21, 2021, we announced that we were changing our name from Hancock Jaffe Laboratories, Inc. to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of deep venous CVI. In addition to the VenoValve, we announced that we have a second product in the early stages of development called enVVe. In connection with this change in strategy, we indicated that we are not pursuing further development of the CoreoGraft, which is now outside of our primary focus area.

 

VenoValve

 

The VenoValve is a porcine based valve developed at enVVeno Medical to be implanted in the deep venous system of the leg to treat severe CVI. By reducing reflux, and lowering pressure (venous hypertension) within the deep venous system of the leg, the VenoValve has the potential to reduce or eliminate the symptoms of severe deep venous CVI, including the potential to heal recurring venous leg ulcers. The current version of the VenoValve is designed to be implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh.

 

There are presently no FDA approved medical devices to address valvular incompetence in the deep venous system, or effective treatments for deep venous CVI. Current treatment options include compression garments, or constant leg elevation, and would care for venous ulcers. These treatments are generally ineffective, as they attempt to alleviate the symptoms of CVI without addressing the underlying causes of the disease. In addition, we believe compliance with compression garments and leg elevation is extremely low, especially among the elderly. The premise behind the VenoValve is that by reducing the underlying causes of CVI, reflux and venous hypertension, the debilitating symptoms of CVI will decrease, resulting in improvement in the quality of the lives of CVI sufferers.

 

We estimate that there are approximately 2.4 million people in the U.S. that suffer from deep venous CVI due to valvular incompetence.

 

2

 

 

Background

 

Chronic venous disease (“CVD”) is the world’s most prevalent chronic disease. CVD is generally classified using a standardized system known as CEAP (clinical, etiological, anatomical, and pathophysiological). The CEAP system consists of seven clinical classifications (C0 to C6) with C5 to C6 being the most severe cases of CVD.

 

Chronic Venous Insufficiency (“CVI”) is a subset of CVD and is generally used to describe patients with C4 to C6 CVD. CVI is a debilitating condition that affects the venous system of the leg causing pain, swelling, edema, skin changes, and ulcerations. The human leg contains three vein systems: the deep vein system, the superficial vein system, and the perforator vein system which connects the deep system to the superficial system. The deep venous system is located below the muscle and facia in the center portion of the leg and is responsible for approximately 90% of the blood flow. In order for blood to return to the heart from the foot, ankle, and lower leg, the calf muscle serves as a pump and pushes the blood up the veins of the leg against gravity and through a series of one-way valves. Each valve is supposed to open as blood passes through, and then close as blood progresses up the veins of the leg to the next valve. CVI occurs when the one-way valves in the veins of the leg fail and become incompetent. When the valves fail, gravity causes the blood to flow backwards and in the wrong direction (reflux). As blood pools in the lower leg, pressure inside the veins increases (venous hypertension). Reflux, and the resulting venous hypertension, causes the leg to swell, resulting in debilitating pain, and in the most severe cases, venous ulcers. The VenoValve is being developed to treat CVI in the deep venous system with a focus on severe patients with C4b, C5 and C6 CVI.

 

We estimate that approximately 2.4 million people in the U.S. have C5 to C6 CVI due to reflux in the deep venous system, including patients that develop venous leg ulcers (C6 patients). Over one million new severe cases of CVI occur each year in the U.S., mostly from patients who have experienced a deep vein thrombosis or blood clot. The average patient seeking treatment of a venous ulcer spends as much as $30,000 a year on wound care, and the total direct medical costs from venous ulcer sufferers in the U.S. has been estimated to exceed $38 billion a year. Aside from the direct medical costs, severe CVI sufferers experience a significantly reduced quality of life. Daily activities such as preparing meals, housework, and personal hygiene (washing and bathing) become difficult due to reduced mobility. For many severe CVI sufferers, intense pain, which frequently occurs at night, prevents patients from getting adequate sleep. Severe CVI sufferers are known to miss approximately 40% more work days than the average worker. A high percentage of venous ulcer patients also experience severe itching, leg swelling, and an odorous discharge. Wound dressing changes, which occur several times a week, can be extremely painful. Venous ulcers from deep venous CVI are very difficult to heal, and a significant percentage of venous ulcers remain unhealed for more than a year. Even if healed, recurrence rates for venous ulcers are known to be high (20% to 40%) within the first year and as high as 60% after five years.

 

3

 

 

VenoValve Clinical Status

 

After consultation with the FDA, and as a precursor to the U.S. pivotal trial, we conducted a small first-in-human study for the VenoValve in Colombia which included eleven (11) patients. In addition to providing safety and efficacy data, the purpose of the first-in-human study was to provide proof of concept, and to provide valuable feedback to make any necessary product modifications or adjustments to our surgical implantation procedure for the VenoValve prior to conducting the U.S. pivotal trial. Endpoints for the VenoValve first-in-human study included safety (device related adverse events), reflux, measured by doppler, a VCSS score used by the clinician to measure disease severity and progress, a VAS score used by the patient to measure pain, and a quality of life measurement.

 

Final results from the one (1) year first-in-human study were presented at the Charing Cross International Symposium in April of 2021. Among the eleven (11) patients in the study, reflux improved an average of 54%, Venous Clinical Severity Scores (“VCSSs”) improved an average of 56%, and visual analog scale (VAS) scores, which are used by patients to measure pain, improved an average of 76%, all at one (1) year when compared to pre-surgery levels. VCSS scores are commonly used by clinicians in practice and in clinical trials to objectively assess outcomes in the treatment of venous disease, and include ten characteristics including pain, inflammation, skin changes such as pigmentation and induration, the number of active ulcers, and ulcer duration. The improvement in VCSS scores is significant and indicates the VenoValve patients who had severe CVI pre-surgery, had mild CVI or the complete absence of disease at one-year post surgery.

 

There were no device related safety incidences during the one (1) year first-in-human study. Non-device related safety incidences were minor and included one (1) fluid pocket (which was aspirated), intolerance from Coumadin anticoagulation therapy, three (3) minor wound infections (treated with antibiotics), and one occlusion due to patient non-compliance with anti-coagulation therapy.

 

In preparation for the VenoValve U.S. pivotal trial, on March 5, 2021, we submitted an IDE application with the FDA.

 

An investigational device exemption or IDE from the FDA is required before a medical device company can proceed with a pivotal trial for a class III medical device. On April 1, 2021, we received notification from the FDA that our IDE application was approved. We have named the U.S. pivotal trial for the VenoValve the SAVVE (Surgical Anti-reflux Veno Valve Endoprosthesis) study. It is a prospective, non-blinded, single arm, multi-center study of seventy-five (75) CVI patients to be enrolled at up to 20 U.S. sites.

 

No product modifications for the VenoValve were necessary following the first-in-human study and the SAVVE trial is evaluating the same device that was used in the first-in-human study. Endpoints for the SAVVE trial mirror those endpoints used for the first-in-human study. The primary safety endpoint for the pivotal trial is a material adverse safety event (mortality, deep wound infection, major bleeding, ipsilateral deep vein thrombosis, pulmonary embolism) in no more than twenty six percent (26%) of the patients at one (1) month post implantation, and the primary effectiveness endpoint for the pivotal trial is improvement in reflux of at least thirty percent (30%), measured at six (6) months post VenoValve implantation. In the first-in-human study there were no reported material adverse safety events at one (1) month post implantation, and reflux improved an average of fifty six percent (56%) at six (6) months post implantation. VCSS scoring to measure disease manifestations, VAS scores to measure pain, and quality of life measurements will also be monitored in the study.

 

4

 

 

On August 3, 2020, we announced that the FDA granted Breakthrough Device Designation status to the VenoValve. The FDA’s Breakthrough Devices Program was established to enable priority review for devices that provide more effective treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions. The goal of the FDA’s Breakthrough Devices Program is to provide patients and health care providers with timely access to medical devices by speeding up their development, assessment, and review, while preserving the FDA’s mission to protect and promote public health.

 

At the end of the VenoValve first-in-human study, eight (8) study participants agreed to additional monitoring. In August of 2021, longer term follow-up data was presented at the Society of Vascular Surgery Conference in San Diego, for the cohort of eight (8) patients. That data indicated no recurrences of the severe CVI that was present pre-VenoValve, including no ulcer recurrences for those patients whose venous ulcers had healed following VenoValve surgery. There were no reported safety issues from the end of one (1) year first-in-human study to the end of the two (2) year reporting period. In addition, the patients continued to improve, reporting 63%, 60%, and 93%, average improvements in reflux, VCSS, and VAS scores, respectively, at an average of two (2) years post VenoValve surgery compared to pre-VenoValve levels.

 

In October of 2021, we announced that the first patient in the SAVVE pivotal trial underwent successful VenoValve implantation surgery and had been discharged from the hospital. The surgery was performed by Dr. Adriana Laser, associate professor of surgery at Albany Medical College and a vascular surgeon with Albany Med Vascular Surgery. As of December 31, 2021, ten (10) of our clinical trial sites were activated and eligible to enroll patients in the SAVVE pivotal trial. As of March 24, 2022 we have sixteen (16) clinical trial sites that are active to enroll patients in the SAVVE trial and expect to have nineteen (19) active sites by March 31, 2022. Also, as of March 24, 2022, we have completed nine (9) successful surgeries in the SAVVE pivotal trial for the VenoValve. We expect to have our tenth surgery completed by March 31, 2022.

 

The resurgence of COVID and the Omicron variant had both direct and indirect consequences on our clinical trial. Several of our clinical sites put elective surgeries on hold and prohibited potential study subjects from coming to the hospital for screening. Further, as reported in the media, COVID resurgences put an enormous strain on all hospital resources including clinical staffs. In addition to caring for the influx of COVID patients, hospitals become short staffed due to their own employees’ COVID sicknesses, resulting in clinical staff being reassigned to cover the shortfall. The lack of available clinical personnel both slows enrollment and impacts the speed at which we can activate clinical sites.

 

Finally, COVID impacts our patient population. Patients with COVID or who have had COVID within ninety (90) days of their screening, are excluded from our study until after the ninety (90) day period has passed. In addition, concerns about getting COVID impact the patients’ willingness to undergo an elective surgical procedure with a one-night hospital stay. As hospital clinical operations return to more normal levels, our goal is to fully enroll the SAVVE pivotal trial by the end of 2022 or the beginning of 2023. We continue to monitor the ongoing overall impact of COVID on the SAVVE clinical trial and will issue updates when appropriate.

 

In February of 2021, we raised $41.4 million of capital in a public offering of our common stock. In September of 2021, we raised $20 million dollars of capital in a registered direct offering priced at the market under Nasdaq rules and purchased by a fund managed by Perceptive Advisors, a leading life sciences investment firm. We finished 2021 with approximately $55 million of cash. At our existing cash burn rate of approximately $4 million per quarter, we should have sufficient cash to fund operations through the end of 2024 and into 2025. With primary endpoints following full enrollment in the SAVVE pivotal trial of thirty (30) days for safety, and six (6) months for effectiveness, we expect to have primary endpoint data well in advance of the need to raise additional capital.

 

5

 

 

Government Regulation

 

Our product candidates and our operations are subject to extensive regulation by the FDA, and other federal and state authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our product candidates are subject to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act (“FDCA”), as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, distribution, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising, promotion, marketing, and import and export of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements of the FDCA.

 

PMA Approval Pathway

 

Class III devices such as the VenoValve generally require pre-market approval (PMA) before they can be marketed in the U.S. The PMA review and approval process is more demanding than the 510(k) premarket notification process. In a PMA, the manufacturer must demonstrate that the device is safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and human clinical trials. The PMA also must contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. Following receipt of a PMA, the FDA determines whether the application is sufficiently complete to permit a substantive review. If FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA’s review often takes significantly longer, and can take several years. An advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the panel’s recommendation. In addition, the FDA generally will conduct a pre-approval inspection of the applicant or its third-party manufacturers’ manufacturing facility or facilities to ensure compliance with the QSR. The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s).

 

The FDA may approve a PMA with post-approval conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval, or requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance when deemed necessary to protect the public health or to provide additional safety and efficacy data for the device in a larger population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval can result in material adverse enforcement action, including withdrawal of the approval. Certain changes to an approved device, such as changes in manufacturing facilities, methods or quality control procedures, or changes in the design performance specifications, which affect the safety or effectiveness of the device, require submission of a PMA supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as extensive clinical data or the convening of an advisory panel. Certain other changes to an approved device require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation and technical basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness. The VenoValve will require the approval of a PMA.

 

Clinical Trials in Support of PMA

 

Clinical trials are almost always required to support a PMA submission. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA’s investigational device exemption (IDE) regulations, which govern investigational device labeling, prohibit promotion of the investigational device and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a “significant risk,” to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. The VenoValve required IDE applications prior to human testing in the United States, and we believe any future products such as the enVVE will also require IDE applications before human testing in the United States.

 

An IDE application must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.

 

In addition to IDE approval, a human, the study must be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the study, and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. Acceptance of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of human subjects. During a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical study are also subject to FDA’s regulations and must obtain patient informed consent, rigorously follow the investigational plan and study protocol, control the disposition of the investigational device and comply with all reporting and recordkeeping requirements. Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits.

 

6

 

 

Post-market Regulation

 

After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply. These include: establishing registration and device listing with the FDA; QSR requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the design and manufacturing process; labeling regulations and FDA prohibitions against the promotion of investigational products, or “off-label” uses of cleared or approved products; requirements related to promotional activities; clearance or approval of product modifications that could significantly affect safety or effectiveness or that would constitute a major change in intended use of one of our cleared devices; medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur; correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA; and post-market surveillance activities and regulations.

 

Regulation Outside of the U.S.

 

Each country or territory outside of the U.S. has its own rules and regulations with respect to the manufacture, marketing and sale of medical devices. For example, in December of 2018, we received regulatory approval from Instituto Nacional de Vigilancia de Medicamentos y Alimentos, the Colombian equivalent of the U.S. Food and Drug Administration, for our first-in-human study for the VenoValve in Colombia. At this time, other than the first-in-human trial in Colombia, we have not determined which countries outside of the U.S., if any, we will seek approval for our product candidates.

 

Our Competitive Strengths

 

We believe we will offer the venous disease treatment market a compelling value proposition with the launch of our product candidates, if approved, for the following reasons:

 

  ● We have extensive experience of proprietary processing and manufacturing methodology specifically applicable to the design, processing, manufacturing and sterilization of our biologic tissue devices.
  ● We operate a 14,507 square foot manufacturing facility in Irvine, California. Our facility is designed expressly for the manufacture of Class III tissue based implantable medical devices and is equipped for research and development, prototype fabrication, current good manufacturing practices, or cGMP, and manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices.
  ● We have attracted senior executives who are experienced in research and development and who have worked on numerous medical devices that have received FDA approval or CE marking. We also have the advantage of an experienced board of directors and scientific advisory board who will provide guidance as we move towards market launch.

 

Intellectual Property

 

We possess an extensive proprietary processing and manufacturing methodology specifically applicable to the design, processing, manufacturing and sterilization of biologic devices. This includes FDA compliant quality control and assurance programs, proprietary tissue processing technologies demonstrated to eliminate recipient immune responses, trusted relationship with abattoir suppliers, and a combination of tissue preservation and gamma irradiation that enhances device functions and guarantees sterility. We have filed several patent applications for the VenoValve with the U.S. Patent and Trademark Office (USPTO) and throughout the world. In February of 2021, we received a notice for allowance from the USPTO for an application focusing on novel aspects of the VenoValve Frame.

 

Employees

 

As of March 24, 2022, we had 24 full-time employees. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees.

 

Corporate Information

 

We were incorporated in Delaware on December 22, 1999. Our principal executive offices are located at 70 Doppler, Irvine, California, 92618, and our telephone number is (949) 261-2900. Our corporate website address is www.envveno.com. The information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

 

7

 

 

ITEM 1A. Risk Factors

 

Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report, before deciding to invest in our securities. If any of the following risks materialize, our business, financial condition, results of operation and prospects will likely be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose all or part of your investment.

 

Summary

 

The risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors and the other reports and documents filed by us with the SEC.

 

  ● We have incurred significant losses since our inception, expect to incur significant losses in the future and may never achieve or sustain profitability;
  ● We currently depend entirely on the successful and timely regulatory approval and commercialization of our current lead product candidate, and any future product candidates, which may not receive regulatory approval or, if our current lead or any future product candidate does receive regulatory approval, we may not be able to successfully commercialize them;
  ● The success of our current or future products, if approved, will be determined based on whether surgeons and patients in our target markets accept them;
  ● Failure to scale up the manufacturing process of our current or future product candidates in a timely manner, or at all;
  ● Our ability to retain and recruit key personnel, including the development of a sales and marketing infrastructure;
  ● Reliance on third party suppliers for certain components of our product candidates;
  ● If we successfully develop product candidates, our ability to commercialize and distribute our product candidates in the United States and internationally, depends on our ability to demonstrate the efficacy and financial viability of our products to doctors, hospitals, insurance companies, and other stakeholders;
  ● Changes in external competitive market factors;
  ● Uncertainties in generating sustained revenue or achieving profitability;
  ● Unanticipated working capital or other cash requirements;
  ● Changes in FDA regulations, including testing procedures, for medical devices and related promotional and marketing activities;
  ● Our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to obtain, additional financing;
  ● Our ability to obtain and maintain intellectual property protection for our product candidates;
  ● Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing product candidates and limit commercialization of any products that we may develop;
  ● Our ability to maintain the listing of our securities on the Nasdaq Capital Market; and
  ● Changes in our business strategy or an inability to execute our strategy due to unanticipated changes in the medical device industry or the impact of COVID-19 on our clinical trials.

 

Risks Related to Our Business and Strategy

 

We have incurred significant losses since our inception, expect to incur significant losses in the future and may never achieve or sustain profitability.

 

We have historically incurred substantial net losses, including net losses of $16.5 million and $9.1 million for the years ended December 31, 2021 and 2020, respectively. As a result of our historical losses, we had an accumulated deficit of $81.9 million as of December 31, 2021. Our losses have resulted primarily from costs related to general and administrative expenses relating to our operations, as well as our research programs and the development of our product candidates. Currently, we are not generating revenue from operations, and we expect to incur losses for the foreseeable future as we seek to obtain regulatory approval for our lead product candidate. Additionally, we expect that our general and administrative expenses will increase due to the additional operational costs associated with our SAVVE study as well as the projected expansion of our operations. We do not expect to generate significant revenue until any of our product candidates are licensed or sold, if ever. We may never generate significant revenue or become profitable. Even if we do achieve profitability, we may be unable to sustain or increase profitability on a quarterly or annual basis. Our failure to achieve and subsequently sustain profitability could harm our business, financial condition, results of operations and cash flows.

 

We currently depend entirely on the successful and timely regulatory approval and commercialization of our current lead product candidate, and any future product candidates, which may not receive regulatory approval or, if any of our product candidates do receive regulatory approval, we may not be able to successfully commercialize them.

 

We currently have one product candidate, the VenoValve, and our business presently depends entirely on our success with this product candidate. In order for our current lead and any future product candidates to succeed they need to be approved by regulatory authorities, which may never happen. Our product candidates are based on technologies that have not been used previously in the manner we propose. Market acceptance of our product candidates will largely depend on our ability to demonstrate their relative safety, efficacy, cost-effectiveness and ease of use. We may not be able to successfully develop and commercialize our product candidates. If we fail to do so, we will not be able to generate substantial revenues, if any.

 

We are subject to rigorous and extensive regulation by the FDA in the United States and by comparable agencies in other jurisdictions, including the European Medicines Agency, or EMA, in the European Union, or EU. Our lead product candidate is currently in development and we have not received FDA approval for our product candidate. Our product candidates may not be marketed in the United States until they have been approved by the FDA and may not be marketed in other jurisdictions until they have received approval from the appropriate foreign regulatory agencies. Each product candidate requires significant research, development, preclinical testing and extensive clinical investigation before submission of any regulatory application for marketing approval.

 

8

 

 

Obtaining regulatory approval requires substantial time, effort and financial resources, and we may not be able to obtain approval of any of our product candidates on a timely basis, or at all. The number, size, design and focus of preclinical and clinical trials that will be required for approval by the FDA, the EMA or any other foreign regulatory agency varies depending on the device, the disease or condition that the product candidates are designed to address and the regulations applicable to particular products. Preclinical and clinical data can be interpreted in different ways, which could delay, limit or preclude regulatory approval. The FDA, the EMA and other foreign regulatory agencies can delay, limit or deny approval of a product for many reasons, including, but not limited to:

 

  ● a product candidate may not be shown to be safe or effective;
  ● the clinical and other benefits of a product candidate may not outweigh its safety risks;
  ● we may not be able to enroll enough patients to complete our product studies;
  ● clinical trial results may be negative or inconclusive, or adverse medical events may occur during a clinical trial;
  ● trial patients may expire from reasons unrelated to our product, impairing our trials;
  ● the results of clinical trials may not meet the level of statistical significance required by regulatory agencies for approval;
  ● regulatory agencies may interpret data from pre-clinical and clinical trials in different ways than we do;
  ● regulatory agencies may not approve the manufacturing process or determine that the manufacturing is not in accordance with current good manufacturing practices, or cGMPs;
  ● a product candidate may fail to comply with regulatory requirements; and/or
  ● regulatory agencies might change their approval policies or adopt new regulations.

 

If our product candidates are not approved at all or quickly enough to provide net revenues to defray our operating expenses, our business, financial condition, operating results and prospects could be harmed.

 

If we are unable to successfully raise additional capital, our future clinical trials and product development could be limited and our long-term viability may be threatened.

 

We have experienced negative operating cash flows since our inception and have funded our operations primarily from proceeds received from sales of our capital stock, the issuance of the convertible and non-convertible notes, and the sale of our products to larger medical device companies. We will need to seek additional funds in the future through equity or debt financings, or strategic alliances with third parties, either alone or in combination with equity financings, to complete our product development initiatives. These financings could result in substantial dilution to the holders of our common stock, or require contractual or other restrictions on our operations or on alternatives that may be available to us. If we raise additional funds by issuing debt securities, these debt securities could impose significant restrictions on our operations. Any such required financing may not be available in amounts or on terms acceptable to us, and the failure to procure such required financing could have a material and adverse effect on our business, financial condition and results of operations, or threaten our ability to continue as a going concern.

 

Our present and future capital requirements will be significant and will depend on many factors, including:

 

  ● the progress and results of our development efforts for our product candidates;
  ● the costs, timing and outcome of regulatory review of our product candidates;
  ● the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
  ● the effect of competing technological and market developments;
  ● market acceptance of our product candidates;
  ● the rate of progress in establishing coverage and reimbursement arrangements with domestic and international commercial third-party payors and government payors;
  ● the ability to achieve revenue growth and improve gross margins;
  ● the extent to which we acquire or in-license other products and technologies; and
  ● legal, accounting, insurance and other professional and business-related costs.

 

We may not be able to acquire additional funds on acceptable terms, or at all. If we are unable to raise adequate funds, we may have to liquidate some or all of our assets or delay, reduce the scope of or eliminate some or all of our development programs.

 

If we do not have, or are not able to obtain, sufficient funds, we may be required to delay development or commercialization of our product candidates. We also may have to reduce the resources devoted to our product candidates or cease operations. Any of these factors could harm our operating results.

 

9

 

 

The COVID-19 pandemic has significantly negatively impacted our business.

 

The COVID-19 pandemic has disrupted the global economy and has negatively impacted large populations including people and businesses that may be directly or indirectly involved with the operation of our Company, the manufacturing, development, and testing of our product candidate, and the clinical trials for our product candidate. The full scope and economic impact of COVID-19 is still unknown. There are many risks from COVID-19 that could generally and negatively impact economies and healthcare providers in the countries where we do business, the medical device industry as a whole, and development stage, pre-revenue companies such as NVNO. To-date, the primary impacts of COVID-19 to our operations were stay-at-home work requirements, travel restrictions limiting our ability to initiate and continue animal studies and patient trials, suspensions of elective surgeries at trial sites limiting our ability to enroll patients in SAVVE, and disruptions to scheduled meetings with regulatory agencies such as the FDA. Notwithstanding these impacts, we were able to use remote work tools, communications solutions, and other methods to continue our trials and regulatory submissions. The resurgence of COVID and the Omicron variant caused several of our activated clinical sites to put elective surgeries on hold and prohibit potential study subjects from coming to the hospital for screening. Labor shortages due to Omicron have also negatively impacted hospital staffing in all departments, including clinical research. In addition to caring for the influx of COVID patients, hospitals become short staffed due to their own employees’ COVID sicknesses, resulting in clinical staff being reassigned to cover the shortfall. The lack of available clinical personnel both slows enrollment and impacts the speed at which we can activate clinical sites. COVID also impacts our patient population. Patients with COVID or who have had COVID within ninety (90) days of their screening, are excluded from our study until after the ninety (90) day period has passed. In addition, concerns about getting COVID impact the patients’ willingness to undergo an elective surgical procedure with a one-night hospital stay. As a result, the COVID resurgence has slowed patient enrollment for the SAVVE clinical trial and has resulted in delays in new clinical sites being activated for enrollment. We are increasing the number of SAVVE sites and ensuring they are geographically dispersed to attempt to mitigate the impact of reductions in elective surgery schedules. At this time, we have identified the following COVID-19 related risks that we believe have a greater likelihood of negatively impacting our Company, including, but not limited to:

 

  ● Federal, State and local shelter-in-place directives which limit our employees from accessing our facility to manufacture, develop and test our product candidates;
  ● Federal, State and local shelter-in-place directives which limit our ability to enroll sites or patients in our SAVVE trial;
  ● Travel restrictions and quarantine requirements which prevent us from initiating and continuing animal studies and patient trials both inside and outside of the United States;
  ● The burden on hospitals and medical personnel resulting in the cancellation of non-essential medical procedures such as surgical procedures needed to implant our product candidates for pre-clinical and clinical trials;
  ● Delays in the procurement of certain supplies and equipment that are needed to develop and test our product candidates;
  ● Travel restrictions which prevent patients from participating and continuing the participation in clinical trials.

 

We may never be able to generate sufficient revenue from the commercialization of our product candidates to achieve and maintain profitability.

 

Our ability to operate profitably in the future will depend upon, among other items, our ability to (i) fully develop product candidates, (ii) scale up our business and operational structure, (iii) obtain regulatory approval of product candidates from the FDA, (iv) market and sell product candidates, (v) successfully gain market acceptance of our product candidates, and (vi) obtain sufficient and on-time supply of components from our third-party suppliers. If our product candidates are never successfully commercialized, we may never receive a return on our investments in product development, regulatory compliance, manufacturing, and quality assurance, which may cause us to fail to generate revenue and gain economies of scale from such investments.

 

10

 

 

We only utilize a few suppliers for porcine tissue for our product candidate and the loss of a supplier could have an adverse impact on our business.

 

We rely on one domestic third-party vendor to supply porcine tissue for our product candidate. Our ability to supply our current and future product candidates commercially, if approved, depends, in part, on our ability to obtain this porcine tissue in accordance with our specifications and with regulatory requirements and in sufficient quantities to meet demand. Our ability to obtain porcine tissue may be affected by matters outside our control, including that this supplier may cancel our arrangements on short notice or have disruptions to their operations.

 

If we are required to establish additional or replacement suppliers for the porcine tissue, it may not be accomplished quickly and our operations could be disrupted. Even if we are able to find replacement suppliers, the replacement suppliers may need to be qualified and may require additional regulatory authority approval, which could result in further delay. In the event of a supply disruption, our product inventories may be insufficient to supply our customers and the development of any future product candidates would be delayed, limited or prevented, which could have an adverse impact on our business.

 

We depend upon third-party suppliers for certain components of our product candidate, making us vulnerable to supply problems and price fluctuations, which could harm our business.

 

We rely on a number of third-party suppliers to provide certain components of our product candidate. We do not have long-term supply agreements with most of our suppliers, and, in many cases, we purchase goods on a purchase order basis. Our suppliers may encounter problems for a variety of reasons, including unanticipated demand from larger customers, failure to follow specific protocols and procedures, failure to comply with applicable regulations, equipment malfunction, quality or yield problems and environmental factors, any of which could delay or impede their ability to meet our demand. Our reliance on these third-party suppliers also subjects us to other risks that could harm our business, including:

 

  ● interruption of supply resulting from modifications to, or discontinuation of, a supplier’s operations;
  ● delays in product shipments resulting from defects, reliability issues or changes in components from suppliers;
  ● price fluctuations due to a lack of long-term supply arrangements for key components with our suppliers;
  ● errors in manufacturing components, which could negatively impact the effectiveness or safety of our product candidates or cause delays in shipment of our product candidates;
  ● discontinued production of components, which could significantly delay our production and sales and impair operating margins;
  ● inability to obtain adequate supplies in a timely manner or on commercially reasonable terms;
  ● difficulty locating and qualifying alternative suppliers, especially with respect to our sole-source supplies;
  ● delays in production and sales caused by switching components, which may require product redesign and/or new regulatory submissions;
  ● delays due to evaluation and testing of devices from alternative suppliers and corresponding regulatory qualifications;
  ● non-timely delivery of components due to our suppliers supplying products for a range of customers;
  ● the failure of our suppliers to comply with strictly enforced regulatory requirements, which could result in disruption of supply or increased expenses; and
  ● inability of suppliers to fulfill orders and meet requirements due to financial hardships.

 

In addition, there are a limited number of suppliers and third-party manufacturers that operate under the FDA’s Quality System Regulation, or QSR, requirements, maintain certifications from the International Organization for Standardization that are recognized as harmonized standards in the European Economic Area, or EEA, and that have the necessary expertise and capacity to supply components for our product candidates. As a result, it may be difficult for us to locate manufacturers for our anticipated future needs, and our anticipated growth may strain the ability of our current suppliers to deliver products, materials and components to us. If we are unable to arrange for third-party manufacturing of components for our product candidates, or to do so on commercially reasonable terms, we may not be able to complete development of, market and sell our current or new product candidates. Further, any supply interruption from our suppliers or failure to obtain additional suppliers for any of the components used in our product candidates would limit our ability to manufacture our product candidates. Failure to meet these commitments could result in legal action by our customers, loss of customers or harm to our ability to attract new customers, any of which could have a material and adverse effect on our business, financial condition, results of operations and growth.

 

11

 

 

If we successfully develop product candidates, we will have to demonstrate the efficacy and financial viability of our products to doctors, hospitals, insurance companies, and other stakeholders.

 

There are multiple stakeholders that determine the success of a medical device, including doctors, hospitals, medical insurance companies, and others. Educating these stakeholders on the benefits of product candidates will require a significant commitment by a marketing team and sales organization. Surgeons and hospitals may be slow to change their practices because of familiarity with existing devices and/or treatments, perceived risks arising from the use of new devices, lack of experience using new devices, lack of clinical data supporting the benefits of such devices or the cost of new devices. There may never be widespread adoption of our product candidates by surgeons and hospitals. In addition, medical insurance companies would need to understand the costs and benefits of our product candidates compared to the existing standards of care, if they are to provide reimbursement for the cost of our product candidates and the procedures to implant our product candidates. We may have difficulty and may never achieve the market acceptance that we need from doctors, hospitals, medical insurance companies and others that are necessary for a successful product.

 

We may be unable to convince hospital facilities to approve the use of our product candidates.

 

In the United States, in order for surgeons to use our product candidates, the hospital facilities where these surgeons treat patients will typically require that the product candidates receive approval from the facility’s VAC. VACs typically review the comparative effectiveness and cost of medical devices used in the facility. The makeup and evaluation processes for VACs vary considerably, and it can be a lengthy, costly and time-consuming effort to obtain approval by the relevant VAC. For example, even if we have an agreement with a hospital system for the purchase of a product, in most cases, they must obtain VAC approval by each hospital within the system to sell at that particular hospital. Additionally, hospitals typically require separate VAC approval for each specialty in which a product is used, which may result in multiple VAC approval processes within the same hospital even if such product has already been approved for use by a different specialty group. VAC approval is often needed for each different product to be used by the surgeons in that specialty. In addition, hospital facilities and group purchasing organizations, or GPOs, which manage purchasing for multiple facilities, may also require us to enter into a purchasing agreement and satisfy numerous elements of their administrative procurement process, which can also be a lengthy, costly and time-consuming effort. If we do not receive access to hospital facilities in a timely manner, or at all, via these VAC and purchasing contract processes, or otherwise, or if we are unable to secure contracts on commercially reasonable terms in a timely manner, or at all, our costs may increase, our sales may decrease and our operating results may be harmed.

 

Our long-term growth depends on our ability to develop and commercialize additional product candidates.

 

The medical device industry is highly competitive and subject to rapid change and technological advancements. Therefore, it is important to our business that we continue to enhance our product candidate offerings and introduce new product candidates. Developing new product candidates is expensive and time-consuming. Even if we are successful in developing additional product candidates, the success of any new product candidates or enhancements to existing product candidates will depend on several factors, including our ability to:

 

  ● properly identify and anticipate surgeon and patient needs;
  ● develop and introduce new product candidates or enhancements in a timely manner;
  ● develop an effective and dedicated sales and marketing team;
  ● avoid infringing upon the intellectual property rights of others;
  ● demonstrate, if required, the safety and efficacy of new product candidates with data from preclinical studies and clinical trials;
  ● obtain the necessary regulatory clearances or approvals for new product candidates or enhancements;
  ● be fully FDA-compliant with marketing of new product candidates or modified product candidates;
  ● provide adequate training to potential users of our product candidates; and
  ● receive adequate coverage and reimbursement for procedures performed with our product candidates.

 

12

 

 

If we are unsuccessful in developing and commercializing additional devices in other areas, our ability to realize our revenue may be impaired.

 

New technologies, techniques or products could emerge that might offer better combinations of price and performance than the products and services that we plan to offer. Existing markets for surgical devices are characterized by rapid technological change and innovation. It is critical to our success that we anticipate changes in technology and customer requirements and physician, hospital and healthcare provider practices. It is also important that we successfully introduce new, enhanced and competitive product candidates to meet our prospective customers’ needs on a timely and cost-effective basis. At the same time, however, we must carefully manage our introduction of new product candidates. If potential customers believe that such product candidates will offer enhanced features or be sold for a more attractive price, they may delay purchases until such product candidates are available. We may also continue to offer older obsolete products as we transition to new product candidates, and we may not have sufficient experience managing transitions. If we do not successfully innovate and introduce new technology into our anticipated product lines or successfully manage the transitions of our technology to new product offerings, our revenue, results of operations and business could be adversely impacted.

 

Our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, industry standards, distribution reach or customer requirements. We anticipate that we will face strong competition in the future as current or future competitors develop new or improved product candidates and as new companies enter the market with novel technologies.

 

If we are unable to produce an adequate supply of our product candidates for use in our current and planned clinical trials or for commercialization because of our limited manufacturing resources or our facility is damaged or becomes inoperable, our regulatory, development and commercialization efforts may be delayed.

 

Our manufacturing resources for our product candidates are limited. We currently manufacture our product candidates for our research and development and clinical trial purposes at our manufacturing facility in Irvine, California. If our existing manufacturing facility experiences a disruption, we would have no other means of manufacturing our product candidates until we are able to restore the manufacturing capability at our current facility or develop alternative manufacturing facilities. Additionally, any damage to or destruction of our facilities or our equipment, prolonged power outage or contamination at our facilities would significantly impair our ability to produce our product candidates and prepare our product candidates for clinical trials.

 

Additionally, in order to produce our product candidates in the quantities that will be required for commercialization, we will have to increase or “scale up” our production process over the current level of production. We may encounter difficulties in scaling up our production, including issues involving yields, controlling and anticipating costs, quality control and assurance, supply and shortages of qualified personnel. If our scaled-up production process is not efficient or results in a product that does not meet quality or other standards, we may be unable to meet market demand and our revenues, business and financial prospects would be adversely affected. Further, third parties with whom we may develop relationships may not have the ability to produce the quantities of the materials we may require for clinical trials or commercial sales or may be unable to do so at prices that allow us to price our products competitively.

 

Our facility and equipment would be costly to replace and could require substantial lead time to repair or replace. The facility may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, flooding, fire, vandalism and power outages, which may render it difficult to operate our business for some period of time. While we have taken precautions to safeguard our facilities, any inability to operate our business during such periods could lead to the loss of customers or harm to our reputation. We also possess insurance for damage to our property and the disruption of our business, but this insurance may not be sufficient to cover all of our potential losses and this insurance may not continue to be available to us on acceptable terms, or at all.

 

13

 

 

We currently have no sales and marketing infrastructure and we may not be able to build a sales and marketing infrastructure sufficient for us to commercialize our current product candidate or future product candidates, if approved, and may be unable to do so or may never generate sufficient revenue to achieve or sustain profitability.

 

In order to commercialize products that are approved by regulatory agencies, we will have to increase our expenditures to undertake development or commercialization activities. If we are unable to successfully execute commercialization activities, we may have to curtail the development of our product candidates, reduce or delay development programs, delay potential commercialization of our product candidates or reduce the scope of any sales or marketing activities.

 

If it becomes necessary for us to establish a sales and marketing infrastructure, we may not be able to do so or we may not realize a positive return on this investment. We would have to compete with established and well-funded medical device companies to recruit, hire, train and retain sales and marketing personnel. Once hired, the training process is lengthy because it requires significant education of new sales representatives to achieve the level of clinical competency with our products expected by specialists. Upon completion of the training, we expect our sales representatives would typically require lead time in the field to grow their network of accounts and achieve the productivity levels we expect them to reach in any individual territory. If we are unable to attract, motivate, develop and retain a sufficient number of qualified sales personnel, or if our sales representatives do not achieve the productivity levels in the time period we expect them to, our revenue will not grow at the rate we expect and our business, results of operations and financial condition will suffer. Also, to the extent we hire sales personnel from our competitors, we may be required to wait until applicable non-competition provisions have expired before deploying such personnel in restricted territories or incur costs to relocate personnel outside of such territories. Any of these risks may adversely affect our ability to increase sales of our product candidates. If we are unable to expand our sales and marketing capabilities, we may not be able to effectively commercialize our product candidates, which would adversely affect our business, results of operations and financial condition.

 

Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing product candidates and limit commercialization of any products that we may develop.

 

Our business exposes us to the risk of product liability claims that are inherent in the manufacturing, distribution, and sale of medical devices. This risk exists even if a device is cleared or approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. Manufacturing and marketing of our commercial devices and clinical testing of our product candidates, may expose us to product liability and other tort claims. Furthermore, surgeons may misuse our product candidates or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our product candidates are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Regardless of the merit or eventual outcome, product liability claims may result in:

 

  ● significant litigation costs;
  ● decreased demand for our product candidates and any product candidates that we may develop;
  ● damage to our reputation;
  ● withdrawal of clinical trial participants;
  ● substantial monetary awards to trial participants, patients or other claimants;
  ● loss of revenue; and
  ● the inability to commercialize any product candidates that we may develop.

 

Although we maintain liability insurance, the coverage limits of our insurance policies may not be adequate, and one or more successful claims brought against us may have a material adverse effect on our business and results of operations. If we are unable to obtain insurance in the future at an acceptable cost or on acceptable terms with adequate coverage, we will be exposed to significant liabilities.

 

14

 

 

The loss of our executive officers or our inability to attract and retain qualified personnel may adversely affect our business, financial conditions and results of operations.

 

Our business and operations depend to a significant degree on the skills, efforts and continued services of our executive officers who have critical industry experience and relationships. Although we have entered into employment agreements with our executive officers, they may terminate their employment with us at any time. Accordingly, these executive officers may not remain associated with us. The efforts of these persons will be critical to us as we continue to develop our product candidates and business. We do not carry key person life insurance on any of our management, which would leave our company uncompensated for the loss of any of our executive officers.

 

Further, competition for highly-skilled and qualified personnel is intense. As such, our future viability and ability to achieve sales and profit will also depend on our ability to attract, train, retain and motivate highly qualified personnel in the diverse areas required for continuing our operations. If we were to lose the services one or more of our current executive officers or if we are unable to attract, hire and retain qualified personnel, we may experience difficulties in competing effectively, developing and commercializing our products and implementing our business strategies, which could have a material adverse effect on our business, operations and financial condition.

 

Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited.

 

As of December 31, 2021 and 2020, we had available federal net operating loss carryforwards, or NOLs, of approximately $45.7 million and $35.0 million. Pre-2018 federal NOLs carryovers of $12.0 million may be carried forward for twenty years and begin to expire in 2029. Under the Tax Act, post-2017 federal NOLs can be carried forward indefinitely and the annual limit of deduction equals 80% of taxable income. However, to the extent the Company utilizes its NOL carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is used. As of December 31, 2021, and 2020, the Company had net operating loss carryforwards for state income tax purposes of approximately $45.7 million and $35.0 million, respectively, which can be carried forward for twenty years and begin to expire in 2028.

 

As of December 31, 2021, we also had federal research and development tax credit carryforwards of approximately $0.2 million which begin to expire in 2027. In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” (generally defined as a cumulative change in equity ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period) may be subject to limitations on its ability to utilize its NOLs and certain credit carryforwards to offset future taxable income and taxes. We have analyzed the tax impacts of ownership changes that occurred in 2018 and in 2021. While those ownership changes have resulted in limits to the amount of NOLs that may be used in a given year, these are all post 2017 NOLs and are carried forward indefinitely. Future changes in our stock ownership, as well as other changes that may be outside of our control, could result in additional ownership changes. Our NOLs and credit carryforwards may also be limited under similar provisions of state law. We have recorded a full valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future tax benefits of such assets.

 

15

 

 

Risks Related to Regulatory Approval and Other Governmental Regulations

 

Our business and product candidates are subject to extensive governmental regulation and oversight, and our failure to comply with applicable regulatory requirements could harm our business.

 

Our product candidates and operations are subject to extensive regulation in the United States by the FDA and by regulatory agencies in other countries where we anticipate conducting business activities. The FDA regulates the development, testing, manufacturing, labeling, storage, record-keeping, promotion, marketing, sales, distribution and post-market support and reporting of medical devices in the United States. The regulations to which we are subject are complex and may become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales.

 

In order to conduct a clinical investigation involving human subjects for the purpose of demonstrating the safety and effectiveness of a medical device, a company must, among other things, apply for and obtain Institutional Review Board, or IRB, approval of the proposed investigation. In addition, if the clinical study involves a “significant risk” (as defined by the FDA) to human health, the sponsor of the investigation must also submit and obtain FDA approval of an IDE application. Our product candidates are considered significant risk devices requiring IDE approval prior to investigational use. We may not be able to obtain FDA and/or IRB approval to undertake clinical trials in the United States for any new devices we intend to market in the United States in the future. If we obtain such approvals, we may not be able to conduct studies which comply with the IDE and other regulations governing clinical investigations or the data from any such trials may not support clearance or approval of the investigational device. Failure to obtain such approvals or to comply with such regulations could have a material adverse effect on our business, financial condition and results of operations. It is uncertain whether clinical trials will meet desired endpoints, produce meaningful or useful data and be free of unexpected adverse effects, or that the FDA will accept the validity of foreign clinical study data, and such uncertainty could preclude or delay market clearance or authorizations resulting in significant financial costs and reduced revenue.

 

Our product candidates may be subject to extensive governmental regulation in foreign jurisdictions, such as the EEA, and our failure to comply with applicable requirements could cause our business, results of operations and financial condition to suffer.

 

In the EEA, our product candidates will need to comply with the Essential Requirements set forth in Medical Device Regulation. Compliance with these requirements is a prerequisite to be able to affix a CE mark to a product, without which a product cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements and obtain the right to affix the CE mark to our product candidates, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. The conformity assessment procedure requires the involvement of a Notified Body, which is an organization designated by a competent authority of an EEA country to conduct conformity assessments. The Notified Body would audit and examine the Technical File and the quality system for the manufacture, design and final inspection of our products. The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure and quality management system audit conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements. This Certificate entitles the manufacturer to affix the CE mark to its medical products after having prepared and signed a related EC Declaration of Conformity.

 

As a general rule, demonstration of conformity of medical products and their manufacturers with the Essential Requirements must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use and that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device (e.g., product labeling and instructions for use) are supported by suitable evidence. This assessment must be based on clinical data, which can be obtained from (1) clinical studies conducted on the devices being assessed, (2) scientific literature from similar devices whose equivalence with the assessed device can be demonstrated or (3) both clinical studies and scientific literature. However, the pre-approval and post-market clinical requirements are much more rigorous. The conduct of clinical studies in the EEA is governed by detailed regulatory obligations. These may include the requirement of prior authorization by the competent authorities of the country in which the study takes place and the requirement to obtain a positive opinion from a competent Ethics Committee. This process can be expensive and time-consuming.

 

16

 

 

The FDA regulatory approval, clearance and license process is complex, time-consuming and unpredictable.

 

In the United States, our product candidates are expected to be regulated as medical devices. Before our medical device product candidates may be marketed in the United States, we must submit, and the FDA must approve a PMA application. For the PMA approval process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. In addition, modifications to products that are approved through a PMA application generally require FDA approval. The time required to obtain approval, clearance or license by the FDA to market a new therapy is unpredictable but typically takes many years and depends upon many factors, including the substantial discretion of the FDA.

 

Our product candidates could fail to receive regulatory approval, clearance or license for many reasons, including the following:

 

  ● the FDA may disagree with the design or implementation of our clinical trials or study endpoints;
  ● we may be unable to demonstrate to the satisfaction of the FDA that our product candidates are safe and effective for their proposed indications or that our product candidates provide significant clinical benefits;
  ● the results of our clinical trials may not meet the level of statistical significance required by the FDA for approval, clearance or license or may not support approval of a label that could command a price sufficient for us to be profitable;
  ● the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;
  ● the opportunity for bias in the clinical trials as a result of the open-label design may not be adequately handled and may cause our trial to fail;
  ● our product candidates may be subject to an FDA advisory committee review, which may be requested at the sole discretion of the FDA, and which may result in unexpected delays or hurdles to approval;
  ● the FDA may determine that the manufacturing processes at our facilities or facilities of third-party manufacturers with which we contract for clinical and commercial supplies are inadequate;
  ● the FDA may determine we cannot continue our clinical trials due to adverse patient reactions including patient deaths for reasons unrelated to our products; and
  ● the approval, clearance or license policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.

 

Even if we were to obtain approval, clearance or license, the FDA may grant approval, clearance or license contingent on the performance of costly post-marketing clinical trials or may approve our product candidates with a label that does not include the labeling claims necessary or desirable for successful commercialization of our product candidates. Any of the above could materially harm our product candidates’ commercial prospects.

 

17

 

 

Even if our product candidates are approved by regulatory authorities, if we fail to comply with ongoing regulatory requirements, or if we experience unanticipated problems with our product candidates, our product candidates could be subject to restrictions or withdrawal from the market.

 

The manufacturing processes, post-approval clinical data and promotional activities of any product candidate for which we obtain marketing approval will be subject to continual review and periodic inspections by the FDA and other regulatory bodies. Even if regulatory approval of our product candidates is granted in the United States, the approval may be subject to limitations on the indicated uses for which the product candidates may be marketed or contain requirements for costly post-marketing testing and surveillance to monitor the safety or effectiveness of the product. Later discovery of previously unknown and unanticipated problems with our product candidates, including but not limited to unanticipated severity or frequency of adverse events, delays or problems with the manufacturer or manufacturing processes, or failure to comply with regulatory requirements, may result in restrictions on such product candidates or manufacturing processes, withdrawal of the product candidates from the market, voluntary or mandatory recall, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties.

 

We are required to report certain malfunctions, deaths and serious injuries associated with our products once approved by regulatory bodies, which can result in voluntary corrective actions or agency enforcement actions.

 

All manufacturers marketing medical devices in the EEA are legally bound to report incidents involving devices they produce or sell to the regulatory agency, or competent authority, in whose jurisdiction the incident occurred. Under the EU Medical Devices Directive (Directive 93/42/EEC), an incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health. In addition, under the EU MDR, the manufacturers are obligated to publish Periodic Safety Update Report (annually for high risk devices) which will be uploaded to EUDAMED and require conformity assessment by Notified Bodies.

 

Malfunction or misuse of our product candidates could result in future voluntary corrective actions, such as recalls, including corrections (e.g., customer notifications), or agency action, such as inspection or enforcement actions. If malfunctions or misuse do occur, we may be unable to correct the malfunctions adequately or prevent further malfunctions or misuse, in which case we may need to cease manufacture and distribution of the affected products, initiate voluntary recalls, and redesign the products or the instructions for use for those products. Regulatory authorities may also take actions against us, such as ordering recalls, imposing fines, or seizing the affected products. Any corrective action, whether voluntary or involuntary, will require the dedication of our time and capital, may distract management from operating our business, and may harm our business, results of operations and financial condition.

 

Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for product candidates or to manufacture, market or distribute product candidates after clearance or approval is obtained.

 

From time to time, legislation is drafted and introduced in the U.S. Congress that could significantly change the statutory provisions governing the regulation of medical devices or the reimbursement thereof. In addition, the FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our product candidates. For example, as part of the Food and Drug Administration Safety and Innovation Act, or FDASIA, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance goal commitments and enacted several “Medical Device Regulatory Improvements” and miscellaneous reforms, which are further intended to clarify and improve medical device regulation both pre- and post-clearance or approval. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to manufacture, market or distribute our product candidates or future products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:

 

  ● additional testing prior to obtaining clearance or approval;
  ● changes to manufacturing methods;
  ● recall, replacement or discontinuance of our systems or future products; or
  ● additional record keeping.

 

18

 

 

Any of these changes could require substantial time and cost and could harm our business and our financial results.

 

The highly publicized PIP scandal (use of non-medical grade silicone in breast implants) in 2010 led to publishing the first version of EU Medical Device Regulation (MDR) by European Commission in 2012. After 347 amendments by European Parliament in 2014, followed by various versions, the final version of the new EU Medical Device Regulation (MDR 2017/745) was published on May 5, 2017. The official entry to force of the MDR started on May 26, 2017 with the transition period of 3 years. The date of application of all existing and new medical devices under MDR is May 26, 2020; however, Notified Bodies are currently not accepting any new CE Mark applications under MDD (Medical Device Directives). All existing MDD CE certificates become void on May 26, 2024. EU requires that all existing and new medical device undergo assessment under MDR as if they are new product application.

 

The changes from EU Medical Device Directives (MDD) to Medical Device Regulation (MDR) are significant, with stricter clinical requirements and post-market surveillance, shift from pre-approval to Life-cycle approach, centralized EUDAMED database for public transparency (e.g. Periodic Safety Update Reports) and device registration, more device specific requirements (e.g. Common Specifications), legal liability for defective devices, etc. The QMS audit under MDR will be much more rigorous, including audits and assessment of suppliers and device testing. In addition, EU MDR introduces new stakeholders participating during the application review process, which will result in a longer and more burdensome assessment of our new products. The new stakeholders will include Medical Device Coordination Group (MDCG) established by Member States and Expert Panels appointed by European Union.

 

Further, under the FDA’s Medical Device Reporting or MDR regulations, we are required to report to the FDA any incident in which our product candidates may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Any adverse event involving our products could result in future voluntary corrective actions, such as product actions or customer notifications, or regulatory authority actions, such as inspection, mandatory recall or other enforcement action. Repeated product malfunctions may result in a voluntary or involuntary product recall, which could divert managerial and financial resources, impair our ability to manufacture our product candidates in a cost-effective and timely manner and have an adverse effect on our reputation, financial condition and operating results.

 

Moreover, depending on the corrective action we take to redress a product’s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals or clearances for the device before we may market or distribute the corrected device. Seeking such approvals or clearances may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our product candidates, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, withdrawals or clearances or approvals or civil or criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales as well as face significant adverse publicity or regulatory consequences, which could harm our business, including our ability to market our product candidates in the future.

 

19

 

 

We are subject to federal, state and foreign healthcare laws and regulations, and a finding of failure to comply with such laws and regulations could have a material and adverse effect on our business.

 

Our operations are, and will continue to be, directly and indirectly affected by various federal, state or foreign healthcare laws, including, but not limited to, those described below. These laws include:

 

  ● the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Violations of the federal Anti-kickback Statute may result in substantial civil or criminal penalties, including criminal fines of up to $25,000, imprisonment of up to five years, civil penalties under the Civil Monetary Penalties Law of up to $50,000 for each violation, plus three times the remuneration involved, civil penalties under the federal False Claims Act of up to $11,000 for each claim submitted, plus three times the amounts paid for such claims and exclusion from participation in the Medicare and Medicaid programs;
  ● the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other federal third-party payors that are false or fraudulent. Suits filed under the False Claims Act, known as “qui tam” actions, can be brought by any individual on behalf of the government and such individuals, commonly known as “whistleblowers,” may share in any amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the False Claims Act, the government may impose penalties of not less than $5,500 and not more than $11,000, plus three times the amount of the damages that the government sustains due to the submission of a false claim and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs;
  ● the federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
  ● HIPAA, as amended by the HITECH Act, and their respective implementing regulations, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information. Failure to comply with the HIPAA privacy and security standards can result in civil monetary penalties up to $50,000 per violation, not to exceed $1.5 million per calendar year for non-compliance of an identical provision, and, in certain circumstances, criminal penalties with fines up to $250,000 per violation and/or imprisonment. State attorneys general can bring a civil action to enjoin a HIPAA violation or to obtain statutory damages up to $25,000 per violation on behalf of residents of his or her state. HIPAA also imposes criminal penalties for fraud against any healthcare benefit program and for obtaining money or property from a healthcare benefit program through false pretenses and provides for broad prosecutorial subpoena authority and authorizes certain property forfeiture upon conviction of a federal healthcare offense. Significantly, the HIPAA provisions apply not only to federal programs, but also to private health benefit programs. HIPAA also broadened the authority of the U.S. Office of Inspector General of the U.S. Department of Health and Human Services to exclude participants from federal healthcare programs;
  ● the federal physician sunshine requirements under the Patient Protection and Affordable Care Act, or PPACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, which is defined broadly to include other healthcare providers and teaching hospitals and ownership and investment interests held by physicians and their immediate family members. Manufacturers are required to submit reports to CMS by the 90th day of each calendar year. Failure to submit the required information may result in civil monetary penalties up to an aggregate of $150,000 per year (and up to an aggregate of $1 million per year for “knowing failures”) for all payments, transfers of value or ownership or investment interests not reported in an annual submission, and may result in liability under other federal laws or regulations; and
  ● analogous state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third- party payor, including commercial insurers; state laws that require device companies to comply with the industry’s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Any failure by us to ensure that our employees and agents comply with applicable state and foreign laws and regulations could result in substantial penalties or restrictions on our ability to conduct business in those jurisdictions, and our results of operations and financial condition could be materially and adversely affected.

 

20

 

 

The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, it is possible that some of our business activities, including our relationships with surgeons and other healthcare providers, some of whom recommend, purchase and/or prescribe our product candidates, and our distributors, could be subject to challenge under one or more of such laws.

 

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

 

Regulatory healthcare reform measures and other legislative changes may have a material and adverse effect on business, results of operations and financial condition.

 

FDA regulations and guidance are often revised or reinterpreted by FDA and such actions may significantly affect our business and our product candidates. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times for our product candidates. Delays in receipt of, or failure to receive, regulatory approvals for our product candidates would have a material and adverse effect on our business, results of operations and financial condition.

 

In March 2010, the PPACA was signed into law, which includes a deductible 2.3% excise tax on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, that began on January 1, 2013. Although a two year moratorium was placed on the medical device excise tax in 2016 and extended through December 31, 2019, it was permanently repealed on December 20, 2019. Other elements of the PPACA, including comparative effectiveness research, an independent payment advisory board and payment system reforms, including shared savings pilots and other provisions, may significantly affect the payment for, and the availability of, healthcare services and result in fundamental changes to federal healthcare reimbursement programs, any of which may materially affect numerous aspects of our business, results of operations and financial condition.

 

In addition, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. On August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect on April 1, 2013, and will remain in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012, or the ATRA, was signed into law which further reduced Medicare payments to certain providers, including hospitals.

 

We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, and services or additional pricing pressures.

 

21

 

 

Our relationships with physician consultants, owners and investors could be subject to additional scrutiny from regulatory enforcement authorities and could subject us to possible administrative, civil or criminal sanctions.

 

Federal and state laws and regulations impose restrictions on our relationships with physicians who are consultants, owners and investors. We may enter into consulting agreements, license agreements and other agreements with physicians in which we provide cash as compensation. We have or may have other written and oral arrangements with physicians, including for research and development grants and for other purposes as well.

 

We could be adversely affected if regulatory agencies were to interpret our financial relationships with these physicians, who may be in a position to influence the ordering of and use of our product candidates for which governmental reimbursement may be available, as being in violation of applicable laws. If our relationships with physicians are found to be in violation of the laws and regulations that apply to us, we may be required to restructure the arrangements and could be subject to administrative, civil and criminal penalties, including exclusion from participation in government healthcare programs, imprisonment, and the curtailment or restructuring of our operations, any of which could negatively impact our ability to operate our business and our results of operations.

 

Our company and many of our collaborators and potential collaborators are required to comply with the Federal Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act and implementing regulation affecting the transmission, security and privacy of health information, and failure to comply could result in significant penalties.

 

Numerous federal and state laws and regulations, including the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Health Information Technology for Economic and Clinical Health Act, or the HITECH Act, govern the collection, dissemination, security, use and confidentiality of health information that identifies specific patients. HIPAA and the HITECH Act require our surgeon and hospital customers and potential customers to comply with certain standards for the use and disclosure of health information within their companies and with third parties. The Privacy Standards and Security Standards under HIPAA establish a set of standards for the protection of individually identifiable health information by health plans, health care clearinghouses and certain health care providers, referred to as Covered Entities, and the business associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable health information may be exchanged. Notably, whereas HIPAA previously directly regulated only these Covered Entities, the HITECH Act makes certain of HIPAA’s privacy and security standards also directly applicable to Covered Entities’ business associates. As a result, both Covered Entities and business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy Standards and Security Standards.

 

HIPAA requires Covered Entities (like many of our customers and potential customers) and business associates to develop and maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information and provides for civil monetary penalties for HIPAA violations. The HITECH Act also increased the civil and criminal penalties that may be imposed against Covered Entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA.

 

Any new legislation or regulation in the area of privacy and security of personal information, including personal health information, could also adversely affect our business operations. If we do not comply with existing or new applicable federal or state laws and regulations related to patient health information, we could be subject to criminal or civil sanctions and any resulting liability could adversely affect our financial condition.

 

In addition, countries around the world have passed or are considering legislation that would impose data breach notification requirements and/or require that companies adopt specific data security requirements. If we experience a data breach that triggers one or more of these laws, we may be subject to breach notification obligations, civil liability and litigation, all of which could also generate negative publicity and have a negative impact on our business.

 

22

 

 

We are currently, and in the future may be, subject to various governmental regulations related to the manufacturing of product candidates, and we may incur significant expenses to comply with, experience delays in our product commercialization as a result of, and be subject to material sanctions if we or our contract manufacturers violate these regulations.

 

Our manufacturing processes and facility are required to comply with the FDA’s QSR, which covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage, and shipping of product candidates. Although we believe we are compliant with the QSRs, the FDA enforces the QSR through periodic announced or unannounced inspections of manufacturing facilities. We have been, and anticipate in the future being, subject to such inspections, as well as to inspections by other federal and state regulatory agencies. We are required to register our manufacturing facility with the FDA and list all devices that are manufactured. We also operate an International Organization for Standards, or ISO, 13485 certified facility and annual audits are required to maintain that certification. The suppliers of our components are also required to comply with the QSR and are subject to inspections. We have limited ability to ensure that any such third-party manufacturers will take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. Failure to comply with applicable FDA requirements, or later discovery of previously unknown problems with our products or manufacturing processes, including our failure or the failure of one of our third-party manufacturers to take satisfactory corrective action in response to an adverse QSR inspection, can result in, among other things:

 

  ● administrative or judicially imposed sanctions;
  ● injunctions or the imposition of civil penalties;
  ● recall or seizure of our product candidates;
  ● total or partial suspension of production or distribution;
  ● the FDA’s refusal to grant future clearance or pre-market approval for our product candidates;
  ● withdrawal or suspension of marketing clearances or approvals;
  ● clinical holds;
  ● warning letters;
  ● refusal to permit the import or export of our product candidates; and
  ● criminal prosecution of us or our employees.

 

Any of these actions, in combination or alone, could prevent us from marketing, distributing, or selling our products and would likely harm our business. In addition, a product defect or regulatory violation could lead to a government-mandated or voluntary recall by us. Regulatory agencies in other countries have similar authority to recall devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert management attention and financial resources, could expose us to product liability or other claims, including contractual claims from parties to whom we sold products and harm our reputation with customers. A recall involving any of our product candidates would be particularly harmful to our business and financial results and, even if we remedied a particular problem, would have a lasting negative effect on our reputation and demand for our products.

 

23

 

 

Risks Related to Our Intellectual Property

 

If we are unable to adequately protect our proprietary technology or maintain issued patents that are sufficient to protect our product candidates, others could compete against us more directly, which could harm our business, financial condition and results of operations.

 

Our success may depend in part on our success in obtaining and maintaining issued patents and other intellectual property rights in the United States and elsewhere and protecting our proprietary technologies. If we do not adequately protect our intellectual property and proprietary technologies, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.

 

We have filed patent applications for our VenoValve product and Implantable Vein Frame Two product with the U.S. Patent and Trademark Office but there are no assurances that patents will be issued.

 

Our patents may not have, or our pending patent applications that mature into issued patents may not include, claims with a scope sufficient to protect our products, any additional features we develop for our current products or any new products. Other parties may have developed technologies that may be related or competitive to our products, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position. The patent positions of medical device companies, including our patent position, may involve complex legal and factual questions, and, therefore, the scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated or circumvented. Proceedings challenging our patents could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents that we may own may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to commercialize our implant systems.

 

Furthermore, though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or trade secrets by consultants, suppliers, vendors, former employees and current employees. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If any of these developments were to occur, they each could have a negative impact on our business and competitive position.

 

Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential competitor’s product. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.

 

In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our products are invalidated or found unenforceable, our financial position and results of operations could be negatively impacted. In addition, if a court found that valid, enforceable patents held by third parties covered one or more of our products, our financial position and results of operations could be harmed.

 

We rely upon unpatented trade secrets, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we will seek to protect, in part, by entering into confidentiality agreements with our employees and our collaborators and consultants. We also have agreements with our employees and selected consultants that obligate them to assign their inventions to us and have non-compete agreements with some, but not all, of our consultants. It is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise become known or be independently discovered by our competitors.

 

24

 

 

Obtaining and maintaining our patent protection depends on compliance with various procedures, document submission requirements, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

 

The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payments such as maintenance and annuity fee payments and other provisions during the patent procurement process as well as over the life span of an issued patent. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.

 

We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights to, or use, our technology.

 

Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. Our business, product candidates and methods could infringe the patents or other intellectual property rights of third parties.

 

The medical device industry is characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many medical device companies with substantially greater resources than us have employed intellectual property litigation as a way to gain a competitive advantage. We may become involved in litigation, interference proceedings, oppositions, reexamination, protest or other potentially adverse intellectual property proceedings as a result of alleged infringement by us of the rights of others or as a result of priority of invention disputes with third parties, either in the United States or internationally. We may also become a party to patent infringement claims and litigation or interference proceedings declared by the USPTO to determine the priority of inventions. Third parties may also challenge the validity of any of our issued patents and we may initiate proceedings to enforce our patent rights and prevent others from infringing on our intellectual property rights. Any claims relating to the infringement of third-party proprietary rights or proprietary determinations, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, diversion of our management’s attention and resources, or entrance into royalty or license agreements that are not advantageous to us. In any of these circumstances, we may need to spend significant amounts of money, time and effort defending our position. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.

 

Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material and adverse effect on us. If we are unable to avoid infringing the intellectual property rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of intellectual property in court or redesign our product candidates.

 

25

 

 

Risks Related to Ownership of Our Securities

 

The trading price of our securities is likely to be volatile and could be subject to wide fluctuations in response to a variety of factors.

 

The trading price of our securities is likely to be volatile and could be subject to wide fluctuations in response to a variety of factors, which include:

 

  ● whether we achieve our anticipated corporate objectives;
  ● actual or anticipated fluctuations in our financial condition and operating results;
  ● changes in financial or operational estimates or projections;
  ● the development status of our product candidates and when our product candidates receive regulatory approval if at all;
  ● our execution of our sales and marketing, manufacturing and other aspects of our business plan;
  ● performance of third parties on whom we rely to manufacture our product candidate components and product candidates, including their ability to comply with regulatory requirements;
  ● the results of our preclinical studies and clinical trials;
  ● results of operations that vary from those of our competitors and the expectations of securities analysts and investors;
  ● our announcement of significant contracts, acquisitions or capital commitments;
  ● announcements by our competitors of competing products or other initiatives;
  ● announcements by third parties of significant claims or proceedings against us;
  ● regulatory and reimbursement developments in the United States and internationally;
  ● future sales of our common stock;
  ● product liability claims;
  ● healthcare reform measures in the United States;
  ● additions or departures of key personnel; and
  ● general economic or political conditions in the United States or elsewhere.

 

In addition, the stock market in general, and the stock of medical device companies like ours in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the issuer. These market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

 

We have issued a significant number of options and warrants and may continue to do so in the future. The vesting and, if applicable, exercise of these securities and the sale of the shares of common stock issuable thereunder may dilute your percentage ownership interest and may also result in downward pressure on the price of our common stock.

 

As of the date of this Annual Report, we have issued and outstanding options to purchase 3,463,107 shares of our common stock with a weighted average exercise price of $9.14, 402,082 restricted stock units subject to vesting, and warrants to purchase 6,311,705 shares of our common stock with a weighted average exercise price of $8.81. Further, we have 619,087 shares available for issuance under our Amended and Restated 2016 Omnibus Incentive Plan. The number of shares subject to the Plan may be adjusted from time to time such that shares authorized under the plan shall at all times be equal to at least 20% of the issued and outstanding shares of the Company on a fully diluted basis. Because the market for our common stock is thinly traded, the sales and/or the perception that those sales may occur, could adversely affect the market price of our common stock. Furthermore, the mere existence of a significant number of shares of common stock issuable upon vesting and, if applicable, exercise of these securities may be perceived by the market as having a potential dilutive effect, which could lead to a decrease in the price of our common stock.

 

We will need to raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain and can be expected to dilute current stockholders’ ownership interests.

 

We will need to raise additional capital in the future. Such additional capital may not be available on reasonable terms or at all. Any future issuance of our equity or equity-backed securities may dilute then-current stockholders’ ownership percentages. If we are unable to obtain required additional capital, we may have to curtail our growth plans or cut back on existing business.

 

We may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such as convertible notes, restricted stock, stock options and warrants, which may adversely impact our financial condition.

 

26

 

 

Future sales or issuances of substantial amounts of our common stock could result in significant dilution.

 

Any future issuance of our equity or equity-backed securities, including, potentially, the issuance of securities in connection with a merger transaction, may dilute then-current stockholders’ ownership percentages and could also result in a decrease in the fair market value of our equity securities, because our assets would be owned by a larger pool of outstanding equity. As stated above, we intend to conduct additional rounds of financing in the future and we may need to raise additional capital through public or private offerings of our common stock or other securities that are convertible into or exercisable for our common stock. We may also issue securities in connection with hiring or retaining employees and consultants (including stock options issued under an equity incentive plan), as payment to providers of goods and services, in connection with future acquisitions or for other business purposes. Our Board of Directors may at any time authorize the issuance of additional common stock without stockholder approval, subject only to the total number of authorized shares of common stock set forth in our articles of incorporation. The terms of equity securities issued by us in future transactions may be more favorable to new investors, and may include dividend and/or liquidation preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect. Also, the future issuance of any such additional shares of common stock or other securities may create downward pressure on the trading price of the common stock. There can be no assurance that any such future issuances will not be at a price (or exercise prices) below the price at which shares of the common stock are then traded on Nasdaq or other then-applicable over-the-counter quotation system or exchange.

 

Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our Common Stock.

 

While we are currently in compliance with Nasdaq’s continued listing requirements, we have received deficiency notices in the past and there is no guarantee that we will be able to continue to meet the continued listing requirements of Nasdaq. In the event we are unable to do so, our securities may be delisted from The Nasdaq Stock Market. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair your ability to sell or purchase our Common Stock when you wish to do so. In the event of a delisting, we would expect to take actions to restore our compliance with Nasdaq Marketplace Rules, but our common stock may not be listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with the Nasdaq Marketplace Rules.

 

We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act. We may remain an emerging growth company until as late as December 2023 (the fiscal year-end following the fifth anniversary of the completion of our initial public offering), though we may cease to be an emerging growth company earlier under certain circumstances, including (1) if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30, in which case we would cease to be an emerging growth company as of the following December 31, or (2) if our gross revenue exceeds $1.07 billion in any fiscal year. Emerging growth companies may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

In addition, Section 102 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

27

 

 

Provisions of our charter documents or Delaware law could delay or prevent an acquisition of us, even if the acquisition would be beneficial to our stockholders, which could make it more difficult for you to change management.

 

Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. In addition, these provisions may frustrate or prevent any attempt by our stockholders to replace or remove our current management by making it more difficult to replace or remove our board of directors. These provisions include, but are not limited to:

 

  ● a classified board of directors so that not all directors are elected at one time;
  ● a prohibition on stockholder action through written consent;
  ● no cumulative voting in the election of directors;
  ● the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director;
  ● a requirement that special meetings of the stockholders may be called only by our chairman of the board, chief executive officer or president, or by a resolution adopted by a majority of our board of directors;
  ● an advance notice requirement for stockholder proposals and nominations;
  ● the authority of our board of directors to issue preferred stock with such terms as our board of directors may determine; and
  ● a requirement of approval of not less than 50% of all outstanding shares of our capital stock entitled to vote to amend any bylaws by stockholder action, or to amend specific provisions of our amended and restated certificate of incorporation.

 

In addition, the Delaware General Corporate Law, or DGCL, prohibits a publicly held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who, together with its affiliates, owns, or within the last three years has owned, 15% or more of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, the DGCL may discourage, delay, or prevent a change in control of our company.

 

Furthermore, our amended and restated certificate of incorporation specifies that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of the DGCL by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers.

 

We do not anticipate paying any cash dividends on our common stock in the foreseeable future and, as such, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

 

We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. In addition, and any future loan arrangements we enter into may contain, terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

 

28

 

 

ITEM 1B. Unresolved Staff Comments

 

None

 

ITEM 2. Properties and Facilities

 

We lease a 14,507 square foot manufacturing facility in Irvine, California. We amended our lease on November 17, 2021 to extend the term an additional 60 months from its September 30, 2022 expiration date to a new expiration date of September 30, 2027. Our facility is designed expressly for the manufacture of biologic vascular grafts and is equipped for research and development, prototype fabrication, cGMP manufacturing and shipping for Class III medical devices, including biologic cardiovascular devices. We believe that our facilities are sufficient for the near future as there is present capacity to manufacture up to approximately 24,000 venous valves per year to meet potential market demands.

 

ITEM 3. Legal Proceedings

 

From time to time, we may be subject to litigation and arbitration claims incidental to its business. Such claims may not be covered by our insurance coverage, and even if they are, if claims against us are successful, they may exceed the limits of applicable insurance coverage.

 

On July 9, 2020, the Company was served with a civil complaint filed in the Superior Court for the State of California, County of Orange by a former employee, Robert Rankin, who resigned his employment on or about March 30, 2020. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01146555-CU-WR-CJC and was filed on May 27, 2020. The complaint asserts several causes of action, including a cause of action for failure to timely pay Mr. Rankin’s accrued and unused vacation and three months’ severance under his July 16, 2018 employment agreement with the Company. Mr. Rankin alleges that he was forced to resign, however, we believe that he did not give the Company notice or an opportunity to cure the allegations. The complaint seeks, inter alia, back pay, unpaid wages, compensatory damages, punitive damages, attorneys’ fees, and costs. On September 3, 2020 the Company and its Chief Executive Officer were served with a second complaint filed in the Superior Court for the State of California, County of Orange by Mr. Rankin. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01157857 and was filed on August 31, 2020. The complaint asserts several causes of action, including defamation, unlawful labor code violations, sex-based discrimination, unfair competition, and seeks damages for lost wages, emotional and mental distress, consequential damages, punitive damages and attorney’s fees and costs. Mr. Rankin resigned as the Company’s Chief Financial Officer, Secretary and Treasurer on March 30, 2020. The Company has denied all claims in both matters (which have now been consolidated) and has filed a counterclaim asserting that Rankin has breached his employment agreement with the Company to the Company’s damage. The Company continues to believe it has meritorious defenses to both matters, which are set for trial June 27, 2022.

 

ITEM 4. Mine and Safety Disclosure

 

Not applicable.

 

29

 

 

PART II

 

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market Information

 

Our common stock trades on Nasdaq under the symbol “NVNO.” Our listed warrants trade on Nasdaq under the symbol “NVNOW.”

 

Holders of Record

 

On March 24, 2022, the closing price per share of our common stock and listed warrants were $5.00 and $0.19, respectively as reported on The Nasdaq Capital Market. We had approximately 76 stockholders of record and 1 listed warrant holder of record as of March 24, 2022. On March 24, 2022 there were 9,469,850 shares of our common stock issued and outstanding and 69,000 shares of common stock issuable upon exercise of listed warrants issued and outstanding. In addition, we believe that a significant number of beneficial owners of our common stock and listed warrants hold their shares in street name.

 

Securities Authorized for Issuance under Equity Compensation Plan

 

The following information is as of December 31, 2021.

 

Plan Category  Number of
securities to
be issued upon
exercise of
outstanding
options		   Weighted-average
exercise price of
outstanding
options		   Number of
granted restricted
stock unit awards
outstanding		   Number of
securities
remaining
available for
future
issuance
under equity
compensation
plans		 
Equity compensation plans approved by security holders   3,441,907   $           9.16    402,082    640,287 
Equity compensation plans not approved by security holders   -    -         - 
    3,441,907   $9.16    402,082    640,287 

 

Dividend Policy

 

We have never declared or paid any cash dividends on our capital stock. We do not anticipate paying cash dividends on our common stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects, the requirements of current or then-existing debt instruments and other factors our board of directors may deem relevant.

 

Recent Sales of Unregistered Securities

 

None

 

Repurchases of Equity Securities by Our Company

 

None.

 

ITEM 6. Selected Financial Data

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

30

 

 

ITEM 7.

 Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion should be read in conjunction with our consolidated financial statements and the related notes contained elsewhere in this Annual Report on Form 10-K and in our other Securities and Exchange Commission filings. The following discussion may contain predictions, estimates, and other forward-looking statements that involve a number of risks and uncertainties, including those discussed under “Risk Factors” and elsewhere in this Annual Report on Form 10-K. These risks could cause our actual results to differ materially from any future performance suggested below.

 

Overview

 

enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with deep venous Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Our products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in the deep venous system of the leg, and is called the VenoValve®. The VenoValve is currently being evaluated in our SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and have been commercially successful. We currently lease a 14,507 sq. ft. manufacturing facility in Irvine, California, where we manufacture medical devices for our clinical trials, and which has capacity for commercial manufacturing.

 

On September 21, 2021, we announced that we were changing our name from Hancock Jaffe to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of venous disease. In addition to the VenoValve, we announced that we have begun development of a second device for the treatment of venous disease which we are calling enVVe. In connection with this change in strategy, we indicated that we are not pursuing further development of the CoreoGraft, which is now outside of our primary focus area.

 

Results of Operations

 

Comparison of the year ended December 31, 2021 to the year ended December 31, 2020

 

Net Loss

 

We reported net losses of $16.5 million and $9.1 million for the years ended December 31, 2021 and 2020, respectively, representing an increase in net loss of $7.4 million or 81%, resulting from, as described in further detail below, an increase in operating expenses of $7.8 million, and an decrease in other expense (income) of $0.4 million.

 

Revenues

 

As a developmental stage company, our revenue, if any, is expected to be diminutive and dependent on our ability to commercialize our product candidates which is not expected in the near future.

 

Selling, General and Administrative Expenses

 

For the year ended December 31, 2021, selling, general and administrative expenses increased by $6.3 million or 129%, to $11.2 million from $4.9 million for the year ended December 31, 2020. Of this increase, $5.3 million was due to share based compensation from grants made during 2021, which increased share-based compensation cost to $6.0 million in 2021 from $0.7 million in 2020. The remaining $1.0 million increase reflects $0.3 million in higher compensation due to the elevation of our chief financial officer from interim, with the related costs included in consulting expenses, to full-time, with the related costs included in compensation, and directors’ cash compensation in 2021, an increase in insurance expense of $0.2 million primarily from the Company’s D&O insurance, $0.2 million from higher Delaware franchise taxes in 2021, $0.2 million from consulting for reimbursement codes for the Company’s product once commercially approved, $0.4 million from higher information technology and other office expense to support increases in staff, partially offset by a $0.3 million decrease in legal expenses which decreased because of the resolution of several matters in 2020.

 

31

 

 

Research and Development Expenses

 

For the year ended December 31, 2021, research and development expenses increased by $1.4 million or 35%, to $5.7 million from $4.3 million for the year ended December 31, 2020. The increase is primarily due to an increase of $1.1 million in compensation from the increases in staffing to support the SAVVE trial and continued product development, $0.5 million in higher lab costs and supplies, also to support the SAVVE trial and product development, an increase of $0.4 million for lab quality testing to prepare for regulatory audits and the SAVVE trial, partially offset by a $0.6 million decrease in trial related consulting as the Columbian first in human trial wrapped up in 2020 and the SAVVE trial was not launched until late in 2021. We expect our research and development costs will continue at these levels with more moderate increases as we move through the SAVVE trial.

 

Gain on Extinguishment of Note Payable

 

For the year ended December 31, 2021 the Company recorded a one-time $0.3 million gain on extinguishment of note payable due to the forgiveness of the loan it had obtained under the PPP program authorized by the CARES act.

 

Change in Fair Value of Derivative Liability

 

For the year ended December 21, 2020, we recorded a loss on the change in fair value of derivative liabilities of $0.1 million. Our derivative liabilities were related to warrants issued in connection with our Bridge Offering in February 2020. There were no similar instruments outstanding during the year ended December 31, 2021.

 

Other Expenses

 

Other expenses in 2020 primarily consisted of and $0.1 million in charges for warrants to purchase 6,400 shares of common stock issued to a consultant and for repricing of warrants issued to the placement agent in the Company’s February 2020 private placement, and a $0.1 million expense for warrants issued to certain participants in the exchange of preferred stock for common stock.

 

Liquidity and Capital Resources

 

For the twelve-months ended December 31, 2021, the Company incurred losses from operations of $16.9 million and used $11.8 million cash in operating activities. The net cash used in operating activities during 2021 increased by $4.1 from $7.7 million for the year ended December 31, 2020.

 

The losses and the uses of cash are primarily due to the Company’s administrative and product research and development activities. Administrative functions relate to costs to support the Company’s public reporting and investor relations activities as well as internal administrative functions. Research and development activities are for continued product development and clinical trials for the VenoValve. The Company will continue to incur these costs to complete its clinical trials, enhance products, develop new products, and operate as a public company. Although we have discretion in how we use the Company’s cash resources, we expect to continue these activities for the foreseeable future as we seek to obtain regulatory approval for our lead product candidate. We are not currently generating revenue.

 

Our cash flows from investing activity have historically consisted of purchases of property and equipment for our lab and offices. In the year ended December 31, 2021 we purchased $0.4 million of property and equipment consisting of $0.2 million for lab and test equipment, and $0.2 million for other computer equipment and software. In the year ended December 31, 2020 we purchased $0.2 million of property and equipment consisting of $0.1 million for lab and test equipment and $0.1 million for other computer equipment and software. We do not currently have material commitments for capital expenditures or other expenditures with the exception of our facility lease commitment of $0.4 million per year. However, we expect a modest increase in cash used in investment activities as we continue SAVVE and plan for commercialization of the VenoValve.

 

The Company has historically funded its operations through financing activities such as the capital raises completed in 2020 and 2021. During 2021, the Company raised an aggregate of $57.4 million in net proceeds in private and public placements of its securities. During 2020, the Company raised an aggregate of $14.7 million in net proceeds in private and public placements of its common stock and of its preferred stock. Our cash balance as of December 31, 2021, is $54.7 million.

 

Our future capital requirements will remain dependent upon a variety of factors, especially including the success of our clinical trials and related product development costs and our ability to successfully bring products to market. At our existing cash burn rate of approximately $4 million per quarter, we should have sufficient cash to fund operations through the end of 2024 and into 2025. With primary endpoints following full enrollment in the SAVVE pivotal trial of thirty (30) days for safety, and six (6) months for effectiveness, we expect to have primary endpoint data well in advance of the need to raise additional capital. Any inability to raise additional financing would have a material adverse effect on us.

 

Based upon our cash and working capital as of December 31, 2021, we have sufficient capital resources to meet our obligations as they become due within one year after the date of this Annual Report and sustain operations.

 

32

 

 

Off-Balance Sheet Arrangements

 

None.

 

Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide the information requested by paragraph (a)(5) of this Item.

 

Critical Accounting Policies and Estimates

 

Basis of Presentation

 

The accompanying audited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.

 

Stock-Based Compensation

 

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and recognized over the period services are required to be provided in exchange for the award, usually the vesting period. Forfeitures of unvested stock options are recorded when they occur.

 

Concentrations

 

The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $54.5 million and $9.1 million as of December 31, 2021 and 2020, respectively.

 

ITEM 7A. Quantitative and Qualitative Disclosure About Market Risk

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

 

ITEM 8. Financial Statements and Supplementary Data

 

Please see the financial statements beginning on page F-1 following the signature pages in this Annual Report on Form 10-K and incorporated herein by reference.

 

33

 

 

ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not Applicable.

 

ITEM 9A. Controls and Procedures

 

Evaluation of Controls and Procedures

 

Our management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer (who is our Principal Executive Officer) and our Chief Financial Officer (who is our Principal Financial Officer and Principal Accounting Officer), of the effectiveness of the design of our disclosure controls and procedures (as defined by Exchange Act Rules 13a-15(e) or 15d-15(e)) as of December 31, 2021, pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2021 to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission’s rules and forms.

 

Inherent Limitations on Effectiveness of Controls

 

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

 

Management’s Report on Internal Control Over Financial Reporting

 

There were changes in our internal control over financial reporting identified in connection with the evaluation required by Exchange Act Rule 13a-15(d) during the quarter ended December 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. The change was to remediate and eliminate our previously disclosed material weakness over reporting of complex financial transactions. Management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. Controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles.

 

Under the supervision and with the participation of our management, including the principal executive officer and principal financial officer, we conducted an evaluation as to the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, our management used the criteria for effective internal control set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 2013 Internal Control – Integrated Framework. Based on this assessment, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.

 

This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to a permanent exemption of the Commission that permits the Company to provide only management’s report in this Annual Report on Form 10-K. Accordingly, our management’s assessment of the effectiveness of our internal control over financial reporting as of December 31, 2021 has not been audited by our auditors, Marcum LLP.

 

Item 9B. Other Information

 

Not Applicable. 

 

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 

Not Applicable.

 

34

 

 

PART III

 

ITEM 10. Directors, Executive Officers and Corporate Governance

 

Listed below are the names of the directors and executive officers of the Company, their ages as of the date of this Annual Report, their positions held and the year they commenced service with the Company.

 

Name   Age   Position(s) Held   Year of Service Commencement
Robert A. Berman   59   Director, Chief Executive Officer   2018
Craig Glynn   60   Chief Financial Officer and Treasurer   2020
Dr. Francis Duhay   61   Director   2018
Dr. Sanjay Shrivastava   54   Director   2018
Matthew M. Jenusaitis   60   Director   2019
Robert C. Gray   75   Director   2019
Marc H. Glickman, M.D.   73   Senior Vice President and Chief Medical Officer   2016

 

Robert A. Berman Robert Berman has served as our Chief Executive Officer and a member of our Board of Directors since April of 2018. Mr. Berman has over 25 years of experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies. From September 2012 until July 2017, he served as the President, Chief Executive Officer, and a member of the Board of Directors of ITUS Corporation (now called Anixa Biosciences), which at the time he joined the company was a developer of flat panel display technologies, and under his leadership became a Nasdaq listed cancer therapeutics company. From 2000 to March 2007, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation, where he successfully transitioned the company from being an incubator of internet startups into a preeminent, publicly traded company for licensing and enforcing patented technologies with a market cap exceeding $2 billion. Mr. Berman started his career at the law firm of Blank Rome. Mr. Berman has a B.S. in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and holds a J.D. from the Northwestern University School of Law, where he is an adjunct faculty member. We believe that Mr. Berman is qualified to serve as a member of our board of directors because of his experience in a broad variety of areas including healthcare, finance, acquisitions, marketing, compliance, turnarounds, and the development and licensing of emerging technologies.

 

Dr. Francis Duhay has served as member of our board of directors since October 2018. A trained cardiac and thoracic surgeon, Dr. Duhay has served the President and Chief Operating officer of Aegis Surgical Inc. and Atrius Inc., makers of cardiac accessory devices, since 2016, and as a Partner in K5_Ventures, an early stage venture fund since 2017. Dr. Duhay is the former Chief Medical Officer at Edwards Life Sciences, a world leader in heart valve products, where he led medical and clinical affairs for transcatheter and surgical heart valves. During his tenure at Edwards Life Sciences, from 2008 to 2016, Dr. Duhay led the preparation and submission, and ultimate regulatory approval, of two FDA Premarket Approval (PMA) applications for transcatheter and surgical heart valve therapies and was responsible for the design and execution of the applicable clinical trials. From April 2008 to October 2011, Dr. Duhay was also the Vice President and General Manager of the Ascendra™ transcatheter heart valve business unit at Edwards, where he grew the unit from sixteen to eighty employees and contributed to annual growth in sales from $3 million to $250 million. From 1998 to 2003, Dr. Duhay served as the Chief of the Department of Cardiothoracic Surgery and Cardiology at Kaiser Permanente. Dr. Duhay has also served as an industry representative and clinical expert, and a member of the working group for ISO 5840, the international quality standard for the design, development, and testing of heart valves. Dr. Duhay received his MBA from the University of Hawaii - Shidler College of Business and received his board certification for Cardiothoracic Surgery and General Surgery from the Duke University School of Medicine and from the University of California, San Francisco, respectively. We believe that Dr. Duhay is qualified to serve as a member of our board of directors because he is a trained cardiac and thoracic surgeon and former Chief Medical Officer at Edwards Life Sciences.

 

35

 

 

Dr. Sanjay Shrivastava has served as a member of our board of directors since October 2018. He has been involved in developing, commercializing, evaluating, and acquiring medical devices for more than 21 years, including serving in leadership positions in research and development, business development, and marketing at J&J, BTG, plc, Medtronic, Abbott Vascular, and Edwards Life Sciences. He is presently serving as the chief executive officer at Innova Vascular, Inc., a medical device company funded largely via an investment from a publicly traded medical device company. Prior to this, he co-founded BlackSwan Vascular, Inc., which is a clinical stage medical device company and where he serves on the board of directors. He led the strategic alliance for BlackSwan with Sirtex Medical, which was announced in 2020. Dr. Shrivastava worked on several acquisition and investment deals during his roles as a senior director, business development at J&J and a vice president, upstream marketing and strategy at BTG, a medical device and specialty pharmaceutical company with annual revenue of about $800 million. At Medtronic, Dr. Shrivastava was the Director of Global Marketing for the Cardiac and Vascular Group where he helped build the embolization business, from its initiation to a substantial revenue with a very high CAGR over a period of six years. Dr. Shrivastava was a Manager of Research and Development for the peripheral vascular business at Abbott Vascular and a Principal Research and Development Engineer for Trans-Catheter heart valves at Edwards Life Sciences. Dr. Shrivastava received his Bachelor of Science in engineering at the Indian Institute of Technology and a doctorate degree in materials science and engineering from the University of Florida. We believe that Dr. Shrivastava is qualified to serve as a member of our board of directors because of having served in Chief Executive Officer and board of director positions at several medical device start-ups, and leadership positions in research and development, business development, and marketing at Innova Vascular, Inc., BTG, Medtronic, Abbott Vascular, and Edwards Life Sciences.

 

Matthew M. Jenusaitis has served as a member of our board of directors since September 2019. He has over 30 years of health care experience with an emphasis on building and selling companies that develop medical devices to treat vascular diseases. Since March 2015, Mr. Jenusaitis has been a senior administrative executive at the UC San Diego Health System. He currently serves as the Chief Administrative Officer for UCSD’s Moore’s Cancer Center and UCSD Oncology. From June 2009 to March 2015, Mr. Jenusaitis was President and CEO of OCTANe Foundation for Innovation, a non-profit focused on the development of innovation in Orange County, CA. Over the course of his career, Mr. Jenusaitis has been on the board of directors of Pulsar Vascular (2008-2017), which was sold to Johnson and Johnson, Creagh Medical (2008-2015), which was sold to SurModics, and Precision Wire Components (2009-2014), which was sold to Creganna Medical. Mr. Jenusaitis was also a Senior Vice President at ev3 (April 2006 to July 2008), which was sold to Covidian and later purchased by Medtronics. In addition, Mr. Jenusaitis was the President of the Peripheral Division at Boston Scientific (July 2003 to August 2005) and was an Executive in Residence at Warburg Pincus (September 2005 to March 2006). Mr. Jenusaitis has an MBA from the University of California, Irvine, a Masters Degree in Biomedical Engineering from Arizona State University, and a Bachelors Degree in Chemical Engineering from Cornell University. We believe that Mr. Jenusaitis is qualified to serve as a member of our board of directors because of over 30 years of health care experience with an emphasis on building and selling companies that develop medical devices to treat vascular diseases and his prior board experiences.

 

Robert C. Gray has served as a member of our board of directors since September 2019. He had a 20-year career at Highmark, Inc., one of America’s largest health insurance organizations, which serves over 20 million subscribers, and includes Highmark Blue Cross Blue Shield Pennsylvania, Highmark Blue Cross Blue Shield Delaware, and Highmark Blue Cross Blue Shield West Virginia, which he retired from in 2008. While at Highmark, Mr. Gray helped increase revenues to $12.3 billion from $6.9 billion, and helped generate an operating gain of $375 million from an operating loss of $91 million. In addition to being the board chairman, Chief Executive Officer, and President of several of Highmark’s subsidiaries and affiliated companies, Mr. Gray was the Chief Financial Officer of Highmark’s parent company and was the primary contact to Highmark’s board of directors for Highmark’s audit, investment and compensation (incentive plans) committees. His many responsibilities at Highmark included rate setting and reimbursement negotiations. Following Highmark, Mr. Gray co-founded U.S. Holdings LLC (U.S. Implants LLC.), a national distributor of orthopedic implants, and has served as Vice President since 2009. Since 2011, Mr. Gray has also been self-employed as a strategy and financial consultant. Mr. Gray engaged in Postgraduate Studies at the University of North Carolina–Chapel Hill and has an undergraduate degree from Bucknell University. We believe that Mr. Gray is qualified to serve as a member of our board of directors because of his financial and medical reimbursement expertise having served as the Chief Financial Officer at Highmark, Inc., one of America’s largest health insurance organization.

 

Marc H. Glickman, M.D. has served as our Senior Vice President and Chief Medical Officer since May 2016 and served as member of our board of directors from July 2016 to August 2017. In 1981, Dr. Glickman started a vascular practice in Norfolk, Virginia. He established the first Vein Center in Virginia and also created a dialysis access center. He was employed by Sentara Health Care as director of Vascular Services until he retired in 2014. Dr. Glickman is a board certified vascular surgeon. Dr. Glickman received his Doctor of Medicine from Case Western Reserve, in Cleveland, Ohio and completed his residency at the University of Washington, Seattle. He is board certified in Vascular Surgery and was the past president of the Vascular Society of the Americas. He has served on the advisory boards of Possis Medical, Cohesion Technologies, Thoratec, GraftCath, Inc., TVA medical, Austin, Texas.

 

Craig Glynn was hired as our interim Chief Financial Officer in April 2020 and has subsequently been elevated to our fulltime Chief Financial Officer effective January 2021. Mr. Glynn has more than thirty-five years of experience providing financial services to a variety of public and private companies, including in the role as Chief Financial Officer. In 2012, Mr. Glynn founded Edward Thomas Associates, a firm that provides public and private companies with accounting and finance services, including chief financial officer services. Mr. Glynn has been a Managing Director of Edward Thomas Associates since 2012. Mr. Glynn has a proven record of success managing the financial aspects of dynamic organizations either as a member of the management team or in a consulting capacity. He started his career as an auditor with Deloitte and went on to be the CFO and Controller of several technology, manufacturing, and distribution companies. Mr. Glynn earned his BS and MS degrees in Accounting from California State University Northridge. He is a member of the American Institute of CPAs.

 

36

 

 

Family Relationships

 

There are no arrangements between our directors and any other person pursuant to which our directors were nominated or elected for their positions. There are no family relationships between any of our directors or executive officers.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Exchange Act requires our directors, executive officers and ten percent stockholders to file initial reports of ownership and reports of changes in ownership of our common stock with the Commission. Directors, executive officers and ten percent stockholders are also required to furnish us with copies of all Section 16(a) forms that they file. Based upon a review of these filings, we believe that all required Section 16(a) reports were made on a timely basis during fiscal year 2021.

 

Board Composition

 

Our business and affairs are organized under the direction of our board of directors, which currently consists of five members. Our directors hold office until the earlier of their death, incapacity, removal or resignation, or until their successors have been elected and qualified. Our board of directors does not have a formal policy on whether the roles of a Chief Executive Officer and Chairman of our board of directors should be separate. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis. Our bylaws provide that the authorized number of directors may be changed only by resolution of the board of directors.

 

We have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the competitive landscape.

 

Our amended and restated certificate of incorporation divides our board of directors into three classes, with staggered three-year terms, as follows:

 

Class I Directors (serving until the 2024 Annual Meeting of Stockholders, or until their earlier death, disability, resignation or removal):

 

Dr. Francis Duhay* and Dr. Sanjay Shrivastava*

 

Class II Directors (serving until the 2022 Annual Meeting of Stockholders, or until their earlier death, disability, resignation or removal):

 

Matthew M. Jenusaitis*, Robert A. Berman

 

Class III Director (serving until the 2023 Annual Meeting of Stockholders, or until his earlier death, disability, resignation or removal):

 

Robert C. Gray*

 

(*) Independent Director.

 

At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms then expire will serve until the third annual meeting following their election and until their successors are duly elected and qualified. The authorized size of our board of directors is currently five members. The authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed between the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This classification of the board of directors may have the effect of delaying or preventing changes in our control or management. Our directors may be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock.

 

37

 

 

Director Independence

 

The Nasdaq Marketplace Rules require a majority of a listed company’s board of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq Marketplace Rules require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act.

 

Under Rule 5605(a)(2) of the Nasdaq Marketplace Rules, a director will only qualify as an “independent director” if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3 of the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries.

 

Our board of directors has reviewed the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his background, employment and affiliations, including family relationships, our board of directors has determined that each of Dr. Duhay, Mr. Gray, Mr. Jenusaitis and Dr. Shrivastava is an “independent director” as defined under Rule 5605(a)(2) of the Nasdaq Marketplace Rules. Our board of directors also determined that Mr. Gray, Mr. Jenusaitis and Dr. Shrivastava will serve on our audit committee, Mr. Gray and Mr. Jenusaitis and Dr. Shrivastava will serve on our compensation committee, and Dr. Duhay, Mr. Jenusaitis and Dr. Shrivastava will serve on our nominating and corporate governance committee, and that each of the committees satisfy the independence standards for such committees established by the SEC and the Nasdaq Marketplace Rules, as applicable. In making such determinations, our board of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director.

 

Meetings of the Board and Stockholders

 

Our board of directors met in person and telephonically seven times during 2021 and also acted by unanimous written consent. There were four Audit Committee meetings, two Compensation meetings and one Nominating and Corporate Governance meeting held in 2021. Our board of directors had 100% attendance for the Annual Meeting that was held on November 30, 2021. It is our policy that all directors must attend all stockholder meetings, barring extenuating circumstances.

 

38

 

 

Board Committees

 

Our board of directors has established three standing committees—audit, compensation, and nominating and corporate governance—each of which operates under a charter that has been approved by our board of directors. Copies of each committee’s charter are posted on the Investors section of our website, which is located at www.envvenojaffe.com. Each committee has the composition and responsibilities described below. Our board of directors may from time to time establish other committees.

 

Audit Committee

 

Our audit committee consists of Mr. Gray, who is the chair of the audit committee, Mr. Jenusaitis and Dr. Shrivastava. Our board of directors has determined that each of the members of our audit committee satisfies the Nasdaq Marketplace Rules and SEC independence requirements. The functions of this committee include, among other things:

 

  ● evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;
  ● reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;
  ● reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and discussing the statements and reports with our independent auditors and management;
  ● reviewing with our independent auditors and management significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;
  ● reviewing our major financial risk exposures, including the guidelines and policies to govern the process by which risk assessment and risk management is implemented; and
  ● reviewing and evaluating on an annual basis the performance of the audit committee, including compliance of the audit committee with its charter.

 

Our board of directors has determined that Mr. Gray qualifies as an “audit committee financial expert” within the meaning of applicable SEC regulations and meets the financial sophistication requirements of the Nasdaq Marketplace Rules. Both our independent registered public accounting firm and management periodically meet privately with our audit committee.

 

39

 

 

Compensation Committee

 

Our compensation committee consists of Dr. Shrivastava, who is the chair of the committee, Mr. Gray and Mr. Jenusaitis. Our board of directors has determined that each of the members of our compensation committee is an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code of 1986, as amended, or the Code, and satisfies the Nasdaq Marketplace Rules independence requirements. The functions of this committee include, among other things:

 

  ● reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) our overall compensation strategy and policies;
  ● reviewing and approving the compensation, the performance goals and objectives relevant to the compensation, and other terms of employment of our Chief Executive Officers and our other executive officers;
  ● reviewing and approving (or if it deems appropriate, making recommendations to the full board of directors regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;
  ● reviewing and approving the terms of any employment agreements, severance arrangements, change in control protections and any other compensatory arrangements for our executive officers;
  ● reviewing with management and approving our disclosures under the caption “Compensation Discussion and Analysis” in our periodic reports or proxy statements to be filed with the SEC; and
  ● preparing the report that the SEC requires in our annual proxy statement.

 

Nominating and Corporate Governance Committee

 

Our nominating and corporate governance committee consists of Dr. Duhay, who is the chair of the committee, Mr. Jenusaitis and Dr. Shrivastava. Our board of directors has determined that each of the members of this committee satisfies the Nasdaq Marketplace Rules independence requirements. The functions of this committee include, among other things:

 

  ● identifying, reviewing and evaluating candidates to serve on our board of directors consistent with criteria approved by our board of directors;
  ● evaluating director performance on our board of directors and applicable committees of our board of directors and determining whether continued service on our board of directors is appropriate;
  ● evaluating, nominating and recommending individuals for membership on our board of directors; and
  ● evaluating nominations by stockholders of candidates for election to our board of directors.

 

40

 

 

Code of Conduct

 

Our board of directors has adopted a written code of conduct that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted on our website a current copy of the code and all disclosures that are required by law or Nasdaq Marketplace Rules concerning any amendments to, or waivers from, any provision of the code.

 

Board Leadership Structure

 

Our board of directors is free to select the Chairman of the board of directors and a Chief Executive Officer in a manner that it considers to be in the best interests of our company at the time of selection. Currently, Robert A. Berman serves as our Chief Executive Officer. The office of the Chairman of the board of directors has been vacant since May 2019. We currently believe that this leadership structure is in our best interests and strikes an appropriate balance between our Chief Executive Officer’s responsibility for the day-to-day management of our company and the Chairman of the board of directors’ responsibility to provide oversight, including setting the board of directors’ meeting agendas and presiding at executive sessions of the independent directors. Additionally, four of our five members of our board of directors have been deemed to be “independent” by the board of directors, which we believe provides sufficient independent oversight of our management. Our board of directors has not designated a lead independent director.

 

Our board of directors, as a whole and also at the committee level, plays an active role overseeing the overall management of our risks. Our Audit Committee reviews risks related to financial and operational items with our management and our independent registered public accounting firm. Our board of directors is in regular contact with our Chief Executive Officer, who reports directly to our board of directors and who supervises day-to-day risk management.

 

Role of Board in Risk Oversight Process

 

Our board of directors believes that risk management is an important part of establishing, updating and executing on our business strategy. Our board of directors has oversight responsibility relating to risks that could affect the corporate strategy, business objectives, compliance, operations, and the financial condition and performance of our company. Our board of directors focuses its oversight on the most significant risks facing us and on our processes to identify, prioritize, assess, manage and mitigate those risks. Our board of directors receives regular reports from members of our senior management on areas of material risk to us, including strategic, operational, financial, legal and regulatory risks. While our board of directors has an oversight role, management is principally tasked with direct responsibility for management and assessment of risks and the implementation of processes and controls to mitigate their effects on us.

 

Certain Legal Proceedings

 

None of the Company’s directors or executive officers have been involved, in the past ten years and in a manner material to an evaluation of such director’s or officer’s ability or integrity to serve as a director or executive officer, in any of those “Certain Legal Proceedings” more fully detailed in Item 401(f) of Regulation S-K, which include but are not limited to, bankruptcies, criminal convictions and an adjudication finding that an individual violated federal or state securities laws.

 

41

 

 

ITEM 11. Executive Compensation

 

The following table sets forth total compensation paid to our named executive officers for the years ended December 31, 2021 and 2020. Individuals we refer to as our “named executive officers” include our current Chief Executive Officer, our current and previous Chief Financial Officer and our other most highly compensated executive officer whose salary and bonus for services rendered in all capacities exceeded $100,000 during the fiscal year ended December 31, 2021.

 

Name and
Principal Position		  Year   Salary ($)   Bonus ($)   Option Awards ($)   Other Equity Incentive Plan Compensation ($)   Nonqualified
Deferred Compensation Earnings ($)		   All Other Compensation ($)   Total
($)		 
Robert A. Berman   2021    400,000    250,000    7,674,046(3)   1,340,000 (9)        15,655(12)   9,679,701 
Chief Executive Officer   2020    400,000    200,000    478,171(4)             15,808(13)   1,093,979 
Craig Glynn   2021    225,000    25,000    2,960,418(5)   335,000(10)        651(14)   3,546,069 
Chief Financial Officer   2020    143,000(1)        32,020(6)             -    175,020 
Marc H. Glickman, M.D.   2021    350,000    50,000    4,247,442(7)   670,000 (11)        56,948(15)   5,374,390 
Chief Medical Officer and Senior Vice President   2020    350,000(2)   50,000    321,928(8)   -    -    53,976(16)   775,904 

 

(1) Mr. Glynn served as our Chief Financial Officer on an interim basis during 2020. Amounts in this column for Mr. Glynn include the amounts paid to him in that capacity during 2020. In January 2021, the board of directors elevated Mr. Glynn to permanent Chief Financial Officer. The company entered into an employment agreement with Mr. Glynn in February 2021.
   
(2) Beginning July 26, 2019, Dr. Glickman’s annual base salary rate under his employment agreement dated July 26, 2019, which superseded his prior employment agreement, was $350,000. Amounts in this column for Dr. Glickman reflect his base salary earned for 2019.
   
(3) Represents the grant date fair value of 838,000 stock options granted on February 18, 2021, and 349,781 stock options granted on November 30, 2021, computed in accordance with FASB ASC Topic 718. The February options vest quarterly over a two-year period and the November options vest quarterly over a three-year period.
   
(4) Represents the grant date fair value of 40,000 stock options granted on July 18, 2020, computed in accordance with FASB ASC Topic 718. The options vest monthly over a three-year period. Also included is the fair value of his existing 43,209 options that were repriced from $124.75 per share to $10.00 per share.
   
(5) Represents the grant date fair value of 324,000 stock options granted on February 18, 2021 and 125,925 stock options granted on November 30, 2021, computed in accordance with FASB ASC Topic 718. The options vest quarterly over a three-year period.
   
(6) Represents the grant date fair value of 4,000 stock options granted on July 18, 2020, computed in accordance with FASB ASC Topic 718. The options vest quarterly over a three-year period.
   
(7) Represents the grant date fair value of 406,000 stock options granted on February 18, 2021 and 265,700 stock options granted on November 30, 2021, computed in accordance with FASB ASC Topic 718. The February options vest quarterly over a two-year period and the November options vest quarterly over a three-year period.

 

42

 

 

(8) Represents the grant date fair value of 40,000 stock options granted on July 18, 2020, computed in accordance with FASB ASC Topic 718. The options vest monthly over a three-year period.
   
(9) Represents the grant date fair value of 200,000 shares of restricted stock units granted on November 30, 2021, computed based on the closing price of the Company’s stock on the grant date.
   
(10) Represents the grant date fair value of 50,000 shares of restricted stock units granted on November 30, 2021, computed based on the closing price of the Company’s stock on the grant date.
   
(11) Represents the grant date fair value of 100,000 shares of restricted stock units granted on November 30, 2021, computed based on the closing price of the Company’s stock on the grant date.
   
(12) Includes company paid healthcare of $1,155 and 401(k) match of $14,500.
   
(13) Includes company paid healthcare of $1,404 and 401(k) match of $14,404.
   
(14) Includes company paid healthcare of $651.
   
(15) Includes company paid healthcare of $42,447 and 401(k) match of $14,500.
   
(16) Includes company paid healthcare of $39,691 and 401(k) match of $14,285.

 

43

 

 

Employment Agreements

 

We have entered into various employment agreements with certain of our executive officers. Set forth below is a summary of many of the material provisions of such agreements, which summaries do not purport to contain all of the material terms and conditions of each such agreement. For purposes of the following employment agreements:

 

  ● “Cause” generally means the executive’s (i) willful misconduct or gross negligence in the performance of his or her duties to us; (ii) willful failure to perform his or her duties to us or to follow the lawful directives of the Chief Executive Officer (other than as a result of death or disability); (iii) indictment for, conviction of or pleading of guilty or nolo contendere to, a felony or any crime involving moral turpitude: (iv) repeated failure to cooperate in any audit or investigation of our business or financial practices; (v) performance of any material act of theft, embezzlement, fraud, malfeasance, dishonesty or misappropriation of our property; or (vi) material breach of his or her employment agreement or any other material agreement with us or a material violation of our code of conduct or other written policy.
  ● “Good reason” generally means, subject to certain notice requirements and cure rights, without the executive’s consent, (i) material diminution in his or her base salary or annual bonus opportunity; (ii) material diminution in his or her authority or duties (although a change in title will not constitute “good reason”), other than temporarily while physically or mentally incapacitated, as required by applicable law; (iii) relocation of his or her primary work location by more than 25 miles from its then current location; or (iv) a material breach by us of a material term of the employment agreement.
  ● “Change of control” generally means (i) the acquisition, other than from us, by any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Exchange Act), other than us or any subsidiary, affiliate (within the meaning of Rule 144 promulgated under the Securities Act) or employee benefit plan of ours, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 50% of the combined voting power of our then outstanding voting securities entitled to vote generally in the election of directors; (ii) a reorganization, merger, consolidation or recapitalization of us, other than a transaction in which more than 50% of the combined voting power of the outstanding voting securities of the surviving or resulting entity immediately following such transaction is held by the persons who, immediately prior to the transaction, were the holders of our voting securities; or (iii) a complete liquidation or dissolution of us, or a sale of all or substantially all of our assets.

 

Robert A. Berman

 

On March 30, 2018, we entered into an employment agreement with Robert A. Berman, our current Chief Executive Officer and director. Pursuant to the terms of his employment agreement, Mr. Berman’s base salary is $400,000, subject to annual review and adjustment at the discretion of our compensation committee, and he will be eligible for an annual year-end discretionary bonus of up to 50% of his base salary, subject to the achievement of key performance indicators, as determined by our compensation committee. The initial term of Mr. Berman’s employment agreement may be terminated at anytime with or without cause and with or without notice or for good reason thereunder. In connection with his employment, Mr. Berman received an initial equity grant of an option to purchase 43,209 options with 8,642 vesting on the date of his Employment Agreement, March 30, 2018, and the remaining 80% vesting ratably on a monthly basis over the following 24 months. In February 2021, the board of directors approved an option grant to Mr. Berman to purchase 838,000 shares of common stock at an exercise price of $8.20 per shares (the closing price of the Company’s common stock on February 18, 2021). The stock option vests in equal quarterly installments over a two year period. Additionally, the board of directors paid Mr. Berman a cash bonus of $250,000 for 2021 and $200,000 for 2020.

 

Mr. Berman is entitled to participate in our employee benefit, pension and/or profit sharing plans, and we will pay certain health and dental premiums on his behalf. Mr. Berman’s employment agreement prohibits him from inducing, soliciting or entertaining any of our employees to leave our employ during the term of the agreement and for 12 months thereafter.

 

Pursuant to the terms of his employment agreement, Mr. Berman is entitled to severance in the event of certain terminations of employment. In the event Mr. Berman’s employment is terminated by us without cause and other than by reason of disability or he resigns for good reason, subject to his timely executing a release of claims in our favor and in addition to certain other accrued benefits, he is entitled to receive 6 month of base salary if termination occurred prior to the second anniversary of his employment or 12 months of continued base salary on and after the second anniversary of his employment (or 24 months if such termination occurs within 24 months following a change of control).

 

44

 

 

Craig Glynn

 

On February 19, 2021, the Company entered into an employment agreement with Mr. Glynn, in connection with Mr. Glynn’s elevation to full time Chief Financial Officer in addition to treasurer and secretary of the Company. Pursuant to the employment agreement, Mr. Glynn will earn $225,000 per year. In addition, Mr. Glynn will receive stock options to purchase 324,000 shares of common stock of the Company at an exercise price of $8.20 per shares (the closing price of the Company’s common stock on February 18, 2021). The stock options vest in equal quarterly installments over a three year period with a six month cliff. The employment agreement further provides that Mr. Glynn is entitled to participate in any employee benefit plans that the Company has adopted or may adopt.

 

Pursuant to the terms of the employment agreement, Mr. Glynn’s employment agreement is terminable due to Mr. Glynn’s disability or death, for “Cause” (as defined in the employment agreement) or without “Cause” by the Company, and for “Good Reason” (as defined in the employment agreement) or voluntarily by Mr. Glynn. In the event of Mr. Glynn’s death or disability, or termination for “Cause” by the Company or without “Good Reason” by Mr. Glynn, Mr. Glynn (or his estate) is entitled to receive any unpaid base salary through the termination date, reimbursement for unreimbursed business expenses, accrued but unused vacation time in accordance with the Company’s policy and any other payments or benefits that Mr. Glynn as entitled to in accordance with any Company benefit plans (collectively, the “Accrued Benefits”). Upon termination without “Cause” (other than by reason of death or disability) or resignation for “Good Reason,” Mr. Glynn will be entitled to three months of severance for each year Mr. Glynn is employed up to one year of severance, in addition to all Accrued Benefits. Any outstanding unvested securities owned by Mr. Glynn on the termination date will vest (or terminate) in accordance with the terms of such grant.

 

Prior to his full time role as Chief Financial Officer, on April 6, 2020 he was appointed as Interim Chief Financial Officer and Interim Treasurer. For his services as Interim Chief Financial Officer and Interim Treasurer, Mr. Glynn was paid $10,000 per month of employment.

 

45

 

 

Marc H. Glickman, M.D.

 

On July 22, 2016, we entered into an employment agreement with Marc H. Glickman, M.D., our Senior Vice President and Chief Medical Officer (the “Pre-existing Employment Agreement”). Pursuant to the terms of his Pre-existing Employment Agreement, Dr. Glickman’s base salary is $300,000, subject to annual review and adjustment at the discretion of our board of directors, and he will be eligible for an annual year-end discretionary bonus of up to 50% of his base salary, subject to the achievement of key performance indicators, as determined by our board of directors. In connection with his Pre-existing Employment Agreement, Dr. Glickman received an initial equity grant of an option to purchase up to 7,380 shares of our common stock with 20% of the shares vesting immediately and 80% vesting on a monthly basis over 24 months thereafter. The initial term of Dr. Glickman’s Pre-existing Employment Agreement ended on December 31, 2018 and was automatically extended for additional three-year terms.

 

On July 26, 2019, we entered into an employment agreement with Dr. Glickman (the “New Employment Agreement”) that supersedes the terms of the Pre-existing Employment Agreement. Pursuant to the terms of the New Employment Agreement, Dr. Glickman’s base salary is $350,000 per year, subject to annual review and adjustment at the discretion of the Board. In connection with entering into the New Employment Agreement, Dr. Glickman’s existing seven thousand three hundred and eighty (7,380) options (“Existing Options”) to purchase Company common stock at two hundred and fifty dollars ($250.00) per share until October 1, 2026, were repriced to fifty dollars ($50.00) per share. Additionally, Dr. Glickman, in connection to the New Employment Agreement, was granted stock options for the right to purchase seven thousand two hundred (7,200) common stock at a price equal to two dollars ($50.00) per share exercisable until July 26, 2029, which shall vest quarterly over a three (3) year period. In February 2021, the board of directors approved an option grant to Dr. Glickman to purchase 406,000 shares of common stock at an exercise price of $8.20 per shares (the closing price of the Company’s common stock on February 18, 2021). The stock option vests in equal quarterly installments over a two year period. Additionally, the board of directors paid Mr. Berman a cash bonus of $50,000.

 

Pursuant to the terms of the New Employment Agreement, Dr. Glickman is an at-will employee and is entitled to severance in the event of certain terminations of his employment. In the event that Dr. Glickman’s employment is terminated by the Company without Cause (as defined in the New Employment Agreement), other than by reason of Disability (as defined in the New Employment Agreement), or he resigns for Good Reason (as defined in the New Employment Agreement), subject to his timely executing a release of claims in favor of the Company and in addition to certain other accrued benefits, Dr. Glickman is entitled to receive three months of his base salary for each year that he has been employed by the Company at the time of termination, up to a total of one year of his base salary.

 

Potential Payments Upon Termination or Change-in-Control

 

Pursuant to the terms of the employment agreements discussed above, we will pay severance in the event of certain terminations of employment. In the event employment is terminated by us without cause and other than by reason of disability or if the executive resigns for good reason, subject to his or her timely executing a release of claims in our favor and in addition to certain other accrued benefits, he or she is entitled to receive severance pursuant to the terms of his or her employment agreements discussed above.

 

46

 

 

Outstanding Equity Awards at Fiscal Year-End

 

The following table sets forth information regarding equity awards held by our named executive officers as of December 31, 2021.

 

Name  Number of securities underlying unexercised options (#) exercisable   Number of securities underlying unexercised options (#) unexercisable   Equity incentive plan awards: Number of securities underlying unexercised unearned options (#)   Option exercise price ($)  

Option

expiration date

Robert A. Berman,   43,209(1)   -(1)   N/A   $10.00   September 23, 2028
Chief Executive Officer   19,333(2)   20,667(2)       $10.00   July 18, 2030
    364,297(3)   473,703(3)       $8.20   February 18, 2031
    

349,781

(4)   

349,781

(4)      

$

6.70

  

November 30, 2031

                        
Marc H. Glickman, M.D.   3,000(5)   4,200(5)   N/A   $50.00   July 25, 2029
Chief Medical Officer and Senior Vice President   7,380(5)   -    N/A   $50.00   October 1, 2026
    19,333(2)   20,667(2)   -   $10.00   July 18, 2030
    176,497(3)   229,503(3)       $8.20   February 18, 2031
    

265,700

(4)   

265,700

(4)      

$

6.70

  

November 30, 2031

                        
Craig Glynn, Chief Financial Officer (6)   1,933(7)   2,067(7)   N/A   $10.00   July 18, 2030
    93,900(8)   230,100(8)       $8.20   February 18, 2031
    

125,925

(4)   

125,925

(4)      

$

6.70

  

November 30, 2031

 

  (1) Options were granted on September 24, 2018, and vested 20% on the date of his Employment Agreement, March 30, 2018, and the remaining 80% vests ratably on a monthly basis over the 24 months following the date of his Employment Agreement.
  (2) Options were granted on July 18, 2020 and vest ratably on a monthly basis over 36 months.
  (3) Options were granted on February 18, 2021 and vest ratably on a quarterly basis over two years.
  (4)

Options were granted on November 30, 2021 and vest ratably on a quarterly basis over three years.

  (5) On July 26, 2019, the Company entered a new employment agreement with Dr. Glickman that superseded the terms of his existing employment agreement. In connection with entering into the new employment agreement, Dr. Glickman’s existing 7,380 options that were granted on October 1, 2016 were repriced from $250.00 to $50.00 per share. Additionally, on July 26, 2019, Dr. Glickman was granted 7,200 options at $50.00 per share vesting quarterly over a three-year period.
  (6) Mr. Glynn was elevated to permanent Chief Financial Officer in January 2021.
  (7) Options were granted on July 18, 2020 and vest ratably on a quarterly basis over three years.
  (8) Options were granted on February 18, 2021 and vest ratably on a quarterly basis over three years.

 

Name  Grant Date  Number of unearned restricted stock units that have not vested     Market value of unearned restricted stock units that have not vested (a)     
Robert A. Berman, Chief Executive Officer     11/30/2021     200,000(1)  $1,318,000 
              
Marc H. Glickman, M.D., Chief Medical Officer and Senior Vice President     11/30/2021     100,000(1)  $659,000 
              
Craig Glynn, Chief Financial Officer     11/30/2021     50,000(1)  $329,500 

 

  (a) Determined by multiplying the number of restricted stock units that have not vested by $6.59, the closing price of NVNO’s common stock on December 31, 2021.
     
  (1) On November 30, 2021, Mr. Berman was granted 200,000 restricted stock units, Dr. Glickman was granted 100,000 restricted stock units, and Mr. Glynn was granted 50,000 restricted stock units. The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve.

 

47

 

 

Employee Benefit Plans

 

Amended and Restated 2016 Omnibus Incentive Plan

 

On October 1, 2016, our board of directors and our stockholders adopted and approved the enVVeno Medical Corporation 2016 Omnibus Incentive Plan, and, subsequently, on April 26, 2018, our board of directors and our stockholders adopted and approved the Amended and Restated 2016 Omnibus Incentive Plan which was subsequently amended by Amendment No. 1 to the Amended and Restated 2016 Omnibus Incentive Plan following receipt of stockholder approval on December 17, 2020 and by Amendment No. 2 to the Amended and Restated 2016 Omnibus Incentive Plan following receipt of stockholder approval on November 30, 2021 (as amended, the “2016 Plan”). The principal features of the 2016 Plan are summarized below. This summary is qualified in its entirety by reference to the text of the 2016 Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part.

 

Share Reserve

 

We currently have reserved 4,500,000 shares of our common stock for issuance under the 2016 Plan, provided, however, if at any time the Company issues additional shares of Common Stock or securities that are convertible or exercisable into shares of Common Stock (other than pursuant to the Plan) then the number of shares authorized to be awarded under the Plan shall increase to an amount equal to no less than 20% of the issued and outstanding shares of common stock of the Company on a fully diluted basis. Such increase, if any, shall occur automatically upon each applicable issuance of securities by the Company. All shares available for issuance under the Plan may be granted as incentive stock options under Code Section 422. The shares of common stock issuable under the 2016 Plan will consist of authorized and unissued shares, treasury shares or shares purchased on the open market or otherwise, all as determined by our company from time to time.

 

If any award is canceled, terminates, expires or lapses for any reason prior to the issuance of shares or if shares are issued under the 2016 Plan and thereafter are forfeited to us, the shares subject to such awards and the forfeited shares will not count against the aggregate number of shares of common stock available for grant under the 2016 Plan. In addition, the following items will not count against the aggregate number of shares of common stock available for grant under the 2016 Plan: (1) shares issued under the 2016 Plan repurchased or surrendered at no more than cost or pursuant to an option exchange program, (2) any award that is settled in cash rather than by issuance of shares of common stock, (3) shares surrendered or tendered in payment of the option price or purchase price of an award or any taxes required to be withheld in respect of an award or (4) awards granted in assumption of or in substitution for awards previously granted by an acquired company.

 

Administration

 

The 2016 Plan may be administered by our board of directors or our compensation committee. Our compensation committee, in its discretion, selects the individuals to whom awards may be granted, the time or times at which such awards are granted and the terms and conditions of such awards. Our board of directors also has the authority, subject to the terms of the 2016 Plan, to amend existing options (including to reduce the option’s exercise price), to institute an exchange program by which outstanding options may be surrendered in exchange for options that may have different exercise prices and terms, restricted stock, and/or cash or other property.

 

Eligibility

 

Awards may be granted under the 2016 Plan to officers, employees, directors, consultants and advisors of us and our affiliates. Incentive stock options may be granted only to employees of us or our subsidiaries.

 

48

 

 

Awards

 

The 2016 Plan permits the granting of any or all of the following types of awards:

 

  ● Stock Options. Stock options entitle the holder to purchase a specified number of shares of common stock at a specified price (the exercise price), subject to the terms and conditions of the stock option grant. Our compensation committee may grant either incentive stock options, which must comply with Code Section 422, or nonqualified stock options. Our compensation committee sets exercise prices and terms and conditions, except that stock options must be granted with an exercise price not less than 100% of the fair market value of our common stock on the date of grant (excluding stock options granted in connection with assuming or substituting stock options in acquisition transactions). Unless our compensation committee determines otherwise, fair market value means, as of a given date, the closing price of our common stock. At the time of grant, our compensation committee determines the terms and conditions of stock options, including the quantity, exercise price, vesting periods, term (which cannot exceed 10 years) and other conditions on exercise.
  ● Stock Appreciation Rights. Our compensation committee may grant SARs, as a right in tandem with the number of shares underlying stock options granted under the 2016 Plan or as a freestanding award. Upon exercise, SARs entitle the holder to receive payment per share in stock or cash, or in a combination of stock and cash, equal to the excess of the share’s fair market value on the date of exercise over the grant price of the SAR. The grant price of a tandem SAR is equal to the exercise price of the related stock option and the grant price for a freestanding SAR is determined by our compensation committee in accordance with the procedures described above for stock options. Exercise of a SAR issued in tandem with a stock option will reduce the number of shares underlying the related stock option to the extent of the SAR exercised. The term of a freestanding SAR cannot exceed 10 years, and the term of a tandem SAR cannot exceed the term of the related stock option.
  ● Restricted Stock, Restricted Stock Units and Other Stock-Based Awards. Our compensation committee may grant awards of restricted stock, which are shares of common stock subject to specified restrictions, and restricted stock units, or RSUs, which represent the right to receive shares of our common stock in the future. These awards may be made subject to repurchase, forfeiture or vesting restrictions at our compensation committee’s discretion. The restrictions may be based on continuous service with us or the attainment of specified performance goals, as determined by our compensation committee. Stock units may be paid in stock or cash or a combination of stock and cash, as determined by our compensation committee. Our compensation committee may also grant other types of equity or equity-based awards subject to the terms and conditions of the 2016 Plan and any other terms and conditions determined by our compensation committee.
  ● Performance Awards. Our compensation committee may grant performance awards, which entitle participants to receive a payment from us, the amount of which is based on the attainment of performance goals established by our compensation committee over a specified award period. Performance awards may be denominated in shares of common stock or in cash, and may be paid in stock or cash or a combination of stock and cash, as determined by our compensation committee. Cash-based performance awards include annual incentive awards.

 

49

 

 

Clawback

 

All cash and equity awards granted under the 2016 plan will be subject to all applicable laws regarding the recovery of erroneously awarded compensation, any implementing rules and regulations under such laws, any policies we adopted to implement such requirements and any other compensation recovery policies as we may adopt from time to time.

 

Change in Control

 

Under the 2016 Plan, in the event of a change in control (as defined in the 2016 Plan), outstanding awards will be treated in accordance with the applicable transaction agreement. If no treatment is provided for in the transaction agreement, each award holder will be entitled to receive the same consideration that stockholders receive in the change in control for each share of stock subject to the award holder’s awards, upon the exercise, payment or transfer of the awards, but the awards will remain subject to the same terms, conditions and performance criteria applicable to the awards before the change in control, unless otherwise determined by our compensation committee. In connection with a change in control, outstanding stock options and SARs can be cancelled in exchange for the excess of the per share consideration paid to stockholders in the transaction, minus the option or SARs exercise price.

 

Subject to the terms and conditions of the applicable award agreements, awards granted to non-employee directors will fully vest on an accelerated basis, and any performance goals will be deemed to be satisfied at target. For awards granted to all other service providers, vesting of awards will depend on whether the awards are assumed, converted or replaced by the resulting entity.

 

  ● For awards that are not assumed, converted or replaced, the awards will vest upon the change in control. For performance awards, the amount vesting will be based on the greater of (1) achievement of all performance goals at the “target” level or (2) the actual level of achievement of performance goals as of our fiscal quarter end preceding the change in control, and will be prorated based on the portion of the performance period that had been completed through the date of the change in control.
  ● For awards that are assumed, converted or replaced by the resulting entity, no automatic vesting will occur upon the change in control. Instead, the awards, as adjusted in connection with the transaction, will continue to vest in accordance with their terms and conditions. In addition, the awards will vest if the award recipient has a separation from service within two years after a change in control by us other than for “cause” or by the award recipient for “good reason” (each as defined in the applicable award agreement). For performance awards, the amount vesting will be based on the greater of (1) achievement of all performance goals at the “target” level or (2) the actual level of achievement of performance goals as of our fiscal quarter end preceding the change in control, and will be prorated based on the portion of the performance period that had been completed through the date of the separation from service.

 

Amendment and Termination of the 2016 Plan

 

Unless earlier terminated by our board of directors, the 2016 Plan will terminate, and no further awards may be granted, 10 years after October 1, 2016, the date on which it was approved by our stockholders. Our board of directors may amend, suspend or terminate the 2016 Plan at any time, except that, if required by applicable law, regulation or stock exchange rule, stockholder approval will be required for any amendment. The amendment, suspension or termination of the 2016 Plan or the amendment of an outstanding award generally may not, without a participant’s consent, materially impair the participant’s rights under an outstanding award.

 

50

 

 

Limitation of Liability and Indemnification Matters

 

Our amended and restated certificate of incorporation limits the liability of our directors for monetary damages for breach of their fiduciary duties, except for liability that cannot be eliminated under the DGCL. Consequently, our directors will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except liability for any of the following:

 

  ● any breach of their duty of loyalty to us or our stockholders;
  ● acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
  ● unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the DGCL; or
  ● any transaction from which the director derived an improper personal benefit.

 

Our amended and restated bylaws also provide that we will indemnify our directors and executive officers and may indemnify our other officers and employees and other agents to the fullest extent permitted by law. Our amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our amended and restated bylaws would permit indemnification. We have obtained directors’ and officers’ liability insurance.

 

We have entered into separate indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated bylaws. These agreements, among other things, provide for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by this person in any action or proceeding arising out of this person’s services as a director or executive officer or at our request. We believe that these provisions and agreements are necessary to attract and retain qualified persons as directors and executive officers.

 

The above description of the indemnification provisions of our amended and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is incorporated by reference as an exhibit to the registration statement to which this prospectus forms a part.

 

The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder’s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and may be unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.

 

Director Compensation

 

The Board determines the form and amount of director compensation after its review of recommendations made by the Compensation Committee. A substantial portion of each director’s annual retainer is in the form of equity. Under the Company’s nonemployee director compensation program members of the Board who are not also Company employees (“Non-Employee Directors”) are granted options worth up to thirty-seven thousand five hundred dollars ($37,500) per annum (the “Annual Award”). Prior to February 18, 2021, the equity portion of director compensation included eight hundred options and restricted stock units (“RSU’s” worth up to twenty-five thousand dollars ($25,000) per annum. A Non-Employee Director who is newly appointed to the Board other than in connection with an annual meeting of stockholders will generally receive a grant of two thousand four hundred (2,400) options and RSUs worth up to seventy-five thousand dollars ($75,000) upon appointment (an “Initial Award”), which covers their compensation for their first three years of service. The Initial Award and Annual Award to Non-Employee Directors will vest as long as they remain directors in equal annual portions over three years following the date in which the award is granted.

 

51

 

 

The table below shows the compensation paid to our non-employee directors during 2021 and 2020.

 

Name       Fees earned or paid in cash   Stock awards ($)  

Option awards

($)(4)

   Non-equity incentive plan compensation ($)  

Nonqualified deferred compensation earnings

($)

   All other compensation($)   Total ($) 
Francis Duhay,   2021   $32,500    -   $37,500(2)   -    -    -   $70,000 
M.D.   2020   $20,000   $25,000(1)  $31,180(3)   -    -    -   $76,180 
Dr. Sanjay   2021   $37,500    -   $37,500(2)   -    -    -   $75,000 
Shrivastava   2020   $25,000    25,000(1)   31,180(3)   -    -    -   $81,180 
Robert Gray   2021   $40,000    -   $37,500(2)                 $77,500 
    2020   $27,500   $25,000(1)  $31,180(3)                 $83,680 
Matthew    2021   $37,500    -   $37,500(2)                 $75,000 
Jenusaitis   2020   $25,000   $25,000(1)  $31,180(3)                 $81,180 

 

(1) Under the Company’s nonemployee director compensation program, Dr. Duhay, Dr. Shrivastava, Mr. Gray and Mr. Jenusaitis were each granted 2,500 Restricted Stock Grants on July 17, 2020, which based on the Company’s closing stock price on the grant date were valued at $10.00 per share. These Restricted Stock Grants fully vested on December 31, 2020.

 

(2) Under the Company’s nonemployee director compensation program, Dr. Duhay, Dr. Shrivastava, Mr. Gray and Mr. Jenusaitis were each granted 5,673 options to purchase shares of our common stock on February 18, 2021 at an exercise price of $8.20 per share. The options were valued at $6.61 per share as of the date of the grant. All of these options vest in equal quarterly portions from the grant date through December 31, 2021, such that they are fully vested at December 31, 2021, and valued in accordance with FASB ASC Topic 718.

 

(3) Under the Company’s nonemployee director compensation program, Dr. Duhay, Dr. Shrivastava, Mr. Gray and Mr. Jenusaitis were each granted 4,000 options to purchase shares of our common stock on July 17, 2020 at an exercise price of $10.00 per share. The options were valued at $7.80 per share as of the date of the grant. All of these options vest in equal quarterly portions from the grant date through December 31, 2020, such that they are fully vested at December 31, 2020, and valued in accordance with FASB ASC Topic 718.

 

(4) Under the Company’s nonemployee director compensation program, Dr. Duhay, Dr. Shrivastava, Mr. Gray and Mr. Jenusaitis were each granted 7,211 options to purchase shares of our common stock on November 30, 2021, as part of their compensation for the year ending December 31, 2022, at an exercise price of $6.70 per share. The options were valued at $5.20 per share as of the date of the grant and will vest in equal quarterly portions starting on March 31, 2022 and through December 31, 2022, such that they are fully vested at December 31, 2022. The grant date value of each grant determined in accordance with FASB ASC Topic 718 was $37,500.

 

52

 

 

ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table lists, as of March 24, 2022, the number of shares of common stock of our Company that are beneficially owned by (i) each person or entity known to our Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each officer and director of our Company; and (iii) all officers and directors as a group.

 

Applicable percentage ownership is based on 9,469,850 shares of common stock outstanding as the date of this Form 10-K. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting or dispositive power with respect to such securities. In addition, pursuant to such rules, we deemed outstanding shares of common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60 days of March 24, 2022. We did not deem such shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the beneficial owners named in the table below have sole voting and dispositive power with respect to all shares of our common stock that they beneficially own, subject to applicable community property laws.

 

      Beneficial Ownership  
Name and Address of Beneficial Owner (1)     Number of
Shares		       Percentage  
5% Stockholders                
Perceptive Life Sciences Master Fund Ltd.(2)     937,515       9.9 %
                 
Named Executive Officers and Directors                
Robert A. Berman (3)     627,177       6.2 %
Marc Glickman, M.D.(4)     302,577       3.1 %
Craig Glynn (5)     143,554       1.5 %
Francis Duhay, M.D. (6)     27,036       *  
Dr. Sanjay Shrivastava (7)     16,764       *  
Robert Gray(8)     19,689       *  
Matthew Jenusaitis (9)     18,959       *  
All directors and executive officers as a group (7 persons)     1,155,757       10.9 %

 

* Represents beneficial ownership of less than 1%.

 

(1) Except as otherwise noted below, the address for each person or entity listed in the table is c/o enVVeno Medical Corporation, 70 Doppler, Irvine, California 92618.
(2) Based on a Schedule 13G filed by the Perceptive Live Sciences Master Fund Ltd. (the “Master Fund”). The Master Fund directly holds 781,615 shares of common stock and 1,759,035 pre-funded warrants. The pre-funded warrants may not be exercised if the Master Fund would beneficially own more than 9.9% of the Company’s outstanding shares of common stock after giving effect to such exercise. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
(3) Includes 588,071 shares of common stock issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.
(4) Includes 278,836 shares of common stock that are issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.
(5) Includes 133,060 shares of common stock that are issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.
(6) Includes 13,476 shares of common stock that are issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.
(7) Includes 13,476 shares of common stock that are issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.
(8) Includes 13,076 shares of common stock that are issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.
(9) Includes 13,076 shares of common stock that are issuable upon exercise of options that are currently exercisable or exercisable within 60 days of March 24, 2022.

 

53

 

 

ITEM 13. Certain Relationships and Related Transactions, and Director Independence

 

The following is a description of transactions since January 1, 2021 to which we were a party in which (i) the amount involved exceeded or will exceed the lesser of (A) $120,000 or (B) one percent of our average total assets at year end for the last two completed fiscal years and (ii) any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of, or person sharing the household with, any of the foregoing persons, who had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other similar arrangements, which are described under “Executive Compensation.”

 

None

 

Indemnification of Officers and Directors

 

Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the DGCL. Further, we intend to enter into indemnification agreements with each of our directors and officers, and we intend to purchase a policy of directors’ and officers’ liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For further information, see “Executive Compensation—Limitations of Liability and Indemnification Matters.”

 

To the best of our knowledge, during the past two fiscal years, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds the lesser of (A) $120,000 or (B) one percent of our average total assets at year end for the last two completed fiscal years, and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation to our officers and directors in the ordinary course of business).

 

Policies and Procedures for Related Party Transactions

 

All future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.

 

Director Independence

 

The information provided in Item 10, under the subheading “Director Independence” is incorporated herein.

 

54

 

 

ITEM 14. Principal Accounting Fees and Services

 

Audit Fees. The aggregate fees billed by Marcum LLP (“Marcum”) for professional services rendered for the audit of our annual financial statements, review of the financial information included in our Forms 10-Q for the respective periods and other required filings with the SEC for the years ended December 31, 2021 and 2020 totaled $126,000 and $244,000, respectively. The above amounts include interim procedures, audit fees, fees related to registration statements filed during those years, and attendance at audit committee meetings.

 

All Other Fees. None.

 

Procedures For Board of Directors Pre-Approval of Audit and Permissible Non-Audit Services of Independent Auditor

 

Our audit committee is ultimately responsible for reviewing and approving, in advance, any audit and any permissible non-audit engagement or relationship between us and our independent registered public accounting firm. Our engagement of Marcum to conduct all audit and permissible non-audit related activities incurred during fiscal years 2021 and 2020 were approved by our audit committee in accordance with these procedures.

 

PART IV

 

ITEM 15. Exhibits and Financial Statements Schedules

 

1. Consolidated Financial Statements

 

Our financial statements and the notes thereto, together with the report of our independent registered public accounting firm on those financial statements, are hereby filed as part of this report beginning on page F-1.

 

2. Financial Statement Schedules

 

All financial statement schedules have been omitted since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto.

 

55

 

 

3. Exhibits

 

The following is a complete list of exhibits filed as part of this Form 10-K. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

 

Exhibit Number   Description
     
3.1   Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed on September 16, 2020).
3.2   Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on June 6, 2018).
3.3   Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1to the Registrant’s Current Report on Form 8-K filed on December 2, 2020).
3.4   Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on October 1, 2021).
4.1   Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (No. 333-220372) filed on September 7, 2017).
4.2   Form of Series A Preferred Stock Placement Agents’ Warrant (incorporated by reference to Exhibit 4.4 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on December 14, 2017).
4.3   Form of Series B Preferred Stock Placement Agents’ Warrant (incorporated by reference to Exhibit 4.5 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on December 14, 2017).
4.4   Form of Common Stock Purchase Warrant (issued in connection with the 2017 Notes) (incorporated by reference to Exhibit 4.6 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on December 14, 2017).
4.5   Form of Underwriters’ Warrant (incorporated by reference to Exhibit 4.7 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on January 26, 2018).
4.6   Form of Warrant to Purchase Shares of Common Stock (issued to Mr. Cantor) (incorporated by reference to Exhibit 4.8 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on December 14, 2017).
4.7   Form of Amended and Restated Common Stock Purchase Warrant (issued in connection with the 2017 Notes) (incorporated by reference to Exhibit 4.9 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on January 26, 2018).
4.8   Form of Common Stock Purchase Warrant (issued in connection with the 2018 Notes) (incorporated by reference to Exhibit 4.10 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on January 26, 2018).
4.9   Form of Second Amended and Restated Common Stock Purchase Warrant (issued in connection with the 2017 Notes) (incorporated by reference to Exhibit 4.11 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on April 16, 2018).
4.10   Form of Amended and Restated Common Stock Purchase Warrant (issued in connection with the 2018 Notes) (incorporated by reference to Exhibit 4.12 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on April 16, 2018).
4.11   Form of Warrant Agreement (incorporated by reference to Exhibit 4.13 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on May 14, 2018).
4.12   Amendment to Warrant to Purchase Shares (incorporated by reference to Exhibit 4.14 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on April 16, 2018).
4.13   Form of Warrant Certificate (incorporated by reference to Exhibit 4.15 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on May 14, 2018).
4.14   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on March 2, 2020).
4.15   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on April 28, 2020).
4.16   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on June 3, 2020).
4.17   Form of Warrant Agent Agreement, inclusive of Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on July 21, 2020).
4.18   Form of Private Placement Warrant (incorporated by reference to Exhibit 4.18 to the Registrant’s Registration Statement on Form S-1/A (No. 333-239658) filed on July 16, 2020).
4.19   Form of Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on October 8, 2020).
4.20   Form of Warrant Agent Agreement (including Form of Warrant Certificate) (incorporated by reference to Exhibit 4.20 to the Registrant’s Registration Statement on Form S-1/A (No. 333 -251528) filed on February 5, 2021).
4.21   Form of Pre-Funded Warrant (Form of Placement Agency Agreement, dated September 3, 2021 (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on September 8, 2021).
4.22   Form of Warrant (Form of Placement Agency Agreement, dated September 3, 2021 (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on September 8, 2021).
4.23   Description of the Company’s Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.21 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020)
10.1   Form of Indemnification Agreement (incorporated by reference to Exhibit 10.30 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on December 14, 2017).

 

56

 

 

10.2   Employment Agreement, dated as of March 30, 2018, by and between the Registrant and Robert A. Berman. (incorporated by reference to Exhibit 10.47 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on April 16, 2018).
10.3   Amended and Restated 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.50 to the Registrant’s Registration Statement on Form S-1/A (No. 333-220372) filed on May 14, 2018).
10.4   Amendment No. 1 to Amended and Restated 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.4 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020).
10.5   Amendment No. 2 to Amended and Restated 2016 Omnibus Incentive Plan.*
10.6   Form of Stock Option Grant under Amended and Restated 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.44 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018).
10.7   Form of Restricted Stock Unit under Amended and Restated 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.45 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2018).
10.8   Employment Agreement, dated as of July 26, 2019, by and between enVVeno Medical Corporation and Marc Glickman, M.D. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 1, 2019).
10.9   Form of Securities Purchase Agreement dated as of February 25, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on March 2, 2020).
10.10   Form of Securities Purchase Agreement, dated as of April 24, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on April 28, 2020).
10.11   Form of Placement Agency Agreement, dated as of April 24, 2020, by and between enVVeno Medical Corporation and Spartan Capital Securities, LLC (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on April 28, 2020).
10.12   Form of Securities Purchase Agreement dated as of June 1, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on June 3, 2020).
10.13   Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.53 to the Registrant’s Registration Statement on Form S-1/A (No. 333-239658) filed on July 16, 2020).
10.14   Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.54 to the Registrant’s Registration Statement on Form S-1/A (No. 333-239658) filed on July 16, 2020).
10.15   Form of Securities Purchase Agreement, dated as of October 7, 2020 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on October 8, 2020).
10.16   Form of Placement Agency Agreement, dated as of October 7, 2020 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on October 8, 2020).
10.17   Employment Agreement, dated as of February 19, 2021, by and between enVVeno Medical Corporation and Craig Glynn (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020).
10.18   At-the-Market Offering Agreement, dated August 12, 2021, by and between enVVeno Medical Corporation and Ladenburg Thalmann & Co. Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on August 12, 2021).
10.19   Form of Securities Purchase Agreement, dated September 3, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on September 8, 2021).
10.20   Form of Placement Agency Agreement, dated September 3, 2021 (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed on September 8, 2021).
14.1   Code of Conduct (incorporated by reference to Exhibit 14.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020).
21.1   Subsidiaries of the registrant incorporated by reference to Exhibit 21.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2020).
23.1   Consent of Marcum LLP, independent registered public accounting firm*
31.1   Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act. *
31.2   Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Sarbanes-Oxley Act. *
32   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act**
101.INS   Inline XBRL Instance Document*
101.SCH   Inline XBRL Taxonomy Extension Schema Document*
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document*

 

* Filed herewith.
** Furnished and not filed herewith.

 

ITEM 16. Form 10-K Summary

 

Not applicable

 

57

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: March 28, 2022 ENVVENO MEDICAL CORPORATION
     
  By: /s/ Robert Berman
    Robert Berman
    Chief Executive Officer
    (Principal Executive Officer)
     
  By: /s/ Craig Glynn
    Craig Glynn
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

58

 

 

ENVVENO MEDICAL CORPORATION

ANNUAL REPORT ON FORM 10-K

 

INDEX TO AUDITED FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm (PCAOB: 688) F-2
Balance Sheets as of December 31, 2021 and 2020 F-3
Statements of Operations for the Years Ended December 31, 2021 and 2020 F-4
Statements of Stockholders’ Equity for the Years Ended December 31, 2021 and 2020 F-5
Statements of Cash Flows for the Years Ended December 31, 2021 and 2020 F-6
Notes to Financial Statements F-8

 

F-1
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and Board of Directors of

enVVeno Medical Corporation

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of enVVeno Medical Corporation (the “Company”) as of December 31, 2021 and 2020, the related statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Marcum llp

 

Marcum llp

 

We have served as the Company’s auditor since 2015.

 

New York, NY

March 28, 2022

 

F-2
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

BALANCE SHEETS

 

   2021   2020 
   December 31, 
   2021   2020 
         
Assets          
Current Assets:          
Cash and cash equivalents  $54,727,740   $9,334,584 
Prepaid expenses and other current assets   312,350    234,467 
Total Current Assets   55,040,090    9,569,051 
Property and equipment, net   617,855    398,967 
Operating lease right-of-use assets, net   1,986,704    539,974 
Security deposits and other assets   54,493    29,843 
Total Assets  $57,699,142   $10,537,835 
           
Liabilities and Stockholders’ Equity          
Current Liabilities:          
Accounts payable  $560,083   $1,390,362 
Accrued expenses and other current liabilities   728,876    1,168,969 
Note Payable   -    312,700 
Current portion of operating lease liabilities   291,104    314,202 
Total Current Liabilities   1,580,063    3,186,233 
Long-term operating lease liabilities   1,714,871    253,746 
Total Liabilities   3,294,934    3,439,979 
           
Commitments and Contingencies (Note 9)   -      
           
Stockholders’ Equity:          
Preferred stock, par value $0.00001, 10,000,000 shares authorized: no shares issued or outstanding   -    - 
Common stock, par value $0.00001, 250,000,000 shares authorized, 9,469,850 and 2,541,529 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively   95    25 
Additional paid-in capital   136,255,346    72,421,242 
Accumulated deficit   (81,851,233)   (65,323,411)
Total Stockholders’ Equity   54,404,208    7,097,856 
Total Liabilities and Stockholders’ Equity  $57,699,142   $10,537,835 

 

The accompanying notes are an integral part of these financial statements.

 

F-3
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

STATEMENTS OF OPERATIONS

 

   2021   2020 
   For the Years Ended 
   December 31, 
   2021   2020 
         
Operating Expenses:          
Selling, general and administrative expenses  $11,164,858   $4,882,877 
Research and development expenses   5,727,645    4,252,249 
Loss from Operations   (16,892,503)   (9,135,126)
Other (Income) Expense:          
Gain on extinguishment of note payable   (312,700)   - 
Interest (income) expense, net   (18,709)   (3,739)
Change in fair value of derivative liabilities   -    (211,807)
Other (income) expense   (33,272)   215,906 
Total Other (Income) Expense   (364,681)   360 
           
Net Loss   (16,527,822)   (9,135,486)
Deemed dividend to Series C Preferred Stockholders   -    (607,220)
Net Loss Attributable to Common Stockholders  $(16,527,822)  $(9,742,706)
           
Net Loss Per Basic and Diluted Common Share:  $(1.90)  $(7.54)
           
Weighted Average Number of Common Shares Outstanding:          
Basic and Diluted   8,679,824    1,291,469 

 

The accompanying notes are an integral part of these financial statements.

 

F-4
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
  

Series C
Convertible

Preferred Stock

   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Equity 
Balance at January 1, 2020   -   $-    717,274   $7   $57,177,858   $(56,187,925)  $989,940 
Common stock issued in private placement offering [1]             52,000    1    24,304    -    24,305 
Common stock issued in public offerings [2]             1,148,996    11    9,847,890    -    9,847,901 
Preferred stock issued in private placement [3]   4,205,406    42    -    -    1,358,060    -    1,358,102 
Preferred stock exchange to common stock   (4,205,406)   (42)   243,125    2    40    -    - 
Common stock issued for exercise of warrants             367,660    4    2,985,751    -    2,985,755 
Reclassification of Warrant Derivatives to Equity             -    -    334,230    -    334,230 
Share-Based Compensation             12,474    -    693,109    -    693,109 
Net loss             -    -    -    (9,135,486)   (9,135,486)
Balance at December 31, 2020   -   $-    2,541,529   $25   $72,421,242   $(65,323,411)  $7,097,856 

 

[1] net of offering costs of $0.1 million.
[2] net of offering costs of $2.2 million.
[3] net of offering costs of $0.2 million.

 

   Shares   Amount   Capital   Deficit   Equity 
   Common Stock  

Additional

Paid-in

   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Deficit   Equity 
Balance at January 1, 2021   2,541,529   $25   $72,421,242   $(65,323,411)  $7,097,856 
                          
Common stock issued in public offering   5,914,284    59    38,127,717    -    38,127,776 
                          
Common stock issued for exercise of warrants   52,827    1    245,249    -    245,250 
                          
Fair Value of Warrants Issued   -    -    211,976    -    211,976 
Shares issued in satisfaction of trade payable   5,772    -    37,576    -    37,576 
Common stock issued in At The Market Transactions (ATM)   170,963    2    960,273    -    960,275 
Common stock issued in registered direct offering   781,615    8    18,273,583    -    18,273,591 
Shared-Based Compensation   2,860    -    5,977,730    -    5,977,730 
Net loss   -    -    -    (16,527,822)   (16,527,822)
Balance at December 31, 2021   9,469,850    95    136,255,346    (81,851,233)   54,404,208 

 

The accompanying notes are an integral part of these financial statements.

 

F-5
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

STATEMENTS OF CASH FLOWS

 

   2021   2020 
   For the Years Ended 
   December 31, 
   2021   2020 
Cash Flows from Operating Activities          
Net loss  $(16,527,822)  $(9,135,486)
Adjustments to reconcile net loss to net cash used in operating
activities:		          
Share-based compensation   5,999,178    881,213 
Depreciation and amortization   149,002    97,549 
Amortization of right-of-use assets   303,907    286,423 
Change in fair value of derivatives   -    (211,807)
Gain on extinguishment of note payable   (312,700)   - 
Loss on disposition of fixed assets   -    27,802 
Changes in operating assets and liabilities:          
Prepaid expenses and other current assets   (37,883)   (117,820)
Security deposit and other assets   (24,650)   - 
Accounts payable   (832,703)   169,173 
Accrued expenses   (249,565)   614,428 
Payments on lease liabilities   (312,610)   (288,685)
Total adjustments   4,681,976    1,458,276 
Net Cash Used in Operating Activities   (11,845,846)   (7,677,210)
           
Cash Flows from Investing Activities          
Purchase of property and equipment   (367,890)   (180,291)
Net Cash Used in Investing Activities   (367,890)   (180,291)
           
Cash Flows from Financing Activities          
Proceeds from private placement, net   -    570,341 
Proceeds from shares issued under ATM   960,275    - 
Proceeds from registered direct offering   18,273,591    - 
Proceeds from public offerings, net   38,127,776    9,847,901 
Proceeds from preferred stock issued in private placement, net   -    1,358,102 
Proceeds from issuance of note payable   -    312,700 
Proceeds from warrant exercises   245,250    2,985,755 
Net Cash Provided by Financing Activities   57,606,892    15,074,799 
           
Net Increase (Decrease) in Cash, Cash Equivalent, and Restricted Cash   45,393,156    7,217,298 
Cash, cash equivalents and restricted cash - Beginning of year   9,334,584    2,117,286 
Cash, cash equivalents and restricted cash - End of year  $54,727,740   $9,334,584 

 

The accompanying notes are an integral part of these financial statements.

 

F-6
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

STATEMENTS OF CASH FLOWS - continued

 

   Year Ended 
   December 31, 
   2021   2020 
Supplemental Disclosures of Cash Flow Information:          
Cash Paid During the Period For:          
Interest paid  $-   $- 
Income taxes paid  $-   $- 
Non-Cash Investing and Financing Activities          
Gain on extinguishment of note payable  $(312,700)  $- 
Fair value of common stock issued in satisfaction of trade payable   35,576    - 
Fair value of warrants issued to Preferred Exchange Participants, SABR and re-priced placement agent warrant   (211,976)   - 
Derivative liabilities reclassified to equity  $-   $334,229 

 

The accompanying notes are an integral part of these financial statements.

 

F-7
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Note 1 – Business Organization and Nature of Operations

 

enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with deep venous Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Our products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in our deep venous system of the leg, and is called the VenoValve®. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and have been commercially successful. We currently lease a 14,507 sq. ft. manufacturing facility in Irvine, California, where we manufacture medical devices for our clinical trials, and which has capacity for commercial manufacturing.

 

On September 21, 2021, we announced that we were changing our name from Hancock Jaffe to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of venous disease. In addition to the VenoValve, we announced that we have begun development of a second device for the treatment of venous disease which we are calling enVVe. In connection with this change in strategy, we indicated that we are not pursuing further development of the CoreoGraft, which is now outside of our primary focus area.

 

Note 2 – Management’s Liquidity Plan

 

As of December 31, 2021, the Company had a cash balance of $54.7 million and working capital of $53.5 million. Although the Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products, Management believes that our capital resources at December 31, 2021, are sufficient to meet our obligations as they become due within one year after the date of this Annual Report, and sustain operations.

 

Note 3 – Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.

 

Property and Equipment, Net

 

Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from 5 to 7 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.

 

Impairment of Long-lived Assets

 

The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.

 

F-8
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

 

Fair Value of Financial Instruments

 

The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

 

FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 Quoted prices available in active markets for identical assets or liabilities trading in active markets.
   
Level 2 Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
   
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

 

Financial instruments, including accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Derivative liabilities are accounted for at fair value on a recurring basis.

 

F-9
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

Derivative Liabilities

 

Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification.

 

Net Loss per Share

 

The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period including warrants exercisable for little or no cash consideration. Net loss attributable to common stockholders in 2020 consists of net loss adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock (see Note 10 - Stockholders Equity Series C Convertible Preferred Stock). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, would have been anti-dilutive.

 

F-10
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Stock-Based Compensation

 

The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and nonemployees. The accounting treatment for share-based payments to employees and non-employees is substantially equivalent.

 

Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the service period required for the award.

 

The fair value of the Company’s stock options is estimated at the date of grant using the Black-Scholes based option valuation model. For the expected term, the Company uses SEC Staff Accounting Bulletin No. 107 simplified method for “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) if an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 to 90 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.

 

The volatility assumption is based on the historical volatility of the Company’s common stock with an equivalent remaining expected term. The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining expected term.

 

For option grants without performance conditions, the Company recognizes compensation expense over the requisite service period ratably, recognizing expense for each tranche of each grant starting on the grant date. For grants that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method. Compensation expense for grants with performance conditions is recognized only for those awards expected to vest.

 

Forfeitures of unvested stock options are recorded when they occur.

 

Concentrations

 

The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $54.5 million and $9.1 million as of December 31, 2021 and 2020, respectively.

 

Recently Adopted Accounting Standards

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this standard did not have a material impact on our financial statements.

 

Recent Accounting Standards

 

In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our financial statements and related disclosures.

 

In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU No. 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

In October 2021, the FASB issued Accounting Standards Update 2021-08 (“ASU No. 2021-08”), Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

F-11
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Note 4 – Property and Equipment

 

As of December 31, 2021, and 2020, property and equipment consist of the following:

 

   2021   2020 
   December 31, 
   2021   2020 
Laboratory equipment  $522,539   $320,830 
Furniture and fixtures   124,093    98,392 
Computer equipment   164,298    65,078 
Leasehold improvements   192,668    158,092 
Software   251,163    244,479 
Total property and equipment   1,254,761    886,871 
Less: accumulated depreciation   (636,906)   (487,904)
Property and equipment, net  $617,855   $398,967 

 

Depreciation expense was $0.1 million for the years ended December 31, 2021 and 2020. Depreciation expense is reflected in general and administrative expenses in the accompanying statements of operations.

 

Note 5 – Right-of-Use Assets and Lease Liabilities

 

On November 17, 2021, the Company amended its operating lease for its manufacturing facility in Irvine, California, to extend the term an additional 60 months from its September 30, 2022 expiration date to a new expiration date of September 30, 2027. The initial lease rate at the date of the amendment was $30,206 per month with escalating payments. In connection with the lease, the Company is obligated to pay $7,254 monthly for operating expenses for building repairs and maintenance. The Company has no other operating or financing leases with terms greater than 12 months.

 

The Company determined the lease liabilities using the Company’s estimated incremental borrowing rate of 3.95% to estimate the present value of the remaining monthly lease payments.

 

Our operating lease cost is as follows:

 

  

For the Year Ended

December 31, 2021

 
Operating lease cost  $345,857 

 

Supplemental cash flow information related to our operating lease is as follows:

 

  

For the Year Ended

December 31, 2021

 
Operating cash flow information:     
Cash paid for amounts included in the measurement of lease
liabilities		  $354,561 

 

Remaining lease term and discount rate for our operating lease is as follows:

 

   December 31, 2021 
Remaining lease term   5.7 years 
Discount rate   3.95%

 

Maturity of our lease liabilities by fiscal year for our operating lease is as follows:

 

      
Year ended December 31, 2022  $365,190 
Year ended December 31, 2023   376,146 
Year ended December 31, 2024   387,435 
Year ended December 31, 2025   399,054 
Year ended December 31, 2026   411,024 
Year ended December 31, 2027   315,153 
Total  $2,254,002 
Less: Imputed interest   (248,027)
Present value of our lease liability  $2,005,975 

 

F-12
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Note 6 – Accrued Expenses

 

As of December 31, 2021 and 2020, accrued expenses consist of the following:

 

   2021   2020 
   December 31, 
   2021   2020 
Accrued compensation costs  $524,529   $473,799 
Accrued professional fees   84,375    79,650 
Accrued research and development   59,922    368,809 
Accrued warrants   

-

    

188,104

 

Other

   60,050    58,607 
Accrued expenses  $728,876   $1,168,969 

 

Note 7 – Note Payable

 

On April 12, 2020, the Company obtained a loan (the “Loan”) in the amount of $312,700, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020.

 

The Loan, which was in the form of a Note dated April 12, 2020, was to mature on April 12, 2022, and bore interest at a rate of 1% per annum, payable monthly commencing on November 12, 2020. On September 8, 2021, the Company was notified the Loan and any accrued interest had been forgiven. In connection with this, the Company recorded a gain on extinguishment of debt of $312,700.

 

Note 8 – Income Taxes

 

The following summarizes the Company’s income tax provision (benefit):

   For the Years Ended December 31, 
   2021   2020 
Federal:          
Current  $-   $- 
Deferred   (2,700,372)   (1,828,584)
           
State and local:          
Current   

-

    - 
Deferred   (900,124)   (609,528)
Current and Deferred Federal, State and Local, Tax Expense (Benefit)   (3,600,496)   (2,438,112)
Change in valuation allowance   3,600,496    2,438,112 
Income tax provision (benefit)  $-   $- 

 

The reconciliation between the U.S. statutory federal income tax rate and the Company’s effective tax rate for the year’s ended December 31, 2021 and 2020 is as follows:

 

  

For the Years Ended December 31,

 
   2021   2020 
Tax benefit at federal statutory rate   (21.0)%   (21.0)%
State taxes, net of federal benefit   (7.0)%   (7.0)%
Nondeductible compensation   6.2%   - 
Permanent differences   (0.5)%   2.0%
True up adjustments   0.5%   (0.7)%
Change in valuation allowance   21.8%   26.7%
Effective income tax rate   0.0%   0.0%

 

F-13
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:

 

   2021   2020 
   December 31, 
   2021   2020 
Deferred tax assets:          
Net operating loss carryforwards  $12,881,729   $9,811,086 
Research and development credit carryforwards   185,680    185,680 
Intangible assets   276,184    305,027 
Operating lease liability   78,194    159,025 
Stock-based compensation   923,540    311,304 
Impairment loss   136,612    136,612 
Total gross deferred tax assets   14,481,939    10,908,734 
Deferred tax liabilities          
Operating lease asset   (70,994)   (151,193)
Property and equipment   (102,107)   (49,199)
Total net deferred tax assets   14,308,838    10,708,342 
Less: valuation allowance   (14,308,838)   (10,708,342)
Total  $-   $- 

 

ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s history of operating losses, management believes that recognition of the deferred tax assets arising from the above listed future tax benefits is currently not more likely than not to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $3.6 million and $2.4 million during the years ended December 31, 2021 and 2020, respectively.

 

Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change income taxes may be limited. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s NOL carry forwards are subject to annual limitations due to a greater than 50% ownership change in 2021.

 

At December 31, 2021 and 2020, the Company had post-ownership change net operating loss carryforwards for federal income tax purposes of approximately $45.7 million and $35.0 million, respectively. Pre-2018 federal NOLs of approximately $12.0 million may be carried forward for twenty years and begin to expire in 2029. Based on the 2021 ownership change, the Company expects $7.6 million of its pre-2018 federal NOLs to expire unused. Under the Tax Act, post-2017 federal NOLs in the aggregate amount of $33.0 million can be carried forward indefinitely and the annual limit of deduction equals 80% of taxable income. However, to the extent the Company utilizes its NOL carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized. The Company also has federal research and development tax credit carryforwards of approximately $0.2 million which begin to expire in 2027.

 

As of December 31, 2021 and 2020, the Company had net operating loss carryforwards for state income tax purposes of approximately $45.7 million and $35.0 million, respectively, which can be carried forward for twenty years and begin to expire in 2028.

 

The Company files income tax returns in the U.S. federal jurisdiction as well as California and local jurisdictions and is subject to examination by those taxing authorities. The Company’s federal income taxes for the years beginning in 2018 remain subject to examination. The Company’s state and local income tax returns for the years beginning in 2017 remain subject to examination. No tax audits were initiated during 2021 or 2020.

 

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations.

 

On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the “IRC”) for 2019 and 2020 to permit additional expensing of interest (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k), (iii) making modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years in order to generate a refund of previously paid income taxes and (iv) enhancing the recoverability of alternative minimum tax credits. The Company has evaluated the impact CARES Act on its provision for income taxes and determined there is not a significant impact to income taxes because of the CARES Act.

 

On June 29, 2020, California’s Governor Newsom signed AB85 suspending California net operating loss (“NOL”) utilization and imposing a cap on the amount of business incentives tax credits (R&D credit) for tax years 2020-2022. Given the tax loss in 2020 and an expected tax loss for 2021, the suspension will not have an impact on the Company’s NOL in California. On February 9, 2022, Mr. Newsom signed SB113 which removes the restrictions in AB85 effective for the 2022 tax year.

 

F-14
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Note 9 – Commitments and Contingencies

 

Litigation Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

 

Robert Rankin Complaints

 

On July 9, 2020, the Company was served with a civil complaint filed in the Superior Court for the State of California, County of Orange by a former employee, Robert Rankin, who resigned his employment on or about March 30, 2020. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01146555-CU-WR-CJC and was filed on May 27, 2020. On September 3, 2020 the Company and its Chief Executive Officer were served with a second complaint filed in the Superior Court for the State of California, County of Orange by Mr. Rankin. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01157857 and was filed on August 31, 2020. The complaints assert several causes of action including a cause of action for failure to timely pay Mr. Rankin’s accrued and unused vacation and three months’ severance under his July 16, 2018 employment agreement, defamation, unlawful labor code violations, sex-based discrimination, and unfair competition, and seeks damages for lost wages, emotional and mental distress, consequential damages, punitive damages and attorney’s fees and costs. The Company has denied all claims in both matters (which have now been consolidated) and has filed a counterclaim asserting that Rankin has breached his employment agreement with the Company to the Company’s damage. The Company continues to believe it has meritorious defenses to both matters. As of the date of these financial statements, the amount of loss associated with these complaints, if any, cannot be reasonably estimated. Accordingly, no amounts related to these complaints are accrued as of December 31, 2021.

 

Note 10 –Stockholders’ Equity

 

On November 30, 2020, the Company”) effected a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”). As a result of the Reverse Stock Split, every twenty-five shares of issued and outstanding Common Stock was automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.

 

Equity Issuances

 

During 2021 and 2020 the Company has completed various equity transactions to raise capital through the placement of its common and preferred stock. The following table provides an overview of these transactions.

 

Date  Description  Type  Number of shares   Net Proceeds 
2020              
February 25, 2020  Private placement  Common Stock   52,000   $570,341 
April 28, 2020  Registered Direct Offering  Common Stock   75,472   $811,641 
June 3, 2020  Registered Direct Offering  Common Stock   117,216   $1,161,334 
July 17, 2020  Public Offering  Common Stock   575,000   $3,881,907 
July 17, 2020  Private Placement  Preferred Stock   4,205,406   $1,358,099 
October 9, 2020  Registered Direct Offering  Common Stock   381,308   $4,450,500 
Total              $12,233,822 
                 
2021                
February 11, 2021  Public Offering  Common Stock   5,914,284   $38,127,776 
August 2021  At-the-Market Equity Program  Common Stock   170,963   $970,575 
September 9, 2021  Registered Direct Offering  Common Stock   781,615   $18,273,591 
Total             $57,371,942 

 

F-15
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

Series C Convertible Preferred Stock

 

On July 17, 2020, the Company issued 4,205,406 shares of Preferred Stock in a private placement. On November 17, 2020, the holders of the Preferred Stock purchased in the July 17, 2020 private placement entered exchange agreements with the Company whereby the holders agreed to exchange all of their 4,205,406 shares of Preferred Stock for 243,125 shares of common stock. This was the original conversion rate of the Preferred Stock after giving effect to the 25:1 reverse split of the Company’s common stock.

 

While the Preferred Stock was outstanding, the holders of the Company’s Preferred Stock could vote with holders of the Common Stock, and with any other shares of preferred stock that vote with the Common Stock, with each holder of Preferred Stock being entitled to one vote per share of Preferred Stock, and were entitled to receive 8% non-compounding cumulative dividends, payable when, as and if declared by the Board of Directors. The Series C Preferred Stock ranked senior to the common stock as to dividends and the distribution of assets in the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, or any sale of the Company.

 

In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, or any sale of the Company, the holders of Preferred Stock were entitled to receive, before and in preference to any distribution of any of the assets to the holders of the common stock, or any other series of the Company’s preferred stock that would then be junior to the Preferred Stock, an amount per share equal to $0.37 for each outstanding share of Preferred Stock (the “Original Series C Issue Price”), plus all accrued but unpaid dividends thereon through the date of such event.

 

In certain circumstances, the holders of Preferred Stock were entitled to receive a liquidation preference payment of $0.37 per share of Preferred Stock, plus accrued and unpaid dividends. Those accrued and unpaid dividends were $23,859 in the aggregate as of September 30, 2020 and were reflected as a deemed dividend in determining net loss available to common stockholders during that period. As a result of the exchange of the Preferred Stock for common stock, it is no longer outstanding (see below).

 

The liquidation preference of the Preferred Stock was subordinate and ranks junior to all indebtedness of the Company.

 

The Company had the ability to elect to convert the Preferred Stock to common stock in the event the Company either (i) consummated a merger, or (ii) raised an aggregate of at least $8,000,000 in gross proceeds in a transaction or series of transactions within any twelve (12) month period. In the event the Company elected to affect such a conversion, each share of Series C Preferred Stock would have been convertible into 0.05781 shares of common stock.

 

F-16
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS

 

The Company determined that the Preferred Stock represented permanent equity due to the absence of a redemption feature and that the embedded conversion option was clearly and closely related to the equity host and did not require bifurcation. The $2,431,250 fair value of the warrants was calculated using the Black-Scholes option pricing model, using the $11.00 stock price, an expected term of 7.0 years, volatility of 118.7%, a risk-free rate of 0.47% and expected dividends of 0.00%. The $1,556,000 of gross proceeds were allocated on a relative fair value basis of $607,220 to the Preferred Stock and $948,781 to the warrants. The Preferred Stock includes a contingent beneficial conversion feature (“BCF”) which was valued at its $2,067,155 intrinsic value using the commitment date stock price of $11.00 per share and the effective conversion price of $2.50 per share, but was limited to the $607,220 of proceeds that were allocated to the Preferred Stock.

 

The November 17, 2020 exchange agreements resolved the contingency related to the BCF and, accordingly, the contingent BCF was recognized as a deemed dividend for the purposes of determining the net loss attributable to common stockholders for calculating net loss per share. In addition, since the Company does not have retained earnings, the dividend has been recorded against additional paid-in capital.

 

F-17
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Warrants

 

A summary of warrant activity during the years ended December 31, 2021 and 2020 is presented below:

 

   Common Stock 
   Number of
Warrants		  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Life in

Years

  

Intrinsic

Value

 
Outstanding, January 1, 2020   174,681   $127.50           
Issued    1,702,810    9.26           
Exercised   (367,660)   8.13           
Cancelled   (2,029)   107.50           
Outstanding, January 1, 2021   1,507,802   $20.10    5.3   $448,140 
Issued   4,895,016    4.59           
Exercised   (52,827)   5.03           
Cancelled   (38,286)   16.10           
Outstanding and exercisable, December 31, 2021   6,311,705   $8.80    4.2   $474,464 

 

In November 2020 as part of resolving a dispute, the Company agreed to issue warrants to purchase 17,618 shares of common stock at a purchase price of $8.00 per share, and warrants to purchase 18,056 shares of common stock at a purchase price of $10.25 per share. These amounts were in dispute and were paid pursuant to an investment banking agreement dated February 12, 2020 in connection with financings which occurred in July and October 2020. The fair value of these warrants on the settlement date was $0.1 million and $0.1 million, respectively. The total amount of the payment to settle the dispute was $0.5 million, including the value of the warrants. and was included in the cost of the July and October financings. The fair value of the warrants was determined using the Black-Scholes method with the following assumptions: stock price of $8.00 and $10.35, risk-free interest rate of 0.46%, volatility of 112.7%, annual rate of quarterly dividends of 0%, and an expected term of 2.5 years. The investment banking agreement has now been terminated with no further obligations.

 

In November 2020 the Company’s Board of Directors approved the issuance of warrants to purchase 6,400 shares of common stock to an advisor and warrants to purchase 20,000 shares of common stock to certain participants in the preferred share exchange (see Note 10, Stockholders Equity – Series C Convertible Preferred Stock). Separately the Company agreed to re-price warrants issued to the placement agent for the Company’s February 25, 2020 private placement. These warrants and the re-priced warrant were issued in February 2021. The value of these warrants at December 31, 2020 was $188,804 and is included in accrued expenses. The Company determined their value using the Black-Scholes method with the following assumptions: stock price of $8.65, risk-free interest rate of 0.36%, volatility of 114.3%, annual rate of quarterly dividends of 0%, and an expected term of 2.5 to 3.5 years.

 

F-18
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Warrants – Derivative Liabilities

 

The warrants issued in connection with our February 25, 2020 Bridge Offering were determined to be derivative financial instruments when issued because the Company did not have control of the obligation to obtain shareholder approval by May 25, 2020 to increase the number of authorized shares or to approve a reverse stock split. The accounting treatment of derivative financial instruments required that the Company record the warrants as a liability at fair value and marked-to-market the instruments at fair values as of each subsequent balance sheet date. Any change in fair value is recorded as a change in the fair value of derivative liabilities for each reporting period at each balance sheet date.

 

The warrant derivatives were valued as of the February 25, 2020 issuance date, as of the quarter ended March 31, 2020, as of June 30, 2020, and as of September 15, 2020 when the Company’s stockholders approved an increase in authorized shares in an amount sufficient to allow full exercise of these warrants. The value at issuance was $546,036 and was recorded as a derivative liability. The value of the derivative liability was $199,907 at March 31, 2020, $281,183 at June 30, 2020, and $334,229 at September 15, 2020.

 

The derivative liability increased $53,046 and decreased $211,807 during the three and nine months ended September 30, 2020, respectively. The changes in derivative liability is reflected in Other Income on the accompanying Statement of Operations.

 

The Company reassessed the classification at each balance sheet date to determine if it should be changed as a result of events during the period. On September 15, 2020, the fair value of derivative liabilities was reclassified to equity when the Company’s stockholders approved items comprising a Capital Event. Accordingly, there is no fair value of derivative liabilities as of December 31, 2020.

 

The fair value of the warrants was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The following inputs and assumptions were used for the valuation of the derivative liability:

 

  

February 25,

2020

  

March 31,

2020

  

June 30,

2020

  

September 15,

2020

 
Projected Volatility   97.1%   102.7%   102.7%   110.7%
Risk-Free Rate   1.36%   0.38%   0.29%   0.31%
Contractual Term (Years)   5    5    4.75    4.5 

 

  ● It was assumed the stock price would fluctuate with the Company’s projected volatility.
     
  ● The projected volatility was based on the historical volatility of the Company.
     
  ● If the Company was required to pay the fair value of the warrant in cash as of May 25, 2020, the obligation was discounted at the Company’s estimated cost of debt based on short-term C-CCC bond ratings of 19.5% and 28.5%.
     
  ● The likelihood of the Company calling a shareholder meeting and achieving shareholder approval was 90% as of February 25, 2020.
     
  ● As June 30, 2020, the Company projected shareholder approval would not be obtained until approximately 8/31/20. No mandatory exercise was allowed prior to that date.
     
  ● Until the Company obtained shareholder approval to increase the authorized shares on September 15, 2020, we assumed the warrant holders have an option to require the Company to pay the fair value of the warrants. The derivative value at that date was $334,229.

 

F-19
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis:

 

   Derivative 
   Liabilities 
Balance – January 1, 2020  $- 
Derivative liabilities associated with the issuance of common stock warrants   513,534 
Derivative liabilities associated with the issuance of placement agent warrants   32,502 
Change in fair value of derivative liabilities   (211,807)
Reclassification of warrant derivatives to equity   (334,229)
Balance – December 31, 2020  $- 

 

Note 11 – Share Based Compensation

 

Omnibus Incentive Plan

 

The Company issues share-based awards under its Company’s 2016 Omnibus Incentive Plan, which enables the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, other share based awards and cash awards to associates, directors, consultants, and advisors of the Company and its affiliates, and to improve the ability of the Company to attract, retain, and motivate individuals upon whom the Company’s sustained growth and financial success depend, by providing such persons with an opportunity to acquire or increase their proprietary interest in the Company. Stock options granted under the 2016 Plan may be non-qualified stock options or incentive stock options, within the meaning of Section 422(b) of the Internal Revenue Code of 1986, except that stock options granted to outside directors and any consultants or advisers providing services to the Company or an affiliate shall in all cases be non-qualified stock options. The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant.

 

The 2016 Plan is to be administered by the Board, which has discretion over the awards and grants thereunder. No awards may be issued after November 21, 2026.

 

The Plan was adopted in 2016 and amended in 2018, 2020 and 2021 to increase the number of shares authorized to be awarded under the Plan. As of December 31, 2021 there are 4,500,000 shares authorized under the Plan as a result of the increase authorized by our shareholders in 2021. The number of shares subject to the Plan is automatically adjusted from time to time such that shares authorized under the plan shall at all times be equal to at least 20% of the issued and outstanding shares of the Company on a fully diluted basis. The current number of shares authorized is greater than the 20% minimum.

 

Stock Options

 

The fair value of each option grant is estimated at the grant date using the Black Scholes method. The following assumptions were used in estimating fair value:

 

   2021    2020 
Expected term   5.44 – 6.5 years     5.16 – 5.76 years 
Volatility   112.94 – 103.6%    107.5%
Risk free interest rate   0.08 – 1.20%    0..30 – 0.36%
Dividend yield   0.00%    0.00%

 

The Company estimated the expected term of the options using the simplified method. The Company uses its stock’s historical market information to calculate volatility used in estimating fair value of options granted.

 

F-20
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

A summary of the option activity during the years ended December 31, 2021 and 2020 is presented below:

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
Outstanding, January 1, 2020   99,689   $111.00           
Granted   122,000    10.00           
Forfeited   (11,000)   63.88           
Outstanding, December 31, 2020   210,689   $31.48    8.7   $         - 
Granted   3,246,551   $7.70           
Forfeited   (15,333)   8.36           
Outstanding, December 31, 2021   3,441,907   $9.16    9.3   $- 
                     
Exercisable, December 31, 2021   982,921   $12.94    8.9   $- 

 

The Company includes share-based compensation expense in selling, general and administrative expenses, and recognized $6.0 million and $0.7 million during the years ended December 31, 2021 and 2020, respectively.

 

As of December 31, 2021, there was $15.2 million of unrecognized share-based compensation expense related to outstanding stock options and restricted stock units that will be recognized over the weighted average remaining vesting period of 2 years.

 

F-21
 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Restricted Stock Units

 

The Company also issues restricted shares and restricted stock units under the 2016 Plan. A summary of the restricted share and restricted stock units activity during the years ended December 31, 2021 and 2020 is presented below:

 

   Number of 
   Restricted Shares 
Outstanding, January 1, 2020   7,806 
Granted   10,000 
Shares vested   (12,864)
Outstanding, December 31, 2020   4,942 
Granted   400,000 
Shares Vested   (2,860)
Outstanding, December 31, 2021   402,082 

 

A summary of outstanding restricted stock units as of December 31, 2021 is presented below:

 Schedule of Outstanding and Exercisable Restricted Stock Units

Restricted Stock Units
Grant Date  Restricted Stock Unit for 

Outstanding

Number of

Units

  

Weighted

Average

Remaining

Life In

Years

 
9/13/2019  Common Stock   2,082    0.9 
11/30/2021  Common Stock   400,000    - 
              
   Total   402,082      

 

Note 12 – Net Loss Per Share

 

The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Shares of common stock issuable upon exercise of warrants   4,552,670    1,507,802 
Shares of common stock issuable upon exercise of options and restricted stock units   3,843,989    215,631 
Potentially dilutive common stock equivalents excluded from diluted net loss per share   8,396,659    1,723,433 

 

F-22

EX-10.5 2 ex10-5.htm

 

Exhibit 10.5

 

AMENDMENT NO. 2

 

TO

 

ENVVENO MEDICAL CORPORATION

 

2016 OMNIBUS INCENTIVE PLAN

 

(Effective December 3, 2021)

 

Reference is made to the enVVeno Medical Corporation 2016 Omnibus Incentive Plan (as Amended and Restated Effective April 26, 2018, and as further amended by Amendment No. 1 to the Plan which became effective on December 17, 2020) (the “Plan”). In accordance with Section 5.2 of the Plan, the Board of Directors of enVVeno Medical Corporation (the “Company”) adopted and approved and the stockholders of the Company thereafter approved the amendments to the Plan contemplated by this Amendment No. 2 to the Plan, as follows:

 

Section 4.1 of the Plan is hereby amended to read in its entirety as follows:

 

“4.1. Authorized Number of Shares.

 

Subject to adjustment under Section 15, the total number of Shares authorized to be awarded under the Plan shall initially not exceed 4,500,000, provided, however, if at any time the Company issues additional shares of Common Stock or securities that are convertible or exercisable into shares of Common Stock (other than pursuant to the Plan) then the number of Shares authorized to be awarded under the Plan shall increase to an amount equal to no less than 20% of the issued and outstanding shares of common stock of the Company on a fully diluted basis. Such increase, if any, shall occur automatically upon each applicable issuance of securities by the Company. For the avoidance of doubt, the number of Shares authorized to be awarded under the Plan shall not be decreased, other than adjustments under Section 15. Shares issued under the Plan shall consist in whole or in part of authorized but unissued Shares, treasury Shares, or Shares purchased on the open market or otherwise, all as determined by the Company from time to time.”

 

All other terms and provisions of the Plan shall remain unchanged and in full force and effect as written.

 

 

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the incorporation by reference in the Registration Statement of enVVeno Medical Corporation on Form S-8 (File No. 333-256504) and Form S-3 (File No. 333-237592 and File No. 333-248865) and Post-Effective Amendment No. 1 on Form S-3 (File No. 333-252874) of our report dated March 28, 2022, with respect to our audits of the financial statements of enVVeno Medical Corporation as of December 31, 2021 and 2020 and for each of the two years in the period ended December 31, 2021, which report is included in this Annual Report on Form 10-K of enVVeno Medical Corporation for the year ended December 31, 2021.

 

/s/ Marcum llp  
   
Marcum llp  
   
New York, NY  
March 28, 2022  

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

I, Robert Berman, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of enVVeno Medical Corporation;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) [Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 28, 2022   /s/ Robert Berman
  Name: Robert Berman
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

I, Craig Glynn, certify that:

 

  1. I have reviewed this Annual Report on Form 10-K of enVVeno Medical Corporation;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) [Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-493313];
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

March 28, 2022   /s/ Craig Glynn
  Name: Craig Glynn
  Title: Chief Financial Officer
    (Principal Financial Officer)

 

 

 

 EX-32 6 ex32.htm

 

Exhibit 32

 

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of enVVeno Medical Corporation on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Robert Berman, as Chief Executive Officer and principal executive officer and Craig Glynn, as Chief Financial Officer and principal financial officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of the undersigned’s knowledge and belief, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
  2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

 

/s/ Robert Berman  
Robert Berman  
Chief Executive Officer and Principal Executive Officer  
   
Dated: March 28, 2022  
   
/s/ Craig Glynn  
Craig Glynn  
Chief Financial Officer and Principal Financial Officer  

 

Dated: March 28, 2022  

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

 

 

 EX-101.SCH 7 nvno-20211231.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Business Organization and Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Management’s Liquidity Plan link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Right-of-Use Assets and Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Share Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Right-of-Use Assets and Lease Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Share Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Management’s Liquidity Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Schedule of Operating Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of Operating Remaining Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Maturity of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Right-of-Use Assets and Lease Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Note Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Income Tax Provision (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Equity Transactions to Raise Capital Through the Placement (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Stock Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Assumption Used for Valuation of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Stock Options Assumptions in Estimated Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Stock Option Activity Restricted Shares (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Outstanding and Exercisable Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Share Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Dilutive Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nvno-20211231_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 nvno-20211231_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 nvno-20211231_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Common Stock, $0.00001 par value [Member] Warrant to Purchase Common Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] Private Placement [Member] IPO [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Long-Lived Tangible Asset [Axis] Laboratory Equipment [Member] Furniture and Fixtures [Member] Computer Equipment [Member] Leasehold Improvements [Member] Software Development [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Present value of monthly lease payments [Member] Paycheck protection program [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Income Statement Location [Axis] Research and Development [Member] Series C Convertible Preferred Stock [Member] Exchange Agreements [Member] Securties Purchase Agreement [Member] Warrant [Member] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Dividend Rate [Member] Warrants [Member] Related Party [Axis] Spartan Capital Securities LLC [Member] Warrant One [Member] Measurement Input, Exercise Price [Member] Measurement Input, Expected Term [Member] Title of Individual [Axis] Board of Directors [Member] Advisor [Member] Plan Name [Axis] 2016 Incentive Plan [Member] Selling, General and Administrative Expenses [Member] Award Type [Axis] Restricted Stock [Member] Antidilutive Securities [Axis] Restricted Stock Units (RSUs) [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Prepaid expenses and other current assets Total Current Assets Property and equipment, net Operating lease right-of-use assets, net Security deposits and other assets Total Assets Liabilities and Stockholders’ Equity Current Liabilities: Accounts payable Accrued expenses and other current liabilities Note Payable Current portion of operating lease liabilities Total Current Liabilities Long-term operating lease liabilities Total Liabilities Commitments and Contingencies (Note 9) Stockholders’ Equity: Preferred stock, par value $0.00001, 10,000,000 shares authorized: no shares issued or outstanding Common stock, par value $0.00001, 250,000,000 shares authorized, 9,469,850 and 2,541,529 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Equity Total Liabilities and Stockholders’ Equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Selling, general and administrative expenses Research and development expenses Loss from Operations Other (Income) Expense: Gain on extinguishment of note payable Interest (income) expense, net Change in fair value of derivative liabilities Other (income) expense Total Other (Income) Expense Net Loss Deemed dividend to Series C Preferred Stockholders Net Loss Attributable to Common Stockholders Net Loss Per Basic and Diluted Common Share: Weighted Average Number of Common Shares Outstanding: Basic and Diluted Beginning balance, value Beginning balance, shares Common stock issued in private placement offering Common stock issued in private placement offering, shares Common stock issued in public offering Common stock issued in public offering, shares Preferred stock issued in private placement Preferred stock issued in private placement, shares Preferred stock exchange to common stock Preferred stock exchange to common stock, shares Common stock issued for exercise of warrants Common stock issued for exercise of warrants, shares Fair Value of Warrants Issued Shares issued in satisfaction of trade payable Shares issued in satisfaction of trade payable, shares Common stock issued in At The Market Transactions (ATM) Common stock issued in At The Market Transactions (ATM), shares Common stock issued in registered direct offering Common stock issued in registered direct offering, shares Reclassification of Warrant Derivatives to Equity Shared-Based Compensation Shared-Based Compensation, shares Net loss Ending balance, value Ending balance, shares Net of offering costing Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation Depreciation and amortization Amortization of right-of-use assets Change in fair value of derivatives Loss on disposition of fixed assets Changes in operating assets and liabilities: Prepaid expenses and other current assets Security deposit and other assets Accounts payable Accrued expenses Payments on lease liabilities Total adjustments Net Cash Used in Operating Activities Cash Flows from Investing Activities Purchase of property and equipment Net Cash Used in Investing Activities Cash Flows from Financing Activities Proceeds from private placement, net Proceeds from shares issued under ATM Proceeds from registered direct offering Proceeds from public offerings, net Proceeds from preferred stock issued in private placement, net Proceeds from issuance of note payable Proceeds from warrant exercises Net Cash Provided by Financing Activities Net Increase (Decrease) in Cash, Cash Equivalent, and Restricted Cash Cash, cash equivalents and restricted cash - Beginning of year Cash, cash equivalents and restricted cash - End of year Supplemental Disclosures of Cash Flow Information: Interest paid Income taxes paid Non-Cash Investing and Financing Activities Gain on extinguishment of note payable Fair value of common stock issued in satisfaction of trade payable Fair value of warrants issued to Preferred Exchange Participants, SABR and re-priced placement agent warrant Derivative liabilities reclassified to equity Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Organization and Nature of Operations Management’s Liquidity Plan Accounting Policies [Abstract] Significant Accounting Policies Property, Plant and Equipment [Abstract] Property and Equipment Right-of-use Assets And Lease Liabilities Right-of-Use Assets and Lease Liabilities Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Note Payable Income Tax Disclosure [Abstract] Income Taxes Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Stockholders’ Equity Share-based Payment Arrangement [Abstract] Share Based Compensation Earnings Per Share [Abstract] Net Loss Per Share Use of Estimates Property and Equipment, Net Impairment of Long-lived Assets Income Taxes Fair Value of Financial Instruments Derivative Liabilities Net Loss per Share Stock-Based Compensation Concentrations Recently Adopted Accounting Standards Recent Accounting Standards Schedule of Property and Equipment Schedule of Operating Lease Cost Schedule of Supplemental Cash Flow Information Related to Operating Lease Schedule of Operating Remaining Lease Term and Discount Rate Schedule of Maturity of Lease Liabilities Schedule of Accrued Expenses Schedule of Income Tax Provision (Benefit) Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities Schedule of Equity Transactions to Raise Capital Through the Placement Schedule of Stock Warrant Activity Schedule of Assumption Used for Valuation of Derivative Liability Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis Schedule of Stock Options Assumptions in Estimated Fair Value Schedule of Stock Option Activity Schedule of Stock Option Activity Restricted Shares Schedule of Outstanding and Exercisable Restricted Stock Units Schedule of Dilutive Net Loss Per Common Share Cash [custom:WorkingCapital-0] Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property plant and equipment useful life Cash FDICInsured amount Cash uninsured amount Total property and equipment Less: accumulated depreciation Property and equipment, net Depreciation expense Schedule Of Operating Lease Cost Operating lease cost Schedule Of Supplemental Cash Flow Information Related To Operating Lease Cash paid for amounts included in the measurement of lease liabilities Remaining lease term Discount rate Year ended December 31, 2022 Year ended December 31, 2023 Year ended December 31, 2024 Year ended December 31, 2025 Year ended December 31, 2026 Year ended December 31, 2027 Total Less: Imputed interest Present value of our lease liability Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Operating lease renewal term Initial lease rate per month Operating expenses for building repairs and maintenance Financing leases term description Accrued compensation costs Accrued professional fees Accrued research and development Accrued warrants Other Accrued expenses Notes payable amount Maturity date Interest rate Gain on extinguishment of debt Fedral: Current Fedral: Deferred State and local: Current State and local: Deferred Current and Deferred Federal, State and Local, Tax Expense (Benefit) Change in valuation allowance Income tax provision (benefit) Tax benefit at federal statutory rate State taxes, net of federal benefit Nondeductible compensation Permanent differences True up adjustments Change in valuation allowance Effective income tax rate Net operating loss carryforwards Research and development credit carryforwards Intangible assets Operating lease liability Stock-based compensation Impairment loss Total gross deferred tax assets Operating lease asset Property and equipment Total net deferred tax assets Less: valuation allowance Total Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Tax Credit Carryforward, Valuation Allowance Equity Method Investment, Ownership Percentage Federal Income Tax Expense (Benefit), Continuing Operations Operating loss carryforwards expired Operating loss carryforwards expired unused Operating Loss Carryforwards [custom:AnnualLimitOfDeductionPercentage] Net operating loss carryforwards Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of shares issued during the period Net Proceeds issued during the period Number of Warrants, Outstanding Weighted Average Exercise Price, Outstanding Number of Warrants, Issued Weighted Average Exercise Price, Issued Number of Warrants, Exercised Weighted Average Exercise Price, Exercised Number of Warrants, Cancelled Weighted Average Exercise Price, Cancelled Weighted average remaining life in years, Outstanding Intrinsic value, Outstanding Number of Warrants, Outstanding and exercisable Weighted Average Exercise Price, Outstanding and exercisable Weighted average remaining life in years, Outstanding and exercisable Intrinsic value, Outstanding and exercisable Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Risk-Free Rate Contractual Term (Years) Balance – January 1, 2020 Derivative liabilities associated with the issuance of common stock warrants Derivative liabilities associated with the issuance of placement agent warrants Change in fair value of derivative liabilities Reclassification of warrant derivatives to equity Balance – December 31, 2020 Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Common stock par value Conversion of stock Purchase price percentage Preferred stock, liquidation preference per share Deemed dividend Conversion of stock, description Fair value adjustment Warrants and rights outstanding measurement input Expected term Warrants and rights outstanding measurement input Net proceeds from warrant exercises after deducting underwrites and placement agents fees and expenses Fair value adjustment Warrants description Warrants intrinstic Class of Warrant or Right, Number of Securities Called by Warrants or Rights Payment of dispute settlements Derivative liability Increase in derivative liability Decrease in derivative liability Derivative liability, description Derivative difference description Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Expected term Volatility, minimum Volatility, maximum Volatility Risk free interest rate, minimum Risk free interest rate, maximum Dividend yield Number of options beginning Weighted Average Exercise Price Outstanding beginning Number of options granted Weighted Average Exercise Price, Granted Number of options forfeited Weighted Average Exercise Price, Forfeited Weighted Average Remaining life in years Aggregate intrinsic value Number of options ending Weighted Average Exercise Price Outstanding Ending Aggregate intrinsic value Number of options exercisable Weighted Average Exercise Price Outstanding, Exercisable Weighted Average Remaining life in years, exercisable Outstanding shares, beginning Granted Shares Vested Outstanding shares, ending Restricted Stock Unit for Outsatnding number of units, restricted stock Weighted Average Remaining Life In Years Stock options Common Stock, Capital Shares Reserved for Future Issuance Number of shares authorized greater than minimum percentage Vesting period Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive common stock equivalents excluded from diluted net loss per share Security deposits and other assets noncurrent. Deferred revenue - related party. Common stock issued in private placement offering. Preferred stock issued in private placement. Preferred stock exchange to common stock. Reclassification of warrant derivatives to equity. Deemed dividend. Common stock issued in at market transactions shares. Warrants intrinstic. Common stock issued in registered direct offering. Accrued franchise taxes. Accrued research and development. Proceeds from share issued under Atm net Proceeds from registered direct offering net amount. Fair value of common stock issued in satisfaction of trade payable. Derivative liabilities reclassified to equity. Paycheck protection program [Member] Gain on extinguishment of note payable. Exercise Price Range Ten [Member] Exercise Price Range Eleven [Member] Exercise Price Range Twelve [Member] Exercise Price Range Thirteen [Member] Exercise Price Range Fourteen [Member] Exercise Price Range Fifteen [Member] Exercise Price Range Sixteen [Member] Exercise Price Range Seventeen [Member] Exercise Price Range Eighteen [Member] Exercise Price Range Nineteen [Member] Exercise Price Range Twenty [Member] Exercise Price Range Twenty One [Member] Exercise Price Range Twenty Two [Member] Warrants Outstanding, Exercisable Into Common stock. The number of shares reserved for issuance pertaining to the outstanding exercisable warrants as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied. Securties Purchase Agreement [Member] Warrants [Member] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Exercise Price Range Five [Member] Exercise Price Range Six [Member] Exercise Price Range Seven [Member] Exercise Price Range Eight [Member] Exercise Price Range Nine [Member] Operating lease liability. Operating lease asset. Property and equipment. Warrant to Purchase Common Stock [Member] Common Stock, $0.00001 par value [Member] Working Capital. AdditionalPaidInCapitalFairValueOfWarrantsIssued. Sequencing [Policy Text Block] Series C Convertible Preferred Stock [Member] New accounting adopted [Policy Text Block] Shares issued in satisfaction of trade payable. Warrants description. Shares issued in satisfaction of trade payable, shares Common stock issued in at the market transactions . Common stock issued in registered direct offering, shares Laboratory Equipment [Member] Preferred stock issued in private placement, shares Preferred stock exchange to common stock, shares. Potentially dilutive common stock equivalents [TableTextBlock] Options Outstanding, Exercisable Into Common stock. Schedule of share based compensation stock options activity restricted shares [Table Text Block] Present value of monthly lease payments [Member] Accrued warrants. Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments granted in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average exercise price. Share based compensation arrangement by share based payment award non option equity instruments foreitures in period weighted average exercise price. Share based compensation arrangement by share based payment award equity instruments non options equity outstanding weighted average remaining contractual terms. Share based compensation arrangement by share based payment award equity instruments non options equity outstanding weighted average remaining contractual term. Sharebased compensation arrangement by sharebased payment award equity instruments non options equity aggregate intrinsic value outstanding. Fair value of warrants issued to preferred exchange participants sabr and repriced placement agent warrant. Stock issued during period shares for exercise of warrants shares. Derivative liability measurement difference description. Common Stock One [Member] Common Stock Two [Member] Common Stock Three [Member] Stock option percentage description. 2016 Incentive Plan [Member] Potentially dilutive common stock equivalents excluded from diluted net loss per share. Research and Development [Member] Share based compensation shares authorized under stock option plans exercise price range options exercisable into common stock. Annual limit of deduction percentage. Schedule of assumption used for valuation of fdrivative liability [TableTextBlock]. Schedule of equity warrent [TableTextBlock] Stock Issued during period shares for exercise of warrantsi. Common stock issued in private placement offering shares. Schedule of outstanding and exercisable warrants [TableTextBlock] Derivative liability masurement input term. Fair value net derivative asset liability imeasured on recurring basis unobservable inputs reconciliation reclassification issues one. Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation reclassification of warrant derivatives to equity. Schedule of operating remaining lease term and discount rate [TableTextBlock] Spartan Capital Securities LLC [Member] Board of Directors [Member] Advisor [Member] Purchase Price Perentage. Current and deferred federal, state and local, tax expense (benefit). Exchange Agreements [Member] Warrant One [Member] Weighted average remaining life, restricted stock awards. Stock Option and Restricted Stock Units [Member] Percentage of authorized number of shares. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Interest Income (Expense), Net Derivative, Gain (Loss) on Derivative, Net Other Nonoperating Income (Expense) Nonoperating Income (Expense) Preferred Stock Dividends, Income Statement Impact Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding Gain (Loss) on Disposition of Assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Deposit Assets Increase (Decrease) in Accounts Payable Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Debt Disclosure [Text Block] Income Tax, Policy [Policy Text Block] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Deferred Tax Assets, Gross Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net State and Local Income Tax Expense (Benefit), Continuing Operations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs Warrants and Rights Outstanding, Measurement Input Equity, Fair Value Adjustment Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period EX-101.PRE 11 nvno-20211231_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Mar. 24, 2022
Jun. 30, 2021
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 001-38325    
Entity Registrant Name enVVeno Medical Corporation    
Entity Central Index Key 0001661053    
Entity Tax Identification Number 33-0936180    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 70 Doppler    
Entity Address, City or Town Irvine    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 92618    
City Area Code (949)    
Local Phone Number 261-2900    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period true    
Entity Shell Company false    
Entity Public Float     $ 58.5
Entity Common Stock, Shares Outstanding   9,469,850  
ICFR Auditor Attestation Flag false    
Auditor Firm ID 688    
Auditor Name Marcum llp    
Auditor Location New York, NY    
Common Stock, $0.00001 par value [Member]      
Title of 12(b) Security Common Stock, $0.00001 par value    
Trading Symbol NVNO    
Security Exchange Name NASDAQ    
Warrant to Purchase Common Stock [Member]      
Title of 12(b) Security Warrant to Purchase Common Stock    
Trading Symbol NVNOW    
Security Exchange Name NASDAQ    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 54,727,740 $ 9,334,584
Prepaid expenses and other current assets 312,350 234,467
Total Current Assets 55,040,090 9,569,051
Property and equipment, net 617,855 398,967
Operating lease right-of-use assets, net 1,986,704 539,974
Security deposits and other assets 54,493 29,843
Total Assets 57,699,142 10,537,835
Current Liabilities:    
Accounts payable 560,083 1,390,362
Accrued expenses and other current liabilities 728,876 1,168,969
Note Payable 312,700
Current portion of operating lease liabilities 291,104 314,202
Total Current Liabilities 1,580,063 3,186,233
Long-term operating lease liabilities 1,714,871 253,746
Total Liabilities 3,294,934 3,439,979
Commitments and Contingencies (Note 9)  
Stockholders’ Equity:    
Preferred stock, par value $0.00001, 10,000,000 shares authorized: no shares issued or outstanding
Common stock, par value $0.00001, 250,000,000 shares authorized, 9,469,850 and 2,541,529 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively 95 25
Additional paid-in capital 136,255,346 72,421,242
Accumulated deficit (81,851,233) (65,323,411)
Total Stockholders’ Equity 54,404,208 7,097,856
Total Liabilities and Stockholders’ Equity $ 57,699,142 $ 10,537,835
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.00001 $ 0.00001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.00001 $ 0.00001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 9,469,850 2,541,529
Common stock, shares outstanding 9,469,850 2,541,529
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating Expenses:    
Selling, general and administrative expenses $ 11,164,858 $ 4,882,877
Research and development expenses 5,727,645 4,252,249
Loss from Operations (16,892,503) (9,135,126)
Other (Income) Expense:    
Gain on extinguishment of note payable (312,700)
Interest (income) expense, net (18,709) (3,739)
Change in fair value of derivative liabilities (211,807)
Other (income) expense (33,272) 215,906
Total Other (Income) Expense (364,681) 360
Net Loss (16,527,822) (9,135,486)
Deemed dividend to Series C Preferred Stockholders (607,220)
Net Loss Attributable to Common Stockholders $ (16,527,822) $ (9,742,706)
Net Loss Per Basic and Diluted Common Share: $ (1.90) $ (7.54)
Weighted Average Number of Common Shares Outstanding:    
Basic and Diluted 8,679,824 1,291,469
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Changes in Stockholders' Equity - USD ($)
Series C Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 7 $ 57,177,858 $ (56,187,925) $ 989,940
Beginning balance, shares at Dec. 31, 2019 717,274      
Common stock issued in private placement offering [1]   $ 1 24,304 24,305
Common stock issued in private placement offering, shares [1]   52,000      
Common stock issued in public offering [2]   $ 11 9,847,890 9,847,901
Common stock issued in public offering, shares [2]   1,148,996      
Preferred stock issued in private placement [3] $ 42 1,358,060 1,358,102
Preferred stock issued in private placement, shares [3] 4,205,406        
Preferred stock exchange to common stock $ (42) $ 2 40
Preferred stock exchange to common stock, shares (4,205,406) 243,125      
Common stock issued for exercise of warrants   $ 4 2,985,751 2,985,755
Common stock issued for exercise of warrants, shares   367,660      
Reclassification of Warrant Derivatives to Equity   334,230 334,230
Shared-Based Compensation   693,109 693,109
Shared-Based Compensation, shares   12,474      
Net loss   (9,135,486) (9,135,486)
Ending balance, value at Dec. 31, 2020 $ 25 72,421,242 (65,323,411) 7,097,856
Ending balance, shares at Dec. 31, 2020 2,541,529      
Common stock issued in public offering   $ 59 38,127,717 38,127,776
Common stock issued in public offering, shares   5,914,284      
Common stock issued for exercise of warrants   $ 1 245,249 245,250
Common stock issued for exercise of warrants, shares   52,827      
Fair Value of Warrants Issued   211,976 211,976
Shares issued in satisfaction of trade payable   37,576 37,576
Shares issued in satisfaction of trade payable, shares   5,772      
Common stock issued in At The Market Transactions (ATM)   $ 2 960,273 960,275
Common stock issued in At The Market Transactions (ATM), shares   170,963      
Common stock issued in registered direct offering   $ 8 18,273,583 18,273,591
Common stock issued in registered direct offering, shares   781,615      
Shared-Based Compensation   5,977,730 5,977,730
Shared-Based Compensation, shares   2,860      
Net loss   (16,527,822) (16,527,822)
Ending balance, value at Dec. 31, 2021   $ 95 $ 136,255,346 $ (81,851,233) $ 54,404,208
Ending balance, shares at Dec. 31, 2021   9,469,850      
[1] net of offering costs of $0.1 million.
[2] net of offering costs of $2.2 million.
[3] net of offering costs of $0.2 million.
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Changes in Stockholders' Equity (Parenthetical)
$ in Millions
 12 Months Ended
Dec. 31, 2020
USD ($)
Private Placement [Member]  
Net of offering costing $ 0.1
Private Placement [Member] | Preferred Stock [Member]  
Net of offering costing 0.2
IPO [Member]  
Net of offering costing $ 2.2
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash Flows from Operating Activities    
Net loss $ (16,527,822) $ (9,135,486)
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 5,999,178 881,213
Depreciation and amortization 149,002 97,549
Amortization of right-of-use assets 303,907 286,423
Change in fair value of derivatives (211,807)
Gain on extinguishment of note payable (312,700)
Loss on disposition of fixed assets 27,802
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (37,883) (117,820)
Security deposit and other assets (24,650)
Accounts payable (832,703) 169,173
Accrued expenses (249,565) 614,428
Payments on lease liabilities (312,610) (288,685)
Total adjustments 4,681,976 1,458,276
Net Cash Used in Operating Activities (11,845,846) (7,677,210)
Cash Flows from Investing Activities    
Purchase of property and equipment (367,890) (180,291)
Net Cash Used in Investing Activities (367,890) (180,291)
Cash Flows from Financing Activities    
Proceeds from private placement, net 570,341
Proceeds from shares issued under ATM 960,275
Proceeds from registered direct offering 18,273,591
Proceeds from public offerings, net 38,127,776 9,847,901
Proceeds from preferred stock issued in private placement, net 1,358,102
Proceeds from issuance of note payable 312,700
Proceeds from warrant exercises 245,250 2,985,755
Net Cash Provided by Financing Activities 57,606,892 15,074,799
Net Increase (Decrease) in Cash, Cash Equivalent, and Restricted Cash 45,393,156 7,217,298
Cash, cash equivalents and restricted cash - Beginning of year 9,334,584 2,117,286
Cash, cash equivalents and restricted cash - End of year 54,727,740 9,334,584
Supplemental Disclosures of Cash Flow Information:    
Interest paid
Income taxes paid
Non-Cash Investing and Financing Activities    
Gain on extinguishment of note payable (312,700)
Fair value of common stock issued in satisfaction of trade payable 35,576
Fair value of warrants issued to Preferred Exchange Participants, SABR and re-priced placement agent warrant (211,976)
Derivative liabilities reclassified to equity $ 334,229
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Business Organization and Nature of Operations
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization and Nature of Operations

Note 1 – Business Organization and Nature of Operations

 

enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with deep venous Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Our products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in our deep venous system of the leg, and is called the VenoValve®. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and have been commercially successful. We currently lease a 14,507 sq. ft. manufacturing facility in Irvine, California, where we manufacture medical devices for our clinical trials, and which has capacity for commercial manufacturing.

 

On September 21, 2021, we announced that we were changing our name from Hancock Jaffe to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of venous disease. In addition to the VenoValve, we announced that we have begun development of a second device for the treatment of venous disease which we are calling enVVe. In connection with this change in strategy, we indicated that we are not pursuing further development of the CoreoGraft, which is now outside of our primary focus area.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Management’s Liquidity Plan
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Management’s Liquidity Plan

Note 2 – Management’s Liquidity Plan

 

As of December 31, 2021, the Company had a cash balance of $54.7 million and working capital of $53.5 million. Although the Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products, Management believes that our capital resources at December 31, 2021, are sufficient to meet our obligations as they become due within one year after the date of this Annual Report, and sustain operations.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

Note 3 – Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.

 

Property and Equipment, Net

 

Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from 5 to 7 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.

 

Impairment of Long-lived Assets

 

The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

 

Fair Value of Financial Instruments

 

The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

 

FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 Quoted prices available in active markets for identical assets or liabilities trading in active markets.
   
Level 2 Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
   
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

 

Financial instruments, including accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Derivative liabilities are accounted for at fair value on a recurring basis.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

Derivative Liabilities

 

Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification.

 

Net Loss per Share

 

The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period including warrants exercisable for little or no cash consideration. Net loss attributable to common stockholders in 2020 consists of net loss adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock (see Note 10 - Stockholders Equity Series C Convertible Preferred Stock). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, would have been anti-dilutive.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Stock-Based Compensation

 

The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and nonemployees. The accounting treatment for share-based payments to employees and non-employees is substantially equivalent.

 

Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the service period required for the award.

 

The fair value of the Company’s stock options is estimated at the date of grant using the Black-Scholes based option valuation model. For the expected term, the Company uses SEC Staff Accounting Bulletin No. 107 simplified method for “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) if an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 to 90 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.

 

The volatility assumption is based on the historical volatility of the Company’s common stock with an equivalent remaining expected term. The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining expected term.

 

For option grants without performance conditions, the Company recognizes compensation expense over the requisite service period ratably, recognizing expense for each tranche of each grant starting on the grant date. For grants that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method. Compensation expense for grants with performance conditions is recognized only for those awards expected to vest.

 

Forfeitures of unvested stock options are recorded when they occur.

 

Concentrations

 

The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $54.5 million and $9.1 million as of December 31, 2021 and 2020, respectively.

 

Recently Adopted Accounting Standards

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this standard did not have a material impact on our financial statements.

 

Recent Accounting Standards

 

In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our financial statements and related disclosures.

 

In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU No. 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

In October 2021, the FASB issued Accounting Standards Update 2021-08 (“ASU No. 2021-08”), Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 4 – Property and Equipment

 

As of December 31, 2021, and 2020, property and equipment consist of the following:

 

   2021   2020 
   December 31, 
   2021   2020 
Laboratory equipment  $522,539   $320,830 
Furniture and fixtures   124,093    98,392 
Computer equipment   164,298    65,078 
Leasehold improvements   192,668    158,092 
Software   251,163    244,479 
Total property and equipment   1,254,761    886,871 
Less: accumulated depreciation   (636,906)   (487,904)
Property and equipment, net  $617,855   $398,967 

 

Depreciation expense was $0.1 million for the years ended December 31, 2021 and 2020. Depreciation expense is reflected in general and administrative expenses in the accompanying statements of operations.

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Right-of-Use Assets and Lease Liabilities
 12 Months Ended
Dec. 31, 2021
Right-of-use Assets And Lease Liabilities  
Right-of-Use Assets and Lease Liabilities

Note 5 – Right-of-Use Assets and Lease Liabilities

 

On November 17, 2021, the Company amended its operating lease for its manufacturing facility in Irvine, California, to extend the term an additional 60 months from its September 30, 2022 expiration date to a new expiration date of September 30, 2027. The initial lease rate at the date of the amendment was $30,206 per month with escalating payments. In connection with the lease, the Company is obligated to pay $7,254 monthly for operating expenses for building repairs and maintenance. The Company has no other operating or financing leases with terms greater than 12 months.

 

The Company determined the lease liabilities using the Company’s estimated incremental borrowing rate of 3.95% to estimate the present value of the remaining monthly lease payments.

 

Our operating lease cost is as follows:

 

  

For the Year Ended

December 31, 2021

 
Operating lease cost  $345,857 

 

Supplemental cash flow information related to our operating lease is as follows:

 

  

For the Year Ended

December 31, 2021

 
Operating cash flow information:     
Cash paid for amounts included in the measurement of lease
liabilities		  $354,561 

 

Remaining lease term and discount rate for our operating lease is as follows:

 

   December 31, 2021 
Remaining lease term   5.7 years 
Discount rate   3.95%

 

Maturity of our lease liabilities by fiscal year for our operating lease is as follows:

 

      
Year ended December 31, 2022  $365,190 
Year ended December 31, 2023   376,146 
Year ended December 31, 2024   387,435 
Year ended December 31, 2025   399,054 
Year ended December 31, 2026   411,024 
Year ended December 31, 2027   315,153 
Total  $2,254,002 
Less: Imputed interest   (248,027)
Present value of our lease liability  $2,005,975 

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses

Note 6 – Accrued Expenses

 

As of December 31, 2021 and 2020, accrued expenses consist of the following:

 

   2021   2020 
   December 31, 
   2021   2020 
Accrued compensation costs  $524,529   $473,799 
Accrued professional fees   84,375    79,650 
Accrued research and development   59,922    368,809 
Accrued warrants   

-

    

188,104

 

Other

   60,050    58,607 
Accrued expenses  $728,876   $1,168,969 

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Note Payable
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
Note Payable

Note 7 – Note Payable

 

On April 12, 2020, the Company obtained a loan (the “Loan”) in the amount of $312,700, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020.

 

The Loan, which was in the form of a Note dated April 12, 2020, was to mature on April 12, 2022, and bore interest at a rate of 1% per annum, payable monthly commencing on November 12, 2020. On September 8, 2021, the Company was notified the Loan and any accrued interest had been forgiven. In connection with this, the Company recorded a gain on extinguishment of debt of $312,700.

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 8 – Income Taxes

 

The following summarizes the Company’s income tax provision (benefit):

   For the Years Ended December 31, 
   2021   2020 
Federal:          
Current  $-   $- 
Deferred   (2,700,372)   (1,828,584)
           
State and local:          
Current   

-

    - 
Deferred   (900,124)   (609,528)
Current and Deferred Federal, State and Local, Tax Expense (Benefit)   (3,600,496)   (2,438,112)
Change in valuation allowance   3,600,496    2,438,112 
Income tax provision (benefit)  $-   $- 

 

The reconciliation between the U.S. statutory federal income tax rate and the Company’s effective tax rate for the year’s ended December 31, 2021 and 2020 is as follows:

 

  

For the Years Ended December 31,

 
   2021   2020 
Tax benefit at federal statutory rate   (21.0)%   (21.0)%
State taxes, net of federal benefit   (7.0)%   (7.0)%
Nondeductible compensation   6.2%   - 
Permanent differences   (0.5)%   2.0%
True up adjustments   0.5%   (0.7)%
Change in valuation allowance   21.8%   26.7%
Effective income tax rate   0.0%   0.0%

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:

 

   2021   2020 
   December 31, 
   2021   2020 
Deferred tax assets:          
Net operating loss carryforwards  $12,881,729   $9,811,086 
Research and development credit carryforwards   185,680    185,680 
Intangible assets   276,184    305,027 
Operating lease liability   78,194    159,025 
Stock-based compensation   923,540    311,304 
Impairment loss   136,612    136,612 
Total gross deferred tax assets   14,481,939    10,908,734 
Deferred tax liabilities          
Operating lease asset   (70,994)   (151,193)
Property and equipment   (102,107)   (49,199)
Total net deferred tax assets   14,308,838    10,708,342 
Less: valuation allowance   (14,308,838)   (10,708,342)
Total  $-   $- 

 

ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s history of operating losses, management believes that recognition of the deferred tax assets arising from the above listed future tax benefits is currently not more likely than not to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $3.6 million and $2.4 million during the years ended December 31, 2021 and 2020, respectively.

 

Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change income taxes may be limited. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s NOL carry forwards are subject to annual limitations due to a greater than 50% ownership change in 2021.

 

At December 31, 2021 and 2020, the Company had post-ownership change net operating loss carryforwards for federal income tax purposes of approximately $45.7 million and $35.0 million, respectively. Pre-2018 federal NOLs of approximately $12.0 million may be carried forward for twenty years and begin to expire in 2029. Based on the 2021 ownership change, the Company expects $7.6 million of its pre-2018 federal NOLs to expire unused. Under the Tax Act, post-2017 federal NOLs in the aggregate amount of $33.0 million can be carried forward indefinitely and the annual limit of deduction equals 80% of taxable income. However, to the extent the Company utilizes its NOL carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized. The Company also has federal research and development tax credit carryforwards of approximately $0.2 million which begin to expire in 2027.

 

As of December 31, 2021 and 2020, the Company had net operating loss carryforwards for state income tax purposes of approximately $45.7 million and $35.0 million, respectively, which can be carried forward for twenty years and begin to expire in 2028.

 

The Company files income tax returns in the U.S. federal jurisdiction as well as California and local jurisdictions and is subject to examination by those taxing authorities. The Company’s federal income taxes for the years beginning in 2018 remain subject to examination. The Company’s state and local income tax returns for the years beginning in 2017 remain subject to examination. No tax audits were initiated during 2021 or 2020.

 

Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations.

 

On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the “IRC”) for 2019 and 2020 to permit additional expensing of interest (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k), (iii) making modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years in order to generate a refund of previously paid income taxes and (iv) enhancing the recoverability of alternative minimum tax credits. The Company has evaluated the impact CARES Act on its provision for income taxes and determined there is not a significant impact to income taxes because of the CARES Act.

 

On June 29, 2020, California’s Governor Newsom signed AB85 suspending California net operating loss (“NOL”) utilization and imposing a cap on the amount of business incentives tax credits (R&D credit) for tax years 2020-2022. Given the tax loss in 2020 and an expected tax loss for 2021, the suspension will not have an impact on the Company’s NOL in California. On February 9, 2022, Mr. Newsom signed SB113 which removes the restrictions in AB85 effective for the 2022 tax year.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 9 – Commitments and Contingencies

 

Litigation Claims and Assessments

 

In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

 

Robert Rankin Complaints

 

On July 9, 2020, the Company was served with a civil complaint filed in the Superior Court for the State of California, County of Orange by a former employee, Robert Rankin, who resigned his employment on or about March 30, 2020. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01146555-CU-WR-CJC and was filed on May 27, 2020. On September 3, 2020 the Company and its Chief Executive Officer were served with a second complaint filed in the Superior Court for the State of California, County of Orange by Mr. Rankin. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01157857 and was filed on August 31, 2020. The complaints assert several causes of action including a cause of action for failure to timely pay Mr. Rankin’s accrued and unused vacation and three months’ severance under his July 16, 2018 employment agreement, defamation, unlawful labor code violations, sex-based discrimination, and unfair competition, and seeks damages for lost wages, emotional and mental distress, consequential damages, punitive damages and attorney’s fees and costs. The Company has denied all claims in both matters (which have now been consolidated) and has filed a counterclaim asserting that Rankin has breached his employment agreement with the Company to the Company’s damage. The Company continues to believe it has meritorious defenses to both matters. As of the date of these financial statements, the amount of loss associated with these complaints, if any, cannot be reasonably estimated. Accordingly, no amounts related to these complaints are accrued as of December 31, 2021.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 10 –Stockholders’ Equity

 

On November 30, 2020, the Company”) effected a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”). As a result of the Reverse Stock Split, every twenty-five shares of issued and outstanding Common Stock was automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.

 

Equity Issuances

 

During 2021 and 2020 the Company has completed various equity transactions to raise capital through the placement of its common and preferred stock. The following table provides an overview of these transactions.

 

Date  Description  Type  Number of shares   Net Proceeds 
2020              
February 25, 2020  Private placement  Common Stock   52,000   $570,341 
April 28, 2020  Registered Direct Offering  Common Stock   75,472   $811,641 
June 3, 2020  Registered Direct Offering  Common Stock   117,216   $1,161,334 
July 17, 2020  Public Offering  Common Stock   575,000   $3,881,907 
July 17, 2020  Private Placement  Preferred Stock   4,205,406   $1,358,099 
October 9, 2020  Registered Direct Offering  Common Stock   381,308   $4,450,500 
Total              $12,233,822 
                 
2021                
February 11, 2021  Public Offering  Common Stock   5,914,284   $38,127,776 
August 2021  At-the-Market Equity Program  Common Stock   170,963   $970,575 
September 9, 2021  Registered Direct Offering  Common Stock   781,615   $18,273,591 
Total             $57,371,942 

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

 

Series C Convertible Preferred Stock

 

On July 17, 2020, the Company issued 4,205,406 shares of Preferred Stock in a private placement. On November 17, 2020, the holders of the Preferred Stock purchased in the July 17, 2020 private placement entered exchange agreements with the Company whereby the holders agreed to exchange all of their 4,205,406 shares of Preferred Stock for 243,125 shares of common stock. This was the original conversion rate of the Preferred Stock after giving effect to the 25:1 reverse split of the Company’s common stock.

 

While the Preferred Stock was outstanding, the holders of the Company’s Preferred Stock could vote with holders of the Common Stock, and with any other shares of preferred stock that vote with the Common Stock, with each holder of Preferred Stock being entitled to one vote per share of Preferred Stock, and were entitled to receive 8% non-compounding cumulative dividends, payable when, as and if declared by the Board of Directors. The Series C Preferred Stock ranked senior to the common stock as to dividends and the distribution of assets in the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, or any sale of the Company.

 

In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, or any sale of the Company, the holders of Preferred Stock were entitled to receive, before and in preference to any distribution of any of the assets to the holders of the common stock, or any other series of the Company’s preferred stock that would then be junior to the Preferred Stock, an amount per share equal to $0.37 for each outstanding share of Preferred Stock (the “Original Series C Issue Price”), plus all accrued but unpaid dividends thereon through the date of such event.

 

In certain circumstances, the holders of Preferred Stock were entitled to receive a liquidation preference payment of $0.37 per share of Preferred Stock, plus accrued and unpaid dividends. Those accrued and unpaid dividends were $23,859 in the aggregate as of September 30, 2020 and were reflected as a deemed dividend in determining net loss available to common stockholders during that period. As a result of the exchange of the Preferred Stock for common stock, it is no longer outstanding (see below).

 

The liquidation preference of the Preferred Stock was subordinate and ranks junior to all indebtedness of the Company.

 

The Company had the ability to elect to convert the Preferred Stock to common stock in the event the Company either (i) consummated a merger, or (ii) raised an aggregate of at least $8,000,000 in gross proceeds in a transaction or series of transactions within any twelve (12) month period. In the event the Company elected to affect such a conversion, each share of Series C Preferred Stock would have been convertible into 0.05781 shares of common stock.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS

 

The Company determined that the Preferred Stock represented permanent equity due to the absence of a redemption feature and that the embedded conversion option was clearly and closely related to the equity host and did not require bifurcation. The $2,431,250 fair value of the warrants was calculated using the Black-Scholes option pricing model, using the $11.00 stock price, an expected term of 7.0 years, volatility of 118.7%, a risk-free rate of 0.47% and expected dividends of 0.00%. The $1,556,000 of gross proceeds were allocated on a relative fair value basis of $607,220 to the Preferred Stock and $948,781 to the warrants. The Preferred Stock includes a contingent beneficial conversion feature (“BCF”) which was valued at its $2,067,155 intrinsic value using the commitment date stock price of $11.00 per share and the effective conversion price of $2.50 per share, but was limited to the $607,220 of proceeds that were allocated to the Preferred Stock.

 

The November 17, 2020 exchange agreements resolved the contingency related to the BCF and, accordingly, the contingent BCF was recognized as a deemed dividend for the purposes of determining the net loss attributable to common stockholders for calculating net loss per share. In addition, since the Company does not have retained earnings, the dividend has been recorded against additional paid-in capital.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Warrants

 

A summary of warrant activity during the years ended December 31, 2021 and 2020 is presented below:

 

   Common Stock 
   Number of
Warrants		  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Life in

Years

  

Intrinsic

Value

 
Outstanding, January 1, 2020   174,681   $127.50           
Issued    1,702,810    9.26           
Exercised   (367,660)   8.13           
Cancelled   (2,029)   107.50           
Outstanding, January 1, 2021   1,507,802   $20.10    5.3   $448,140 
Issued   4,895,016    4.59           
Exercised   (52,827)   5.03           
Cancelled   (38,286)   16.10           
Outstanding and exercisable, December 31, 2021   6,311,705   $8.80    4.2   $474,464 

 

In November 2020 as part of resolving a dispute, the Company agreed to issue warrants to purchase 17,618 shares of common stock at a purchase price of $8.00 per share, and warrants to purchase 18,056 shares of common stock at a purchase price of $10.25 per share. These amounts were in dispute and were paid pursuant to an investment banking agreement dated February 12, 2020 in connection with financings which occurred in July and October 2020. The fair value of these warrants on the settlement date was $0.1 million and $0.1 million, respectively. The total amount of the payment to settle the dispute was $0.5 million, including the value of the warrants. and was included in the cost of the July and October financings. The fair value of the warrants was determined using the Black-Scholes method with the following assumptions: stock price of $8.00 and $10.35, risk-free interest rate of 0.46%, volatility of 112.7%, annual rate of quarterly dividends of 0%, and an expected term of 2.5 years. The investment banking agreement has now been terminated with no further obligations.

 

In November 2020 the Company’s Board of Directors approved the issuance of warrants to purchase 6,400 shares of common stock to an advisor and warrants to purchase 20,000 shares of common stock to certain participants in the preferred share exchange (see Note 10, Stockholders Equity – Series C Convertible Preferred Stock). Separately the Company agreed to re-price warrants issued to the placement agent for the Company’s February 25, 2020 private placement. These warrants and the re-priced warrant were issued in February 2021. The value of these warrants at December 31, 2020 was $188,804 and is included in accrued expenses. The Company determined their value using the Black-Scholes method with the following assumptions: stock price of $8.65, risk-free interest rate of 0.36%, volatility of 114.3%, annual rate of quarterly dividends of 0%, and an expected term of 2.5 to 3.5 years.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Warrants – Derivative Liabilities

 

The warrants issued in connection with our February 25, 2020 Bridge Offering were determined to be derivative financial instruments when issued because the Company did not have control of the obligation to obtain shareholder approval by May 25, 2020 to increase the number of authorized shares or to approve a reverse stock split. The accounting treatment of derivative financial instruments required that the Company record the warrants as a liability at fair value and marked-to-market the instruments at fair values as of each subsequent balance sheet date. Any change in fair value is recorded as a change in the fair value of derivative liabilities for each reporting period at each balance sheet date.

 

The warrant derivatives were valued as of the February 25, 2020 issuance date, as of the quarter ended March 31, 2020, as of June 30, 2020, and as of September 15, 2020 when the Company’s stockholders approved an increase in authorized shares in an amount sufficient to allow full exercise of these warrants. The value at issuance was $546,036 and was recorded as a derivative liability. The value of the derivative liability was $199,907 at March 31, 2020, $281,183 at June 30, 2020, and $334,229 at September 15, 2020.

 

The derivative liability increased $53,046 and decreased $211,807 during the three and nine months ended September 30, 2020, respectively. The changes in derivative liability is reflected in Other Income on the accompanying Statement of Operations.

 

The Company reassessed the classification at each balance sheet date to determine if it should be changed as a result of events during the period. On September 15, 2020, the fair value of derivative liabilities was reclassified to equity when the Company’s stockholders approved items comprising a Capital Event. Accordingly, there is no fair value of derivative liabilities as of December 31, 2020.

 

The fair value of the warrants was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The following inputs and assumptions were used for the valuation of the derivative liability:

 

  

February 25,

2020

  

March 31,

2020

  

June 30,

2020

  

September 15,

2020

 
Projected Volatility   97.1%   102.7%   102.7%   110.7%
Risk-Free Rate   1.36%   0.38%   0.29%   0.31%
Contractual Term (Years)   5    5    4.75    4.5 

 

  ● It was assumed the stock price would fluctuate with the Company’s projected volatility.
     
  ● The projected volatility was based on the historical volatility of the Company.
     
  ● If the Company was required to pay the fair value of the warrant in cash as of May 25, 2020, the obligation was discounted at the Company’s estimated cost of debt based on short-term C-CCC bond ratings of 19.5% and 28.5%.
     
  ● The likelihood of the Company calling a shareholder meeting and achieving shareholder approval was 90% as of February 25, 2020.
     
  ● As June 30, 2020, the Company projected shareholder approval would not be obtained until approximately 8/31/20. No mandatory exercise was allowed prior to that date.
     
  ● Until the Company obtained shareholder approval to increase the authorized shares on September 15, 2020, we assumed the warrant holders have an option to require the Company to pay the fair value of the warrants. The derivative value at that date was $334,229.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis:

 

   Derivative 
   Liabilities 
Balance – January 1, 2020  $- 
Derivative liabilities associated with the issuance of common stock warrants   513,534 
Derivative liabilities associated with the issuance of placement agent warrants   32,502 
Change in fair value of derivative liabilities   (211,807)
Reclassification of warrant derivatives to equity   (334,229)
Balance – December 31, 2020  $- 

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Share Based Compensation
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Share Based Compensation

Note 11 – Share Based Compensation

 

Omnibus Incentive Plan

 

The Company issues share-based awards under its Company’s 2016 Omnibus Incentive Plan, which enables the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, other share based awards and cash awards to associates, directors, consultants, and advisors of the Company and its affiliates, and to improve the ability of the Company to attract, retain, and motivate individuals upon whom the Company’s sustained growth and financial success depend, by providing such persons with an opportunity to acquire or increase their proprietary interest in the Company. Stock options granted under the 2016 Plan may be non-qualified stock options or incentive stock options, within the meaning of Section 422(b) of the Internal Revenue Code of 1986, except that stock options granted to outside directors and any consultants or advisers providing services to the Company or an affiliate shall in all cases be non-qualified stock options. The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant.

 

The 2016 Plan is to be administered by the Board, which has discretion over the awards and grants thereunder. No awards may be issued after November 21, 2026.

 

The Plan was adopted in 2016 and amended in 2018, 2020 and 2021 to increase the number of shares authorized to be awarded under the Plan. As of December 31, 2021 there are 4,500,000 shares authorized under the Plan as a result of the increase authorized by our shareholders in 2021. The number of shares subject to the Plan is automatically adjusted from time to time such that shares authorized under the plan shall at all times be equal to at least 20% of the issued and outstanding shares of the Company on a fully diluted basis. The current number of shares authorized is greater than the 20% minimum.

 

Stock Options

 

The fair value of each option grant is estimated at the grant date using the Black Scholes method. The following assumptions were used in estimating fair value:

 

   2021    2020 
Expected term   5.44 – 6.5 years     5.16 – 5.76 years 
Volatility   112.94 – 103.6%    107.5%
Risk free interest rate   0.08 – 1.20%    0..30 – 0.36%
Dividend yield   0.00%    0.00%

 

The Company estimated the expected term of the options using the simplified method. The Company uses its stock’s historical market information to calculate volatility used in estimating fair value of options granted.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

A summary of the option activity during the years ended December 31, 2021 and 2020 is presented below:

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
Outstanding, January 1, 2020   99,689   $111.00           
Granted   122,000    10.00           
Forfeited   (11,000)   63.88           
Outstanding, December 31, 2020   210,689   $31.48    8.7   $         - 
Granted   3,246,551   $7.70           
Forfeited   (15,333)   8.36           
Outstanding, December 31, 2021   3,441,907   $9.16    9.3   $- 
                     
Exercisable, December 31, 2021   982,921   $12.94    8.9   $- 

 

The Company includes share-based compensation expense in selling, general and administrative expenses, and recognized $6.0 million and $0.7 million during the years ended December 31, 2021 and 2020, respectively.

 

As of December 31, 2021, there was $15.2 million of unrecognized share-based compensation expense related to outstanding stock options and restricted stock units that will be recognized over the weighted average remaining vesting period of 2 years.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 

Restricted Stock Units

 

The Company also issues restricted shares and restricted stock units under the 2016 Plan. A summary of the restricted share and restricted stock units activity during the years ended December 31, 2021 and 2020 is presented below:

 

   Number of 
   Restricted Shares 
Outstanding, January 1, 2020   7,806 
Granted   10,000 
Shares vested   (12,864)
Outstanding, December 31, 2020   4,942 
Granted   400,000 
Shares Vested   (2,860)
Outstanding, December 31, 2021   402,082 

 

A summary of outstanding restricted stock units as of December 31, 2021 is presented below:

 Schedule of Outstanding and Exercisable Restricted Stock Units

Restricted Stock Units
Grant Date  Restricted Stock Unit for 

Outstanding

Number of

Units

  

Weighted

Average

Remaining

Life In

Years

 
9/13/2019  Common Stock   2,082    0.9 
11/30/2021  Common Stock   400,000    - 
              
   Total   402,082      

 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share

Note 12 – Net Loss Per Share

 

The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Shares of common stock issuable upon exercise of warrants   4,552,670    1,507,802 
Shares of common stock issuable upon exercise of options and restricted stock units   3,843,989    215,631 
Potentially dilutive common stock equivalents excluded from diluted net loss per share   8,396,659    1,723,433 

 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.

 
Property and Equipment, Net

Property and Equipment, Net

 

Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from 5 to 7 years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.

 
Impairment of Long-lived Assets

Impairment of Long-lived Assets

 

The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 
Income Taxes

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

 

FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 Quoted prices available in active markets for identical assets or liabilities trading in active markets.
   
Level 2 Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
   
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.

 

Financial instruments, including accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Derivative liabilities are accounted for at fair value on a recurring basis.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS
Derivative Liabilities

Derivative Liabilities

 

Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification.

 
Net Loss per Share

Net Loss per Share

 

The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period including warrants exercisable for little or no cash consideration. Net loss attributable to common stockholders in 2020 consists of net loss adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock (see Note 10 - Stockholders Equity Series C Convertible Preferred Stock). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, would have been anti-dilutive.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 
Stock-Based Compensation

Stock-Based Compensation

 

The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and nonemployees. The accounting treatment for share-based payments to employees and non-employees is substantially equivalent.

 

Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the service period required for the award.

 

The fair value of the Company’s stock options is estimated at the date of grant using the Black-Scholes based option valuation model. For the expected term, the Company uses SEC Staff Accounting Bulletin No. 107 simplified method for “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) if an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 to 90 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.

 

The volatility assumption is based on the historical volatility of the Company’s common stock with an equivalent remaining expected term. The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining expected term.

 

For option grants without performance conditions, the Company recognizes compensation expense over the requisite service period ratably, recognizing expense for each tranche of each grant starting on the grant date. For grants that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method. Compensation expense for grants with performance conditions is recognized only for those awards expected to vest.

 

Forfeitures of unvested stock options are recorded when they occur.

 
Concentrations

Concentrations

 

The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $54.5 million and $9.1 million as of December 31, 2021 and 2020, respectively.

 
Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this standard did not have a material impact on our financial statements.

 
Recent Accounting Standards

Recent Accounting Standards

 

In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our financial statements and related disclosures.

 

In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU No. 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

In October 2021, the FASB issued Accounting Standards Update 2021-08 (“ASU No. 2021-08”), Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.

 

 

ENVVENO MEDICAL CORPORATION

f/k/a HANCOCK JAFFE LABORATORIES, INC.

NOTES TO FINANCIAL STATEMENTS

 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

As of December 31, 2021, and 2020, property and equipment consist of the following:

 

   2021   2020 
   December 31, 
   2021   2020 
Laboratory equipment  $522,539   $320,830 
Furniture and fixtures   124,093    98,392 
Computer equipment   164,298    65,078 
Leasehold improvements   192,668    158,092 
Software   251,163    244,479 
Total property and equipment   1,254,761    886,871 
Less: accumulated depreciation   (636,906)   (487,904)
Property and equipment, net  $617,855   $398,967 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Right-of-Use Assets and Lease Liabilities (Tables)
 12 Months Ended
Dec. 31, 2021
Right-of-use Assets And Lease Liabilities  
Schedule of Operating Lease Cost

Our operating lease cost is as follows:

 

  

For the Year Ended

December 31, 2021

 
Operating lease cost  $345,857 
Schedule of Supplemental Cash Flow Information Related to Operating Lease

Supplemental cash flow information related to our operating lease is as follows:

 

  

For the Year Ended

December 31, 2021

 
Operating cash flow information:     
Cash paid for amounts included in the measurement of lease
liabilities		  $354,561 
Schedule of Operating Remaining Lease Term and Discount Rate

Remaining lease term and discount rate for our operating lease is as follows:

 

   December 31, 2021 
Remaining lease term   5.7 years 
Discount rate   3.95%
Schedule of Maturity of Lease Liabilities

Maturity of our lease liabilities by fiscal year for our operating lease is as follows:

 

      
Year ended December 31, 2022  $365,190 
Year ended December 31, 2023   376,146 
Year ended December 31, 2024   387,435 
Year ended December 31, 2025   399,054 
Year ended December 31, 2026   411,024 
Year ended December 31, 2027   315,153 
Total  $2,254,002 
Less: Imputed interest   (248,027)
Present value of our lease liability  $2,005,975 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

As of December 31, 2021 and 2020, accrued expenses consist of the following:

 

   2021   2020 
   December 31, 
   2021   2020 
Accrued compensation costs  $524,529   $473,799 
Accrued professional fees   84,375    79,650 
Accrued research and development   59,922    368,809 
Accrued warrants   

-

    

188,104

 

Other

   60,050    58,607 
Accrued expenses  $728,876   $1,168,969 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Provision (Benefit)

The following summarizes the Company’s income tax provision (benefit):

   For the Years Ended December 31, 
   2021   2020 
Federal:          
Current  $-   $- 
Deferred   (2,700,372)   (1,828,584)
           
State and local:          
Current   

-

    - 
Deferred   (900,124)   (609,528)
Current and Deferred Federal, State and Local, Tax Expense (Benefit)   (3,600,496)   (2,438,112)
Change in valuation allowance   3,600,496    2,438,112 
Income tax provision (benefit)  $-   $- 
Schedule of Effective Income Tax Rate Reconciliation

The reconciliation between the U.S. statutory federal income tax rate and the Company’s effective tax rate for the year’s ended December 31, 2021 and 2020 is as follows:

 

  

For the Years Ended December 31,

 
   2021   2020 
Tax benefit at federal statutory rate   (21.0)%   (21.0)%
State taxes, net of federal benefit   (7.0)%   (7.0)%
Nondeductible compensation   6.2%   - 
Permanent differences   (0.5)%   2.0%
True up adjustments   0.5%   (0.7)%
Change in valuation allowance   21.8%   26.7%
Effective income tax rate   0.0%   0.0%
Schedule of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:

 

   2021   2020 
   December 31, 
   2021   2020 
Deferred tax assets:          
Net operating loss carryforwards  $12,881,729   $9,811,086 
Research and development credit carryforwards   185,680    185,680 
Intangible assets   276,184    305,027 
Operating lease liability   78,194    159,025 
Stock-based compensation   923,540    311,304 
Impairment loss   136,612    136,612 
Total gross deferred tax assets   14,481,939    10,908,734 
Deferred tax liabilities          
Operating lease asset   (70,994)   (151,193)
Property and equipment   (102,107)   (49,199)
Total net deferred tax assets   14,308,838    10,708,342 
Less: valuation allowance   (14,308,838)   (10,708,342)
Total  $-   $- 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Tables)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Schedule of Equity Transactions to Raise Capital Through the Placement

During 2021 and 2020 the Company has completed various equity transactions to raise capital through the placement of its common and preferred stock. The following table provides an overview of these transactions.

 

Date  Description  Type  Number of shares   Net Proceeds 
2020              
February 25, 2020  Private placement  Common Stock   52,000   $570,341 
April 28, 2020  Registered Direct Offering  Common Stock   75,472   $811,641 
June 3, 2020  Registered Direct Offering  Common Stock   117,216   $1,161,334 
July 17, 2020  Public Offering  Common Stock   575,000   $3,881,907 
July 17, 2020  Private Placement  Preferred Stock   4,205,406   $1,358,099 
October 9, 2020  Registered Direct Offering  Common Stock   381,308   $4,450,500 
Total              $12,233,822 
                 
2021                
February 11, 2021  Public Offering  Common Stock   5,914,284   $38,127,776 
August 2021  At-the-Market Equity Program  Common Stock   170,963   $970,575 
September 9, 2021  Registered Direct Offering  Common Stock   781,615   $18,273,591 
Total             $57,371,942 
Schedule of Stock Warrant Activity

A summary of warrant activity during the years ended December 31, 2021 and 2020 is presented below:

 

   Common Stock 
   Number of
Warrants		  

Weighted

Average

Exercise

Price

  

Weighted

Average

Remaining

Life in

Years

  

Intrinsic

Value

 
Outstanding, January 1, 2020   174,681   $127.50           
Issued    1,702,810    9.26           
Exercised   (367,660)   8.13           
Cancelled   (2,029)   107.50           
Outstanding, January 1, 2021   1,507,802   $20.10    5.3   $448,140 
Issued   4,895,016    4.59           
Exercised   (52,827)   5.03           
Cancelled   (38,286)   16.10           
Outstanding and exercisable, December 31, 2021   6,311,705   $8.80    4.2   $474,464 
Schedule of Assumption Used for Valuation of Derivative Liability

The fair value of the warrants was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The following inputs and assumptions were used for the valuation of the derivative liability:

 

  

February 25,

2020

  

March 31,

2020

  

June 30,

2020

  

September 15,

2020

 
Projected Volatility   97.1%   102.7%   102.7%   110.7%
Risk-Free Rate   1.36%   0.38%   0.29%   0.31%
Contractual Term (Years)   5    5    4.75    4.5 
Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis

The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis:

 

   Derivative 
   Liabilities 
Balance – January 1, 2020  $- 
Derivative liabilities associated with the issuance of common stock warrants   513,534 
Derivative liabilities associated with the issuance of placement agent warrants   32,502 
Change in fair value of derivative liabilities   (211,807)
Reclassification of warrant derivatives to equity   (334,229)
Balance – December 31, 2020  $- 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Share Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Options Assumptions in Estimated Fair Value

The fair value of each option grant is estimated at the grant date using the Black Scholes method. The following assumptions were used in estimating fair value:

 

   2021    2020 
Expected term   5.44 – 6.5 years     5.16 – 5.76 years 
Volatility   112.94 – 103.6%    107.5%
Risk free interest rate   0.08 – 1.20%    0..30 – 0.36%
Dividend yield   0.00%    0.00%
Schedule of Stock Option Activity

A summary of the option activity during the years ended December 31, 2021 and 2020 is presented below:

           Weighted     
       Weighted   Average     
       Average   Remaining   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   In Years   Value 
Outstanding, January 1, 2020   99,689   $111.00           
Granted   122,000    10.00           
Forfeited   (11,000)   63.88           
Outstanding, December 31, 2020   210,689   $31.48    8.7   $         - 
Granted   3,246,551   $7.70           
Forfeited   (15,333)   8.36           
Outstanding, December 31, 2021   3,441,907   $9.16    9.3   $- 
                     
Exercisable, December 31, 2021   982,921   $12.94    8.9   $- 
Schedule of Stock Option Activity Restricted Shares

The Company also issues restricted shares and restricted stock units under the 2016 Plan. A summary of the restricted share and restricted stock units activity during the years ended December 31, 2021 and 2020 is presented below:

 

   Number of 
   Restricted Shares 
Outstanding, January 1, 2020   7,806 
Granted   10,000 
Shares vested   (12,864)
Outstanding, December 31, 2020   4,942 
Granted   400,000 
Shares Vested   (2,860)
Outstanding, December 31, 2021   402,082 
Schedule of Outstanding and Exercisable Restricted Stock Units

A summary of outstanding restricted stock units as of December 31, 2021 is presented below:

 Schedule of Outstanding and Exercisable Restricted Stock Units

Restricted Stock Units
Grant Date  Restricted Stock Unit for 

Outstanding

Number of

Units

  

Weighted

Average

Remaining

Life In

Years

 
9/13/2019  Common Stock   2,082    0.9 
11/30/2021  Common Stock   400,000    - 
              
   Total   402,082      
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Net Loss Per Share (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Dilutive Net Loss Per Common Share

The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Shares of common stock issuable upon exercise of warrants   4,552,670    1,507,802 
Shares of common stock issuable upon exercise of options and restricted stock units   3,843,989    215,631 
Potentially dilutive common stock equivalents excluded from diluted net loss per share   8,396,659    1,723,433 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Management’s Liquidity Plan (Details Narrative)
$ in Millions
Dec. 31, 2021
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash $ 54.7
[custom:WorkingCapital-0] $ 53.5
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Cash FDICInsured amount $ 250,000  
Cash uninsured amount $ 54,500,000 $ 9,100,000
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment useful life 5 years  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment useful life 7 years  
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Property and Equipment (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 1,254,761 $ 886,871
Less: accumulated depreciation (636,906) (487,904)
Property and equipment, net 617,855 398,967
Laboratory Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment 522,539 320,830
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment 124,093 98,392
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment 164,298 65,078
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment 192,668 158,092
Software Development [Member]    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 251,163 $ 244,479
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0.1 $ 0.1
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Operating Lease Cost (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
Right-of-use Assets And Lease Liabilities  
Operating lease cost $ 345,857
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details) - USD ($)
 12 Months Ended
Nov. 17, 2021
Dec. 31, 2021
Right-of-use Assets And Lease Liabilities    
Cash paid for amounts included in the measurement of lease liabilities $ 30,206 $ 354,561
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Operating Remaining Lease Term and Discount Rate (Details)
Dec. 31, 2021
Right-of-use Assets And Lease Liabilities  
Remaining lease term 5 years 8 months 12 days
Discount rate 3.95%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Maturity of Lease Liabilities (Details)
Dec. 31, 2021
USD ($)
Right-of-use Assets And Lease Liabilities  
Year ended December 31, 2022 $ 365,190
Year ended December 31, 2023 376,146
Year ended December 31, 2024 387,435
Year ended December 31, 2025 399,054
Year ended December 31, 2026 411,024
Year ended December 31, 2027 315,153
Total 2,254,002
Less: Imputed interest (248,027)
Present value of our lease liability $ 2,005,975
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Right-of-Use Assets and Lease Liabilities (Details Narrative) - USD ($)
 12 Months Ended
Nov. 17, 2021
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Operating lease renewal term 60 months  
Initial lease rate per month $ 30,206 $ 354,561
Operating expenses for building repairs and maintenance $ 7,254  
Financing leases term description The Company has no other operating or financing leases with terms greater than 12 months  
Discount rate   3.95%
Present value of monthly lease payments [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Discount rate   3.95%
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Accrued Expenses (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Accrued compensation costs $ 524,529 $ 473,799
Accrued professional fees 84,375 79,650
Accrued research and development 59,922 368,809
Accrued warrants 188,104
Other 60,050 58,607
Accrued expenses $ 728,876 $ 1,168,969
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Note Payable (Details Narrative) - USD ($)
 12 Months Ended
Sep. 08, 2021
Apr. 12, 2020
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Notes payable amount     $ 312,700
Gain on extinguishment of debt $ 312,700   $ 312,700
Paycheck protection program [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Notes payable amount   $ 312,700    
Maturity date   Apr. 12, 2022    
Interest rate   1.00%    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Income Tax Provision (Benefit) (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Fedral: Current
Fedral: Deferred (2,700,372) (1,828,584)
State and local: Current  
State and local: Deferred (900,124) (609,528)
Current and Deferred Federal, State and Local, Tax Expense (Benefit) (3,600,496) (2,438,112)
Change in valuation allowance 3,600,496 2,438,112
Income tax provision (benefit)
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Effective Income Tax Rate Reconciliation (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Tax benefit at federal statutory rate (21.00%) (21.00%)
State taxes, net of federal benefit (7.00%) (7.00%)
Nondeductible compensation 6.20%
Permanent differences (0.50%) 2.00%
True up adjustments 0.50% (0.70%)
Change in valuation allowance 21.80% 26.70%
Effective income tax rate 0.00% 0.00%
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 12,881,729 $ 9,811,086
Research and development credit carryforwards 185,680 185,680
Intangible assets 276,184 305,027
Operating lease liability 78,194 159,025
Stock-based compensation 923,540 311,304
Impairment loss 136,612 136,612
Total gross deferred tax assets 14,481,939 10,908,734
Operating lease asset (70,994) (151,193)
Property and equipment (102,107) (49,199)
Total net deferred tax assets 14,308,838 10,708,342
Less: valuation allowance (14,308,838) (10,708,342)
Total
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Operating Loss Carryforwards [Line Items]    
Tax Credit Carryforward, Valuation Allowance $ 3.6 $ 2.4
Equity Method Investment, Ownership Percentage 50.00%  
Federal Income Tax Expense (Benefit), Continuing Operations $ 45.7 35.0
Operating loss carryforwards expired $ 12.0  
Operating loss carryforwards expired unused   7.6
[custom:AnnualLimitOfDeductionPercentage] 80.00%  
Net operating loss carryforwards $ 45.7 $ 35.0
Research and Development [Member]    
Operating Loss Carryforwards [Line Items]    
Operating Loss Carryforwards 0.2  
Domestic Tax Authority [Member]    
Operating Loss Carryforwards [Line Items]    
Operating Loss Carryforwards $ 33.0  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Equity Transactions to Raise Capital Through the Placement (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 09, 2021
Nov. 17, 2020
Oct. 09, 2020
Jul. 17, 2020
Jun. 03, 2020
Apr. 28, 2020
Feb. 25, 2020
Feb. 11, 2020
Aug. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Net Proceeds issued during the period                   $ 57,371,942 $ 12,233,822
Common Stock [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issued during the period 781,615   381,308 575,000 117,216 75,472 52,000 5,914,284 170,963 5,914,284 1,148,996 [1]
Net Proceeds issued during the period $ 18,273,591   $ 4,450,500 $ 3,881,907 $ 1,161,334 $ 811,641 $ 570,341 $ 38,127,776 $ 970,575    
Preferred Stock [Member]                      
Accumulated Other Comprehensive Income (Loss) [Line Items]                      
Number of shares issued during the period   4,205,406                  
Net Proceeds issued during the period   $ 1,358,099                  
[1] net of offering costs of $2.2 million.
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Warrant Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Equity [Abstract]    
Number of Warrants, Outstanding 1,507,802 174,681
Weighted Average Exercise Price, Outstanding $ 20.10 $ 127.50
Number of Warrants, Issued 4,895,016 1,702,810
Weighted Average Exercise Price, Issued $ 4.59 $ 9.26
Number of Warrants, Exercised (52,827) (367,660)
Weighted Average Exercise Price, Exercised $ 5.03 $ 8.13
Number of Warrants, Cancelled (38,286) (2,029)
Weighted Average Exercise Price, Cancelled $ 16.10 $ 107.50
Weighted average remaining life in years, Outstanding 5 years 3 months 18 days  
Intrinsic value, Outstanding $ 448,140  
Number of Warrants, Outstanding and exercisable 6,311,705 1,507,802
Weighted Average Exercise Price, Outstanding and exercisable $ 8.80 $ 20.10
Weighted average remaining life in years, Outstanding and exercisable 4 years 2 months 12 days  
Intrinsic value, Outstanding and exercisable $ 474,464 $ 448,140
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Assumption Used for Valuation of Derivative Liability (Details)
 24 Months Ended
Sep. 15, 2020
Jun. 30, 2020
Mar. 31, 2020
Feb. 25, 2022
Feb. 25, 2020
Measurement Input, Price Volatility [Member]          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Risk-Free Rate 110.7 102.7 102.7   97.1
Measurement Input, Risk Free Interest Rate [Member]          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Risk-Free Rate 0.31 0.29 0.38   1.36
Measurement Input, Expected Term [Member]          
Fair Value Measurement Inputs and Valuation Techniques [Line Items]          
Contractual Term (Years) 4 years 6 months 4 years 9 months 5 years 5 years  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis (Details)
 12 Months Ended
Dec. 31, 2020
USD ($)
Equity [Abstract]  
Balance – January 1, 2020
Derivative liabilities associated with the issuance of common stock warrants 513,534
Derivative liabilities associated with the issuance of placement agent warrants 32,502
Change in fair value of derivative liabilities (211,807)
Reclassification of warrant derivatives to equity (334,229)
Balance – December 31, 2020
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Details Narrative)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 09, 2021
shares
Nov. 17, 2020
shares
Nov. 17, 2020
shares
Nov. 10, 2020
USD ($)
$ / shares
shares
Oct. 09, 2020
shares
Jul. 17, 2020
shares
Jun. 03, 2020
shares
Apr. 28, 2020
shares
Feb. 25, 2020
USD ($)
shares
Feb. 11, 2020
shares
Aug. 31, 2021
shares
Oct. 31, 2020
USD ($)
Jul. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
Sep. 30, 2020
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
shares
$ / shares
Dec. 31, 2020
$ / shares
shares
Nov. 30, 2020
$ / shares
Sep. 15, 2020
USD ($)
Jun. 30, 2020
USD ($)
Mar. 31, 2020
USD ($)
Subsidiary, Sale of Stock [Line Items]                                          
Common stock par value | $ / shares                               $ 0.00001 $ 0.00001 $ 0.00001      
Purchase price percentage           8.00%                              
Expected term                               7 years          
Derivative liability                 $ 546,036                   $ 334,229 $ 281,183 $ 199,907
Increase in derivative liability                           $ 53,046              
Decrease in derivative liability                             $ 211,807            
Derivative liability, description                 If the Company was required to pay the fair value of the warrant in cash as of May 25, 2020, the obligation was discounted at the Company’s estimated cost of debt based on short-term C-CCC bond ratings of 19.5% and 28.5%                        
Derivative difference description                 The likelihood of the Company calling a shareholder meeting and achieving shareholder approval was 90% as of February 25, 2020                        
Advisor [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Fair value adjustment       $ 188,804                                  
Measurement Input, Share Price [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Warrants and rights outstanding measurement input | $ / shares                               $ 11.00          
Warrants and rights outstanding measurement input | shares                               11.00          
Measurement Input, Price Volatility [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Warrants and rights outstanding measurement input       112.7                       118.7   114.3      
Measurement Input, Risk Free Interest Rate [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Warrants and rights outstanding measurement input       0.46                       0.47   0.36      
Measurement Input, Expected Dividend Rate [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Warrants and rights outstanding measurement input       0                       0.00   0      
Measurement Input, Exercise Price [Member] | Minimum [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Warrants and rights outstanding measurement input | $ / shares       $ 8.00                           $ 8.65      
Measurement Input, Exercise Price [Member] | Maximum [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Warrants and rights outstanding measurement input | $ / shares       $ 10.35                                  
Measurement Input, Expected Term [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Expected term       2 years 6 months                                  
Measurement Input, Expected Term [Member] | Minimum [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Expected term                                   2 years 6 months      
Measurement Input, Expected Term [Member] | Maximum [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Expected term                                   3 years 6 months      
Preferred Stock [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Number of shares issued during the period | shares     4,205,406                                    
Fair value adjustment                               $ 607,220          
Common Stock [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Number of shares issued during the period | shares 781,615       381,308 575,000 117,216 75,472 52,000 5,914,284 170,963         5,914,284 1,148,996 [1]        
Common Stock [Member] | Board of Directors [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares       6,400                                  
Common Stock [Member] | Spartan Capital Securities LLC [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares       20,000                                  
Warrant [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Fair value adjustment                               $ 2,431,250          
Warrant [Member] | Spartan Capital Securities LLC [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Fair value adjustment                         $ 100,000                
Warrants and rights outstanding measurement input | $ / shares       $ 8.00                                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares       17,618                                  
Warrants [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Fair value adjustment                               $ 948,781          
Warrants description                               The Preferred Stock includes a contingent beneficial conversion feature (“BCF”) which was valued at its $2,067,155 intrinsic value using the commitment date stock price of $11.00 per share and the effective conversion price of $2.50 per share, but was limited to the $607,220 of proceeds that were allocated to the Preferred Stock          
Warrants intrinstic                               $ 2,067,155          
Warrant One [Member] | Spartan Capital Securities LLC [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Fair value adjustment                       $ 100,000                  
Warrants and rights outstanding measurement input | $ / shares       $ 10.25                                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares       18,056                                  
Series C Convertible Preferred Stock [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Net proceeds from warrant exercises after deducting underwrites and placement agents fees and expenses                               $ 1,556,000          
Series C Convertible Preferred Stock [Member] | Securties Purchase Agreement [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Preferred stock, liquidation preference per share | $ / shares                           $ 0.37 $ 0.37            
Conversion of stock, description                                 The Company had the ability to elect to convert the Preferred Stock to common stock in the event the Company either (i) consummated a merger, or (ii) raised an aggregate of at least $8,000,000 in gross proceeds in a transaction or series of transactions within any twelve (12) month period. In the event the Company elected to affect such a conversion, each share of Series C Preferred Stock would have been convertible into 0.05781 shares of common stock.        
Private Placement [Member] | Exchange Agreements [Member] | Preferred Stock [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Conversion of stock | shares   4,205,406                                      
Private Placement [Member] | Exchange Agreements [Member] | Common Stock [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Conversion of stock | shares   243,125                                      
Private Placement [Member] | Series C Convertible Preferred Stock [Member]                                          
Subsidiary, Sale of Stock [Line Items]                                          
Number of shares issued during the period | shares           4,205,406                              
Deemed dividend                             $ 23,859            
[1] net of offering costs of $2.2 million.
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Options Assumptions in Estimated Fair Value (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Volatility, minimum 112.94%  
Volatility, maximum 103.60%  
Volatility   107.50%
Risk free interest rate, minimum 0.08% 0.30%
Risk free interest rate, maximum 1.20% 0.36%
Dividend yield 0.00% 0.00%
Minimum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 5 years 5 months 8 days 5 years 1 month 28 days
Maximum [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 6 years 6 months 5 years 9 months 3 days
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Option Activity (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Number of options beginning 210,689 99,689
Weighted Average Exercise Price Outstanding beginning $ 31.48 $ 111.00
Number of options granted 3,246,551 122,000
Weighted Average Exercise Price, Granted $ 7.70 $ 10.00
Number of options forfeited (15,333) (11,000)
Weighted Average Exercise Price, Forfeited $ 8.36 $ 63.88
Weighted Average Remaining life in years 9 years 3 months 18 days 8 years 8 months 12 days
Aggregate intrinsic value  
Number of options ending 3,441,907 210,689
Weighted Average Exercise Price Outstanding Ending $ 9.16 $ 31.48
Aggregate intrinsic value
Number of options exercisable 982,921  
Weighted Average Exercise Price Outstanding, Exercisable $ 12.94  
Weighted Average Remaining life in years, exercisable 8 years 10 months 24 days  
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Stock Option Activity Restricted Shares (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Outstanding shares, beginning 4,942 7,806
Granted 400,000 10,000
Shares Vested (2,860) (12,864)
Outstanding shares, ending 402,082 4,942
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Outstanding and Exercisable Restricted Stock Units (Details) - shares
Nov. 30, 2021
Sep. 13, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]          
Restricted Stock Unit for Common Stock Common Stock      
Outsatnding number of units, restricted stock 400,000 2,082 402,082 4,942 7,806
Weighted Average Remaining Life In Years 10 months 24 days      
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Share Based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Equity Method Investment, Ownership Percentage 50.00%  
Share-based compensation $ 5,999,178 $ 881,213
Restricted Stock [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation $ 15,200,000  
Vesting period 2 years  
Selling, General and Administrative Expenses [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation $ 6,000,000.0 $ 700,000
2016 Incentive Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock options The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant  
Common Stock, Capital Shares Reserved for Future Issuance 4,500,000  
Equity Method Investment, Ownership Percentage 20.00%  
Number of shares authorized greater than minimum percentage 20.00%  
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Dilutive Net Loss Per Common Share (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive common stock equivalents excluded from diluted net loss per share 8,396,659 1,723,433
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive common stock equivalents excluded from diluted net loss per share 4,552,670 1,507,802
Restricted Stock Units (RSUs) [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive common stock equivalents excluded from diluted net loss per share 3,843,989 215,631
XML 65 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001661053 2021-01-01 2021-12-31 0001661053 NVNO:CommonStock0.00001ParValueMember 2021-01-01 2021-12-31 0001661053 NVNO:WarrantToPurchaseCommonStockMember 2021-01-01 2021-12-31 0001661053 2021-06-30 0001661053 2022-03-24 0001661053 2021-12-31 0001661053 2020-12-31 0001661053 2020-01-01 2020-12-31 0001661053 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001661053 us-gaap:CommonStockMember 2019-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001661053 us-gaap:RetainedEarningsMember 2019-12-31 0001661053 2019-12-31 0001661053 us-gaap:CommonStockMember 2020-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001661053 us-gaap:RetainedEarningsMember 2020-12-31 0001661053 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001661053 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001661053 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001661053 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001661053 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001661053 us-gaap:SeriesCPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001661053 us-gaap:CommonStockMember 2021-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001661053 us-gaap:RetainedEarningsMember 2021-12-31 0001661053 us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001661053 us-gaap:IPOMember 2020-01-01 2020-12-31 0001661053 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember 2020-01-01 2020-12-31 0001661053 srt:MinimumMember 2021-01-01 2021-12-31 0001661053 srt:MaximumMember 2021-01-01 2021-12-31 0001661053 NVNO:LaboratoryEquipmentMember 2021-12-31 0001661053 NVNO:LaboratoryEquipmentMember 2020-12-31 0001661053 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001661053 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001661053 us-gaap:ComputerEquipmentMember 2021-12-31 0001661053 us-gaap:ComputerEquipmentMember 2020-12-31 0001661053 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001661053 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001661053 us-gaap:SoftwareDevelopmentMember 2021-12-31 0001661053 us-gaap:SoftwareDevelopmentMember 2020-12-31 0001661053 2021-11-17 0001661053 2021-11-16 2021-11-17 0001661053 NVNO:PresentValueOfMonthlyLeasePaymentsMember 2021-12-31 0001661053 NVNO:PaycheckProtectionProgramMember 2020-04-12 0001661053 NVNO:PaycheckProtectionProgramMember 2020-04-11 2020-04-12 0001661053 2021-09-07 2021-09-08 0001661053 us-gaap:DomesticCountryMember 2021-12-31 0001661053 NVNO:ResearchAndDevelopmentMember 2021-12-31 0001661053 2020-11-30 0001661053 NVNO:SeriesCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2020-07-15 2020-07-17 0001661053 us-gaap:PreferredStockMember us-gaap:PrivatePlacementMember NVNO:ExchangeAgreementsMember 2020-11-16 2020-11-17 0001661053 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember NVNO:ExchangeAgreementsMember 2020-11-16 2020-11-17 0001661053 2020-07-17 0001661053 NVNO:SeriesCConvertiblePreferredStockMember NVNO:SecuritiesPurchaseAgreementMember 2020-09-30 0001661053 NVNO:SeriesCConvertiblePreferredStockMember us-gaap:PrivatePlacementMember 2020-01-01 2020-09-30 0001661053 NVNO:SeriesCConvertiblePreferredStockMember NVNO:SecuritiesPurchaseAgreementMember 2020-01-01 2020-12-31 0001661053 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001661053 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001661053 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-31 0001661053 NVNO:SeriesCConvertiblePreferredStockMember 2021-01-01 2021-12-31 0001661053 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001661053 NVNO:WarrantsMember 2021-01-01 2021-12-31 0001661053 NVNO:WarrantsMember 2021-12-31 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember us-gaap:WarrantMember 2020-11-10 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember NVNO:WarrantOneMember 2020-11-10 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember us-gaap:WarrantMember 2020-07-01 2020-07-31 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember NVNO:WarrantOneMember 2020-10-01 2020-10-31 0001661053 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2020-11-10 0001661053 srt:MaximumMember us-gaap:MeasurementInputExercisePriceMember 2020-11-10 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-11-10 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-11-10 0001661053 us-gaap:MeasurementInputExpectedDividendRateMember 2020-11-10 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-11-10 0001661053 NVNO:BoardOfDirectorsMember us-gaap:CommonStockMember 2020-11-10 0001661053 NVNO:SpartanCapitalSecuritiesLLCMember us-gaap:CommonStockMember 2020-11-10 0001661053 NVNO:AdvisorMember 2020-11-09 2020-11-10 0001661053 srt:MinimumMember us-gaap:MeasurementInputExercisePriceMember 2020-11-30 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-11-30 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-11-30 0001661053 us-gaap:MeasurementInputExpectedDividendRateMember 2020-11-30 0001661053 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2020-11-30 0001661053 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2020-11-30 0001661053 2020-02-25 0001661053 2020-03-31 0001661053 2020-06-30 0001661053 2020-09-15 0001661053 2020-07-01 2020-09-30 0001661053 2020-01-01 2020-09-30 0001661053 2020-02-24 2020-02-25 0001661053 us-gaap:CommonStockMember 2020-02-24 2020-02-25 0001661053 us-gaap:CommonStockMember 2020-04-26 2020-04-28 0001661053 us-gaap:CommonStockMember 2020-06-01 2020-06-03 0001661053 us-gaap:CommonStockMember 2020-07-15 2020-07-17 0001661053 us-gaap:PreferredStockMember 2020-11-15 2020-11-17 0001661053 us-gaap:CommonStockMember 2020-10-08 2020-10-09 0001661053 us-gaap:CommonStockMember 2020-02-10 2020-02-11 0001661053 us-gaap:CommonStockMember 2021-08-01 2021-08-31 0001661053 us-gaap:CommonStockMember 2021-09-07 2021-09-09 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-02-25 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-06-30 0001661053 us-gaap:MeasurementInputPriceVolatilityMember 2020-09-15 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-02-25 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-06-30 0001661053 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-09-15 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-02-24 2022-02-25 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-03-30 2020-03-31 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-06-29 2020-06-30 0001661053 us-gaap:MeasurementInputExpectedTermMember 2020-09-14 2020-09-15 0001661053 NVNO:TwoThousandSixteenOmnibusIncentivePlanMember 2021-01-01 2021-12-31 0001661053 NVNO:TwoThousandSixteenOmnibusIncentivePlanMember 2021-12-31 0001661053 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0001661053 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0001661053 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001661053 srt:MinimumMember 2020-01-01 2020-12-31 0001661053 srt:MaximumMember 2020-01-01 2020-12-31 0001661053 2019-09-12 2019-09-13 0001661053 2019-09-13 0001661053 2021-11-29 2021-11-30 0001661053 2021-11-30 0001661053 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001661053 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001661053 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001661053 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001661053 false FY 10-K true 2021-12-31 --12-31 2021 false 001-38325 enVVeno Medical Corporation DE 33-0936180 70 Doppler Irvine CA 92618 (949) 261-2900 Common Stock, $0.00001 par value NVNO NASDAQ Warrant to Purchase Common Stock NVNOW NASDAQ No No Yes Yes Non-accelerated Filer true true true false false 58500000 9469850 688 Marcum llp New York, NY 54727740 9334584 312350 234467 55040090 9569051 617855 398967 1986704 539974 54493 29843 57699142 10537835 560083 1390362 728876 1168969 312700 291104 314202 1580063 3186233 1714871 253746 3294934 3439979 0.00001 0.00001 10000000 10000000 0 0 0 0 0.00001 0.00001 250000000 250000000 9469850 9469850 2541529 2541529 95 25 136255346 72421242 -81851233 -65323411 54404208 7097856 57699142 10537835 11164858 4882877 5727645 4252249 -16892503 -9135126 312700 18709 3739 211807 33272 -215906 364681 -360 -16527822 -9135486 607220 -16527822 -9742706 -1.90 -7.54 8679824 1291469 717274 7 57177858 -56187925 989940 52000 1 24304 24305 1148996 11 9847890 9847901 4205406 42 1358060 1358102 -4205406 -42 243125 2 40 367660 4 2985751 2985755 334230 334230 12474 693109 693109 -9135486 -9135486 2541529 25 72421242 -65323411 7097856 100000 2200000 200000 2541529 25 72421242 -65323411 7097856 5914284 59 38127717 38127776 52827 1 245249 245250 211976 211976 5772 37576 37576 170963 2 960273 960275 781615 8 18273583 18273591 2860 5977730 5977730 -16527822 -16527822 9469850 95 136255346 -81851233 54404208 -16527822 -9135486 5999178 881213 149002 97549 303907 286423 211807 312700 -27802 37883 117820 24650 -832703 169173 -249565 614428 -312610 -288685 4681976 1458276 -11845846 -7677210 367890 180291 -367890 -180291 570341 960275 18273591 38127776 9847901 1358102 312700 245250 2985755 57606892 15074799 45393156 7217298 9334584 2117286 54727740 9334584 -312700 35576 -211976 334229 <p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z17hCjUvswu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_829_zbt9AoA29Vqh">Business Organization and Nature of Operations</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enVVeno Medical Corporation is a med-tech company focused on improving the standard of care in the treatment of venous disease. We are developing tissue-based solutions that are designed to be life sustaining or life enhancing for patients with deep venous Chronic Venous Insufficiency (CVI). CVI occurs when valves inside of the veins of the leg fail, resulting in insufficient blood being returned to the heart. Our products are being developed to address large unmet medical needs by either offering treatments where none currently exist or by substantially increasing the current standards of care. Our lead product is a porcine based device to be surgically implanted in our deep venous system of the leg, and is called the VenoValve®. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal trial for the purpose of obtaining approval to market and sell the device from the U.S. Food and Drug Administration (“FDA”). Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and have been commercially successful. We currently lease a 14,507 sq. ft. manufacturing facility in Irvine, California, where we manufacture medical devices for our clinical trials, and which has capacity for commercial manufacturing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 21, 2021, we announced that we were changing our name from Hancock Jaffe to enVVeno Medical Corporation and that our development strategy is to focus on the treatment of venous disease. In addition to the VenoValve, we announced that we have begun development of a second device for the treatment of venous disease which we are calling enVVe. In connection with this change in strategy, we indicated that we are not pursuing further development of the CoreoGraft, which is now outside of our primary focus area.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_801_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zyTe2WPpyGh5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_823_zJQgfhPJKmrk">Management’s Liquidity Plan</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, the Company had a cash balance of $<span id="xdx_902_eus-gaap--Cash_iI_pn5n6_c20211231_zAmca83KbI4a">54.7</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and working capital of $<span id="xdx_907_ecustom--WorkingCapital_iI_pn5n6_c20211231_zzAxSsn58Nx7">53.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. Although the Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products, Management believes that our capital resources at December 31, 2021, are sufficient to meet our obligations as they become due within one year after the date of this Annual Report, and sustain operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 54700000 53500000 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zxCYUOlqzrv1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_824_zfxtnQVY1662">Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zA8CZq74xTd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zrXvehYEyie9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMkuvVWvM114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zdc0vi1w4aS8">Property and Equipment, Net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z1XDMaTTH4ff" title="Property plant and equipment useful life">5</span> to <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zRMhZR8g8km4" title="Property plant and equipment useful life">7 </span>years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zsjuIeNI4Bw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_ztEQgHyvi6A">Impairment of Long-lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrcl2SjSYqv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zqnhag6kje58">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPdo55RWFZkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_znQjdYuPu9vl">Fair Value of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices available in active markets for identical assets or liabilities trading in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Derivative liabilities are accounted for at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p id="xdx_84D_eus-gaap--DerivativesPolicyTextBlock_zrC3GqfZirJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_z8tCNSYwqWj1">Derivative Liabilities</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEVSoMK2zrBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zcewI21aZZsg">Net Loss per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period including warrants exercisable for little or no cash consideration. Net loss attributable to common stockholders in 2020 consists of net loss adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock (see Note 10 - Stockholders Equity <i>Series C Convertible Preferred Stock</i>). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, would have been anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLMThUJpVzhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zoEVS6ciomif">Stock-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and nonemployees. The accounting treatment for share-based payments to employees and non-employees is substantially equivalent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the service period required for the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s stock options is estimated at the date of grant using the Black-Scholes based option valuation model. For the expected term, the Company uses SEC Staff Accounting Bulletin No. 107 simplified method for “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) if an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 to 90 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The volatility assumption is based on the historical volatility of the Company’s common stock with an equivalent remaining expected term. The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining expected term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For option grants without performance conditions, the Company recognizes compensation expense over the requisite service period ratably, recognizing expense for each tranche of each grant starting on the grant date. For grants that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method. Compensation expense for grants with performance conditions is recognized only for those awards expected to vest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forfeitures of unvested stock options are recorded when they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zRd7ReCIQjm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_z7VgvW2FEVhh">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20211231_zEJMd1u3XIIf" title="Cash FDICInsured amount">250,000</span> at each institution. There were aggregate uninsured cash balances of $<span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20211231_zbXS7V4LIBS1" title="Cash uninsured amount">54.5</span> million and $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20201231_zMCoB4EtEX16" title="Cash uninsured amount">9.1</span> million as of December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p id="xdx_84B_ecustom--NewAccountingAdoptedPolicyTextBlock_zfRFClzXoZI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zjifKOv4z6X3"><span id="xdx_862_zDyATLxPzq2">Recently Adopted Accounting Standards</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">In December 2019, the FASB issued ASU No. 2019-12, <i>Simplifying the Accounting for Income Taxes,</i> which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252525">The adoption of this standard did not have a material impact on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEVlHk6oCQj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zIvV3PuXdQpe">Recent Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU No. 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued Accounting Standards Update 2021-08 (“ASU No. 2021-08”), Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--UseOfEstimates_zA8CZq74xTd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zrXvehYEyie9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include the valuation allowance related to the Company’s deferred tax assets, and the valuation of warrants and derivative liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zMkuvVWvM114" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zdc0vi1w4aS8">Property and Equipment, Net</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost, net of accumulated depreciation using the straight-line method over their estimated useful lives, which range from <span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_z1XDMaTTH4ff" title="Property plant and equipment useful life">5</span> to <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zRMhZR8g8km4" title="Property plant and equipment useful life">7 </span>years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Expenditures for maintenance and repairs, which do not extend the economic useful life of the related assets, are charged to operations as incurred, and expenditures, which extend the economic life are capitalized. When assets are retired, or otherwise disposed of, the costs and related accumulated depreciation or amortization are removed from the accounts and any gain or loss on disposal is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y P7Y <p id="xdx_849_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zsjuIeNI4Bw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_867_ztEQgHyvi6A">Impairment of Long-lived Assets</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zrcl2SjSYqv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_865_zqnhag6kje58">Income Taxes</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of December 31, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zPdo55RWFZkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_znQjdYuPu9vl">Fair Value of Financial Instruments</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures the fair value of financial assets and liabilities based on the guidance of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted prices available in active markets for identical assets or liabilities trading in active markets.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs other than quoted prices included in Level 1, such as quotable prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies and similar valuation techniques that use significant unobservable inputs.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including accounts payable are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Derivative liabilities are accounted for at fair value on a recurring basis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p id="xdx_84D_eus-gaap--DerivativesPolicyTextBlock_zrC3GqfZirJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_z8tCNSYwqWj1">Derivative Liabilities</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative financial instruments are recorded as a liability at fair value and are marked-to-market as of each balance sheet date. The change in fair value at each balance sheet date is recorded as a change in the fair value of derivative liabilities on the statement of operations for each reporting period. The fair value of the derivative liabilities was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The Company reassesses the classification of the financial instruments at each balance sheet date. If the classification changes as a result of events during the period, the financial instrument is marked to market and reclassified as of the date of the event that caused the reclassification.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p id="xdx_842_eus-gaap--EarningsPerSharePolicyTextBlock_zEVSoMK2zrBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_860_zcewI21aZZsg">Net Loss per Share</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company computes basic and diluted loss per share by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period including warrants exercisable for little or no cash consideration. Net loss attributable to common stockholders in 2020 consists of net loss adjusted for the convertible preferred stock deemed dividend resulting from the 8% cumulative dividend on the Preferred Stock (see Note 10 - Stockholders Equity <i>Series C Convertible Preferred Stock</i>). Basic and diluted net loss per common share are the same since the inclusion of common stock issuable pursuant to the exercise of warrants and options, would have been anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zLMThUJpVzhc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zoEVS6ciomif">Stock-Based Compensation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and nonemployees. The accounting treatment for share-based payments to employees and non-employees is substantially equivalent.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the service period required for the award.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the Company’s stock options is estimated at the date of grant using the Black-Scholes based option valuation model. For the expected term, the Company uses SEC Staff Accounting Bulletin No. 107 simplified method for “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) if an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 to 90 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The volatility assumption is based on the historical volatility of the Company’s common stock with an equivalent remaining expected term. The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock. The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining expected term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For option grants without performance conditions, the Company recognizes compensation expense over the requisite service period ratably, recognizing expense for each tranche of each grant starting on the grant date. For grants that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method. Compensation expense for grants with performance conditions is recognized only for those awards expected to vest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Forfeitures of unvested stock options are recorded when they occur.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zRd7ReCIQjm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86A_z7VgvW2FEVhh">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20211231_zEJMd1u3XIIf" title="Cash FDICInsured amount">250,000</span> at each institution. There were aggregate uninsured cash balances of $<span id="xdx_903_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20211231_zbXS7V4LIBS1" title="Cash uninsured amount">54.5</span> million and $<span id="xdx_90A_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20201231_zMCoB4EtEX16" title="Cash uninsured amount">9.1</span> million as of December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> 250000 54500000 9100000 <p id="xdx_84B_ecustom--NewAccountingAdoptedPolicyTextBlock_zfRFClzXoZI6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zjifKOv4z6X3"><span id="xdx_862_zDyATLxPzq2">Recently Adopted Accounting Standards</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">In December 2019, the FASB issued ASU No. 2019-12, <i>Simplifying the Accounting for Income Taxes,</i> which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #252525">The adoption of this standard did not have a material impact on our financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zEVlHk6oCQj8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zIvV3PuXdQpe">Recent Accounting Standards</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, the FASB issued Accounting Standards Update 2020-01 (“ASU 2020-01”) Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The amendments in ASU 2020-01 clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for investments under the equity method of accounting in Topic 323, and the guidance in Topic 815, which could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. These amendments improve current GAAP by reducing diversity in practice and increasing comparability of the accounting for these interactions. The amendments in this update are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The adoption of this standard will not have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued Accounting Standards Update 2020-06 (“ASU 2020-06”), Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The amendments in ASU 2020-06 include guidance on convertible instruments and the derivative scope exception for contracts in an entity’s own equity and simplifies the accounting for convertible instruments which include beneficial conversion features or cash conversion features by removing certain separation models in Subtopic 470-20. Additionally, ASU 2020-06 will require entities to use the “if-converted” method when calculating diluted earnings per share for convertible instruments. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued Accounting Standards Update 2021-04 (“ASU No. 2021-04”), Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The guidance in ASU 2021-04 requires the issuer to treat a modification of an equity-classified written call option (the “option”) that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the option or as termination of the original option and issuance of a new option. The amendments in this update are effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; color: #252525"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2021, the FASB issued Accounting Standards Update 2021-08 (“ASU No. 2021-08”), Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We do not expect the adoption of this standard to have a material impact on our financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80C_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6VM3LUgq4nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_829_zB2fpfycsFsk">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSQjaTcKMng4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, and 2020, property and equipment consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_z2nqENeBioti" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20211231_zBwGO74O4Mzb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20201231_zsw4QQTAxUmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zw86HbmAA8Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">522,539</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">320,830</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zWs6ZsBdgBBl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">124,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,392</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z1ppKDa5yzh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zszGcyqJxo3g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">158,092</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zdtyAtp2GCfh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">244,479</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz7Bp_zDbliBlhXEej" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,254,761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">886,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz7Bp_z25XoFX6GVNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: accumulated depreciation</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(636,906</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(487,904</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz7Bp_zJNqtlo773Q1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">617,855</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">398,967</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zONqPTT3y0I6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense was $<span id="xdx_90F_eus-gaap--Depreciation_pn5n6_c20210101__20211231_zHY8Cq5WHCeb" title="Depreciation expense"><span id="xdx_90E_eus-gaap--Depreciation_pn5n6_c20200101__20201231_zjYM3WuVzhBl" title="Depreciation expense">0.1</span></span> million for the years ended December 31, 2021 and 2020. Depreciation expense is reflected in general and administrative expenses in the accompanying statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zSQjaTcKMng4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, and 2020, property and equipment consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_z2nqENeBioti" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20211231_zBwGO74O4Mzb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_494_20201231_zsw4QQTAxUmh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryEquipmentMember_zw86HbmAA8Ol" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Laboratory equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">522,539</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">320,830</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zWs6ZsBdgBBl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Furniture and fixtures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">124,093</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,392</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z1ppKDa5yzh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,078</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zszGcyqJxo3g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">158,092</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zdtyAtp2GCfh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Software</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,163</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">244,479</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz7Bp_zDbliBlhXEej" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total property and equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,254,761</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">886,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENz7Bp_z25XoFX6GVNk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: accumulated depreciation</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(636,906</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(487,904</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz7Bp_zJNqtlo773Q1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Property and equipment, net</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">617,855</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">398,967</td><td style="text-align: left"> </td></tr> </table> 522539 320830 124093 98392 164298 65078 192668 158092 251163 244479 1254761 886871 636906 487904 617855 398967 100000 100000 <p id="xdx_807_eus-gaap--LesseeOperatingLeasesTextBlock_z25nCi4PL9wc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_823_zRZOZGb8IaXi">Right-of-Use Assets and Lease Liabilities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 17, 2021, the Company amended its operating lease for its manufacturing facility in Irvine, California, to extend the term an additional <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dtM_c20211117_zCz1onJmVH1b" title="Operating lease renewal term">60</span> months from its September 30, 2022 expiration date to a new expiration date of September 30, 2027. The initial lease rate at the date of the amendment was $<span id="xdx_90D_eus-gaap--OperatingLeasePayments_pp0p0_c20211116__20211117_zukHxfp5iRV2" title="Initial lease rate per month">30,206</span> per month with escalating payments. In connection with the lease, the Company is obligated to pay $<span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20211116__20211117_zWvMOOliWFaj" title="Operating expenses for building repairs and maintenance">7,254</span> monthly for operating expenses for building repairs and maintenance. <span id="xdx_90E_eus-gaap--LesseeFinanceLeaseDescription_c20211116__20211117_zAGieYPBA4ua" title="Financing leases term description">The Company has no other operating or financing leases with terms greater than 12 months</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined the lease liabilities using the Company’s estimated incremental borrowing rate of <span id="xdx_90D_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPercentage_c20211231__us-gaap--TypeOfArrangementAxis__custom--PresentValueOfMonthlyLeasePaymentsMember_zigrgIVGAWAl" title="Discount rate">3.95</span>% to estimate the present value of the remaining monthly lease payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zFfjYgESMldi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operating lease cost is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zBDsVipCjZ6b" style="display: none">Schedule of Operating Lease Cost</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20210101__20211231_zWsH2f38MCVi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_zclg50IrHdYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">345,857</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zdOixd4d8JNk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zjysjdbVam2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to our operating lease is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zb997vGy342e" style="display: none">Schedule of Supplemental Cash Flow Information Related to Operating Lease</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20210101__20211231_zka52op6KZN8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating cash flow information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasePayments_zNNY871US1tf" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Cash paid for amounts included in the measurement of lease <br/>liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">354,561</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zEXEPNAJ95vf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfOperatingRemainingLeaseTermAndDiscountRateTableTextBlock_znyvqcXB0rv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining lease term and discount rate for our operating lease is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zxDPmwyZdE8e" style="display: none">Schedule of Operating Remaining Lease Term and Discount Rate</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zgQGWnySpyrh" title="Remaining lease term">5.7</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPercentage_c20211231_z0rXCnL7wIEk" title="Discount rate">3.95</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> <p id="xdx_8AC_zJWSsoeYi0Ma" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7Tc8nq2r7Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of our lease liabilities by fiscal year for our operating lease is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zlcAYfilBf4k" style="display: none">Schedule of Maturity of Lease Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20211231_zoVFD6zNUz5h" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z5JmA5yuzAGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Year ended December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">365,190</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_zveJqee37qMb" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,146</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zUolaklLFpA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">387,435</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zW35DyOAiLqa" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">399,054</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zL5ruhBTiFR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">411,024</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zBB4swzja3s6" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2027</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">315,153</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_zNvF6WhWPrwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,254,002</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbC2tk6YRq78" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Imputed interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(248,027</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zk8WP4bRLTh5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of our lease liability</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,005,975</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zwNB4dH6X6Ah" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P60M 30206 7254 The Company has no other operating or financing leases with terms greater than 12 months 0.0395 <p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zFfjYgESMldi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our operating lease cost is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zBDsVipCjZ6b" style="display: none">Schedule of Operating Lease Cost</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20210101__20211231_zWsH2f38MCVi" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td> </td></tr> <tr id="xdx_409_eus-gaap--OperatingLeaseCost_zclg50IrHdYg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">345,857</td><td style="width: 1%; text-align: left"> </td></tr> </table> 345857 <p id="xdx_89B_eus-gaap--ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_zjysjdbVam2b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to our operating lease is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zb997vGy342e" style="display: none">Schedule of Supplemental Cash Flow Information Related to Operating Lease</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20210101__20211231_zka52op6KZN8" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Year Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Operating cash flow information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OperatingLeasePayments_zNNY871US1tf" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Cash paid for amounts included in the measurement of lease <br/>liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">354,561</td><td style="width: 1%; text-align: left"> </td></tr> </table> 354561 <p id="xdx_893_ecustom--ScheduleOfOperatingRemainingLeaseTermAndDiscountRateTableTextBlock_znyvqcXB0rv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remaining lease term and discount rate for our operating lease is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zxDPmwyZdE8e" style="display: none">Schedule of Operating Remaining Lease Term and Discount Rate</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20211231_zgQGWnySpyrh" title="Remaining lease term">5.7</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Discount rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right"><span id="xdx_909_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPercentage_c20211231_z0rXCnL7wIEk" title="Discount rate">3.95</span></td><td style="width: 1%; text-align: left">%</td></tr> </table> P5Y8M12D 0.0395 <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_z7Tc8nq2r7Bg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maturity of our lease liabilities by fiscal year for our operating lease is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zlcAYfilBf4k" style="display: none">Schedule of Maturity of Lease Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20211231_zoVFD6zNUz5h" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_z5JmA5yuzAGl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Year ended December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">365,190</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_zveJqee37qMb" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">376,146</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zUolaklLFpA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">387,435</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zW35DyOAiLqa" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">399,054</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zL5ruhBTiFR8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Year ended December 31, 2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">411,024</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zBB4swzja3s6" style="vertical-align: bottom; background-color: White"> <td>Year ended December 31, 2027</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">315,153</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_zNvF6WhWPrwg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,254,002</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbC2tk6YRq78" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less: Imputed interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(248,027</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_zk8WP4bRLTh5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Present value of our lease liability</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,005,975</td><td style="text-align: left"> </td></tr> </table> 365190 376146 387435 399054 411024 315153 2254002 248027 2005975 <p id="xdx_808_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zRKgH9E71gv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 – <span id="xdx_822_zE1LeskHY7T4">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zFeJMAN8m6kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, accrued expenses consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zdxbpAftSYY" style="display: none">Schedule of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20211231_zE7Q5ZcA2Xp8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20201231_zMx3kkrbAkF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pp0p0_maALAOLzCZ3_zrwrNOPh4728" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued compensation costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">524,529</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">473,799</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALAOLzCZ3_zRZmri9rAVtk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,650</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maALAOLzCZ3_zBDvyiv1Zpgf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedWarrants_iI_pp0p0_maALAOLzCZ3_zzmNzEtxgnA3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued warrants</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0658"> </span></td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">188,104</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALAOLzCZ3_ziYwGSjnTE7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other</p></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,050</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,607</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzCZ3_zdR8PqLaGLN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">728,876</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,168,969</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_zxgS96x8pdQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zFeJMAN8m6kf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, accrued expenses consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zdxbpAftSYY" style="display: none">Schedule of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_495_20211231_zE7Q5ZcA2Xp8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20201231_zMx3kkrbAkF5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pp0p0_maALAOLzCZ3_zrwrNOPh4728" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued compensation costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">524,529</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">473,799</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALAOLzCZ3_zRZmri9rAVtk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">84,375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,650</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--AccruedResearchAndDevelopment_iI_pp0p0_maALAOLzCZ3_zBDvyiv1Zpgf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">368,809</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedWarrants_iI_pp0p0_maALAOLzCZ3_zzmNzEtxgnA3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued warrants</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0658"> </span></td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">188,104</p></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALAOLzCZ3_ziYwGSjnTE7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other</p></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">60,050</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,607</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_mtALAOLzCZ3_zdR8PqLaGLN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued expenses</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">728,876</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,168,969</td><td style="text-align: left"> </td></tr> </table> 524529 473799 84375 79650 59922 368809 188104 60050 58607 728876 1168969 <p id="xdx_806_eus-gaap--DebtDisclosureTextBlock_zpg8yJfIrz88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 – <span id="xdx_82F_zWl0hVPNnQq7">Note Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 12, 2020, the Company obtained a loan (the “Loan”) in the amount of $<span id="xdx_904_eus-gaap--NotesPayableCurrent_c20200412__us-gaap--TypeOfArrangementAxis__custom--PaycheckProtectionProgramMember_pp0p0" title="Notes payable amount">312,700</span>, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the CARES Act, which was enacted March 27, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Loan, which was in the form of a Note dated April 12, 2020, was to mature on <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_dd_c20200411__20200412__us-gaap--TypeOfArrangementAxis__custom--PaycheckProtectionProgramMember_z4pnl7yy1SU3" title="Maturity date">April 12, 2022</span>, and bore interest at a rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPercentage_c20200412__us-gaap--TypeOfArrangementAxis__custom--PaycheckProtectionProgramMember_zpSEvkSsviqf" title="Interest rate">1</span>% per annum, payable monthly commencing on November 12, 2020. On September 8, 2021, the Company was notified the Loan and any accrued interest had been forgiven. In connection with this, the Company recorded a gain on extinguishment of debt of $<span id="xdx_906_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20210907__20210908_pp0p0" title="Gain on extinguishment of debt">312,700</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 312700 2022-04-12 0.01 312700 <p id="xdx_803_eus-gaap--IncomeTaxDisclosureTextBlock_zxRmVLiTKZx" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_823_zJrbg7AGgje8">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z753ng9Kjw43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes the Company’s income tax provision (benefit):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPEH3DlyPLyc" style="display: none">Schedule of Income Tax Provision (Benefit)</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Current</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CurrentFederalTaxExpenseBenefit_c20210101__20211231_zwgoGhNdJ824" style="text-align: right" title="Fedral: Current"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_zlxho0a4qBR7" style="text-align: right" title="Fedral: Current"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Deferred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20210101__20211231_zzwbUFKbmd8l" style="width: 16%; text-align: right" title="Fedral: Deferred">(2,700,372</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_z4XnEoGtdGSe" style="width: 16%; text-align: right" title="Fedral: Deferred">(1,828,584</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State and local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_zzU7Whjk4Lbb" style="text-align: right" title="State and local: Current"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20210101__20211231_zqYxJWtXNrN3" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">(900,124</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_zWtUxgAffSP9" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">(609,528</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt">Current and Deferred Federal, State and Local, Tax Expense (Benefit)</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--CurrentAndDeferredFederalStateAndLocalTaxExpenseBenefit_c20210101__20211231_zQ51GhMO8U6g" style="text-align: right" title="Current and Deferred Federal, State and Local, Tax Expense (Benefit)">(3,600,496</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CurrentAndDeferredFederalStateAndLocalTaxExpenseBenefit_c20200101__20201231_z7Zafy0dOxBk" style="text-align: right">(2,438,112</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zUeRyJCPdXqd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">3,600,496</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zWgI4CQq34W2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">2,438,112</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax provision (benefit)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231_zwW10XX4IMah" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_zYNupf1vkh49" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zzv2kWCdXko3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFmfGmUJSsVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation between the U.S. statutory federal income tax rate and the Company’s effective tax rate for the year’s ended December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zcs4e42u3Myi" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended December 31,</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Tax benefit at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPercentage_c20210101__20211231_zQ8QCdwYoH25" title="Tax benefit at federal statutory rate">(21.0)</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPercentage_c20200101__20201231_zeL8RRPDwMja" title="Tax benefit at federal statutory rate">(21.0)</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPercentage_c20210101__20211231_zQjbMbbOrfaa" title="State taxes, net of federal benefit">(7.0)</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPercentage_c20200101__20201231_zdhrb6lxjFli" title="State taxes, net of federal benefit">(7.0)</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Nondeductible compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_c20210101__20211231_zrOWKM5kRBdf" title="Nondeductible compensation">6.2</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_c20200101__20201231_z8xyYyZwRpXe" title="Nondeductible compensation"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPercentage_c20210101__20211231_zxW7aI94yObi">(0.5</span></td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPercentage_c20200101__20201231_zyvtKZJkh4a2" title="Permanent differences">2.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">True up adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPercentage_c20210101__20211231_z0vl8VCdz3Fa">0.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPercentage_c20200101__20201231_zx6LVR0JXifj" title="True up adjustments">(0.7)</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20210101__20211231_zjI8VZhvEzFa">21.8</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20200101__20201231_ztCX0eucKWe9" title="Change in valuation allowance">26.7</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Effective income tax rate</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20210101__20211231_zbBZzQppen7a" title="Effective income tax rate">0.0</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20200101__20201231_zEDOIJr4XSWd" title="Effective income tax rate">0.0</span></td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A3_zp8jODcXNpHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zegy6PZvPQIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zl97PtkyZLN4" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20211231_zLwKOrivVaFb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20201231_zdoztAuPQUfe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,881,729</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,811,086</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,680</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,680</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DeferredTaxAssetsOperatingLeaseLiability_iI_pp0p0_zcYviUp6cmJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,194</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,025</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">923,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,304</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Impairment loss</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,612</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,612</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,481,939</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,908,734</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsOperatingLeaseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(70,994</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(151,193</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentOne_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(102,107</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(49,199</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total net deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,308,838</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,708,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zIDx7G5VPC39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,308,838</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,708,342</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_zY2ygQ8aTaNg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt">Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AE_zg7lMzJufrO" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Because of the Company’s history of operating losses, management believes that recognition of the deferred tax assets arising from the above listed future tax benefits is currently not more likely than not to be realized and, accordingly, has provided a full valuation allowance. The valuation allowance increased by $<span id="xdx_90E_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20211231_zjBBm5rvOjAl">3.6</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_904_eus-gaap--TaxCreditCarryforwardValuationAllowance_iI_pn5n6_c20201231_zUzNUhhhK1E2">2.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million during the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes to offset its post-change income taxes may be limited. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company’s NOL carry forwards are subject to annual limitations due to a greater than <span id="xdx_904_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20211231_zOWcrfShiR17">50</span>% ownership change in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2021 and 2020, the Company had post-ownership change net operating loss carryforwards for federal income tax purposes of approximately $<span id="xdx_90C_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_pn5n6_c20210101__20211231_zfQajYdc9pZi">45.7 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--FederalIncomeTaxExpenseBenefitContinuingOperations_pn5n6_c20200101__20201231_ztXuYw87r7Q5">35.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. Pre-2018 federal NOLs of approximately $<span id="xdx_90B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_iI_pn5n6_c20211231_zUcraLbVaUq8" title="Operating loss carryforwards expired">12.0</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million may be carried forward for twenty years and begin to expire in 2029. Based on the 2021 ownership change, the Company expects $<span id="xdx_900_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_iI_pn5n6_c20201231_zQfBISurg187" title="Operating loss carryforwards expired unused">7.6</span> million of its pre-2018 federal NOLs to expire unused. Under the Tax Act, post-2017 federal NOLs in the aggregate amount of $<span id="xdx_906_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_z4p3OGoVdqTk">33.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million can be carried forward indefinitely and the annual limit of deduction equals <span id="xdx_905_ecustom--AnnualLimitOfDeductionPercentage_pid_dp_c20210101__20211231_zQaSadGAXTV4">80</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of taxable income. However, to the extent the Company utilizes its NOL carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized. The Company also has federal research and development tax credit carryforwards of approximately $<span id="xdx_909_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231__us-gaap--IncomeStatementLocationAxis__custom--ResearchAndDevelopmentMember_zYVHRUqjZmIl">0.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million which begin to expire in 2027.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, the Company had net operating loss carryforwards for state income tax purposes of approximately $<span id="xdx_902_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_pn5n6_c20210101__20211231_zvyNgo3U9ETf" title="Net operating loss carryforwards">45.7</span> million and $<span id="xdx_909_eus-gaap--StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_pn5n6_c20200101__20201231_zKkCFNoNiTTd" title="Net operating loss carryforwards">35.0</span> million, respectively, which can be carried forward for twenty years and begin to expire in 2028.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction as well as California and local jurisdictions and is subject to examination by those taxing authorities. The Company’s federal income taxes for the years beginning in 2018 remain subject to examination. The Company’s state and local income tax returns for the years beginning in 2017 remain subject to examination. No tax audits were initiated during 2021 or 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s financial statements as of December 31, 2021 and 2020. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2020, the CARES Act was enacted in response to COVID-19 pandemic. Under ASC 740, the effects of changes in tax rates and laws are recognized in the period which the new legislation is enacted. The CARES Act made various tax law changes including among other things (i) increasing the limitation under Section 163(j) of the Internal Revenue Code of 1986, as amended (the “IRC”) for 2019 and 2020 to permit additional expensing of interest (ii) enacting a technical correction so that qualified improvement property can be immediately expensed under IRC Section 168(k), (iii) making modifications to the federal net operating loss rules including permitting federal net operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years in order to generate a refund of previously paid income taxes and (iv) enhancing the recoverability of alternative minimum tax credits. The Company has evaluated the impact CARES Act on its provision for income taxes and determined there is not a significant impact to income taxes because of the CARES Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 29, 2020, California’s Governor Newsom signed AB85 suspending California net operating loss (“NOL”) utilization and imposing a cap on the amount of business incentives tax credits (R&amp;D credit) for tax years 2020-2022. Given the tax loss in 2020 and an expected tax loss for 2021, the suspension will not have an impact on the Company’s NOL in California. On February 9, 2022, Mr. Newsom signed SB113 which removes the restrictions in AB85 effective for the 2022 tax year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z753ng9Kjw43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summarizes the Company’s income tax provision (benefit):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zPEH3DlyPLyc" style="display: none">Schedule of Income Tax Provision (Benefit)</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Current</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--CurrentFederalTaxExpenseBenefit_c20210101__20211231_zwgoGhNdJ824" style="text-align: right" title="Fedral: Current"><span style="-sec-ix-hidden: xdx2ixbrl0681">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--CurrentFederalTaxExpenseBenefit_c20200101__20201231_zlxho0a4qBR7" style="text-align: right" title="Fedral: Current"><span style="-sec-ix-hidden: xdx2ixbrl0683">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Deferred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20210101__20211231_zzwbUFKbmd8l" style="width: 16%; text-align: right" title="Fedral: Deferred">(2,700,372</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_c20200101__20201231_z4XnEoGtdGSe" style="width: 16%; text-align: right" title="Fedral: Deferred">(1,828,584</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">State and local:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">-</p></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_c20200101__20201231_zzU7Whjk4Lbb" style="text-align: right" title="State and local: Current"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20210101__20211231_zqYxJWtXNrN3" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">(900,124</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_c20200101__20201231_zWtUxgAffSP9" style="border-bottom: Black 1.5pt solid; text-align: right" title="State and local: Deferred">(609,528</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 7pt">Current and Deferred Federal, State and Local, Tax Expense (Benefit)</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--CurrentAndDeferredFederalStateAndLocalTaxExpenseBenefit_c20210101__20211231_zQ51GhMO8U6g" style="text-align: right" title="Current and Deferred Federal, State and Local, Tax Expense (Benefit)">(3,600,496</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CurrentAndDeferredFederalStateAndLocalTaxExpenseBenefit_c20200101__20201231_z7Zafy0dOxBk" style="text-align: right">(2,438,112</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20210101__20211231_zUeRyJCPdXqd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">3,600,496</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zWgI4CQq34W2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in valuation allowance">2,438,112</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income tax provision (benefit)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IncomeTaxExpenseBenefit_c20210101__20211231_zwW10XX4IMah" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--IncomeTaxExpenseBenefit_c20200101__20201231_zYNupf1vkh49" style="border-bottom: Black 2.5pt double; text-align: right" title="Income tax provision (benefit)"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td></tr> </table> -2700372 -1828584 -900124 -609528 -3600496 -2438112 3600496 2438112 <p id="xdx_893_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFmfGmUJSsVl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation between the U.S. statutory federal income tax rate and the Company’s effective tax rate for the year’s ended December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zcs4e42u3Myi" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the Years Ended December 31,</b></span></p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Tax benefit at federal statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPercentage_c20210101__20211231_zQ8QCdwYoH25" title="Tax benefit at federal statutory rate">(21.0)</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_dpi_uPercentage_c20200101__20201231_zeL8RRPDwMja" title="Tax benefit at federal statutory rate">(21.0)</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPercentage_c20210101__20211231_zQjbMbbOrfaa" title="State taxes, net of federal benefit">(7.0)</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPercentage_c20200101__20201231_zdhrb6lxjFli" title="State taxes, net of federal benefit">(7.0)</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Nondeductible compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_c20210101__20211231_zrOWKM5kRBdf" title="Nondeductible compensation">6.2</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_c20200101__20201231_z8xyYyZwRpXe" title="Nondeductible compensation"><span style="-sec-ix-hidden: xdx2ixbrl0718">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPercentage_c20210101__20211231_zxW7aI94yObi">(0.5</span></td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_dp_uPercentage_c20200101__20201231_zyvtKZJkh4a2" title="Permanent differences">2.0</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">True up adjustments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPercentage_c20210101__20211231_z0vl8VCdz3Fa">0.5</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPercentage_c20200101__20201231_zx6LVR0JXifj" title="True up adjustments">(0.7)</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_902_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20210101__20211231_zjI8VZhvEzFa">21.8</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPercentage_c20200101__20201231_ztCX0eucKWe9" title="Change in valuation allowance">26.7</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Effective income tax rate</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20210101__20211231_zbBZzQppen7a" title="Effective income tax rate">0.0</span></td><td style="text-align: left">%</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_uPercentage_c20200101__20201231_zEDOIJr4XSWd" title="Effective income tax rate">0.0</span></td><td style="text-align: left">%</td></tr> </table> 0.210 0.210 -0.070 -0.070 0.062 -0.005 0.020 0.005 -0.007 0.218 0.267 0.000 0.000 <p id="xdx_89F_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zegy6PZvPQIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant components of the Company’s deferred tax assets at December 31, 2021 and 2020 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zl97PtkyZLN4" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20211231_zLwKOrivVaFb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20201231_zdoztAuPQUfe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">12,881,729</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,811,086</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development credit carryforwards</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,680</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">185,680</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,027</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DeferredTaxAssetsOperatingLeaseLiability_iI_pp0p0_zcYviUp6cmJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Operating lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,194</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,025</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">923,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,304</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Impairment loss</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,612</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">136,612</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGross_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Total gross deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,481,939</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,908,734</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsOperatingLeaseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Operating lease asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(70,994</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(151,193</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsPropertyPlantAndEquipmentOne_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(102,107</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(49,199</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_iTIC_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total net deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,308,838</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,708,342</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_zIDx7G5VPC39" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Less: valuation allowance</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,308,838</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,708,342</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_zY2ygQ8aTaNg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt">Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">-</span></td><td style="text-align: left"> </td></tr> </table> 12881729 9811086 185680 185680 276184 305027 78194 159025 923540 311304 136612 136612 14481939 10908734 -70994 -151193 -102107 -49199 14308838 10708342 14308838 10708342 3600000 2400000 0.50 45700000 35000000.0 12000000.0 7600000 33000000.0 0.80 200000 45700000 35000000.0 <p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zTo4wO5quYc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_827_zpcUkxFD1sNk">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Litigation Claims and Assessments</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Robert Rankin Complaints</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 9, 2020, the Company was served with a civil complaint filed in the Superior Court for the State of California, County of Orange by a former employee, Robert Rankin, who resigned his employment on or about March 30, 2020. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01146555-CU-WR-CJC and was filed on May 27, 2020. On September 3, 2020 the Company and its Chief Executive Officer were served with a second complaint filed in the Superior Court for the State of California, County of Orange by Mr. Rankin. The case is entitled Rankin v. Hancock Jaffe Laboratories, Inc. et al., Case No. 30-2020-01157857 and was filed on August 31, 2020. The complaints assert several causes of action including a cause of action for failure to timely pay Mr. Rankin’s accrued and unused vacation and three months’ severance under his July 16, 2018 employment agreement, defamation, unlawful labor code violations, sex-based discrimination, and unfair competition, and seeks damages for lost wages, emotional and mental distress, consequential damages, punitive damages and attorney’s fees and costs. The Company has denied all claims in both matters (which have now been consolidated) and has filed a counterclaim asserting that Rankin has breached his employment agreement with the Company to the Company’s damage. The Company continues to believe it has meritorious defenses to both matters. As of the date of these financial statements, the amount of loss associated with these complaints, if any, cannot be reasonably estimated. Accordingly, no amounts related to these complaints are accrued as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zRHPQHwRod1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 –<span id="xdx_821_z75rXuDD21Jh">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 30, 2020, the Company”) effected a one-for-twenty-five (1:25) reverse stock split (the “Reverse Stock Split”) of the shares of the Company’s common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201130_zc0g7CoN8GE2" title="Common stock par value">0.00001</span> per share (the “Common Stock”). As a result of the Reverse Stock Split, every twenty-five shares of issued and outstanding Common Stock was automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Equity Issuances</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zzc3CwdVce3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021 and 2020 the Company has completed various equity transactions to raise capital through the placement of its common and preferred stock. The following table provides an overview of these transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zi26Hstnkvt" style="display: none">Schedule of Equity Transactions to Raise Capital Through the Placement</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Date</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Type</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Number of shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Net Proceeds</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">2020</td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 25, 2020</span></td><td style="width: 2%"> </td> <td style="width: 24%; text-align: justify">Private placement</td><td style="width: 2%"> </td> <td style="width: 16%; text-align: justify">Common Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200224__20200225__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zalKdHiOplb8" title="Number of shares issued during the period">52,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200224__20200225__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfUdSJviNgCk" title="Net Proceeds issued during the period">570,341</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 28, 2020</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200426__20200428__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z130BIRuY1m2" title="Number of shares issued during the period">75,472</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200426__20200428__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDrGdaeIQbLk" title="Net Proceeds issued during the period">811,641</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 3, 2020</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200601__20200603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmD5kWXtGgG4" title="Number of shares issued during the period">117,216</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200601__20200603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwmcsVKqfQE6" title="Net Proceeds issued during the period">1,161,334</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 17, 2020</span></td><td> </td> <td style="text-align: justify">Public Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200715__20200717__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYFnIWSxb4b5" title="Number of shares issued during the period">575,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200715__20200717__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY08gxi5JMd" title="Net Proceeds issued during the period">3,881,907</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 17, 2020</span></td><td> </td> <td style="text-align: justify">Private Placement</td><td> </td> <td style="text-align: justify">Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201115__20201117__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLyDEO4aOD04" title="Number of shares issued during the period">4,205,406</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201115__20201117__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4CB73I4juT2" title="Net Proceeds issued during the period">1,358,099</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 9, 2020</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201008__20201009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFIsJmzocDrc" title="Number of shares issued during the period">381,308</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201008__20201009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOSev3ORentb" title="Net Proceeds issued during the period">4,450,500</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total </b></span></td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200101__20201231_zGEod9NQyxUd" title="Total">12,233,822</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">2021</td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2021</span></td><td> </td> <td style="text-align: justify">Public Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200210__20200211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcnzzL7kLVg7" title="Number of shares issued during the period">5,914,284</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200210__20200211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY0jSMMFBMg4" title="Net Proceeds issued during the period">38,127,776</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2021</span></td><td> </td> <td style="text-align: left">At-the-Market Equity Program</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY2yYwHFc0B5" title="Number of shares issued during the period">170,963</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsI4uv3Ls8gj" title="Net Proceeds issued during the period">970,575</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 9, 2021</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210907__20210909__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPD4JNesiQi3" title="Number of shares issued during the period">781,615</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210907__20210909__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ0fENLMi2K3" title="Net Proceeds issued during the period">18,273,591</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20211231_z7sFRWt3Hof7" title="Net Proceeds issued during the period">57,371,942</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A5_z8PcUOvcxps" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series C Convertible Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 17, 2020, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200715__20200717__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_pdd" title="Number of shares issued during the period">4,205,406</span> shares of Preferred Stock in a private placement. On November 17, 2020, the holders of the Preferred Stock purchased in the July 17, 2020 private placement entered exchange agreements with the Company whereby the holders agreed to exchange all of their <span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_c20201116__20201117__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHm7TCx1Gyck" title="Conversion of stock">4,205,406</span> shares of Preferred Stock for <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20201116__20201117__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpiqZktrB2Ra" title="Conversion of stock">243,125</span> shares of common stock. This was the original conversion rate of the Preferred Stock after giving effect to the 25:1 reverse split of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Preferred Stock was outstanding, the holders of the Company’s Preferred Stock could vote with holders of the Common Stock, and with any other shares of preferred stock that vote with the Common Stock, with each holder of Preferred Stock being entitled to one vote per share of Preferred Stock, and were entitled to receive <span id="xdx_90B_ecustom--PurchasePricePerentage_iI_dp_uPercentage_c20200717_zJNASd5whac1" title="Purchase price percentage">8%</span> non-compounding cumulative dividends, payable when, as and if declared by the Board of Directors. The Series C Preferred Stock ranked senior to the common stock as to dividends and the distribution of assets in the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, or any sale of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, or any sale of the Company, the holders of Preferred Stock were entitled to receive, before and in preference to any distribution of any of the assets to the holders of the common stock, or any other series of the Company’s preferred stock that would then be junior to the Preferred Stock, an amount per share equal to $0.37 for each outstanding share of Preferred Stock (the “Original Series C Issue Price”), plus all accrued but unpaid dividends thereon through the date of such event.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In certain circumstances, the holders of Preferred Stock were entitled to receive a liquidation preference payment of $<span id="xdx_900_eus-gaap--PreferredStockLiquidationPreference_c20200930__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_pdd" title="Preferred stock, liquidation preference per share">0.37</span> per share of Preferred Stock, plus accrued and unpaid dividends. Those accrued and unpaid dividends were $<span id="xdx_90C_ecustom--DeemedDividend_pp0p0_c20200101__20200930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zI12RELJq2Gk" title="Deemed dividend">23,859</span> in the aggregate as of September 30, 2020 and were reflected as a deemed dividend in determining net loss available to common stockholders during that period. As a result of the exchange of the Preferred Stock for common stock, it is no longer outstanding (see below).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The liquidation preference of the Preferred Stock was subordinate and ranks junior to all indebtedness of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConversionOfStockDescription_c20200101__20201231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember" title="Conversion of stock, description">The Company had the ability to elect to convert the Preferred Stock to common stock in the event the Company either (i) consummated a merger, or (ii) raised an aggregate of at least $8,000,000 in gross proceeds in a transaction or series of transactions within any twelve (12) month period. In the event the Company elected to affect such a conversion, each share of Series C Preferred Stock would have been convertible into 0.05781 shares of common stock.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.<br/> NOTES TO CONDENSED FINANCIAL STATEMENTS </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined that the Preferred Stock represented permanent equity due to the absence of a redemption feature and that the embedded conversion option was clearly and closely related to the equity host and did not require bifurcation. The <span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwkufrmvgCXd" title="Fair value of warrants">$2,431,250</span> fair value of the warrants was calculated using the Black-Scholes option pricing model, using the $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z0y2zsb8vvD2" title="Warrants and rights outstanding measurement input">11.00</span> stock price, an expected term of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zmS09jJyUf55" title="Expected term">7.0</span> years, volatility of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zzvefcK8u2X2" title="Warrants and rights outstanding measurement input">118.7</span>%, a risk-free rate of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z8ICERwsvWl8" title="Warrants and rights outstanding measurement input">0.47</span>% and expected dividends of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPercentage_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zO55ZsdgnPUg" title="Warrants and rights outstanding measurement input">0.00</span>%. The $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zF83oGP4JdOl" title="Net proceeds from warrant exercises after deducting underwrites and placement agents fees and expenses">1,556,000</span> of gross proceeds were allocated on a relative fair value basis of $<span id="xdx_90D_eus-gaap--EquityFairValueAdjustment_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKiuIV8YGVR7" title="Fair value adjustment">607,220</span> to the Preferred Stock and $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zDyTsuuZAlmg" title="Fair value adjustment">948,781</span> to the warrants. <span id="xdx_908_ecustom--WarrantsDescription_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zaPe6m2mk1sl" title="Warrants description">The Preferred Stock includes a contingent beneficial conversion feature (“BCF”) which was valued at its $<span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_zAdD2RuihdN8" title="Warrants intrinstic">2,067,155</span> intrinsic value using the commitment date stock price of $<span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uShares_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z5zOv2lOXIeb" title="Warrants and rights outstanding measurement input">11.00</span> per share and the effective conversion price of $2.50 per share, but was limited to the $607,220 of proceeds that were allocated to the Preferred Stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The November 17, 2020 exchange agreements resolved the contingency related to the BCF and, accordingly, the contingent BCF was recognized as a deemed dividend for the purposes of determining the net loss attributable to common stockholders for calculating net loss per share. In addition, since the Company does not have retained earnings, the dividend has been recorded against additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Warrants</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zzriia256abk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant activity during the years ended December 31, 2021 and 2020 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zlqAyAPKBxG2" style="display: none">Schedule of Stock Warrant Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Warrants</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Weighted</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Average</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Exercise</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Price</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Weighted</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Average</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Remaining</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Life in</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Years</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Intrinsic</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Value</p></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2020</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zKW2Nk3iIha9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding">174,681</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice_iS_c20200101__20201231_z6nRnQwxCVp8" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding">127.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued </span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zfqZLnadeDr9" style="text-align: right" title="Number of Warrants, Issued">1,702,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_c20200101__20201231_zqz6kcFBw0y3" style="text-align: right" title="Weighted Average Exercise Price, Issued">9.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zcJug6Nq9eU5" style="text-align: right" title="Number of Warrants, Exercised">(367,660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20200101__20201231_z79EOxELzaW4" style="text-align: right" title="Weighted Average Exercise Price, Exercised">8.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20200101__20201231_z3D0pYRCVKQ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Cancelled">(2,029</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zxL9vASY3ZPc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">107.50</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2021</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zHLqyuoFd0l4" style="text-align: right" title="Number of Warrants, Outstanding">1,507,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice_iS_c20210101__20211231_zUoruiPcm0C3" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">20.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231_zRjPD2x2UVnj" title="Weighted average remaining life in years, Outstanding">5.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding_iS_c20210101__20211231_zrvx0Dd9Rca5" style="text-align: right" title="Intrinsic value, Outstanding">448,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zHtEhKyn0jz3" style="text-align: right" title="Number of Warrants, Issued">4,895,016</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_c20210101__20211231_zt7HSeFG9ww2" style="text-align: right" title="Weighted Average Exercise Price, Issued">4.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_z8nK3Tu8GVsg" style="text-align: right" title="Number of Warrants, Exercised">(52,827</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGApnB5yuC19" style="text-align: right" title="Weighted Average Exercise Price, Exercised">5.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231_zXrWTRhMX41" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Cancelled">(38,286</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zTrixKpk7bth" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">16.10</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding and exercisable, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zdQN6kuKSRRj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding and exercisable">6,311,705</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice_iE_c20210101__20211231_zhhpzcSq3zXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding and exercisable">8.80</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z5lMI0QqLu95" title="Weighted average remaining life in years, Outstanding and exercisable">4.2</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding_iE_c20210101__20211231_zwRF2qMlSFfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Outstanding and exercisable">474,464</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_zeq8NBX2fCa7" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 2020 as part of resolving a dispute, the Company agreed to issue warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201110__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMQALdWcV4di">17,618 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at a purchase price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201110__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuSDOfgGKHvc">8.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, and warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201110__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zKHWoeyvwTE7">18,056 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock at a purchase price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20201110__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zl0p937GhBI2">10.25 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share. These amounts were in dispute and were paid pursuant to an investment banking agreement dated February 12, 2020 in connection with financings which occurred in July and October 2020. The fair value of these warrants on the settlement date was $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zg9er4dexL3d">0.1 million</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20201001__20201031__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember_zqyr1kInFvK2">0.1 million</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. The</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> total amount of the payment to settle the dispute was $<span id="xdx_90D_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20201109__20201110__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember_zfsijVzwQMO5" title="Payment of dispute settlements">0.5 million, including the value of the warrants.</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and was included in the cost of the July and October financings. The fair value of the warrants was determined using the Black-Scholes method with the following assumptions: stock price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201110__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zo9957i7oF7j">8.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201110__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_z4FnBd5co0w8">10.35</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, risk-free interest rate of <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPercentage_c20201110__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z0XjiNdNScl8">0.46</span></span>%, volatility of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPercentage_c20201110__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zgLPrAn26pRl">112.7</span>%, annual rate of quarterly dividends of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPercentage_c20201110__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zeJ5K0EzJ2nh">0</span>%, and an expected term of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201110__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zqdczwY01ub9">2.5 </span>years. The investment banking agreement has now been terminated with no further obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2020 the Company’s Board of Directors approved the issuance of warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201110__srt--TitleOfIndividualAxis__custom--BoardOfDirectorsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6RcC0jLGIM2">6,400 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to an advisor and warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201110__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SpartanCapitalSecuritiesLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNVNECSzZEei">20,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock to certain participants in the preferred share exchange (see Note 10, Stockholders Equity – <i>Series C Convertible Preferred Stock</i>). Separately the Company agreed to re-price warrants issued to the placement agent for the Company’s February 25, 2020 private placement. These warrants and the re-priced warrant were issued in February 2021. The value of these warrants at December 31, 2020 was $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20201109__20201110__srt--TitleOfIndividualAxis__custom--AdvisorMember_zndSPT1t9qUh">188,804 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and is included in accrued expenses. The Company determined their value using the Black-Scholes method with the following assumptions: stock price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_zZ9ZrvxYZ9V6">8.65</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, risk-free interest rate of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPercentage_c20201130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zPuA3WzkNdX3">0.36</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, volatility of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPercentage_c20201130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOyEFMEQxjn5">114.3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, annual rate of quarterly dividends of <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPercentage_c20201130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zoOqWkUkiT1k">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, and an expected term of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_z4kcqJfvAhlk">2.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zwTSE4gAB8k7">3.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants – Derivative Liabilities</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants issued in connection with our February 25, 2020 Bridge Offering were determined to be derivative financial instruments when issued because the Company did not have control of the obligation to obtain shareholder approval by May 25, 2020 to increase the number of authorized shares or to approve a reverse stock split. The accounting treatment of derivative financial instruments required that the Company record the warrants as a liability at fair value and marked-to-market the instruments at fair values as of each subsequent balance sheet date. Any change in fair value is recorded as a change in the fair value of derivative liabilities for each reporting period at each balance sheet date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrant derivatives were valued as of the February 25, 2020 issuance date, as of the quarter ended March 31, 2020, as of June 30, 2020, and as of September 15, 2020 when the Company’s stockholders approved an increase in authorized shares in an amount sufficient to allow full exercise of these warrants. The value at issuance was $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_c20200225_pp0p0" title="Derivative liability">546,036</span> and was recorded as a derivative liability. The value of the derivative liability was $<span id="xdx_906_eus-gaap--DerivativeLiabilitiesCurrent_c20200331_pp0p0" title="Derivative liability">199,907</span> at March 31, 2020, $<span id="xdx_900_eus-gaap--DerivativeLiabilitiesCurrent_c20200630_pp0p0" title="Derivative liability">281,183</span> at June 30, 2020, and $<span id="xdx_902_eus-gaap--DerivativeLiabilitiesCurrent_iI_pp0p0_c20200915_z5sMH3Q6w4rh">334,229</span> at September 15, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The derivative liability increased $<span id="xdx_90B_eus-gaap--DerivativeGainOnDerivative_c20200701__20200930_zAgT5zakPjpf" title="Increase in derivative liability">53,046</span> and decreased $<span id="xdx_900_eus-gaap--DerivativeLossOnDerivative_c20200101__20200930_zveLsPXkOcch" title="Decrease in derivative liability">211,807</span> during the three and nine months ended September 30, 2020, respectively. The changes in derivative liability is reflected in Other Income on the accompanying Statement of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reassessed the classification at each balance sheet date to determine if it should be changed as a result of events during the period. On September 15, 2020, the fair value of derivative liabilities was reclassified to equity when the Company’s stockholders approved items comprising a Capital Event. Accordingly, there is no fair value of derivative liabilities as of December 31, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityTableTextBlock_zgerrqBhLsld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The following inputs and assumptions were used for the valuation of the derivative liability:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z3D5wpOwvB9e" style="display: none">Schedule of Assumption Used for Valuation of Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20200225_z6DlPUt6uNl7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">February 25,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20200331_zAA5NTlIX4X3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">March 31,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20200630_z0rZXl8LWpme" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">June 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20200915_ziOHdnOWjtwc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 15,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dc_uPercentage_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3ibimddceA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 27%; text-align: left">Projected Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">97.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">102.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">102.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">110.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPercentage_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQSxaU7hsO3c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.36</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.38</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.29</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.31</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual Term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200224__20220225__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zvHik0V8ktA2" title="Contractual Term (Years)">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200330__20200331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuc5OLLTgxq2" title="Contractual Term (Years)">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200629__20200630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyxaEQkhr2b6" title="Contractual Term (Years)">4.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200914__20200915__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zqBNSoh3CFag" title="Contractual Term (Years)">4.5</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zQyupj6cGOQ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It was assumed the stock price would fluctuate with the Company’s projected volatility.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The projected volatility was based on the historical volatility of the Company. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DerivativeLiabilityMeasurementDifferenceDescription_c20200224__20200225_zihiSD16iJab" title="Derivative liability, description">If the Company was required to pay the fair value of the warrant in cash as of May 25, 2020, the obligation was discounted at the Company’s estimated cost of debt based on short-term C-CCC bond ratings of 19.5% and 28.5%</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--DerivativeLiabilityMeasurementDifferenceDescriptionoNE_c20200224__20200225_zapiyyztBXnl" title="Derivative difference description">The likelihood of the Company calling a shareholder meeting and achieving shareholder approval was 90% as of February 25, 2020</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As June 30, 2020, the Company projected shareholder approval would not be obtained until approximately 8/31/20. No mandatory exercise was allowed prior to that date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until the Company obtained shareholder approval to increase the authorized shares on September 15, 2020, we assumed the warrant holders have an option to require the Company to pay the fair value of the warrants. The derivative value at that date was $<span id="xdx_90E_eus-gaap--DerivativeLiabilitiesCurrent_c20200915_pp0p0" title="Derivative liability">334,229</span>.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z8rHRdGM2zSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B9_zbhkoGyuzkU" style="display: none">Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20200101__20201231_zbSTMTO1Ocva" style="font-weight: bold; text-align: center">Derivative</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zvf2xw8K8nml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance – January 1, 2020</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_zapz9jBYFWZj" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Derivative liabilities associated with the issuance of common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">513,534</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssuesOne_zAideFef4GV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities associated with the issuance of placement agent warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_zN8nGJJQNH69" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(211,807</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationOfWarrantDerivativesToEquity_zqQ2nQWuJPV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Reclassification of warrant derivatives to equity</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(334,229</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zOvpd5NO5wR9" style="vertical-align: bottom; background-color: White"> <td>Balance – December 31, 2020</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_zGHRxpwzlPQ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.00001 <p id="xdx_89E_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zzc3CwdVce3e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2021 and 2020 the Company has completed various equity transactions to raise capital through the placement of its common and preferred stock. The following table provides an overview of these transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zi26Hstnkvt" style="display: none">Schedule of Equity Transactions to Raise Capital Through the Placement</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Date</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Type</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Number of shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Net Proceeds</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">2020</td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 18%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 25, 2020</span></td><td style="width: 2%"> </td> <td style="width: 24%; text-align: justify">Private placement</td><td style="width: 2%"> </td> <td style="width: 16%; text-align: justify">Common Stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200224__20200225__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zalKdHiOplb8" title="Number of shares issued during the period">52,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200224__20200225__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfUdSJviNgCk" title="Net Proceeds issued during the period">570,341</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 28, 2020</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200426__20200428__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z130BIRuY1m2" title="Number of shares issued during the period">75,472</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200426__20200428__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDrGdaeIQbLk" title="Net Proceeds issued during the period">811,641</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 3, 2020</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200601__20200603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmD5kWXtGgG4" title="Number of shares issued during the period">117,216</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200601__20200603__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwmcsVKqfQE6" title="Net Proceeds issued during the period">1,161,334</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 17, 2020</span></td><td> </td> <td style="text-align: justify">Public Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200715__20200717__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYFnIWSxb4b5" title="Number of shares issued during the period">575,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200715__20200717__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWY08gxi5JMd" title="Net Proceeds issued during the period">3,881,907</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 17, 2020</span></td><td> </td> <td style="text-align: justify">Private Placement</td><td> </td> <td style="text-align: justify">Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201115__20201117__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zLyDEO4aOD04" title="Number of shares issued during the period">4,205,406</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201115__20201117__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z4CB73I4juT2" title="Net Proceeds issued during the period">1,358,099</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 9, 2020</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201008__20201009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFIsJmzocDrc" title="Number of shares issued during the period">381,308</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201008__20201009__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOSev3ORentb" title="Net Proceeds issued during the period">4,450,500</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total </b></span></td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200101__20201231_zGEod9NQyxUd" title="Total">12,233,822</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">2021</td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 11, 2021</span></td><td> </td> <td style="text-align: justify">Public Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200210__20200211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcnzzL7kLVg7" title="Number of shares issued during the period">5,914,284</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200210__20200211__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY0jSMMFBMg4" title="Net Proceeds issued during the period">38,127,776</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2021</span></td><td> </td> <td style="text-align: left">At-the-Market Equity Program</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zY2yYwHFc0B5" title="Number of shares issued during the period">170,963</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210801__20210831__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsI4uv3Ls8gj" title="Net Proceeds issued during the period">970,575</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 9, 2021</span></td><td> </td> <td style="text-align: justify">Registered Direct Offering</td><td> </td> <td style="text-align: justify">Common Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210907__20210909__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPD4JNesiQi3" title="Number of shares issued during the period">781,615</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210907__20210909__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ0fENLMi2K3" title="Net Proceeds issued during the period">18,273,591</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20211231_z7sFRWt3Hof7" title="Net Proceeds issued during the period">57,371,942</span></td><td style="text-align: left"> </td></tr> </table> 52000 570341 75472 811641 117216 1161334 575000 3881907 4205406 1358099 381308 4450500 12233822 5914284 38127776 170963 970575 781615 18273591 57371942 4205406 4205406 243125 0.08 0.37 23859 The Company had the ability to elect to convert the Preferred Stock to common stock in the event the Company either (i) consummated a merger, or (ii) raised an aggregate of at least $8,000,000 in gross proceeds in a transaction or series of transactions within any twelve (12) month period. In the event the Company elected to affect such a conversion, each share of Series C Preferred Stock would have been convertible into 0.05781 shares of common stock. 2431250 11.00 P7Y 118.7 0.47 0.00 1556000 607220 948781 The Preferred Stock includes a contingent beneficial conversion feature (“BCF”) which was valued at its $2,067,155 intrinsic value using the commitment date stock price of $11.00 per share and the effective conversion price of $2.50 per share, but was limited to the $607,220 of proceeds that were allocated to the Preferred Stock 2067155 11.00 <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zzriia256abk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of warrant activity during the years ended December 31, 2021 and 2020 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zlqAyAPKBxG2" style="display: none">Schedule of Stock Warrant Activity</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Warrants</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Weighted</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Average</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Exercise</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Price</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Weighted</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Average</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Remaining</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Life in</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Years</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Intrinsic</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Value</p></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2020</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zKW2Nk3iIha9" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding">174,681</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice_iS_c20200101__20201231_z6nRnQwxCVp8" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding">127.50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued </span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zfqZLnadeDr9" style="text-align: right" title="Number of Warrants, Issued">1,702,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_c20200101__20201231_zqz6kcFBw0y3" style="text-align: right" title="Weighted Average Exercise Price, Issued">9.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zcJug6Nq9eU5" style="text-align: right" title="Number of Warrants, Exercised">(367,660</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20200101__20201231_z79EOxELzaW4" style="text-align: right" title="Weighted Average Exercise Price, Exercised">8.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20200101__20201231_z3D0pYRCVKQ2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Cancelled">(2,029</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zxL9vASY3ZPc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">107.50</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2021</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_zHLqyuoFd0l4" style="text-align: right" title="Number of Warrants, Outstanding">1,507,802</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice_iS_c20210101__20211231_zUoruiPcm0C3" style="text-align: right" title="Weighted Average Exercise Price, Outstanding">20.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20211231_zRjPD2x2UVnj" title="Weighted average remaining life in years, Outstanding">5.3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding_iS_c20210101__20211231_zrvx0Dd9Rca5" style="text-align: right" title="Intrinsic value, Outstanding">448,140</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zHtEhKyn0jz3" style="text-align: right" title="Number of Warrants, Issued">4,895,016</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_c20210101__20211231_zt7HSeFG9ww2" style="text-align: right" title="Weighted Average Exercise Price, Issued">4.59</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_z8nK3Tu8GVsg" style="text-align: right" title="Number of Warrants, Exercised">(52,827</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20211231_zGApnB5yuC19" style="text-align: right" title="Weighted Average Exercise Price, Exercised">5.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20210101__20211231_zXrWTRhMX41" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Cancelled">(38,286</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zTrixKpk7bth" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Cancelled">16.10</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding and exercisable, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zdQN6kuKSRRj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding and exercisable">6,311,705</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice_iE_c20210101__20211231_zhhpzcSq3zXj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Outstanding and exercisable">8.80</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerm_dtY_c20210101__20211231_z5lMI0QqLu95" title="Weighted average remaining life in years, Outstanding and exercisable">4.2</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding_iE_c20210101__20211231_zwRF2qMlSFfa" style="border-bottom: Black 2.5pt double; text-align: right" title="Intrinsic value, Outstanding and exercisable">474,464</td><td style="text-align: left"> </td></tr> </table> 174681 127.50 1702810 9.26 367660 8.13 2029 107.50 1507802 20.10 P5Y3M18D 448140 4895016 4.59 52827 5.03 38286 16.10 6311705 8.80 P4Y2M12D 474464 17618 8.00 18056 10.25 100000 100000 8.00 10.35 0.46 112.7 0 P2Y6M 6400 20000 188804 8.65 0.36 114.3 0 P2Y6M P3Y6M 546036 199907 281183 334229 53046 211807 <p id="xdx_89B_ecustom--ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityTableTextBlock_zgerrqBhLsld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants was determined using a Monte Carlo simulation, incorporating observable market data and requiring judgment and estimates. The following inputs and assumptions were used for the valuation of the derivative liability:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_z3D5wpOwvB9e" style="display: none">Schedule of Assumption Used for Valuation of Derivative Liability</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20200225_z6DlPUt6uNl7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">February 25,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20200331_zAA5NTlIX4X3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">March 31,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20200630_z0rZXl8LWpme" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">June 30,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20200915_ziOHdnOWjtwc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">September 15,</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">2020</p></td><td style="font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--DerivativeLiabilityMeasurementInput_iI_dc_uPercentage_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z3ibimddceA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 27%; text-align: left">Projected Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">97.1</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">102.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">102.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 17%; text-align: right">110.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_405_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPercentage_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQSxaU7hsO3c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-Free Rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.36</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.38</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.29</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.31</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contractual Term (Years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200224__20220225__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zvHik0V8ktA2" title="Contractual Term (Years)">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200330__20200331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuc5OLLTgxq2" title="Contractual Term (Years)">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200629__20200630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyxaEQkhr2b6" title="Contractual Term (Years)">4.75</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_ecustom--DerivativeLiabilityMeasurementInputTerm_dtY_c20200914__20200915__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zqBNSoh3CFag" title="Contractual Term (Years)">4.5</span></td><td style="text-align: left"> </td></tr> </table> 97.1 102.7 102.7 110.7 1.36 0.38 0.29 0.31 P5Y P5Y P4Y9M P4Y6M If the Company was required to pay the fair value of the warrant in cash as of May 25, 2020, the obligation was discounted at the Company’s estimated cost of debt based on short-term C-CCC bond ratings of 19.5% and 28.5% The likelihood of the Company calling a shareholder meeting and achieving shareholder approval was 90% as of February 25, 2020 334229 <p id="xdx_891_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_z8rHRdGM2zSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span id="xdx_8B9_zbhkoGyuzkU" style="display: none">Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"/> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_496_20200101__20201231_zbSTMTO1Ocva" style="font-weight: bold; text-align: center">Derivative</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Liabilities</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iS_zvf2xw8K8nml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance – January 1, 2020</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_zapz9jBYFWZj" style="vertical-align: bottom; background-color: White"> <td style="width: 78%; text-align: left">Derivative liabilities associated with the issuance of common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">513,534</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssuesOne_zAideFef4GV3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liabilities associated with the issuance of placement agent warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,502</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet_zN8nGJJQNH69" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of derivative liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(211,807</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_ecustom--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationOfWarrantDerivativesToEquity_zqQ2nQWuJPV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Reclassification of warrant derivatives to equity</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(334,229</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_iE_zOvpd5NO5wR9" style="vertical-align: bottom; background-color: White"> <td>Balance – December 31, 2020</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">-</span></td><td style="text-align: left"> </td></tr> </table> 513534 32502 -211807 -334229 <p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zCNUE51mmyu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_829_z0uAijgolenb">Share Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Omnibus Incentive Plan </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issues share-based awards under its Company’s 2016 Omnibus Incentive Plan, which enables the Company to grant stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, other share based awards and cash awards to associates, directors, consultants, and advisors of the Company and its affiliates, and to improve the ability of the Company to attract, retain, and motivate individuals upon whom the Company’s sustained growth and financial success depend, by providing such persons with an opportunity to acquire or increase their proprietary interest in the Company. Stock options granted under the 2016 Plan may be non-qualified stock options or incentive stock options, within the meaning of Section 422(b) of the Internal Revenue Code of 1986, except that stock options granted to outside directors and any consultants or advisers providing services to the Company or an affiliate shall in all cases be non-qualified stock options. <span id="xdx_906_ecustom--StockOptionPercentageDescription_c20210101__20211231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenOmnibusIncentivePlanMember_zVscioYC16t3" title="Stock options">The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2016 Plan is to be administered by the Board, which has discretion over the awards and grants thereunder. No awards may be issued after November 21, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Plan was adopted in 2016 and amended in 2018, 2020 and 2021 to increase the number of shares authorized to be awarded under the Plan. As of December 31, 2021 there are <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenOmnibusIncentivePlanMember_zB8Ag7HiD7K4">4,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares authorized under the Plan as a result of the increase authorized by our shareholders in 2021. The number of shares subject to the Plan is automatically adjusted from time to time such that shares authorized under the plan shall at all times be equal to at least <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPercentage_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenOmnibusIncentivePlanMember_zm9aUyn7QTH1">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the issued and outstanding shares of the Company on a fully diluted basis. The current number of shares authorized is greater than the <span id="xdx_90B_ecustom--PercentageOfAuthorizedNumberOfShares_iI_pid_dp_uPercentage_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenOmnibusIncentivePlanMember_zjFGTlWgJAH7" title="Number of shares authorized greater than minimum percentage">20</span>% minimum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock Options</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQsVQ8rmpQi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option grant is estimated at the grant date using the Black Scholes method. The following assumptions were used in estimating fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zhLwX74UmPN" style="display: none">Schedule of Stock Options Assumptions in Estimated Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zIxganGKnAla" title="Expected term">5.44</span> – <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zioclBFmGBW6" title="Expected term">6.5</span> years</span></td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zJ4WKjyLTXo2" title="Expected term">5.16</span> – <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zQgMGAeQREff" title="Expected term">5.76</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPercentage_c20210101__20211231_zq4wHFNqZ7Vk" title="Volatility, minimum">112.94</span> – <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPercentage_c20210101__20211231_zHUKUc6TFa7d" title="Volatility, maximum">103.6</span></span></td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPercentage_c20200101__20201231_z2blpBX7AsX4" title="Volatility">107.5</span></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPercentage_c20210101__20211231_zR38WKHhel9f" title="Risk free interest rate, minimum">0.08</span> – <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPercentage_c20210101__20211231_zJC8pq0jKBOe" title="Risk free interest rate, maximum">1.20</span></span></td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPercentage_c20200101__20201231_zKyzZ0Dbo1Rk" title="Risk free interest rate, minimum">0..30</span> – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPercentage_c20200101__20201231_zlpBfeubZs48" title="Risk free interest rate, maximum">0.36</span></span></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPercentage_c20210101__20211231_ziOQnDMmn8z3" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPercentage_c20200101__20201231_z9G0ZxYFMdz7" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td> </tr> </table> <p id="xdx_8A7_zP4ScGS5umL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company estimated the expected term of the options using the simplified method. The Company uses its stock’s historical market information to calculate volatility used in estimating fair value of options granted.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsqIqONdey59" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the option activity during the years ended December 31, 2021 and 2020 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zGCFW5SXytml" style="display: none">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In Years</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2020</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_z7FFPCAnLfB4" style="width: 14%; text-align: right" title="Number of options beginning">99,689</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zqTcBHCBCLE4" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">111.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zjea9ssvQ3oa" style="text-align: right" title="Number of options granted">122,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zscmo4ctb4xa" style="text-align: right" title="Weighted Average Exercise Price, Granted">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zdmjwO6tYHH3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options forfeited">(11,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zs8XeBo5eqJa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">63.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zDuxH5XoVsha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options beginning">210,689</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zqDHOcMls9t4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">31.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zUbtKpDlik7g" title="Weighted Average Remaining life in years">8.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">         <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z1OrxihUQqYf" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zgARAyJDJ7Sa" style="text-align: right" title="Number of options granted">3,246,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zl4OL2NiH9x5" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_zObVhAiXgtJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options forfeited">(15,333</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_z4igxiCvrqQc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">8.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zhQV7RW4YW3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options ending">3,441,907</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_ziWrltfxnCZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding Ending">9.16</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z7WqvgfX0fEe" title="Weighted Average Remaining life in years">9.3</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_z0WYj1SgsiHe" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_z0qA7ORaFkjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">982,921</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_zMBTWNqRBtjc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Exercisable">12.94</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zOFjqMPYJKBg" title="Weighted Average Remaining life in years, exercisable">8.9</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zZHCNmoJd3Gk" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zbjYCIHLSX7k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company includes share-based compensation expense in selling, general and administrative expenses, and recognized $<span id="xdx_90B_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zeZH69HKXIz3">6.0</span> million and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_z75WDumVp0mb" title="Share-based compensation">0.7</span> million during the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, there was $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zz1eOYLof2d5" title="Share-based compensation">15.2</span> million of unrecognized share-based compensation expense related to outstanding stock options and restricted stock units that will be recognized over the weighted average remaining vesting period of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1A17WQ4kjv" title="Vesting period">2</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVVENO MEDICAL CORPORATION</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>f/k/a HANCOCK JAFFE LABORATORIES, INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted Stock Units</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityRestrictedSharesTableTextBlock_zGr1K4nM9wSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also issues restricted shares and restricted stock units under the 2016 Plan. A summary of the restricted share and restricted stock units activity during the years ended December 31, 2021 and 2020 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zIHYnXXYNuKl" style="display: none">Schedule of Stock Option Activity Restricted Shares</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted Shares</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2020</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231_zGOFLggmEWJ6" style="width: 30%; text-align: right" title="Outstanding shares, beginning">7,806</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231_zLwxioBIOS57" style="text-align: right" title="Granted">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares vested</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231_zfmPOnm01eA6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Vested">(12,864</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2020</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231_z3ghLPgnf7T7" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares, beginning">4,942</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231_zOmFzhSUzCV3" style="text-align: right" title="Granted">400,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Vested</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231_zirgwdtdazic" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Vested">(2,860</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210101__20211231_zzYx5VBdteki" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares, ending">402,082</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AB_zJfxd6i2cYie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zMBhER9oLg9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of outstanding restricted stock units as of December 31, 2021 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B6_z5wlSJ0JxKPl">Schedule of Outstanding and Exercisable Restricted Stock Units</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted Stock Units</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted Stock Unit for</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Outstanding</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Number of</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Units</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Weighted</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Average</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Remaining</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Life In</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Years</p></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: center">9/13/2019</td><td style="width: 2%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock_c20190912__20190913_zeZXVJVxyuv4" title="Restricted Stock Unit for">Common Stock</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20190913_zwUKhFG7Itr3" style="width: 20%; text-align: right" title="Outsatnding number of units">2,082</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOtherThanOptionsWeightedAverageRemainingContractualTerm2_dtY_c20190912__20190913_zmTCnxitYFXa" title="Weighted Average Remaining Life In Years">0.9</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">11/30/2021</td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock_c20211129__20211130_zyfCNt0NvmYa" title="Restricted Stock Unit for">Common Stock</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20211130_zxrqKefAPLvl" style="text-align: right" title="Outsatnding number of units">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOtherThanOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211129__20211130_zWCjYYBhXozf" title="Weighted Average Remaining Life In Years"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center">Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20211231_zUuTdoIbcJ1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Outsatnding number of units, restricted stock">402,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zueKpkwbJ2w" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The option price must be at least 100% of the fair market value on the date of grant and if issued to a 10% or greater shareholder must be 110% of the fair market value on the date of the grant 4500000 0.20 0.20 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQsVQ8rmpQi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of each option grant is estimated at the grant date using the Black Scholes method. The following assumptions were used in estimating fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zhLwX74UmPN" style="display: none">Schedule of Stock Options Assumptions in Estimated Fair Value</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zIxganGKnAla" title="Expected term">5.44</span> – <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zioclBFmGBW6" title="Expected term">6.5</span> years</span></td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MinimumMember_zJ4WKjyLTXo2" title="Expected term">5.16</span> – <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__srt--RangeAxis__srt--MaximumMember_zQgMGAeQREff" title="Expected term">5.76</span> years</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPercentage_c20210101__20211231_zq4wHFNqZ7Vk" title="Volatility, minimum">112.94</span> – <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPercentage_c20210101__20211231_zHUKUc6TFa7d" title="Volatility, maximum">103.6</span></span></td><td style="width: 1%; text-align: left">%</td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPercentage_c20200101__20201231_z2blpBX7AsX4" title="Volatility">107.5</span></td><td style="width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPercentage_c20210101__20211231_zR38WKHhel9f" title="Risk free interest rate, minimum">0.08</span> – <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPercentage_c20210101__20211231_zJC8pq0jKBOe" title="Risk free interest rate, maximum">1.20</span></span></td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPercentage_c20200101__20201231_zKyzZ0Dbo1Rk" title="Risk free interest rate, minimum">0..30</span> – <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPercentage_c20200101__20201231_zlpBfeubZs48" title="Risk free interest rate, maximum">0.36</span></span></td><td style="text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPercentage_c20210101__20211231_ziOQnDMmn8z3" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td> <td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPercentage_c20200101__20201231_z9G0ZxYFMdz7" style="text-align: right" title="Dividend yield">0.00</td><td style="text-align: left">%</td> </tr> </table> P5Y5M8D P6Y6M P5Y1M28D P5Y9M3D 1.1294 1.036 1.075 0.0008 0.0120 0.0030 0.0036 0.0000 0.0000 <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zsqIqONdey59" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the option activity during the years ended December 31, 2021 and 2020 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zGCFW5SXytml" style="display: none">Schedule of Stock Option Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Intrinsic</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">In Years</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2020</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_z7FFPCAnLfB4" style="width: 14%; text-align: right" title="Number of options beginning">99,689</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zqTcBHCBCLE4" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">111.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231_zjea9ssvQ3oa" style="text-align: right" title="Number of options granted">122,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zscmo4ctb4xa" style="text-align: right" title="Weighted Average Exercise Price, Granted">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20200101__20201231_zdmjwO6tYHH3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options forfeited">(11,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zs8XeBo5eqJa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">63.88</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2020</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zDuxH5XoVsha" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options beginning">210,689</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zqDHOcMls9t4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Outstanding beginning">31.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zUbtKpDlik7g" title="Weighted Average Remaining life in years">8.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">         <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20210101__20211231_z1OrxihUQqYf" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20211231_zgARAyJDJ7Sa" style="text-align: right" title="Number of options granted">3,246,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zl4OL2NiH9x5" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.70</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20211231_zObVhAiXgtJ3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of options forfeited">(15,333</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_z4igxiCvrqQc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">8.36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zhQV7RW4YW3j" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options ending">3,441,907</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_ziWrltfxnCZj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding Ending">9.16</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z7WqvgfX0fEe" title="Weighted Average Remaining life in years">9.3</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_z0WYj1SgsiHe" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1065">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_z0qA7ORaFkjl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options exercisable">982,921</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20211231_zMBTWNqRBtjc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Exercisable">12.94</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zOFjqMPYJKBg" title="Weighted Average Remaining life in years, exercisable">8.9</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20210101__20211231_zZHCNmoJd3Gk" title="Aggregate intrinsic value"><span style="-sec-ix-hidden: xdx2ixbrl1073">-</span></span></td><td style="text-align: left"> </td></tr> </table> 99689 111.00 122000 10.00 11000 63.88 210689 31.48 P8Y8M12D 3246551 7.70 15333 8.36 3441907 9.16 P9Y3M18D 982921 12.94 P8Y10M24D 6000000.0 700000 15200000 P2Y <p id="xdx_89C_ecustom--ScheduleOfShareBasedCompensationStockOptionsActivityRestrictedSharesTableTextBlock_zGr1K4nM9wSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also issues restricted shares and restricted stock units under the 2016 Plan. A summary of the restricted share and restricted stock units activity during the years ended December 31, 2021 and 2020 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zIHYnXXYNuKl" style="display: none">Schedule of Stock Option Activity Restricted Shares</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted Shares</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, January 1, 2020</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231_zGOFLggmEWJ6" style="width: 30%; text-align: right" title="Outstanding shares, beginning">7,806</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231_zLwxioBIOS57" style="text-align: right" title="Granted">10,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares vested</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231_zfmPOnm01eA6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Vested">(12,864</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2020</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231_z3ghLPgnf7T7" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares, beginning">4,942</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231_zOmFzhSUzCV3" style="text-align: right" title="Granted">400,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Vested</span></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231_zirgwdtdazic" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares Vested">(2,860</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding, December 31, 2021</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210101__20211231_zzYx5VBdteki" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding shares, ending">402,082</td><td style="text-align: left"> </td></tr> </table> 7806 10000 12864 4942 400000 2860 402082 <p id="xdx_893_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zMBhER9oLg9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of outstanding restricted stock units as of December 31, 2021 is presented below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span style="display: none"><span id="xdx_8B6_z5wlSJ0JxKPl">Schedule of Outstanding and Exercisable Restricted Stock Units</span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="11" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted Stock Units</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Restricted Stock Unit for</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Outstanding</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Number of</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Units</p></td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Weighted</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Average</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Remaining</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Life In</p> <p style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Years</p></td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 25%; text-align: center">9/13/2019</td><td style="width: 2%"> </td> <td style="width: 25%; text-align: center"><span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock_c20190912__20190913_zeZXVJVxyuv4" title="Restricted Stock Unit for">Common Stock</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20190913_zwUKhFG7Itr3" style="width: 20%; text-align: right" title="Outsatnding number of units">2,082</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 20%; text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOtherThanOptionsWeightedAverageRemainingContractualTerm2_dtY_c20190912__20190913_zmTCnxitYFXa" title="Weighted Average Remaining Life In Years">0.9</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">11/30/2021</td><td> </td> <td style="text-align: center"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock_c20211129__20211130_zyfCNt0NvmYa" title="Restricted Stock Unit for">Common Stock</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20211130_zxrqKefAPLvl" style="text-align: right" title="Outsatnding number of units">400,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOtherThanOptionsWeightedAverageRemainingContractualTerm2_dtY_c20211129__20211130_zWCjYYBhXozf" title="Weighted Average Remaining Life In Years"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center">Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20211231_zUuTdoIbcJ1k" style="border-bottom: Black 2.5pt double; text-align: right" title="Outsatnding number of units, restricted stock">402,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> Common Stock 2082 P0Y10M24D Common Stock 400000 402082 <p id="xdx_803_eus-gaap--EarningsPerShareTextBlock_zZB7yKugyT8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note 12 – <span id="xdx_821_zV9oPb1XhqQk">Net Loss Per Share</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9eBI5JL55J5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zAxOXJ2Unjh8" style="display: none">Schedule of Dilutive Net Loss Per Common Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20210101__20211231_zWVjyweBvhQ5" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_zMGA1ijeAosj" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxnc7zdC1Bs9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares of common stock issuable upon exercise of warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,552,670</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,507,802</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z028gx9W3YXl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Shares of common stock issuable upon exercise of options and restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,843,989</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,631</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyrTmRJkqDDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive common stock equivalents excluded from diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,396,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,723,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z1yTnnNKAlNe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"/> <p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z9eBI5JL55J5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zAxOXJ2Unjh8" style="display: none">Schedule of Dilutive Net Loss Per Common Share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20210101__20211231_zWVjyweBvhQ5" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_zMGA1ijeAosj" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zxnc7zdC1Bs9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares of common stock issuable upon exercise of warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,552,670</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,507,802</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z028gx9W3YXl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Shares of common stock issuable upon exercise of options and restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,843,989</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">215,631</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zyrTmRJkqDDg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive common stock equivalents excluded from diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,396,659</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,723,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4552670 1507802 3843989 215631 8396659 1723433 net of offering costs of $0.1 million. net of offering costs of $2.2 million. net of offering costs of $0.2 million. EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

S>0D8C4>F,%[B0H*H\9_+E!C.Q&SN^\[IQSS>I M-AMN-"K9!I>H'\J%I)7;L"0\QT)Q48#$]=B9^-?SOI&W C\Y[M3!'(PG*R&> MS.(N&3N>,0@SC+5A8#1L<8I99HC(C+\UI].H-,##^2O[W/I.OJR8PJG('GFB MT[$S="#!-:LR?2]V7[#VQQH8BTS9?]C5LIX#<:6TR&LP69#S8C^RYSH.!P _ M/ ((:D#P'C \ NC5@-ZI&L(:$)X*Z-> _JF 00T8V-CO@V4C/6.:12,I=B"- M-+&9B;TNBZ8 \\(DUE)+.N6$T]&2,C6I,@2QAA^55IH5"2\V0 /":P6?9J@9S]1G. >5,HEJY&HRRY"[<6W"S=Z$X(@) MW\7V GK>&01>X+? I]WP)987X/<,W+]J@<^ZX3.,2;M_5/OMZ7"O!3X_&?[> M>)=NLKG.H+G.P/(-C@7#W,&Y>6H)+-@+50 -$RE9L4$[_SU9T3W2<_[3H:S7 M*.M99;TCREIS JC8M>5 -]54Y#G5&4O3E@+_BW[C5]CX%7;2F7? ]/X=%%6^ M0FE>1V42_HR*:>.T.F+MS9Z^;^E-9=]&H6=^(W=[Z-1'L< ;!F^%9FU<'\5N M6\2NPG="\X]"ET-OT B]"5:_"5:_,UB/MG93-"9;E-2*J%*8?F9B]Y6O$>X* M^(5,MM:%3F;34J]5R6(<.]0S%WA;X'E!TZ51"$D+ 7U98B[D$) M-1WU&Y,;7BC(<$VDWL4EZ9#[+K5?:%':JKH2FFJTG:;4V%$: 3I?"Z%?%Z90 M-Y\*T3]02P,$% @ QC!\5 ?K0.P4! Z0T !D !X;"]W;W)K&ULS5=M;]LV$/Z^7W$P-J %TDB4WPO;@..D6X"E-9*U M^U#L VV=+2*2J)*4G>S7]TC9LM(X3 9T0/(A)JE[>?C<\7@<;:6ZU0FB@;LL MS?6XE1A3O \"O4PPX_I4%IC3EY54&3M %PIY[)2R-(C"L!=D7.2MRS]C *CB)+P*WNC$&NY6%E+=V# M,TQ3:XEP?-L9;=4^K6)SO+?^P6V>-K/@&F@K#19LP/'C=.FW8CIAH]<*6ZY?@OOX//-.;SY]>TH,.3;6@B6.S]GE9_H M"3\L@BN9FT3#11YC_-! 0*!KY-$>^5GDM7B.RU-HLQ.(PH@= 31[N7KH@=.N MB6P[>ST?D>\6CXF<$GWY&BGU#2SNH2DWY_=N>;KE*H:O?Y))N#28Z7\\@#HU MH(X#U'X"T,6W4IA[N$*3R!@N\PUJ8[V=P*=MCDHGHH YJB4MT7D]%E&__6YX M&H:_>8!V:Z!=KZ$F(\L&<\<@59;ZSI*M4)M)=S@S72GA?I-5&HQ-(0T!LCE[?P]0JS!2I?N/JU[?[KR)]!#6CPT\(R>$0W MZ])%0G_'"1_6&(9>#%^(<)&OH4 E9'S,LU\_@GOD2GO88.&A4(9^/NBJ(2PG M\#O2\>$I\#R&:4PU65!6N H)%W>6)M0O20S6*-'L=:0&BPZ0HI^6'#M3S>SH MA0^3HSJT1P3[GB1BA]+,VOXT"%F/*J M=39*\Y3G+XK0H=2RSBN)T*&HLF>J MJBM0LK P]-&P^/7_2G"G#075/(2,FA%8(' #*7(:,RK_(%=@2'+%A:*V1-U2 MX[GA:4FZN?L01WI^M+\,/=P?K_\UW_C(/HN':X5YK]7/I;VW-E0 MZ8I&7A)J)?XE(O=98!(ZH;:R9F5FB[\/N-_;T\"#1M..:\8.9ZA%TQ=5:Y)K.RXI,AJ=]"KVJWA75Q,C"M>8+ M::C1=\.$WF*HK !]7TEI]A/KH'[=3;X#4$L#!!0 ( ,8P?%0V15H@^P( M %,) 9 >&PO=V]R:W-H965T3#L:GME/;?[]@)*:6 >N1"_#'S_-[, MX'%O(]637@$8\EIPH?O>RICUE>_K; 4%U9=R#0)W%E(5U.!4+7V]5D!SYU1P M/PJ"U"\H$]Z@Y]8F:M"3I>%,P$01718%56]#X'+3]T)ONS!ERY6Q"_Z@MZ9+ MF(&Y7T\4SOP&)6<%",VD( H6?>\ZO!J%@75P%G\9;/3.F%@I8 2<6R3D\5R#>LV9UG%WO$7_Z<2CF#G5,)+\@>5FU?(0U0[1 MOD/KB$-<.\1.:,7,R1I30P<])3=$66M$LP,7&^>-:IBP:9P9A;L,_[:B"LC%& QE7'\C/XBV*[KG&Z1A MP?RL/G)8'1D=.3*,R)T49J7)C<@A_PC@(_]&1+05,8Q.(HXANR1Q^)U$010> M(#3ZNGMP@D[.D1O&MA6+Z-Y0RR4C'# .6^9KQ$Q62A9&'CNBX-=<6, MP;^A2C"QK&)>!?OQ-P*36P.%_G>"5JNAU7*TXB.T)M( ,J.R+P7+(7RM%*$_A UMGC1&!E<%L9:V3I"N!0_BL>B>-A[Y&702?NIFG2[?DO MNVGY;!>VH[@5QXW=!Z%)(S0Y*?2!*D6%(8]W4,Q!G8I=VD"FYY32=D.K?28I M;7]*52M)HK0=[*7TLUV8!.U.$!U.::<1VCDI= K:*)99OC.GZUXP5'0QG=WC M7?2%1'>;@[KGE.@P>+^G@S-)=4UD-X=QIQ5W._M_WP.&49BD<;B7:W^G/16@ MEJYK:R1?"E-=\LUJ\S*X=OUP;WUH7PRN[;W#5,^-.ZJ63&C"88&0P64;2:FJ M@U<3(]>N"F(/:-Y1@_]02P,$% @ QC!\ M5%O2Q[8N P $!, T !X;"]S='EL97,N>&UL[5A1;]HP$/XKD3M-K30U M0$9*5D#:D"I-VJ9*[*D,=AXOK?>2\ABY(Z"7N'T&,TF*D\5%JX3F@&!XLP-5Q M 0ZQ8]2#7>IV97=6,JS3-AYF2K;9BX@S6&::L^"1BA&94,&GFH-71G,NUL[< M \-,":4#8\O&ANJ"I7QR<-?UH*)JGIQ+I:O8+H+[.ZV'[P&;'@CD0C0">\09 MQL."&L.TO+&=:G!E? 8%=?M^75B%TN&T5&5Z>O\<6VV!^DOG_Z MRUJ?[Z@JT*F][N_PV_$IR^A2F/L&')&V_9FE?)DGS:A;6(AZ5-O^ M!-/KQLT]T,;B,F4KED[JKIY/JV9@&S9J_8##/G)3/7X$\W&8'P$,BX,IP'R< M%Q;G7YK/ )V/PS!M R\R0'T&J(_S\B&3ZH/%\?LD]O'/-$FB*(ZQ%9U,O HF MV+K%,7S];)@V\,#B0*1?6VL\VWB%'*X#+*>'*@2;*5Z)V$SQM0;$OV[@D23^ M;&-QP /+ E8[$-\?!VK*[Q-%D%5,&[:#<21), 1JT5^C<8RL3@P??WZP71)% M2>)' /,KB"(,@=V((Y@"T( A452=@WOG4;@YI\+V-[#Q#U!+ P04 " #& M,'Q4EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0 M(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I M6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6 MFD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L# M!!0 ( ,8P?%1H*N09L@0 &4C / >&PO=V]R:V)O;VLN>&ULQ9I= M<]LH%$#_"N.G[$/7MB2G;:;N3&LWNYU)$T^<9A\S1$(V$P1>0/GZ]7M!R>9Z M[=[9%^0G6TA&1Q>X!Y _/1A[=VO,'7MLE';3P=K[SQ@E=N+81OU# ;C8Z'#9=Z\/G3:UT+.\0'QHO22Z.A,!1<2_'@ MWLZ'0W8OG;R52OJGZ2!^5V+ &JEE(Y]%-1V,!LRMS<.?QLIGHSU7R](:I::# M<7?B6E@ORYWB98"\XK\D!9#HX'D&%M;3.QRMB_1P8[P5X;KG',U.QB(VQW#:(K"+JB3[K9 MFNN5<$QJMO2FO%LCR D!.3D@Y$V&((\)R.->(;E;LU-E'G [OR?HWB<>*:V3 M6CC'+NR*:_DTD#^XYJL8PQO'SN3?K:S "FP!@QP! M?B0 /R9N8[G2$J[EVK,O96E:[<$,;&&4+*7 33T>49EZE!83M MI!B(7VO<; MA'$3?H#I2(\D%LFE7*W].U._^^D$^^)X1*W';C4CH9)_;).4RIV((_\7C;-R9*(N/$%OFN2],(=L4?M^-$.6.<6!HS MTS32=PDY=*^9B8-5Z/^.5,H9X^32")8UJA+6W<2AZI\P&V6,<6)E+-B\<99 L^3ID-Q'NA:24 MDJ5>A_PB([Z 8DQ**EEBJ>PFQKV1I-R2)78+,=-G1_.M2%**R1(KAD[D.<:D M?).E]@W44;5*A(7GGJ2.]T$HW^0'\LU<>"X5GI/EE&_RQ+[!T7S9KH$V[U8G M,[.%2?DF3^P;C+EL-QL5AQ-7+UL/&)/<_4J]_;4WFI-,>8E(7RQ!;"2^E_ MTQ [YS;TTGMLH9RR4)[:0BB:;Y.XD.D#B\&8E(7R'BWTK:Y%?*?R!HSWNRD+ M%8DMA#'GHA;60N<,\>R&$\:D+%0DMM#V;)WJFP5EH:)'"[W,VJ\LAWEQN?.2 M@[)0T:.%XE*#_14B&:=U$$Z,2;Z,Z=%"T!W;9A.7%S_#@@,JQ)B4A8K4ZR"$ M>I]0%IJD7@O] M;QM@V",2D+3:*%AJ]_ZZA$+;6HSN$6#LI+KLJ% M9>&C>SE53,(N<]TJ-8.R"WUF>/7Z+Y'7?[A\_@=02P,$% @ QC!\5'Q^ MZ1O4 0 QA\ !H !X;"]?Z)0A&.14&#YE36V/+U7UB? MK/'\)>W:LNT.>;/M\^2XWQWRHMF4TC^$D)>;M&_S3=>GP_G*JAOV;3DOAW7H MV^5[NTY!I]-9&'[.:![G/V=.7D]]^LO$;K7:+M-3M_S8IT/Y97#X[(;WO$FI M-)/7=EBGLFC"<7<]G?V@ M"$&Q?M ,@F;U@VXAZ+9^T!T$W=4/NH>@^_I!,D49IP1)(ZP)M!;D6@B\%@1; M",06)%L(S!9$6PC4%F1;"-P6A%L(Y!:D6PCL%L1;"/16U%L)]%;46PGTUM'' M-H'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z&>AN!WH9Z M&X'>AGH;@=XVVBPAT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M1 M;R?0VU%O)]#;46\GT-M1;R?0VT>;W01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ MZNT$>D?4.Q+H'5'O2*!W1+TC@=X1]8[_J7UW7VSI;#)ZVUKRO4U=-7Z<+$*P#XSY?$&U M]JFQU,21F7&U#O'1S9G5^5+/B8G!8,ARTP1J0C^T-9+)Z(EF>E6%WO,FOO:E M:<:)H\HGO7QQV.I%W=M[$0N5">_\1C M8BQ]]?=1>]H%%;_,CMO[8=RR.P_/NMOU>_SUC(_U+^Q#@/0A0?I0('UD('T, M0?JX!>GC#J2/>Y ^^ "E$111.0JI',54CH(J1U&5H[#*45SE*+!R%%D%BJP" M15:!(JM D56@R"I09!4HL@H4606*K )%5HDBJT215:+(*E%DE2BR2A19)8JL M$D56B2*K1)%5HU+IM#/NO^R4\^ 5!+ 0(4 Q0 ( ,8P?%0'04UB M@0 +$ 0 " 0 !D;V-0&UL4$L! M A0#% @ QC!\5!_LM-_O *P( !$ ( !KP &1O M8U!R;W!S+V-O&UL4$L! A0#% @ QC!\5)E&PO=V]R:W-H M965T&UL4$L! A0#% @ QC!\5*O-NX!G!0 *10 !@ M ("!KPX 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ QC!\5,S"L/:X!P >2H !@ ("!XQL M 'AL+W=O4' !Z(0 & M@(%Q)@ >&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\ M5 %@R&N;!0 -0P !@ ("!C"X 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ QC!\5 3Q?@&,! XPH !D ("!XTX 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\ M5+5A,6/)# ^A\ !D ("!.ED 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\5,YR<:#>" TA4 M !D ("!\GP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\5++["G4! P 708 !D M ("!M9T 'AL+W=O&PO=V]R:W-H965T M"D !X;"]W;W)K&UL4$L! A0# M% @ QC!\5 5'[H$X!0 YPP !D ("!U*< 'AL+W=O M&PO=V]R:W-H965TH*I%"P4 ,8- 9 " @7:T M !X;"]W;W)K&UL4$L! A0#% @ QC!\5(^% M%ZSP @ K 8 !D ("!N+D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\5/Z']CUR P 7 T !D M ("!/,( 'AL+W=O!0 &0 @('EQ0 >&PO M=V]R:W-H965T&UL4$L! A0#% @ QC!\5,L?<$9 @ S 0 !D ("! MHLH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ QC!\5!$DL?,: P \ @ !D ("!1]( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\5,8=;SD? M P R D !D ("!I-L 'AL+W=ORD# P"@ &0 M@('ZW@ >&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\5%?X-CBH P OPL !D M ("!3^8 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ QC!\5.3=Q1(< P Y0H !D ("!QO( M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MQC!\5*&PO=V]R:W-H965T<- 0!X;"]W M;W)K&UL4$L! A0#% @ QC!\5.=P^9[9 @ M-@@ !D ("!PA ! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ QC!\5%O2Q[8N P $!, T M ( !3QL! 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ QC!\5'Q^Z1O4 0 QA\ !H M ( !<"0! 'AL+U]R96QS+W=O<&5S72YX;6Q02P4& #T /0"B$ =R@! end XML 67 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 69 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 129 302 1 true 40 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://envveno.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets Sheet http://envveno.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://envveno.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations Sheet http://envveno.com/role/StatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Statements of Changes in Stockholders' Equity Sheet http://envveno.com/role/StatementsOfChangesInStockholdersEquity Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical) Sheet http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical Statements of Changes in Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Statements of Cash Flows Sheet http://envveno.com/role/StatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Business Organization and Nature of Operations Sheet http://envveno.com/role/BusinessOrganizationAndNatureOfOperations Business Organization and Nature of Operations Notes 8 false false R9.htm 00000009 - Disclosure - Management???s Liquidity Plan Sheet http://envveno.com/role/ManagementsLiquidityPlan Management???s Liquidity Plan Notes 9 false false R10.htm 00000010 - Disclosure - Significant Accounting Policies Sheet http://envveno.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Property and Equipment Sheet http://envveno.com/role/PropertyAndEquipment Property and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Right-of-Use Assets and Lease Liabilities Sheet http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilities Right-of-Use Assets and Lease Liabilities Notes 12 false false R13.htm 00000013 - Disclosure - Accrued Expenses Sheet http://envveno.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 00000014 - Disclosure - Note Payable Sheet http://envveno.com/role/NotePayable Note Payable Notes 14 false false R15.htm 00000015 - Disclosure - Income Taxes Sheet http://envveno.com/role/IncomeTaxes Income Taxes Notes 15 false false R16.htm 00000016 - Disclosure - Commitments and Contingencies Sheet http://envveno.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 00000017 - Disclosure - Stockholders??? Equity Sheet http://envveno.com/role/StockholdersEquity Stockholders??? Equity Notes 17 false false R18.htm 00000018 - Disclosure - Share Based Compensation Sheet http://envveno.com/role/ShareBasedCompensation Share Based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - Net Loss Per Share Sheet http://envveno.com/role/NetLossPerShare Net Loss Per Share Notes 19 false false R20.htm 00000020 - Disclosure - Significant Accounting Policies (Policies) Sheet http://envveno.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://envveno.com/role/SignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Property and Equipment (Tables) Sheet http://envveno.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://envveno.com/role/PropertyAndEquipment 21 false false R22.htm 00000022 - Disclosure - Right-of-Use Assets and Lease Liabilities (Tables) Sheet http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables Right-of-Use Assets and Lease Liabilities (Tables) Tables http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilities 22 false false R23.htm 00000023 - Disclosure - Accrued Expenses (Tables) Sheet http://envveno.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://envveno.com/role/AccruedExpenses 23 false false R24.htm 00000024 - Disclosure - Income Taxes (Tables) Sheet http://envveno.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://envveno.com/role/IncomeTaxes 24 false false R25.htm 00000025 - Disclosure - Stockholders??? Equity (Tables) Sheet http://envveno.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://envveno.com/role/StockholdersEquity 25 false false R26.htm 00000026 - Disclosure - Share Based Compensation (Tables) Sheet http://envveno.com/role/ShareBasedCompensationTables Share Based Compensation (Tables) Tables http://envveno.com/role/ShareBasedCompensation 26 false false R27.htm 00000027 - Disclosure - Net Loss Per Share (Tables) Sheet http://envveno.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://envveno.com/role/NetLossPerShare 27 false false R28.htm 00000028 - Disclosure - Management???s Liquidity Plan (Details Narrative) Sheet http://envveno.com/role/ManagementsLiquidityPlanDetailsNarrative Management???s Liquidity Plan (Details Narrative) Details http://envveno.com/role/ManagementsLiquidityPlan 28 false false R29.htm 00000029 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://envveno.com/role/SignificantAccountingPoliciesPolicies 29 false false R30.htm 00000030 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 30 false false R31.htm 00000031 - Disclosure - Property and Equipment (Details Narrative) Sheet http://envveno.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://envveno.com/role/PropertyAndEquipmentTables 31 false false R32.htm 00000032 - Disclosure - Schedule of Operating Lease Cost (Details) Sheet http://envveno.com/role/ScheduleOfOperatingLeaseCostDetails Schedule of Operating Lease Cost (Details) Details 32 false false R33.htm 00000033 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details) Sheet http://envveno.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeaseDetails Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of Operating Remaining Lease Term and Discount Rate (Details) Sheet http://envveno.com/role/ScheduleOfOperatingRemainingLeaseTermAndDiscountRateDetails Schedule of Operating Remaining Lease Term and Discount Rate (Details) Details 34 false false R35.htm 00000035 - Disclosure - Schedule of Maturity of Lease Liabilities (Details) Sheet http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails Schedule of Maturity of Lease Liabilities (Details) Details 35 false false R36.htm 00000036 - Disclosure - Right-of-Use Assets and Lease Liabilities (Details Narrative) Sheet http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative Right-of-Use Assets and Lease Liabilities (Details Narrative) Details http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables 36 false false R37.htm 00000037 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://envveno.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 37 false false R38.htm 00000038 - Disclosure - Note Payable (Details Narrative) Sheet http://envveno.com/role/NotePayableDetailsNarrative Note Payable (Details Narrative) Details http://envveno.com/role/NotePayable 38 false false R39.htm 00000039 - Disclosure - Schedule of Income Tax Provision (Benefit) (Details) Sheet http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails Schedule of Income Tax Provision (Benefit) (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 41 false false R42.htm 00000042 - Disclosure - Income Taxes (Details Narrative) Sheet http://envveno.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://envveno.com/role/IncomeTaxesTables 42 false false R43.htm 00000043 - Disclosure - Schedule of Equity Transactions to Raise Capital Through the Placement (Details) Sheet http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails Schedule of Equity Transactions to Raise Capital Through the Placement (Details) Details 43 false false R44.htm 00000044 - Disclosure - Schedule of Stock Warrant Activity (Details) Sheet http://envveno.com/role/ScheduleOfStockWarrantActivityDetails Schedule of Stock Warrant Activity (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Assumption Used for Valuation of Derivative Liability (Details) Sheet http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails Schedule of Assumption Used for Valuation of Derivative Liability (Details) Details 45 false false R46.htm 00000046 - Disclosure - Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis (Details) Sheet http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis (Details) Details 46 false false R47.htm 00000047 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://envveno.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://envveno.com/role/StockholdersEquityTables 47 false false R48.htm 00000048 - Disclosure - Schedule of Stock Options Assumptions in Estimated Fair Value (Details) Sheet http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails Schedule of Stock Options Assumptions in Estimated Fair Value (Details) Details 48 false false R49.htm 00000049 - Disclosure - Schedule of Stock Option Activity (Details) Sheet http://envveno.com/role/ScheduleOfStockOptionActivityDetails Schedule of Stock Option Activity (Details) Details 49 false false R50.htm 00000050 - Disclosure - Schedule of Stock Option Activity Restricted Shares (Details) Sheet http://envveno.com/role/ScheduleOfStockOptionActivityRestrictedSharesDetails Schedule of Stock Option Activity Restricted Shares (Details) Details 50 false false R51.htm 00000051 - Disclosure - Schedule of Outstanding and Exercisable Restricted Stock Units (Details) Sheet http://envveno.com/role/ScheduleOfOutstandingAndExercisableRestrictedStockUnitsDetails Schedule of Outstanding and Exercisable Restricted Stock Units (Details) Details 51 false false R52.htm 00000052 - Disclosure - Share Based Compensation (Details Narrative) Sheet http://envveno.com/role/ShareBasedCompensationDetailsNarrative Share Based Compensation (Details Narrative) Details http://envveno.com/role/ShareBasedCompensationTables 52 false false R53.htm 00000053 - Disclosure - Schedule of Dilutive Net Loss Per Common Share (Details) Sheet http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails Schedule of Dilutive Net Loss Per Common Share (Details) Details 53 false false All Reports Book All Reports form10-k.htm ex10-5.htm ex23-1.htm ex31-1.htm ex31-2.htm ex32.htm nvno-20211231.xsd nvno-20211231_cal.xml nvno-20211231_def.xml nvno-20211231_lab.xml nvno-20211231_pre.xml http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 72 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 129, "dts": { "calculationLink": { "local": [ "nvno-20211231_cal.xml" ] }, "definitionLink": { "local": [ "nvno-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "nvno-20211231_lab.xml" ] }, "presentationLink": { "local": [ "nvno-20211231_pre.xml" ] }, "schema": { "local": [ "nvno-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 444, "entityCount": 1, "hidden": { "http://envveno.com/20211231": 23, "http://fasb.org/us-gaap/2021-01-31": 45, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 71 }, "keyCustom": 54, "keyStandard": 248, "memberCustom": 15, "memberStandard": 24, "nsprefix": "NVNO", "nsuri": "http://envveno.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://envveno.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Significant Accounting Policies", "role": "http://envveno.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Property and Equipment", "role": "http://envveno.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Right-of-Use Assets and Lease Liabilities", "role": "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilities", "shortName": "Right-of-Use Assets and Lease Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Accrued Expenses", "role": "http://envveno.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Note Payable", "role": "http://envveno.com/role/NotePayable", "shortName": "Note Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Income Taxes", "role": "http://envveno.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Commitments and Contingencies", "role": "http://envveno.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Stockholders\u2019 Equity", "role": "http://envveno.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Share Based Compensation", "role": "http://envveno.com/role/ShareBasedCompensation", "shortName": "Share Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Net Loss Per Share", "role": "http://envveno.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Balance Sheets", "role": "http://envveno.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://envveno.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Property and Equipment (Tables)", "role": "http://envveno.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Right-of-Use Assets and Lease Liabilities (Tables)", "role": "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables", "shortName": "Right-of-Use Assets and Lease Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Accrued Expenses (Tables)", "role": "http://envveno.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Income Taxes (Tables)", "role": "http://envveno.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Stockholders\u2019 Equity (Tables)", "role": "http://envveno.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Share Based Compensation (Tables)", "role": "http://envveno.com/role/ShareBasedCompensationTables", "shortName": "Share Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Net Loss Per Share (Tables)", "role": "http://envveno.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Management\u2019s Liquidity Plan (Details Narrative)", "role": "http://envveno.com/role/ManagementsLiquidityPlanDetailsNarrative", "shortName": "Management\u2019s Liquidity Plan (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Significant Accounting Policies (Details Narrative)", "role": "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:ConcentrationRiskCreditRisk", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Balance Sheets (Parenthetical)", "role": "http://envveno.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Schedule of Property and Equipment (Details)", "role": "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Property and Equipment (Details Narrative)", "role": "http://envveno.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "Property and Equipment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Schedule of Operating Lease Cost (Details)", "role": "http://envveno.com/role/ScheduleOfOperatingLeaseCostDetails", "shortName": "Schedule of Operating Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-11-162021-11-17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details)", "role": "http://envveno.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeaseDetails", "shortName": "Schedule of Supplemental Cash Flow Information Related to Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "NVNO:ScheduleOfOperatingRemainingLeaseTermAndDiscountRateTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of Operating Remaining Lease Term and Discount Rate (Details)", "role": "http://envveno.com/role/ScheduleOfOperatingRemainingLeaseTermAndDiscountRateDetails", "shortName": "Schedule of Operating Remaining Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "NVNO:ScheduleOfOperatingRemainingLeaseTermAndDiscountRateTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Maturity of Lease Liabilities (Details)", "role": "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails", "shortName": "Schedule of Maturity of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-11-17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Right-of-Use Assets and Lease Liabilities (Details Narrative)", "role": "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative", "shortName": "Right-of-Use Assets and Lease Liabilities (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-11-17", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WorkersCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Accrued Expenses (Details)", "role": "http://envveno.com/role/ScheduleOfAccruedExpensesDetails", "shortName": "Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WorkersCompensationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Note Payable (Details Narrative)", "role": "http://envveno.com/role/NotePayableDetailsNarrative", "shortName": "Note Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-09-072021-09-08", "decimals": "0", "lang": null, "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Income Tax Provision (Benefit) (Details)", "role": "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails", "shortName": "Schedule of Income Tax Provision (Benefit) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredFederalIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Statements of Operations", "role": "http://envveno.com/role/StatementsOfOperations", "shortName": "Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "role": "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "role": "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Income Taxes (Details Narrative)", "role": "http://envveno.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TaxCreditCarryforwardValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Schedule of Equity Transactions to Raise Capital Through the Placement (Details)", "role": "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails", "shortName": "Schedule of Equity Transactions to Raise Capital Through the Placement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Schedule of Stock Warrant Activity (Details)", "role": "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails", "shortName": "Schedule of Stock Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "NVNO:ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-09-15_us-gaap_MeasurementInputPriceVolatilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Assumption Used for Valuation of Derivative Liability (Details)", "role": "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails", "shortName": "Schedule of Assumption Used for Valuation of Derivative Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "NVNO:ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-09-15_us-gaap_MeasurementInputPriceVolatilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilityMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis (Details)", "role": "http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails", "shortName": "Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://envveno.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-11-30", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Schedule of Stock Options Assumptions in Estimated Fair Value (Details)", "role": "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "shortName": "Schedule of Stock Options Assumptions in Estimated Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Percentage", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Schedule of Stock Option Activity (Details)", "role": "http://envveno.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity", "role": "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "shortName": "Statements of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "NVNO:ScheduleOfShareBasedCompensationStockOptionsActivityRestrictedSharesTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Schedule of Stock Option Activity Restricted Shares (Details)", "role": "http://envveno.com/role/ScheduleOfStockOptionActivityRestrictedSharesDetails", "shortName": "Schedule of Stock Option Activity Restricted Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "NVNO:ScheduleOfShareBasedCompensationStockOptionsActivityRestrictedSharesTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-11-292021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "NVNO:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Outstanding and Exercisable Restricted Stock Units (Details)", "role": "http://envveno.com/role/ScheduleOfOutstandingAndExercisableRestrictedStockUnitsDetails", "shortName": "Schedule of Outstanding and Exercisable Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-11-292021-11-30", "decimals": null, "first": true, "lang": "en-US", "name": "NVNO:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unitRef": "Percentage", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Share Based Compensation (Details Narrative)", "role": "http://envveno.com/role/ShareBasedCompensationDetailsNarrative", "shortName": "Share Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_RestrictedStockMember", "decimals": "-5", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Schedule of Dilutive Net Loss Per Common Share (Details)", "role": "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "shortName": "Schedule of Dilutive Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_us-gaap_PrivatePlacementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Statements of Changes in Stockholders' Equity (Parenthetical)", "role": "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "shortName": "Statements of Changes in Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_us-gaap_PrivatePlacementMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Statements of Cash Flows", "role": "http://envveno.com/role/StatementsOfCashFlows", "shortName": "Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Business Organization and Nature of Operations", "role": "http://envveno.com/role/BusinessOrganizationAndNatureOfOperations", "shortName": "Business Organization and Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Management\u2019s Liquidity Plan", "role": "http://envveno.com/role/ManagementsLiquidityPlan", "shortName": "Management\u2019s Liquidity Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 40, "tag": { "NVNO_AccruedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://envveno.com/role/ScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development.", "label": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopment", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_AccruedWarrants": { "auth_ref": [], "calculation": { "http://envveno.com/role/ScheduleOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued warrants.", "label": "Accrued warrants" } } }, "localname": "AccruedWarrants", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_AdditionalPaidInCapitalFairValueOfWarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "AdditionalPaidInCapitalFairValueOfWarrantsIssued.", "label": "Fair Value of Warrants Issued" } } }, "localname": "AdditionalPaidInCapitalFairValueOfWarrantsIssued", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_AdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advisor [Member]", "label": "Advisor [Member]" } } }, "localname": "AdvisorMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_AnnualLimitOfDeductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual limit of deduction percentage.", "label": "[custom:AnnualLimitOfDeductionPercentage]" } } }, "localname": "AnnualLimitOfDeductionPercentage", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "NVNO_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Board of Directors [Member]", "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_CommonStock0.00001ParValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, $0.00001 par value [Member]", "label": "Common Stock, $0.00001 par value [Member]" } } }, "localname": "CommonStock0.00001ParValueMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "domainItemType" }, "NVNO_CommonStockIssuedInAtMarketTransactions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued in at the market transactions\t.", "label": "Common stock issued in At The Market Transactions (ATM)" } } }, "localname": "CommonStockIssuedInAtMarketTransactions", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_CommonStockIssuedInAtMarketTransactionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued in at market transactions shares.", "label": "Common stock issued in At The Market Transactions (ATM), shares" } } }, "localname": "CommonStockIssuedInAtMarketTransactionsShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_CommonStockIssuedInPrivatePlacementOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued in private placement offering.", "label": "Common stock issued in private placement offering" } } }, "localname": "CommonStockIssuedInPrivatePlacementOffering", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_CommonStockIssuedInPrivatePlacementOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued in private placement offering shares.", "label": "Common stock issued in private placement offering, shares" } } }, "localname": "CommonStockIssuedInPrivatePlacementOfferingShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_CommonStockIssuedInRegisteredDirectOffering": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued in registered direct offering.", "label": "Common stock issued in registered direct offering" } } }, "localname": "CommonStockIssuedInRegisteredDirectOffering", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_CommonStockIssuedInRegisteredDirectOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued in registered direct offering, shares", "label": "Common stock issued in registered direct offering, shares" } } }, "localname": "CommonStockIssuedInRegisteredDirectOfferingShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_CurrentAndDeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current and deferred federal, state and local, tax expense (benefit).", "label": "Current and Deferred Federal, State and Local, Tax Expense (Benefit)" } } }, "localname": "CurrentAndDeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_DeemedDividend": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deemed dividend.", "label": "Deemed dividend" } } }, "localname": "DeemedDividend", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NVNO_DeferredTaxAssetsOperatingLeaseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease asset.", "label": "Operating lease asset" } } }, "localname": "DeferredTaxAssetsOperatingLeaseAsset", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_DeferredTaxAssetsOperatingLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease liability.", "label": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiability", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_DeferredTaxAssetsPropertyPlantAndEquipmentOne": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Property and equipment.", "label": "Property and equipment" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipmentOne", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_DerivativeLiabilitiesReclassifiedToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative liabilities reclassified to equity.", "label": "Derivative liabilities reclassified to equity" } } }, "localname": "DerivativeLiabilitiesReclassifiedToEquity", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NVNO_DerivativeLiabilityMeasurementDifferenceDescriptionoNE": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative liability measurement difference description.", "label": "Derivative difference description" } } }, "localname": "DerivativeLiabilityMeasurementDifferenceDescriptionoNE", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "NVNO_DerivativeLiabilityMeasurementInputTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derivative liability masurement input term.", "label": "Contractual Term (Years)" } } }, "localname": "DerivativeLiabilityMeasurementInputTerm", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails" ], "xbrltype": "durationItemType" }, "NVNO_DisclosureRightofuseAssetsAndLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Right-of-use Assets And Lease Liabilities", "terseLabel": "Schedule Of Supplemental Cash Flow Information Related To Operating Lease", "verboseLabel": "Schedule Of Operating Lease Cost" } } }, "localname": "DisclosureRightofuseAssetsAndLeaseLiabilitiesAbstract", "nsuri": "http://envveno.com/20211231", "xbrltype": "stringItemType" }, "NVNO_ExchangeAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange Agreements [Member]", "label": "Exchange Agreements [Member]" } } }, "localname": "ExchangeAgreementsMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssuesOne": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability imeasured on recurring basis unobservable inputs reconciliation reclassification issues one.", "label": "Derivative liabilities associated with the issuance of placement agent warrants" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssuesOne", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationOfWarrantDerivativesToEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value net derivative asset liability measured on recurring basis unobservable inputs reconciliation reclassification of warrant derivatives to equity.", "label": "Reclassification of warrant derivatives to equity" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationReclassificationOfWarrantDerivativesToEquity", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_FairValueOfCommonStockIssuedInSatisfactionOfTradePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of common stock issued in satisfaction of trade payable.", "label": "Fair value of common stock issued in satisfaction of trade payable" } } }, "localname": "FairValueOfCommonStockIssuedInSatisfactionOfTradePayable", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NVNO_FairValueOfWarrantsIssuedToPreferredExchangeParticipantsSabrAndRepricedPlacementAgentWarrant": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants issued to preferred exchange participants sabr and repriced placement agent warrant.", "label": "Fair value of warrants issued to Preferred Exchange Participants, SABR and re-priced placement agent warrant" } } }, "localname": "FairValueOfWarrantsIssuedToPreferredExchangeParticipantsSabrAndRepricedPlacementAgentWarrant", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NVNO_GainOnExtinguishmentOfNotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on extinguishment of note payable.", "label": "Gain on extinguishment of note payable" } } }, "localname": "GainOnExtinguishmentOfNotePayable", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NVNO_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laboratory Equipment [Member]", "label": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "NVNO_NewAccountingAdoptedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New accounting adopted [Policy Text Block]", "label": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingAdoptedPolicyTextBlock", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "NVNO_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck protection program [Member]", "label": "Paycheck protection program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_PercentageOfAuthorizedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of authorized number of shares.", "label": "Number of shares authorized greater than minimum percentage" } } }, "localname": "PercentageOfAuthorizedNumberOfShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "NVNO_PreferredStockIssuedInPrivatePlacement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock issued in private placement.", "label": "Preferred stock issued in private placement" } } }, "localname": "PreferredStockIssuedInPrivatePlacement", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_PreferredStockIssuedInPrivatePlacementShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock issued in private placement, shares", "label": "Preferred stock issued in private placement, shares" } } }, "localname": "PreferredStockIssuedInPrivatePlacementShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_PresentValueOfMonthlyLeasePaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Present value of monthly lease payments [Member]", "label": "Present value of monthly lease payments [Member]" } } }, "localname": "PresentValueOfMonthlyLeasePaymentsMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_ProceedsFromRegisteredDirectOfferingNetAmount": { "auth_ref": [], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from registered direct offering net amount.", "label": "Proceeds from registered direct offering" } } }, "localname": "ProceedsFromRegisteredDirectOfferingNetAmount", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NVNO_ProceedsFromShareIssuedUnderAtmNet": { "auth_ref": [], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from share issued under Atm net", "label": "Proceeds from shares issued under ATM" } } }, "localname": "ProceedsFromShareIssuedUnderAtmNet", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NVNO_PurchasePricePerentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Price Perentage.", "label": "Purchase price percentage" } } }, "localname": "PurchasePricePerentage", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "NVNO_ReclassificationOfWarrantDerivativesToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of warrant derivatives to equity.", "label": "Reclassification of Warrant Derivatives to Equity" } } }, "localname": "ReclassificationOfWarrantDerivativesToEquity", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and Development [Member]", "label": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of assumption used for valuation of fdrivative liability [TableTextBlock].", "label": "Schedule of Assumption Used for Valuation of Derivative Liability" } } }, "localname": "ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityTableTextBlock", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "NVNO_ScheduleOfOperatingRemainingLeaseTermAndDiscountRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of operating remaining lease term and discount rate [TableTextBlock]", "label": "Schedule of Operating Remaining Lease Term and Discount Rate" } } }, "localname": "ScheduleOfOperatingRemainingLeaseTermAndDiscountRateTableTextBlock", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "NVNO_ScheduleOfShareBasedCompensationStockOptionsActivityRestrictedSharesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of share based compensation stock options activity restricted shares [Table Text Block]", "label": "Schedule of Stock Option Activity Restricted Shares" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityRestrictedSharesTableTextBlock", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "NVNO_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securties Purchase Agreement [Member]", "label": "Securties Purchase Agreement [Member]" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_SecurityDepositsAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Security deposits and other assets noncurrent.", "label": "Security deposits and other assets" } } }, "localname": "SecurityDepositsAndOtherAssetsNoncurrent", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "NVNO_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C Convertible Preferred Stock [Member]", "label": "Series C Convertible Preferred Stock [Member]" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments non options equity outstanding weighted average remaining contractual term.", "label": "Weighted average remaining life in years, Outstanding and exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments non options equity outstanding weighted average remaining contractual terms.", "label": "Weighted average remaining life in years, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsEquityOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average exercise price.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments foreitures in period weighted average exercise price.", "label": "Weighted Average Exercise Price, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments granted in period weighted average exercise price.", "label": "Weighted Average Exercise Price, Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award non option equity instruments weighted average exercise price.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price, Outstanding and exercisable", "periodStartLabel": "Weighted Average Exercise Price, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "NVNO_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrants intrinstic.", "label": "Warrants intrinstic" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NVNO_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation shares authorized under stock option plans exercise price range options exercisable into common stock.", "label": "Restricted Stock Unit for" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOptionsExercisableIntoCommonStock", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfOutstandingAndExercisableRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "NVNO_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sharebased compensation arrangement by sharebased payment award equity instruments non options equity aggregate intrinsic value outstanding.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding", "periodEndLabel": "Intrinsic value, Outstanding and exercisable", "periodStartLabel": "Intrinsic value, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsNonOptionsEquityAggregateIntrinsicValueOutstanding", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "monetaryItemType" }, "NVNO_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOtherThanOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining life, restricted stock awards.", "label": "Weighted Average Remaining Life In Years" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOtherThanOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ScheduleOfOutstandingAndExercisableRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "NVNO_SpartanCapitalSecuritiesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spartan Capital Securities LLC [Member]", "label": "Spartan Capital Securities LLC [Member]" } } }, "localname": "SpartanCapitalSecuritiesLLCMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_StockIssuedDuringPeriodSharesForExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued during period shares for exercise of warrantsi.", "label": "Common stock issued for exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodSharesForExerciseOfWarrants", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_StockIssuedDuringPeriodSharesForExerciseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares for exercise of warrants shares.", "label": "Common stock issued for exercise of warrants, shares" } } }, "localname": "StockIssuedDuringPeriodSharesForExerciseOfWarrantsShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_StockIssuedDuringPeriodSharesIssuedInSatisfactionOfTradePayableShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued in satisfaction of trade payable, shares", "label": "Shares issued in satisfaction of trade payable, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedInSatisfactionOfTradePayableShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_StockIssuedDuringPeriodValuePreferredStockExchangeToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock exchange to common stock.", "label": "Preferred stock exchange to common stock" } } }, "localname": "StockIssuedDuringPeriodValuePreferredStockExchangeToCommonStock", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_StockIssuedDuringPeriodValuePreferredStockExchangeToCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock exchange to common stock, shares.", "label": "Preferred stock exchange to common stock, shares" } } }, "localname": "StockIssuedDuringPeriodValuePreferredStockExchangeToCommonStockShares", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "NVNO_StockIssuedDuringPeriodValueSharesIssuedInSatisfactionOfTradePayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued in satisfaction of trade payable.", "label": "Shares issued in satisfaction of trade payable" } } }, "localname": "StockIssuedDuringPeriodValueSharesIssuedInSatisfactionOfTradePayable", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "NVNO_StockOptionPercentageDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock option percentage description.", "label": "Stock options" } } }, "localname": "StockOptionPercentageDescription", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "NVNO_TwoThousandSixteenOmnibusIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2016 Incentive Plan [Member]", "label": "2016 Incentive Plan [Member]" } } }, "localname": "TwoThousandSixteenOmnibusIncentivePlanMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_WarrantOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant One [Member]", "label": "Warrant One [Member]" } } }, "localname": "WarrantOneMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_WarrantToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to Purchase Common Stock [Member]", "label": "Warrant to Purchase Common Stock [Member]" } } }, "localname": "WarrantToPurchaseCommonStockMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "domainItemType" }, "NVNO_WarrantsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants description.", "label": "Warrants description" } } }, "localname": "WarrantsDescription", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "NVNO_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NVNO_WorkingCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Working Capital.", "label": "[custom:WorkingCapital-0]" } } }, "localname": "WorkingCapital", "nsuri": "http://envveno.com/20211231", "presentation": [ "http://envveno.com/role/ManagementsLiquidityPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r370", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r370", "r372", "r373" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r370", "r372", "r373" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r370", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r370", "r372", "r373" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://envveno.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MaximumMember": { "auth_ref": [ "r155", "r173", "r193", "r194", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r343", "r344", "r356", "r357" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r155", "r173", "r193", "r194", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r343", "r344", "r356", "r357" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r155", "r173", "r191", "r193", "r194", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r343", "r344", "r356", "r357" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r155", "r173", "r191", "r193", "r194", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r343", "r344", "r356", "r357" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r124", "r303" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://envveno.com/role/ScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets", "http://envveno.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r30" ], "calculation": { "http://envveno.com/role/ScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r25", "r132" ], "calculation": { "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r43", "r44", "r281", "r282", "r283", "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r15", "r222", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r77", "r78", "r79", "r219", "r220", "r221", "r269" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities", "totalLabel": "Total adjustments" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potentially dilutive common stock equivalents excluded from diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative", "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r71", "r116", "r118", "r122", "r127", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r258", "r260", "r279", "r305", "r307", "r329", "r336" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r37", "r71", "r127", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r258", "r260", "r279", "r305", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r196", "r218" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r22", "r307", "r350", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ManagementsLiquidityPlanDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r22", "r61" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r55", "r61", "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash - End of year", "periodStartLabel": "Cash, cash equivalents and restricted cash - Beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r55", "r280" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash, Cash Equivalent, and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash FDICInsured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash uninsured amount" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r69", "r71", "r91", "r92", "r93", "r96", "r98", "r104", "r105", "r106", "r127", "r143", "r147", "r148", "r149", "r152", "r153", "r171", "r172", "r175", "r179", "r279", "r375" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Cover", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants and rights outstanding measurement input" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative", "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r141", "r331", "r340" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r138", "r139", "r140", "r142", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r77", "r78", "r269" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value", "verboseLabel": "Common stock par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r185" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.00001, 250,000,000 shares authorized, 9,469,850 and 2,541,529 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r109", "r335" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r63", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock, description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r63", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r72", "r243", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Fedral: Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r72", "r243", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State and local: Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r68", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r169" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Note Payable" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r32", "r154" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r33", "r155", "r274" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r72", "r244", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Fedral: Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r72", "r244", "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State and local: Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Total" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r236" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r241", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Operating loss carryforwards expired unused" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Operating loss carryforwards expired" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r239", "r241", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Research and development credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r241", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses": { "auth_ref": [ "r241", "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.", "label": "Impairment loss" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r59", "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r59", "r130" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r267" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://envveno.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "negatedLabel": "Change in fair value of derivative liabilities", "negatedTerseLabel": "Change in fair value of derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows", "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainOnDerivative": { "auth_ref": [ "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.", "label": "Increase in derivative liability" } } }, "localname": "DerivativeGainOnDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityMeasurementDifferenceDescription": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Description of measurement difference between recognized amounts and resulting measurement differences for derivative liabilities.", "label": "Derivative liability, description" } } }, "localname": "DerivativeLiabilityMeasurementDifferenceDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilityMeasurementInput": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure derivative liability.", "label": "Risk-Free Rate" } } }, "localname": "DerivativeLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Decrease in derivative liability" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r75", "r263", "r264", "r265", "r266", "r268" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivative Liabilities" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net Loss Per Basic and Diluted Common Share:" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r99", "r100" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r99", "r100", "r101", "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r73", "r229", "r251" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "Tax benefit at federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r229", "r251" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "verboseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r229", "r251" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r229", "r251" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Nondeductible compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r229", "r251" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "True up adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r229", "r251" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State taxes, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r43", "r44", "r45", "r77", "r78", "r79", "r81", "r86", "r88", "r103", "r128", "r185", "r188", "r219", "r220", "r221", "r246", "r247", "r269", "r281", "r282", "r283", "r284", "r285", "r286", "r345", "r346", "r347", "r380" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFairValueAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.", "label": "Equity, Fair Value Adjustment", "verboseLabel": "Fair value adjustment" } } }, "localname": "EquityFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative", "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r59", "r170" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair value adjustment" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": { "auth_ref": [ "r275", "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Derivative liabilities associated with the issuance of common stock warrants" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) into (out of) level 3 of the fair value hierarchy.", "label": "Change in fair value of derivative liabilities" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "auth_ref": [ "r271", "r276" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "periodEndLabel": "Balance \u2013 December 31, 2020", "periodStartLabel": "Balance \u2013 January 1, 2020" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfFairValueOfLevel3DerivativeLiabilitiesOnFairValueOfRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r72", "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.", "label": "Federal Income Tax Expense (Benefit), Continuing Operations" } } }, "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r59" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Loss on disposition of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r59", "r167", "r168" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://envveno.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment of debt", "negatedLabel": "Gain on extinguishment of note payable" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative", "http://envveno.com/role/StatementsOfCashFlows", "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r129", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r134", "r137" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative", "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative", "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r73", "r230", "r232", "r238", "r248", "r252", "r254", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r74", "r87", "r88", "r115", "r228", "r249", "r253", "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r42", "r226", "r227", "r232", "r233", "r237", "r245" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r58" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r58" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r58" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Security deposit and other assets" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r58", "r295" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Payments on lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r58" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r333" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "negatedLabel": "Interest (income) expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r54", "r56", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Schedule of Operating Lease Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeFinanceLeaseDescription": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's finance lease.", "label": "Financing leases term description" } } }, "localname": "LesseeFinanceLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative", "http://envveno.com/role/ScheduleOfOperatingRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Maturity of Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ended December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Right-of-Use Assets and Lease Liabilities" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r71", "r119", "r127", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r259", "r260", "r261", "r279", "r305", "r306" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r71", "r127", "r279", "r307", "r330", "r338" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r31", "r71", "r127", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r259", "r260", "r261", "r279", "r305", "r306", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Payment of dispute settlements" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAssumptionUsedForValuationOfDerivativeLiabilityDetails", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r55", "r57", "r60" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r40", "r41", "r45", "r46", "r60", "r71", "r80", "r82", "r83", "r84", "r85", "r87", "r88", "r94", "r116", "r117", "r120", "r121", "r123", "r127", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r270", "r279", "r332", "r341" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://envveno.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r82", "r83", "r84", "r85", "r89", "r90", "r95", "r98", "r116", "r117", "r120", "r121", "r123" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net Loss Attributable to Common Stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-Cash Investing and Financing Activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total Other (Income) Expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other (Income) Expense:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note Payable", "verboseLabel": "Notes payable amount" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets", "http://envveno.com/role/NotePayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r116", "r117", "r120", "r121", "r123" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r294", "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfOperatingLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating expenses for building repairs and maintenance" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Present value of our lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r288" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r288" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r290", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Cash paid for amounts included in the measurement of lease liabilities", "verboseLabel": "Initial lease rate per month" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative", "http://envveno.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r287" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r59" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r296", "r299" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfOperatingRemainingLeaseTermAndDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r262" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Business Organization and Nature of Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BusinessOrganizationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r30" ], "calculation": { "http://envveno.com/role/ScheduleOfAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r49" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Net of offering costing" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r50" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r196", "r218" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockDividendsIncomeStatementImpact": { "auth_ref": [], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.", "label": "Preferred Stock Dividends, Income Statement Impact", "negatedLabel": "Deemed dividend to Series C Preferred Stockholders" } } }, "localname": "PreferredStockDividendsIncomeStatementImpact", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r13", "r69", "r175", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred stock, liquidation preference per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13", "r171" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13", "r171" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, par value $0.00001, 10,000,000 shares authorized: no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r20", "r21" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r51" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from public offerings, net" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Net Proceeds issued during the period" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r51" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from preferred stock issued in private placement, net" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r51" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds from private placement, net" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Net proceeds from warrant exercises after deducting underwrites and placement agents fees and expenses" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r52" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from issuance of note payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r51" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from warrant exercises" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r25", "r133" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r136", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r24", "r131" ], "calculation": { "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r133", "r307", "r334", "r339" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets", "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r23", "r133", "r353", "r354" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r10", "r131" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property plant and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r192", "r301", "r302" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r192", "r301", "r304", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r225", "r315", "r358" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r188", "r222", "r307", "r337", "r348", "r349" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r77", "r78", "r79", "r81", "r86", "r88", "r128", "r219", "r220", "r221", "r246", "r247", "r269", "r345", "r347" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Dilutive Net Loss Per Common Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Supplemental Cash Flow Information Related to Operating Lease" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative", "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Income Tax Provision (Benefit)" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value of Level 3 Derivative Liabilities on Fair Value of Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r25", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://envveno.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r196", "r218" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r200", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Stock Options Assumptions in Estimated Fair Value" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Outstanding and Exercisable Restricted Stock Units" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r189", "r195" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stock Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Equity Transactions to Raise Capital Through the Placement" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://envveno.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r58" ], "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative", "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Outsatnding number of units, restricted stock", "periodEndLabel": "Outstanding shares, ending", "periodStartLabel": "Outstanding shares, beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfOutstandingAndExercisableRestrictedStockUnitsDetails", "http://envveno.com/role/ScheduleOfStockOptionActivityRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Shares Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityRestrictedSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails", "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Number of Warrants, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Number of Warrants, Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants, Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r201", "r203" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants, Outstanding and exercisable", "periodStartLabel": "Number of Warrants, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of options forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Number of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value", "periodStartLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r202", "r218" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of options ending", "periodStartLabel": "Number of options beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r201" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r195", "r198" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r196", "r199" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r215", "r223" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionsAssumptionsInEstimatedFairValueDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining life in years, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Remaining life in years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r67", "r76" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "auth_ref": [ "r72", "r228", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "verboseLabel": "Net operating loss carryforwards" } } }, "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r12", "r13", "r14", "r69", "r71", "r91", "r92", "r93", "r96", "r98", "r104", "r105", "r106", "r127", "r143", "r147", "r148", "r149", "r152", "r153", "r171", "r172", "r175", "r179", "r185", "r279", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Cover", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r36", "r43", "r44", "r45", "r77", "r78", "r79", "r81", "r86", "r88", "r103", "r128", "r185", "r188", "r219", "r220", "r221", "r246", "r247", "r269", "r281", "r282", "r283", "r284", "r285", "r286", "r345", "r346", "r347", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Cover", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r77", "r78", "r79", "r103", "r316" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/Cover", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r185", "r188" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Common stock issued in public offering, shares", "verboseLabel": "Number of shares issued during the period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfEquityTransactionsToRaiseCapitalThroughPlacementDetails", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shared-Based Compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r185", "r188" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Common stock issued in public offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shared-Based Compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r71", "r125", "r127", "r279", "r307" ], "calculation": { "http://envveno.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets", "http://envveno.com/role/StatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r70", "r172", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r188", "r190" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfChangesInStockholdersEquityParenthetical", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Management\u2019s Liquidity Plan" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ManagementsLiquidityPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardValuationAllowance": { "auth_ref": [ "r235" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Tax Credit Carryforward, Valuation Allowance" } } }, "localname": "TaxCreditCarryforwardValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/NotePayableDetailsNarrative", "http://envveno.com/role/Right-of-useAssetsAndLeaseLiabilitiesDetailsNarrative", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r107", "r108", "r110", "r111", "r112", "r113", "r114" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfIncomeTaxProvisionBenefitDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "verboseLabel": "Warrants and rights outstanding measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Common Shares Outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WorkersCompensationLiabilityCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://envveno.com/role/ScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued compensation costs" } } }, "localname": "WorkersCompensationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://envveno.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r362": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r364": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r366": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r367": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r368": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r369": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r371": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r372": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r373": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r374": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r375": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r376": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r377": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r378": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r379": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20225997-175313" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r76": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" } }, "version": "2.1" } ZIP 73 0001493152-22-007802-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-007802-xbrl.zip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

MT#*@<[L[64^9X=003!G0+4'HFMX-M': 4O]$U!0>9*G*L$; M]_>B:7E35K-/X!@H:3U#>]59C'PJ'4U;Q5;EH%J/4 YJB91M4(ZQFQQCI1:9 M'TE(+@ZFZN^6!63#5HV=\Q+->\K;FQ ATB5)TK%T;HI_M!VFV+LO:11VJ$24 M?&'8RRLRM + M H6*%>L 08^PRCY&;_KD(^;N/2X:(4.]=5B&7AFU],L=PCTQ& AL=B@\G[\E M"BW#OJ 2T;K8BO* ,44UX;.)/N1TE'=:[_H!\1>NR8/Q7&%:R)+)(Y1SRVMN M42&K[IEZ"R:[A*51*2OG%(LK2.?%EXNSR].7RC%(Q9^QXC^^"UPHX,8 527! MT8.O>(Z@- 95188B?NE63?PM3<$_AJ6:2&Y&$(R<#CC#F),\W](QP,:0R][I2S16J?W%/Y3I2@TE2XIC@&X<+DIZ"9(BAJRBAPFZC(0;O$;6RK,/T M'FEYAL@R12HLKD;FV2/S010/,84.J/5)7B&DQNRGD^LHZ 6$)'TQ'GN$ W%- M>166=QB1OK6WMZ?K(<-+_A!D *-DH@.&333P9A!Q2U40-W:;SF&$^2=QH\*& MU'#VVCNMUPK+N2M=((=]I!\J5PC$N!=[6WLO'7APO;W7;/(2S)H!QSN8;(1) M4[$JH'E]?;TAPROT!&V N,1Y"'95&E5'DM5:% 6HR1XF;Z%OFKM.X&KTV#XG M%PEJ@ZMZ1&!B%?NB,AW#LI0;'436ZC M,!C-D$0]D@YZ>VS\7AT;/]78^-UG%!N_#+[.>71H[DZ[TD_G_6@LK M,%G,?UYLP+!('LSW?ED3WYK-3=/IY=Q/OO,:CP69(N=,/Y(\IT=RH7)!CNRH?1 MVK[.'.=$-V3SV$::2L:E;/C!MB$H8 @06O7!1?AV+@-80?M M'91NVP7A(Z1BNZ8X@FY56BPTIX.3E66$K.L50]7QQ25;DF"%1^G 37F!7298Y4)%F=<.PE?G28>N897>-=T MGO=,L1:KTR"0I"S1F5:ZZB,1OA!3-9@*7:,W'DNBWTER$UF:7*E83$9U\5KR M7:ILJ$19J#LC6$AN=[XX.IB%\E1'V]4Q"'4,@AV# #0#8VL**7+(GS&##T0- MY.[$EZF/*8H8>8],>K7J/54F0A5Q,S6 R1 LW#Z9>?-">;P8$%"Z?JI:,;R= MUW":.G!T$0%=18\!K_(D5=? ")08A5Q53B7)R)@(_(PY%@Q+783&,VE4?1#5 MYZ(4[ZGFH?Z^X\'G*G:4I.RQ$H=VC+JNF6GJ9I.;M'(Y44S9*6.3DZMT\APJ M=@W+)=TR.OF,\J)QCO;ZYZ?%[6W,85!0T&!ND7=.L?79HB?)N;@X!5!E-,). M#,4ZH)R*9;(W\GKG)I^+XU$Q)T3U9TJRN"=-BJ[(^V:0YP*[/Z0ZIIO3E?/^ M/C4DUY!\O\6:QAH45 D4TL5DSFQ8BJ.VBC/<">MVXU+J5**8$HP6HF,.*3Q6 M\PYJ(*V!]%Z+I:1(DD!4OS.J*<"]^;A,0ISYJ?-=4F76) (X"XJ54 J]9[E( M-F8MJZIN)IO9#[NQ2-(XH]R!&CYK^+QG303N/J>234(NO>-PZ1T34LF=YE3_ ME[Q5I*:GX]2SAK\:_NZUV),NK^U:%C4<1?,J-34$.8N<%I6A0I\W.0$\*^O1 MYYHB%AB*.7)84$U)UF"I$&AI\F*/6&FZG]$XN;?HRK?Z75IKXC8>$=EME:K: MCY*AGXJ TJ%TK#47&:=V6WD-JP0+V_2CP ,,K1&N1KA[+?: ^W;Q GW.4XBI M]Z!5N4$Y&I5#H8:M&K;NM=@OML/?0)CNG(;UD-GX3(D<5Q+K#D;:.*W4M 4P M1]=0-V]09Y5-5M)$1,F3P/&)E9H>/-A U)2=(T=H#64UE/T0W^22]U8)24MG MS[O4F.ZG5*:U(DE?5^ LE-\L*/96,+'WN*$-H8HO-PSI+-2+U?(D))5]?I\)2(C-GPNH4YIZM.*A18PV(-B_=:[!F##B\P M,*:<0%PG&98CU86\LT2%VG*EY2RQ G;R1I1F!#+G4#MP9=$W1-HW D39<$65 MQWD9^%YE5 0&(>3V)6X_32$%RJA6PWT-]S],@PWAI=*/"E 5X%IY!"K&Y[-( M//&7&W'H%6:&YH#*&;?L 3#/>=SJ M(K--!JJS@'$*E#H&^*$'NZ+JU+I^DZ2&O]Q6\.#TZ\GA>FM/^P;*S>7JI*=' MSZ[ Y+,$6]J8YA:8"/U! PV*CQ<*(.JD^D>YD7<^A87.3>QSP="LDIYJ0'BJ MZ@H$%GT0):)8%;S*8<02FT.9&FM%;FS+OT5J_(_6SL:V TL)= [>/_8V6N8+ M771I)$6<.-Q$1I=N6%W9;%'9EA:]!W\T&[J3@ ]R\VC#V<>T2,[VTR)/OFRS M-E7S!:LFN6XVR)@*<4]G>N\?KUL;>_DB:>'CJ^#R#6IKJEP@SDS&0A]NS<>R MH7$T "4@*?;R88^+JM=EM0-0]7O1 *2*O'"F)&[$9"ZBBSG!DA=!0&O+K,JA MNN27W9'&#DV:4)#?.="QX'0Z.N/)<@QI=Q#MQUJ*J6I3)@+J7/)2XKA&2<'2 MF@I0"A4U#:+[W)57W4#A M/13>!):[BU,9!TJT"BJ&8$ICI4B+ M>/"C^<2,"N6=VP8?Y!1R%71.H,720$Q2!57:2X53:6 M>1),H=QI7NR9\4%BZC>)(5NS4AM-RM"=^G%SHC#9&.""P%0X7)%&Q7[\V<6 M^XGGN^5X#>ZR=I2A[Q#V2-W8D)HY^S@$]^0\^K3?T#.;)V$)**[ASU^4ME;) MIJEUKR&O,,I8"7FNOKFZ8C'H4E'XB5[,B33)0DH.)M'%<\IGQ[(]D4E>!5$I MFTSJHS>&E?%A*XZX/'"^LV*+/%*"AEQ#&D\+=3D 2&HV;*BSNDW0 @3KH:4C M5F$*24F?8+VU46YW(7,KK8K5*4*>^;G0B1=/AJH, >@._"2QW&U%:=*/1FGRM)"9&4[D\W+ M2G;FLL!<9KCA)%06CQM0\-JP'P!W@\OY*HGZ15>H"D51Y0/4OCWNA&!6FDL; MK&R"X*7K:K"(H:0#IRP;77(3=#:XT;I8")R@ MVIE^76CZ4^6)M07<;CY<[--!290^M:TRX3@;SMFD0X+I!)E3\70H PW.4TE7 MGM^E"L=P?&)D3#JZVE\@1CJ."$O[X0295VGAX9LL'&Z>3C9^LB"H:RD:UU6> M"1!F5(0Q2/G9@9WL:FHV0&A@[T=3""YO8AA"V6/G#(V$C^NW6DS'3']HJPPY K(&RQHL?QXLJ5L?N_IOJYL:Y^5^V8P__JQJ M_>=3V'L4<_]XBO+2L5O47'10[%+-IB:L<4$N#;3+__KIK)8/:N">@K52QX^1 MMCYB8+2X?:$.$-+?5U%/U4II2K"TKC(AE'@TT.DO$>PB1 F MM#R(,\T6Y7_0\74?#]GZS#TXB^KJPY*E$V)P=6:3"9YC!SK>-Y :]SL0(65, M!*J$C_B>I PV':W*(;K=&$TX>K<(^=0+*Z4IE!DK^GU:9B.SKV''&-15D7U9- M%$ 1!MCQK :TM'=?YP@$4=A;1QER=26OAJO,G&D_EH! (8%BG0?RY,FX2&UB M'P/R/,L$;8A*GH96E;%--T[#=#/*L"UF'Y:S5TG'P')B)CP8OUY=*93$T=7( MJ,TE!Z_X29+IE C\#.2/!!0*_H85A%&X;G\'=%D'35&"%C:+J"C&3!D4IE;? MZHJJ F$*,%/" Z),1ZQ/==*\+!JK/JI,A>\B MTZ"R[)PG@\%)NBH[%0V2/CE)18!I.N0:P 5V8#2Z !)TU53V%),<5S;^ I:G M/EVXZ5"8#[&ZPNBM>W+'S#V0\Q3=3MYS9(<[X%'Z39 &K4 M@RBC>OLQ)QC% ]TR!Y\ \, ]YK!M9:HB=F44LEX]H\Y,Q616TY;6;DJKXCKT M3FY-7>7LH,KT5;IP3>;'*[@# &'BK\ $>ZY+B+XNN-HE%4T6;QNG'#A*Z7T< M]JGD@JHZD3K(T\8+BE;%[_/<-(H05$7&K0C!.AJPC@9\:L-&'0U8\K]1Z0\= M^&R3>(PSL.0'#EI/'J/L9FUC>R:P1[50&IB>H%/UHBRE^B @ 6#[I4/H\^^ M*U$-><\)\G0%#U7I$H0@4,0HDZ$+(JR"2#2N8<%!DP "L<:8Y^H]==M:0MVE=E?E4OAKC/R-%R2I_-M5* M_S7T+3?T!;(G@H81"]'C14IVW@4W3P_%\JJ2*C I?43[I7+U%S7WV<=3;;[> MV!JF=4#5SX8=5&1?:HHSYJV-0LOYR=[00K42=O46 UZTXU?^E5&-,1S(E"HE M]V<:K:X$/DQ)X:,)61=CCMYBQ40DB4Q5+#05PH@E4#T.FT[<:,@:3.Q(C'P) M)PQBF\IU->W:QSDGVU"A4JHT-D(%PY6.ZBM4UVDX28:5,C$MK@1/5GD;#N@+ M\N9+7"H]GESRMZ*R-L6I*<%.M!+?WW"O!+2 EGGZ8ZB7J'J:9$HSM MR8'O K$KE/0,1B8>$4NI4A1^7H8R&*G)3WV0II,\#?NJF 3?B M@M7JCWYX%057ND,&+LEP-LU3#RAZ<]083ULKE89E!;;0U*ZB"KJ*LP,670J* MOJ5*[R4%@X(@R*(B>0#IR.!4*[J)^=C<#*.ELO![&%V'-$#,4BV%3<77K+3WI0C2OBNXFCJF)<0FA)4T,2JM=TU+8 G) M2D&XK6D:1?1=]Z- '9LM!24ID%4JQ[NN35DFS)8#%N'MSU\_G\+FH_6\ #T' M$.N=8!2*13G&VMG >C'^,16C=9&N]U$DQ_;PA8 U&#<6F#->"-ZD"';MH+7L M;RI$5JIZYAR[B+&/L"P,4:8J,.P4%E0U08$'2HP)IG%P:&@7- 6NF 7?8] Q MO:4>!J*'PMJD):C*-*8J [8C%!V^R K!H BF"*/@;QCN7 F M?TF?NZK"N.%\CE)\&*-\N;LYR8CJ[+DH.P%F'HB*\N@ I% ^YS2*<.LH[V:A M=H>C()3I;D-&JQ_(M!]Y22$D-*\9H6SU9LEY%6:.5,;ZFG20RIE$(&%B8D\! MT6*@"%@E$L,1J44K"#98WE_D.A[>AW*?*]3FB\!0VBRMNC$8$P.=N3,K($_? M[_B@VT5H0?,5/(QTM?-$=VP:J-9+'">=< PEDH_$C:7$(($-YZ/HX!?]*$9$ M2733(+T3#MI%K2#';HI(9F)K1H6; ST%,W1#TD0]#%](%=SG!-AL6%?-!D4Z M-,HWW0E%/9B>2W[8#;*;_*0U, )%T',GNH\/;8)7@KVP3//ZW O(DL:6CV=K MMC2S_?& 797538M%EDE6M]J__L:*1V8DB]5JC:51MTQL8'M4744FDY&1D1$K MUOJC7K&OEF]E(S!1''V,]')P1;J)'$KHA&X\G4"J0[B!#^>X^;HT(E,.QT$K M%A'6\7+D-/JV:<@14&A^ONBYQ4'66B1K-Z_#5]X&:?**:=(ERWZ)$;G]@8WH MQ$P2[RPZ+VP7ZB;2SGA"\;$N;5ZI\D.:>'*E\N(A,2:?X@LT)V0S(#_[ZOL' M]Q8K4 7 +/\([Y@@=*5J6ZR/"1M5D:?UH/,VNB)FIVIE=]\B&;+* M+*0PR#8MU--V!WFO8> >;QFF[COLP/79[&T#%DS?9 415N>D[>>LA8):MM[D M%:%=9 7D,4],":62^PTW77J+S]7:=).2@3@OP=$EO>207+5[VV;H[%A'#5 Q MSHFB;)42I/*^B;[._.6#/)Z!.]'#X/+I;G+&[X(I5*FK5=I=V*L,0]R1 (AZ MZ;QGAGW\]"P@H;0]5Q4]V@5@T,I;.PRTR@9VT=A3SE0!Q 4?G%"PN&SLZJ[B M+H)TP2#2+4,%GF*5+UA4"" I4-? <$U/UEYB@+8YPT-+=I:CEZA-?1IJ+FAI M&\(9=PETM/F]I3^<@S6 1K<7PMBV&(.[PQ2S>.K_YTL["-Q-./G'UFL> ;5_ MZP/VOU=1^:V'?H>J03^$%0(SK0>Q5 E[O;IEEWH>T/E%2^[^EO9S.QQR&YCL MQRWY7<^6K.@PZ"3MK<#H:AR#2+<"*4<7QB@-+'7QQW:37,YO\I MS'__U"@A1-OYXV-2%OW(')&S2<\F+8/]F5,LD11MQ$T:=A&S- M6\X/#8N=^G!K4E8HO28+Y)_O2<+(R:YJ>HI6$T"/SBOXP'K),X&L>2GNZ M6TO!@%:G.XJO&\DA6 7(EDG>(%[+B< M,GO[1VE%JH+00 Z+=,"JD20[4$)>B\S(M=R%\ZJY"X9XIU;-G/+\E22F:E0.N5Y4EH.Y&" ^<;&,T1+7T&*,+60Y+ M2E7;R=A'4JOQ"[0M^%2YN.5/BHB\10H*OL^B-U(,-S:*J2]49IU&6A,89FU]5%_>L9Q;VU8>ZGAKD M\=%7],6,G>\,]]W<7 A>"NI?7:1!NS7"9]WF/NHV$B1=6:-OVZ1=AD4B?3^; MQE.=\&A=1W[)"S4;?R;XOHH86?FFJ/W(&X?S8C;CXJX??A@AMQ^(?OKIXBXVH;<]FZHX+#) M,Z_I$G$#D-P/$Y=0( ;2Q' 8]1C!5S6Z45G)SRZ4$0\VD6S0P B-4"S/F-Y; M^AA_9[0=H@=LV2&UR/NH@7;.%2 TK84:-[6;D\4H;+10!2RB(B8A&[+&C!/! M2(HZ:B!#UI&2NUAH=,G@-SXO%Q9U^$!50B=&N>BP*222<4](7#"(:AN6#%-/ M58WK% >43^451C@Y,L$*O8Y5-"$-X='RC&37R4Z9P$76C#8 _ M(&&U"@_:>B'H =VPJ5V A)9IDJB;R61\A3 MA?BE3J,[;_E?R )VK."^52V29/BN2Z;JY3JSP+:SO8"33ID5DED-&9/M4J+S M_CRL(@V^L8)[2M]('1X;#$X6+\B)8/GJ6.W\OZX8"SPQJ$(;XJ;&*^<.>5*Z M#9\*&*XF1_ZX/LFYI*?W1[[=0#;/!PD]_.52[(D6>;WK^+S*B$"&26)4DM%+ M^^"56RY%Y@IQCFCHGA5J,[JJT0<=7<78*?84UN(1;QHG' M<.$CC;Q="CT8"WU*%N,>]N#6/>[&&4?ZGR"82_'DW5R-*?9RF8_%Y F<%YW5 M.=S!_7"WRJ9\"P]/!]R+78UC;=0 D$VY:^F#C3'ZDS,_/EK7R'Z4"M#/W[HV M@_[VH=GLQ:\-PTH'%9ZV'*35T@S3'2 MPTV'=MDF.0RMI\4$Q)+T.G^%*Y(N2GK]:Y9RIY@B2M:\UK M-3075=]Q.GJCD9^;O6PG5GIF__Y.9OYGH3H-3!3^O MS>,G,!+[S$V[<@??H676# IMM39MM;?"Y7^T]:=W!X"9IFPFBKK18%9>5=[.=,OCHZJPH;!67[_(PR&MZ>@.-]OF;)LW&JP>H# \ M?XBREM=Q2'O+?ARAMDRC/.1CD;Y0<-EO;Q2$D9,IFI:A*!%:[W_EB=!FAMW94C_L4!6+>!AB*N1%9LH(7<>' MW&!?HXC7-,CLL?R?+VUJ;BL18R*_YD4 M-GTN-W .E$U0B]PL+6WT2WU;A_O"21DM>C;-V33_C?-]OALK?=/IU:(G^UN> M3T>RKJ8;X\LNK (V?ESL#^11&QK7-*O4;+"SP7ZPP>I!/UR4M28^1YR"PI!G M9!13WE7[>CKXU%9(UYR!*FIA.2=-9QO]@,$V"ONO=;\GFR6CZ\;X?S7?+,^D M&2IFZ32E!R2HR@5GK/@*5BZ=[7&VQQL--FJ-6'E]C!=8C"KGTB%97ZEP8E@= M E8>PF0EK)6K9 $L('$&LZ[15<,[4'3.VB6S-?_Z<[W9E]GQ>E>OT=?&)7IC M> A#C@=6U[NF:S6L*'9>=BMD27\#&1/&0 M%R/O&'M; 0)S=?O8L?@RD[A[U9V5C3708MM_ R9@,DW[++(J=&'9GC7H\@/- M"' ^+?_K^*C7GT1.Z1<[R-72S+\P#NRGY'X9-_#BQ5-CV"X5<<8\F $MA:!] MAH.F@??*OUP"49.U"?@J;MYBD(MJ>()0PRPS^E@S(_QK 3-Q=B2,WHY=W$/) M%&0+E'%?1)2S_X:HM0FJE_:T4F?$ZM*Z#6J;0^Y&-&:+41C>);VJ2([L'IR) MF*>E<+30*$"Y:=O3H\KAB2W-L6\8!S:+Z9F(Q8\1^&6433%SQ3G)910 M[2#6>I*>S5F7M#]-/E<:'V\A LO#G%?2=[H7]["N%O/.TE.?C@#C1>S-2AAR M[N7H-LRB/!IB.9#%TH@PZ^X:^XA#XW(U ^7W9U!QDQAN1CC M/4M<>X53ZI: M,S24M6=UYWY<7DI?:$_)>WIB'\\]L1^W)_;AW!/[I<1TW$TA6U]&1:!;"]/T M[^UBE\H]8?):JT#A"S9HYEB$"RP0.I0:C3&M_Q#*C:O(M.Z<<+)X ])XVZ<3MZ&&V.#< MY_P.0R^U&6&+R()3XZ=!$$,T7'Y?5L2A M,(%Y18QHGG[?1S@H9D2OCC!&KU-$9!Z?+RIV_CO^U>2W(J\63:' FMM.YV4T MXTP,8EE_[9A<:H>,N[0I_&1\1[35A7Y+3X;@J8W)JP.Q):IA.N]B)''B1TH- MUYB7!JC6)LF'3CZ^Q7'+._5/>& X?,U.V/?%A=J[2^=!S&0)FIUJG70,7*-2 MKLV^'DW?(28:':TCOT0L>SVK)?X1!7IOVE6; .YD#YO;IM_8OYNUH^W3&RERPYI6T![)NDFTX*D%U*%F1 M"RZE=R?:9KJ'QFMA3TD4C+Q/#E=;U5>)W>)*GC#96QT9KHPN+.Y!)CT04WG_ M\_39"?Y?G]WCHJ*IM!Q#V4FM.(?A,GV9^<0\T$CY"']+$4+:4*2P$^I35ZYF MI\GB>YA6'LY%R11;S)F-]N$KB5N-]_&[' MPF122F+TE:43%IVHK*V\]FAUF4X=$HLB$&\OWQ'G)3G5>]'U*0 M2%&52C4K9)R[NNSBSTX63V,Z"?.80J,]NZ)K\?L.^4!8-HA&XE/!P%!O/D<"6,IH1C"9E=.;]X_&IV3T\3J:Z![[YBC5.X%':2R1I0"YQF: M2+:B&=0@L2/VU"!9S3CRLZ[=;4_R<50("X;0&$VO/7&Z0#K!"9.#88$DZM;% M6VEJ.MYL% 1->0'-*M&J4)OA3*B+;"7=^>>?7O61#H&<',[E[@<8<)SB=/6" MWP+WRMHKENPRIRV0G6Q3ZS-C[\S"-

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end